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Iron is an essential nutrient required for numerous biological processes, particularly 
concerning brain function. However, iron deficiency is the most prevalent nutrient deficiency 
worldwide. Although previous research regarding the effects of iron status and iron 
supplementation on psychological and physiological outcomes is extensive, there are several 
methodological limitations relating to heterogeneity in iron status cut-offs, sample populations, 
and supplementation dosage, duration and formulations. Research has also largely focused 
on iron deficiency anaemia with less known about non-anaemic iron deficiency (NAID), despite 
the increased prevalence of NAID among women of reproductive age. Therefore, this thesis 
aimed to investigate iron status and the effects of iron bis-glycinate chelate supplementation 
on cognitive function, subjective fatigue, mood and wellbeing in iron sufficient (IS) and NAID 
women of reproductive age. Vitamin C co-supplementation was also explored as well as any 
differential effects of this on cognitive function, subjective fatigue, mood and wellbeing. 
Chapter 2 describes a cross-sectional study that explored the association of haemoglobin and 
serum ferritin with cognition, subjective mood, fatigue and wellbeing whilst controlling for the 
confounding effects of dietary iron, menstrual blood loss, physical activity and body mass 
index. Chapter 3 describes a systematic review of findings from randomised controlled trials 
investigating the effects of iron supplementation on cognitive function, mood, fatigue and/or 
wellbeing in women of reproductive age. Chapters 4 and 5 describe randomised, placebo-
controlled, parallel groups trials of a 16-week intervention with iron bis-glycinate chelate or 
iron/vitamin C co-supplementation. Effects on cognition, subjective mood, fatigue and 
wellbeing (Chapter 4) and cerebral haemodynamics and whole-body energy metabolism at 
rest and during cognitive demand (Chapter 5) were assessed in IS and NAID females.  
Serum ferritin concentrations were positively associated with emotional functioning and mental 
health. Although iron status improved following iron/vitamin C co-supplementation, treatment 
effects of both iron and iron/vitamin C were limited and mixed. Iron treatment alone reduced 
feelings of depression and total mood disturbance yet engendered an unexpected reduction 
in physical component summary scores. However, iron/vitamin C treatment resulted in 
improved serial subtraction accuracy whilst increased total haemoglobin concentrations were 
found during cognitive demand for NAID women compared to IS women. Taken together, 
these findings suggest that iron treatment can be beneficial for certain aspects of 
psychological functioning and that the lack of cognitive differences between NAID and IS 
women of reproductive age may be due to cerebral haemodynamic compensation. 
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Dietary supplements are intended to supplement the diet with vitamins and minerals when the 
body is not provided with sufficient levels for both exogenous and endogenous reasons such 
as individual diets and malabsorption, respectively. There has however been a shift in 
motivations behind supplement use; from prevention and treatment of diagnosed deficiencies 
to simply improving and maintaining overall health (Bailey, Gahche, Miller, Thomas, & Dwyer, 
2013; Jenkins et al., 2018). The growing interest surrounding the association between 
multivitamins and better cognitive and physiological functioning (Kennedy & Haskell, 2011) 
and the potential of multivitamins and minerals to reduce the risk of chronic diseases 
(Blumberg, Bailey, Sesso, & Ulrich, 2018) has contributed to this motivational change. 
Consequently, dietary supplements are more frequently used by those who already have 
nutrient-rich diets and healthier lifestyles than those who do not use supplements (Bailey, 
Fulgoni, Keast, & Dwyer, 2012).  
 
Iron deficiency (ID) is the most prevalent nutrient deficiency worldwide and is considered the 
most significant contributor to anaemia onset (World Health Organisation, 2008). Iron 
deficiency and iron deficiency anaemia (IDA) may be asymptomatic or may present with a 
host of symptoms including weakness and fatigue. Consequently, iron supplementation trials 
have been of increased interest worldwide to combat its prevalence. Such trials have largely 
focused upon pregnant women and infants as they are considered most at risk of developing 
IDA due to increased physiological and developmental needs. This IDA can occur despite iron 
homeostasis adaptations to meet the increased need (Fisher & Nemeth, 2017; Lönnerdal, 
2017), whereas in iron-replete individuals such adaptations can enhance the vulnerability to 
exceeding the tolerable upper limit of iron (Brannon & Taylor, 2017). Evidence supports a  
U-shaped risk curve associated with iron where both low and high iron status contribute to 
adverse events such as low birth weight, small for gestational age, preterm delivery in 
response to low and high maternal iron status during pregnancy (Brannon & Taylor, 2017; 
Dewey & Oaks, 2017), impaired cognitive neurodevelopment (Georgieff, 2011; Lozoff et al., 
2006; Lozoff & Georgieff, 2006) and cumulative high brain iron resulting in neurodegenerative 
disease later in life (Agrawal, Berggren, Marks, & Fox, 2017). 
 
This introduction aims to outline the various functions of iron in the human body and the 
associated physiological and behavioural effects. Evaluation of iron status parameters and 
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several factors involved with supplementation will also be discussed, alongside dietary 
sources and the biochemistry of iron homeostasis.   
 
1.2 Dietary sources and classification of iron deficiency and IDA  
 
Iron is an essential trace element for humans as it cannot be synthesised by the body and 
must therefore be obtained from the diet. Fortunately, iron is in abundance in the natural 
environment with both plants and animals contributing to human dietary iron requirements. 
Average dietary iron consumption consists of approximately 5-15 mg/day of elemental iron – 
the total amount of iron available for absorption by the human body. This comprises haem and 
non-haem iron, yet the small intestine only absorbs approximately 1-2 mg/day (Zhu, 
Kaneshiro, & Kaunitz, 2010). Haem iron derives from the proteolytic digestion of animal 
sourced haemoglobin and myoglobin whereas non-haem iron is most abundant in plants such 
as dark green leafy vegetables and non-animal products such as breads, cereals, legumes, 
nuts and seeds (Saunders, Craig, Baines, & Posen, 2013). Although haem iron only 
constitutes 10 % of dietary iron consumed by omnivores, its tightly sequestered structure 
within a protoporphyrin ring ensures a greater bioavailability (20-30 % absorbed) than the less 
tightly sequestered non-haem form (1-10 % absorbed) (Anderson & Frazer, 2017; Beck, 
Conlon, Kruger, & Coad, 2014). Non-haem iron absorption is negatively affected by dietary 
components such as polyphenols, phytates, and tannins, but benefits from the action of small 
organic acids such as citric and ascorbic acid to ensure solubility and successful absorption 
(Anderson & Frazer, 2017).  
 
Iron status thresholds vary dependent upon age, sex and pregnancy. For all individuals, when 
the body’s ability to absorb iron from the diet is diminished and the demand or loss of iron is 
great, the body must rely on mobilisation of serum ferritin iron stores. Therefore, during this 
negative iron balance only serum ferritin concentrations decrease whilst all other iron status 
biomarkers remain stable. This is the first stage of ID and is often undiagnosed due to other 
normal haematologic indices. Upon depletion of these iron stores however, a progressive 
decrease in serum iron, transferrin saturation and hepcidin coupled with an increase in total 
iron-binding capacity (TIBC) and soluble transferrin receptors (sTfR) is documented (Sheikh, 
Hantoushzadeh, Shariat, Farahani, & Ebrahiminasab, 2017). Haemoglobin is one of the final 
biomarkers to be affected and respectively decrease (Figure 1.1); thresholds have been 
established for specified population groups to define anaemia (Table 1.1). Although 
haemoglobin is essential for diagnosing anaemia, the measurement of haemoglobin alone is 




Figure 1.1 The progression of iron deficiency and associated haematological changes associated with each stage. 
From ‘Nutritional anaemias: tools for effective prevention and control’ by World Health Organisation, 2017. 
 
Anaemia can be microcytic (insufficient haemoglobin production; IDA), normocytic (decreased 
blood volume and/or decreased erythropoiesis, e.g., haemoglobinopathies) or macrocytic 
(insufficient cell production and/or maturation, e.g., mega/non-megaloblastic anaemia) in 
nature; therefore, each is associated with a differential diagnosis, yet haemoglobin is reduced 
in all (Moreno Chulilla, Romero Colás, & Gutiérrez Martín, 2009). For an accurate assessment 
of iron status and diagnoses of ID and IDA at a population level, it is recommended to measure 
serum ferritin and sTfR alongside haemoglobin (World Health Organisation, 2007). Within 
intervention studies, it is recommended to use serum ferritin and haemoglobin (World Health 
Organisation, 2007). World guidelines currently define ID in adults, regardless of sex, as 
serum ferritin < 15 µg/L, and in children under 5 years of age when serum ferritin is < 12 µg/L 
unless presented with coexistent inflammation when ferritin is < 30 µg/L (World Health 
Organization, 2011b). These thresholds are to be considered alongside those for haemoglobin 
(Table 1.1) to determine iron sufficient (IS; haemoglobin above anaemic threshold), non-
anaemic iron deficient (NAID; haemoglobin above anaemic threshold) and IDA (haemoglobin 
below anaemic threshold) iron status groups. As serum ferritin is also a known acute phase 
protein (APP), its production can be altered in response to infection or inflammation as in 
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normocytic anaemia of chronic disease (Nairz, Theurl, Wolf, & Weiss, 2016). Therefore, 
measuring markers of inflammation such as C-reactive protein (CRP) is recommended to 
adjust serum ferritin concentrations accordingly or to exclude individuals with elevated 
inflammation from controlled studies (Namaste et al., 2017).  
 
Table 1.1 Haemoglobin thresholds used to define anaemia at sea level. Adapted from Haemoglobin concentrations 
for the diagnosis of anaemia and assessment of severity by World Health Organisation, 2011 
Population group Haemoglobin cut-off (g/L) 
Children 
➢ Aged 6 – 59 months 
➢ Aged 5 – 11 years 







➢ Non-pregnant women (aged ≥ 15 years) 





Men (aged ≥ 15 years) 130 
  
 
1.3 Absorption and homeostasis of non-haem and haem iron  
 
In the human body, non-haem iron can either present itself as soluble ferrous (Fe2+) or 
insoluble ferric (Fe3+) iron. Under physiological pHs, oxidised Fe3+ is the most stable form of 
iron, however this is not beneficial to iron absorption. Fe3+ may bind to transferrin to form 
transferrin-bound iron (TBI), which is soluble for transport into the cell. Alternatively, the acidic 
pH in the proximal duodenum promotes the reduction of Fe3+ to absorbable Fe2+ by the ferric 
reductase enzyme duodenal cytochrome B at the apical membrane of the enterocytes in the 
intestinal lumen (Ems & Huecker, 2020). The production of gastric acid is essential to 
successful iron absorption as although haem iron is absorbed independently of pH, non-haem 
iron requires an acidic pH to be absorbed (Tempel, Chawla, Messina, & Celiker, 2013). Fe2+ 
can then be absorbed into the cell by the iron importer divalent metal transporter 1 (DMT1) 
(Figure 1.2). Although haem iron is absorbed with greater efficacy, there is still disparity as to 
the exact mechanism responsible. Haem iron passes directly across enterocyte brush borders 
through haem-specific receptor mediated endocytosis (Silva & Faustino, 2015). It is postulated 
that intestinal haem is transported into the endocyte cytosol by haem carrier protein 1 
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(Shayeghi et al., 2005) or haem responsive gene 1 (Rajagopal et al., 2008) and is then 
metabolised by haem oxygenase 1 to produce Fe2+ (Jian Wang & Pantopoulos, 2011). 
However, in approximately one of 200-250 people, HFE gene mutations in the autosomal 
recessive disorder hereditary haemochromatosis (HH) lead to excess absorption of non-
transferrin-bound iron by cardiomyocytes, hepatocytes and pancreatic islet cells (Golfeyz, 
Lewis, & Weisberg, 2018). This state of iron overload causes symptoms including abdominal 
and joint pain, fatigue, diabetes and heart failure (Golfeyz et al., 2018). 
 
 
Figure 1.2 Schematic diagram of iron transport into the cells. Fe3+ can be reduced to absorbable Fe2+ in the 
duodenum to facilitate direct transfer into cells through DMT1. Extracellular Fe3+ may chelate plasma transferrin 
to form soluble transferrin bound iron (TBI) to facilitate its transport into cells. TBI binds to transferrin receptor 1 
(TFR1) on the precursor cell surface initiating endocytosis of the TBI/TFR1 complex. The acidic environment of the 
endosome disassociates and reduces Fe3+ to Fe2+, which is transported by DMT1 into the cytosolic labile iron 
pool. Fe2+ may then be destined for storage within ferritin, exported out of the erythroid cells by ferroportin and 
oxidised to Fe3+ by ferroxidase, or for metabolic utilisation within mitochondria (Liu, Fan, Yang, Wang, & Guo, 
2018). 
In the cytoplasm of the enterocyte, Fe2+ ions may be sequestered within the iron-storage 
protein ferritin as Fe3+ within a ferrihydrite structure if iron is not immediately required 
elsewhere (Ems & Huecker, 2020). If iron is required outside of the enterocyte, ferroxidase 
activation of ferritin monomers mobilises Fe2+ ions out of the ferrihydrite structure, across the 
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basolateral membrane and through the transmembrane protein ferroportin into circulation to 
bind transferrin (Ems & Huecker, 2020; Silva & Faustino, 2015). Transferrin bound iron is 
mostly utilised by erythrocyte precursors in the bone marrow to support the daily production 
of approximately 200 billion red blood cells (RBCs) (Knutson, 2017). In humans, RBCs remain 
in the circulation for approximately 120 days before reaching senescence and their 
subsequent removal by circulating macrophages (de Back, Kostova, van Kraaij, van den Berg, 
& van Bruggen, 2014). Senescent RBC haemoglobin is degraded to haem and to prevent its 
intracellular cytotoxicity it is then degraded to Fe2+ (Chiabrando, Vinchi, Fiorito, Mercurio, & 
Tolosano, 2014; Gottlieb, Truman, Cohen, Leichtmann-Bardoogo, & Meyron-Holtz, 2012). 
This may be stored as ferritin or released into the circulation to be recycled in the process 












Figure 1.3 Schematic of the main cells involved in systemic iron homeostasis. Fe2+ is imported into erythroid 
mitochondria to synthesise haem. This is exported out of the mitochondria for incorporation into haemoproteins 
such as haemoglobin in newly synthesised red blood cells. Senescent or damaged RBCs are removed from the 
circulation macrophages of the liver, spleen and bone marrow, by erythrophagocytosis. Macrophages endocytose 
the senescent RBCs into the phagosome, which fuse with lysosomes forming erythrophagolysosomes, where 
RBCs and its haemoglobin are degraded to haem. Haem oxygenase 1 degrades cytosolic haem into Fe2+, which 
may be stored in ferritin or exported out of the macrophage by ferroportin to be returned to the bone marrow as 
TBI for reincorporation into erythrocyte precursors for further haem synthesis. Hepcidin is produced by hepatocytes 
to regulate iron absorption by binding to ferroportin to induce its internalisation and degradation. Liver sinusoidal 
endothelial cells detect fluctuations in iron stores and augment BMP6 expression, which activates the BMP-SMAD 
pathway for hepcidin activation (Knutson, 2017) 
 
Iron levels in the human body are tightly controlled by the circulating peptide hormone 
hepcidin, produced by hepatocytes, which is up or downregulated by the liver’s ability to detect 
intra- and extracellular iron. Hepcidin binds to ferroportin expressed on enterocytes, 
macrophages and hepatocytes to induce its internalisation and degradation (Nemeth et al., 
2004) forcing Fe2+ ions into ferritin stores rather than into the circulating plasma (Ems & 
Huecker, 2020). Therefore, when iron stores are low hepcidin is downregulated, potentiating 
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an increase in ferroportin on the cell surface for greater Fe2+ ions efflux into the circulation. 
Liver sinusoidal endothelial cells detect fluctuations in iron stores and augment BMP6 (bone 
morphogenetic protein 6) expression, which activates the BMP-SMAD pathway for hepcidin 
activation (Rausa et al., 2015; Silvestri, Nai, Dulja, & Pagani, 2019). This pathway is also 
required in states of inflammation during which iron level fluctuations no longer drive hepcidin 
production; interleukin-6, an inflammatory cytokine released by macrophages during 
inflammation, stimulates hepcidin production and ferroportin downregulation (D'Angelo, 2013).  
 
1.4 The functions of iron in the body  
 
As described in section 1.3, iron is tightly regulated within the human body to ensure 
appropriate intra- and extracellular concentrations. It is reasonable to suggest that when 
homeostasis is disturbed, knock-on effects occur across cellular functioning. Iron deficiency 
and IDA may be asymptomatic or may comprise non-haematological symptoms including 
weakness, fatigue, mood changes, behavioural disturbances, an impaired immune response, 
reduced exercise endurance and impaired cognitive function (Beard, 2001; Beard & Connor, 
2003). Similarly, iron accumulation is considered a hallmark of many neurodegenerative 
diseases including Alzheimer’s disease, Parkinson’s disease, multiple system atrophy and 
Huntington’s disease (Ndayisaba, Kaindlstorfer, & Wenning, 2019). Such detrimental effects 
are believed to be a result of iron dyshomeostasis and the essential role iron must play as a 
modulator of various cellular processes in tissues.   
 
 1.4.1 Iron modulates the immune response 
 
As iron is an essential mineral for human health, it is unsurprising that it is a vital component 
in various metabolic processes in the human body but also every living organism. However, 
despite its abundance in the environment, iron is often considered a growth limiting factor due 
to its existence as an insoluble ferric oxide (Abbaspour, Hurrell, & Kelishadi, 2014). 
Consequently, microbes, yeasts and fungi have adopted various mechanisms to capture iron 
in its most suitable form for biological function; for example, bacteria synthesise highly specific 
Fe3+ complexing siderophores to scavenge iron (Ward et al., 2011); yeasts and pathogenic 
fungi use siderophore synthesis and transport for non-reductive iron uptake alongside 
mechanisms of reducing ferric iron to ferrous iron (Bairwa, Hee Jung, & Kronstad, 2017).  
Similarly, the human body recognises the importance of metal ions for such pathogenic 
proliferation and subsequently has evolved various sophisticated strategies to combat 
bacterial invasion by reducing available iron for bacterial propagation. The recycling of iron, 
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as shown in Figure 1.3 is important for conserving a suitable amount of iron for the needs of 
the human body without excess availability for invading pathogens. Indeed, many of the genes 
and proteins that are involved in iron homeostasis as discussed above also have related 
immunological functions to infection and inflammation (Johnson & Wessling-Resnick, 2012; 
Porto & De Sousa, 2007). The two central players involved in the sequestration of iron for 
immune function are hepcidin and ferroportin. In response to an immune attack by an 
extracellular pathogen such as Escherichia coli, hepcidin expression is upregulated by IL-6 to 
bind ferroportin to induce the internalisation and lysosomal degradation of the complex 
(Nemeth et al., 2004). Iron is thereby retained within enterocytes and macrophages resulting 
in hypoferremia and normal to elevated ferritin preventing invading extracellular pathogens 
from thriving off otherwise circulating iron. In contrast, intracellular pathogens like Salmonella 
and Legionella promote the downregulation of ferroportin in favour of the need to retain iron 
within the macrophage for its own use (Paradkar et al., 2008; Willemetz et al., 2017). However, 
in response to such pathogens, hepcidin expression is again upregulated to induce the 
degradation of ferroportin, though this effect is outweighed by a larger induction of ferroportin 
transcription (Manfred Nairz, Haschka, Demetz, & Weiss, 2014). Subsequently, iron export is 
increased, and intracellular iron depleted to prevent intracellular pathogen proliferation.  
 
Macrophages also secrete the iron-binding glycoproteins lactoferrin and lipocalin-2 for the 
modulation of extracellular iron in response to pro-inflammatory cytokines. Lactoferrin can 
sequester free iron to disrupt pathogen propagation (Legrand & Mazurier, 2010). The protein 
has demonstrated antimicrobial activity with its ability to enhance phagocytosis, inhibit 
biofilms, modify microbe-host interactions, and induce apoptosis (Siqueiros-Cendón et al., 
2014). Lipocalin-2, however, directly binds to certain siderophores in their iron-laden or iron-
free forms; for example, enterobactin secreted by E. coli and Salmonella and mycobactin 
secreted by Mycobacterium tuberculosis (Berger et al., 2006) (Johnson et al., 2010). Lipocalin-
2 knockout mice are thus shown to have an increased sensitivity to both extracellular and 
intracellular pathogenic infection due to its antibacterial function and its role in maintaining 
proper immune functionality through modulating normal macrophage function and neutrophil 
maturation (Guglani et al., 2012; Wang et al., 2019).  
 
By consequence of immune activation affecting iron distribution, it is often difficult to 
distinguish between absolute ID and functional iron homeostasis disturbances. Additionally, 
both absolute and functional deficiency may coexist, leading to challenges in interpreting iron 
status as serum ferritin is elevated under inflammatory conditions. Absolute ID and overload 
can however negatively affect immune function. Experimental evidence indicates a 
fundamental role of iron in normal development of the immune system due to its essential role 
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in immune cell proliferation (Hassan et al., 2016). The cell-mediated immune response is 
affected by ID as there is a decrease in T-lymphocyte numbers and increased dysfunction 
leading to significantly lower concentrations of pro-inflammatory cytokines like IL-6 (Aly, 
Fayed, Ismail, & Abdel Hakeem, 2018; Attia, Essa, Nosair, Amin, & El-Agamy, 2009; Beard, 
2001; Ekiz, Agaoglu, Karakas, Gurel, & Yalcin, 2005). Iron is also necessary for monocyte 
and macrophage differentiation (Collins, 2003) and acts as a cofactor in the oxidative burst 
mechanism for eliminating bacterial invasion (Slauch, 2011); thus, during ID, such bactericidal 
activity is attenuated. However, the effects of ID upon humoral immunity remain controversial; 
it is suggested to be less affected in comparison to its cell-mediated counterpart (Beard, 2001; 
Kuvibidila, Kitchens, & Baliga, 1999), yet evidence in children and pregnant women also 
suggests decreased immunoglobulin G (IgG) concentrations (Ekiz et al., 2005; Feng, Yang, & 
Shen, 1994; Hassan et al., 2016; Tang et al., 2006). However, in non-pregnant women of 
reproductive age with IDA, serum immunoglobulins were not significantly lower than controls 
(Sadeghian et al., 2010). In iron overload it is instead postulated that both the cell-mediated 
and humoral immune responses are altered as T-cell numbers are reduced, affecting B-cell 
function (Walker & Walker, 2000). A dysregulated immune response is shown to affect social 
behaviours and promote neuropsychiatric disorders such as depression, schizophrenia and 
autism spectrum disorders (Gibney & Drexhage, 2013; Takahashi, Flanigan, McEwen, & 
Russo, 2018). Animal and human studies have also indicated a role for immune cells in 
cognitive function. Depletion of the cell-mediated immune response in adult mice significantly 
impairs spatial learning and memory (Kipnis, Cohen, Cardon, Ziv, & Schwartz, 2004), as does 
transfusing immune cells from older mice into younger mice (Brynskikh, Warren, Zhu, & 
Kipnis, 2008). Respectively, transferring immune cells or blood from young mice can reverse 
the impairments in cognitive function (Villeda et al., 2011; Villeda et al., 2014). In healthy older 
adults, lower numbers of CD4+ T cells are associated with better cognitive performance, as 
they are the major pro-inflammatory cytokine producer among T cells (Serre-Miranda et al., 
2015) and are associated with reduced hippocampal neurogenesis (Wolf et al., 2009). It is 
postulated that chronic inflammation-stimulated microglial activation induces the amplification 
of additional pro-inflammatory cytokines and reactive oxygen species (ROS) causing 
enhanced neuronal iron uptake (Wang, Song, Jiang, Wang, & Xie, 2013). Iron accumulates in 
a region-specific manner in the ageing brain; increased microglial iron content and the 
deposition of insoluble protein aggregates that colocalise iron are associated with 
neurodegeneration in Alzheimer’s disease and Parkinson’s disease (Ndayisaba et al., 2019). 
Overall, iron plays a key role in pathogenic survival, however the human body has developed 
efficient mechanisms to overcome such attacks. Yet when iron status is compromised, tipping 
the optimal level to a deficient or overload status, immunological function may also be 
compromised to allow increased proliferation of infectious organisms and induce deleterious 
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effects on brain function and behaviour. Similarly, reduced immune activation can preserve 
cognitive function in the ageing brain.  
 
1.4.2 Iron modulates DNA metabolism and mitochondrial function  
 
One of the mechanisms postulated to account for the detrimental effect of ID on the immune 
system is iron-sensitive DNA metabolism. Iron-sulphur clusters function as cofactors for 
enzymes important for successful DNA synthesis and repair including replicative DNA 
polymerases and primases, DNA helicases, nucleases, glycosylases and demethylases 
(Puig, Ramos-Alonso, Romero, & Martinez-Pastor, 2017). Ribonucleotide reductase (RNR) 
similarly is an iron-dependent enzyme responsible for the catalysis of the rate-limiting step in 
the de novo synthesis of deoxyribonucleoside triphosphates (dNTPs) necessary for DNA 
synthesis, replication and repair (Sanvisens, Bano, Huang, & Puig, 2011). Iron deficiency 
decreases the amount of iron available for its cofactor role, though the mechanisms used to 
adapt towards such a deficiency to continue successful DNA metabolism require further 
investigation. In iron deficient states, yeasts and bacteria are shown to replace  
iron-dependent cellular processes with iron-independent alternatives (Sergi Puig, Vergara, & 
Thiele, 2008) or by reducing the cellular demand for iron, respectively (Masse, Salvail, 
Desnoyers, & Arguin, 2007). Such mechanisms are not possible in mammalian systems due 
to the requirement of iron as a cofactor (Sanvisens et al., 2011); although, there is evidence 
to suggest potential strategies for preferential optimisation of RNR over other iron-using 
processes as its activity is either stable or increased when ID is in its early stages (Furukawa, 
Naitoh, Kohno, Tokunaga, & Taketani, 1992).  
 
Iron deficiency and iron overload increase oxidative stress through mitochondrial dysfunction. 
Iron deficiency anaemia is associated with a greater degree of DNA damage in comparison to 
healthy controls and this significantly correlates with the severity of IDA and oxidative stress 
(Aslan et al., 2006). Excess iron accumulation can be cytotoxic, generating increased ROS to 
induce DNA damage, which may eventually lead to cell apoptosis (Nakamura, Naguro, & 
Ichijo, 2019). Iron deficiency and overload disrupt iron-sulphur cluster formation and mediation 
of electron transfer in the respiratory electron transport chain for adenosine triphosphate (ATP) 
generation (Paul, Manz, Torti, & Torti, 2017). Mitochondrial damage also infers a reduction in 
haem for oxygen transport, decreased respiratory control and decreased gluconeogenesis 
(Klempa, Willis, Chengson, Dallman, & Brooks, 1989; Masini et al., 1994); dysfunction of these 
cellular functions is known to be a direct cause of moderate to severe fatigue (Nicolson, 2014). 
This is bolstered by experimental evidence suggesting that iron deficiency provokes a hypoxic 
response in human cardiomyocytes causing mitochondrial dysfunction, diminished ATP 
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production and impaired contractility by consequence of reduced iron-sulphur complex activity 
(Hoes et al., 2018). Energy depletion because of ID is also shown to affect dendritic 
mitochondrial motility in the hippocampus during neuronal development (Bastian, von 
Hohenberg, Georgieff, & Lanier, 2019). Such evidence may be relevant to cognitive and 
behavioural impairments and brain functions in neurodegenerative and neuropsychiatric 
diseases inflicted by changes in brain iron homeostasis, mitochondrial functioning and 
subsequent energy metabolism (Manji et al., 2012; Streck et al., 2014; Wu, Chen, & Jiang, 
2019) 
 
1.4.3 Iron modulates oxygen transport 
 
In humans, myoglobin and haemoglobin are the primary oxygen-binding metalloproteins. Both 
contain iron but function differently; myoglobin is an oxygen storage protein providing oxygen 
to muscle tissue whereas haemoglobin is involved in oxygen transport from the lungs to 
peripheral tissues (Corey, Kimmel, & Leonard, 2014). The primary species of normal adult 
haemoglobin is haemoglobin A, which accounts for approximately 92 % of all total 
haemoglobin concentrations (Pittman, 2011). Haemoglobin is a tetramer, consisting of four 
globin chains; two alpha chains and two beta chains (a2b2) each with a haem group located 
in crevices near the exterior of the molecule that bind oxygen to create oxyhaemoglobin 
(Figure 1.4).  
 
Figure 1.4 Schematic of human haemoglobin A molecule; two α-globin chains (green), two β-globin chains (yellow), 
haem moiety consisting of a protoporphyrin ring and a ferrous iron ion. Adapted from Thomas and Lumb (2012). 
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Each haemoglobin molecule can therefore simultaneously bind up to four oxygen molecules. 
Haemoglobin exists in a taut form (T) and a relaxed form (R). Haemoglobin has allosteric 
properties, thus as oxygenation ensues the globin chains alter their shape to the R-form, 
increasing oxygen affinity for the remaining haem groups (Figure 1.5).  
 
 
Figure 1.5 The allosteric properties of haemoglobin initiating structural changes from ‘tense’ to ‘relaxed’. In the 
deoxygenated form, access to the haem molecule is restricted due to the tense structure. When oxygen does bind 
the haem molecule, a structural change is initiated in the haemoglobin protoporphyrin ring. Interactions between 
adjacent globin chains are relaxed to allow easier access by oxygen to the haem molecule (Thomas & Lumb, 
2012). 
This quaternary conformation change is facilitated by an alkaline pH that prompts the 
dissociation of hydrogen bonds and salt bridges, thereby improving oxygen affinity and 
inducing haemoglobin oxygen saturation (Thomas & Lumb, 2012). This can occur in the alveoli 
under high partial pressures and within a high pH environment, yet under acidic conditions, 
such as in the peripheral tissues, the T-form of haemoglobin is favoured. Hydrogen bonds and 
salt bridges are formed between the globin chains ensuring a low affinity for oxygen and 
instead favouring protons, carbon dioxide and organic phosphates, promoting the release of 
oxygen in a process known as the Bohr effect (Dajnowicz et al., 2016). Therefore, when the 
quantity of functional haemoglobin is reduced, anaemic hypoxia may present due to a 
diminished oxygen-carrying capacity of erythrocytes. Consequently, the heart adapts by 
increasing cardiac workload through increases in blood volume, preload, heart rate and stroke 
load, whilst decreasing afterload to deliver an adequate amount of oxygen to the tissues, 
including the brain (Pereira & Sarnak, 2003). This adaptation potentiates a lesser capacity for 
exercise and the occurrence of dyspnoea and fatigue; prolonged and exacerbated IDA can 
cause compromised cardiac function and result in cardiomyopathy or heart failure (Hegde, 
Rich, & Gayomali, 2006). Similarly, increasing cardiac workload has been shown to invoke an 
increase in cerebral blood flow as a neuroprotective compensatory mechanism against IDA to 
enhance cerebral oxygen delivery (Aliefendioglu et al., 2007; Hare, 2004). Neurovascular 
coupling may explain this mechanism as an optimal blood supply to the brain is required for 
the metabolic consumption of oxygen and glucose as neural fuel substrates (Phillips, Chan, 
Zheng, Krassioukov, & Ainslie, 2016). It therefore seems rational for a compound that can 
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modulate oxygen transport and cardiovascular function to have secondary effects upon brain 
function.  
 
1.4.4 Iron modulates myelination 
 
Oligodendrocytes are iron-containing glial cells in the central nervous system and are the 
principal cells in the brain that stain for iron, which is consistent with knowledge of iron levels 
being greater in myelin-rich white matter than in grey matter (Connor & Menzies, 1996). 
Oligodendrocytes are responsible for myelination of axons, which is required for enabling rapid 
saltatory nerve conduction and axon integrity (Nave & Werner, 2014). Human myelin 
comprises 70 % lipids, 27.7 % of which is cholesterol (Brady, Siegel, Albers, & Price, 2005) 
and iron is a cofactor required for the biosynthesis of each. Similarly, the role of iron in 
oxidative metabolism indirectly affects myelinogenesis. In the developing brain, iron-
containing oligodendrocytes colocalise with the myelinogenic foci; this functional relationship 
between myelin production and iron accumulation is consistent with the observation that the 
highest acquisition of iron in the central nervous system coincides with peak myelination 
(Connor & Menzies, 1996). Iron uptake at peak myelination is associated with its essential 
role in oxidative metabolism (Todorich, Pasquini, Garcia, Paez, & Connor, 2009). Of all cells 
in the brain, oxidative metabolic activity is highest in oligodendrocytes; this is maintained by 
iron-requiring enzymes (i.e., glucose-6-phosphate dehydrogenase) (Cammer, Snyder, 
Zimmerman, Farooq, & Norton, 1982). The pentose-phosphate pathway for glucose 
metabolism is used by oligodendrocytes and reportedly 60 % of glucose used by the brain 
during peak myelination is metabolised via this pathway (Connor & Menzies, 1996). Following 
maximal rates of myelination, the amount of glucose utilised by the pentose phosphate 
pathway reduces to 25 % and iron consumption is reduced despite no decrease in iron staining 
or utilisation (Cammer, 1984; Todorich et al., 2009). As iron is clearly involved in optimal 
oligodendrocyte function, ID can lead to hypomyelination during brain development. Animal 
and human studies have provided support for this (Algarín, Peirano, Garrido, Pizarro, & Lozoff, 
2003; Ortiz et al., 2004; Roncagliolo, Garrido, Walter, Peirano, & Lozoff, 1998; Yu, 
Steinkirchner, Rao, & Larkin, 1986), and there is increasing evidence to suggest that 
oligodendrocytes continue to require a steady iron supply to maintain a consistent metabolic 
rate. Restricting dietary iron in the postweaning period (postnatal days 21-63) of rats 
significantly reduces markers of myelination and oligodendrocyte metabolic activity in the 
cerebrum and hindbrain (Beard, Wiesinger, & Connor, 2003). This suggests that beyond early 
brain development, postnatal ID can affect the production and maintenance of myelin as 
oligodendrocytes require a consistent supply of iron to meet their metabolic needs. Myelin 
deficits in humans reduce information processing speed across the nervous system, which is 
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essential for higher-order cognitive functions, including attention, learning, memory, planning, 
moderating social behaviours and regulating mood (Nickel & Gu, 2018). This implies an 
essential role of iron across the lifespan for myelin facilitation of whole brain neuroplasticity, 
brain function, behaviours and mood.  
 
1.4.5 Iron modulates neurotransmission 
 
Brain maturation extends from childhood and adolescence through to adulthood and includes 
changes in neurotransmitter systems; the development and maturity of the monoaminergic 
neurotransmitter systems exhibit a higher sensitivity spanning childhood and adolescence 
(Pitzer, 2019). During this time period, concentrations of monoamine transporters and 
receptors are continuously modified, initially playing important roles in axonal growth and 
synapse formation and switching to the role of neurotransmission with age (Beard, 2003). 
Altered levels of neurotransmitters are associated with several health conditions. 
Dopaminergic and noradrenergic systems’ dysfunction has been associated with attention 
deficit hyperactivity disorder (ADHD) (Konofal et al., 2008) and schizophrenia (Insel, Schaefer, 
McKeague, Susser, & Brown, 2008); coupled with the white matter changes associated with 
lipid and cholesterol synthesis dysfunction causing profound myelin and oligodendrocyte 
abnormalities (Davis et al., 2003). Additionally, dysfunction of serotonergic, noradrenergic 
and/or dopaminergic systems underlies the monoamine hypothesis of the pathophysiology of 
depression (Delgado, 2000), whilst increased anxiety is also associated with dysfunction of 
serotonergic and noradrenergic systems as a consequence of altered hippocampal brain-
derived neurotrophic factor (BDNF) signalling (Texel et al., 2012).  
 
The synthesis of monoamines serotonin, dopamine and noradrenaline begins with amino acid 
tryptophan hydroxylase (serotonin) and tyrosine hydroxylase (dopamine and noradrenaline). 
Both enzymes are non-haem iron-dependent monooxygenases responsible for the catalysis 
of the iron-mediated incorporation of molecular oxygen into the amino acid substrate and the 
reducing substrate tetrahydrobiopterin to give the hydroxylated products L-DOPA and 5-
hydroxytryptophan, which are converted into dopamine (and subsequently noradrenaline) and 
serotonin respectively (Roberts & Fitzpatrick, 2013). Certainly, it is to be expected that as iron 
modulates monoamine synthesis through its co-factor role, that a reduction in iron for this iron-
dependent neurotransmitter synthesis pathway would result in a decline in neurotransmitter 
production and activity. Although, it is argued that brain ID rarely causes a reduction in the 
activity of these enzymes (Youdim, Ben-Shachar, & Yehuda, 1989) suggesting a method of 
iron conservation for efficient enzyme function in iron deficient states. Recent evidence 
suggests that in those with ID, lowered serum tryptophan concentrations are available for the 
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rate-limiting initial step in serotonin synthesis (Wenninger et al., 2019), which may 
subsequently contribute to the development of mood disorders.  
 
Changes in brain iron levels due to ID have demonstrated a relationship with impaired 
emotional behaviours through altered monoaminergic metabolism. Iron deficiency has a 
universally negative impact upon monoamine production but specific to brain region and stage 
of neural development (Kim & Wessling-Resnick, 2014). Severe ID in children and young 
adults has been shown to affect dopamine frontal-striatal circuits and subsequently 
neurocognitive and motor functioning (Algarin et al., 2013; Lozoff, 2011). Animal studies have 
also identified down-regulation of dopamine receptors 1 (D1) and 2 (D2) in the striatum and 
prefrontal cortex in ID (Erikson, Jones, Hess, Zhang, & Beard, 2001). D2 regulates dopamine 
clearance via dopamine transporter (DAT), where the activity and density in an ID state can 
be downregulated to increase striatal dopamine (Meiergerd, Patterson, & Schenk, 1993). 
Extracellular dopamine is also elevated in the caudate putamen and nucleus accumbens due 
to decreased DAT density (Nelson, Erikson, Pinero, & Beard, 1997) yet is reduced in in the 
prefrontal cortex in comparison to IS controls, which is suggested to be echoed by increased 
anxiety (Li et al., 2011). By consequence of dopamine dysregulation, newly diagnosed IDA 
patients aged 45 years and above have demonstrated a greater risk of developing Parkinson’s 
Disease four or more years after the initial anaemia diagnosis (Hong et al., 2016). Low serum 
ferritin and increased serum hepcidin have also been associated with ADHD (Wang, Huang, 
Zhang, Qu, & Mu, 2017; Yazici, Yazici, & Ustundag, 2019).   
 
Concentrations of extracellular noradrenaline are also elevated by consequence of ID. 
Dopamine--hydroxylase activity is increased by 75 % in caudate homogenates of iron 
deficient rats in comparison to controls, increasing noradrenaline concentrations (Bianco, 
Wiesinger, Earley, Jones, & Beard, 2008). This hydroxylase would normally produce 
noradrenaline from dopamine; thus, its elevation is postulated to be a compensatory 
mechanism for brain ID and the altered dopamine response (Bianco et al., 2008). Results are 
however conflicting regarding the impact ID has on serotonin concentrations. Rat studies have 
shown both reductions (Shukla, Agarwal, Chansuria, & Taneja, 1989) and increases in 
serotonin (Mackler, Person, Miller, Inamdar, & Finch, 1978) following ID, whilst no significant 
differences in prefrontal cortex concentrations in comparison to controls have been shown (Li 
et al., 2011). However, it is interesting to note that the prevalence of IDA is more frequent 
amongst psychiatric patients in comparison to the general population (Korkmaz et al., 2015), 
whilst low serum ferritin and haemoglobin concentrations have been associated with both 
depressive and anxiety disorder incidence (Lever-van Milligen, Vogelzangs, Smit, & Penninx, 
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2014; Vahdat Shariatpanaahi, Vahdat Shariatpanaahi, Moshtaaghi, Shahbaazi, & Abadi, 
2007).  
 
Beyond the monoaminergic system, ID can disrupt the balance between inhibitory and 
excitatory neurotransmitters, -aminobutyric acid (GABA) and glutamate, respectively 
(Ferreira, Neves, & Gozzelino, 2019). Iron deficiency causes elevation of GABA in the 
hippocampus; this is suggestive of an increased inhibitory drive for reducing 
neurotransmission and subsequent brain activity when energy is limited (Rao, Tkac, 
Townsend, Gruetter, & Georgieff, 2003). The excitatory role of glutamate is subsequently 
dampened by ID due to a decrease in glutamate decarboxylase and glutamate 
dehydrogenase (Mittal, Pandey, Mittal, & Agarwal, 2003). Animal models have identified ID-
associated elevations in glutamate in prenatal and postnatal models, suggesting an increased 
synthesis or a decreased release from the neurons (Rao et al., 2003). However, glutamatergic 
neurotransmission utilises >80 % of the total energy expenditure in the brain (Attwell & 
Laughlin, 2001) and it is therefore postulated that glutamatergic neurotransmission is 
decreased in ID because of inefficient energy metabolism (Rao et al., 2003). Coupled with a 
decrease in glutamate catalytic enzymes, and a reduction in glutamate binding synaptic 
membranes (Agarwal, 2001), this leads to high intracellular glutamate levels yet an attenuation 
of glutamatergic signalling in ID. Together, these findings suggest that neurotransmitter 
pathways are influenced by iron status, which can have detrimental effects upon neural activity 
inducing changes in cognition and mood.  
 
1.4.6 Summary of functions 
 
There is a large body of evidence to suggest the essential role of iron in a plethora of 
fundamental cellular functions amongst living organisms. To ensure its longevity, the human 
body has developed protective mechanisms to control iron levels to combat its central role in 
pathogen propagation. Additionally, iron acts as an essential cofactor for DNA metabolism 
and mitochondrial function, resulting in optimum ATP generation for cellular processes. The 
essential role of iron in haemoglobin and myoglobin synthesis is important for oxygen transport 
to the tissues and muscles. Furthermore, there is evidence to suggest an abundant 
requirement of iron in the brain for optimal oligodendrocyte function throughout the lifespan 
and for the development and maintenance of neurotransmitter systems. Disruption of optimal 
iron levels is shown to impair these fundamental biological parameters and diminish brain 
function, behaviour, mood and fatigue.  
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1.5 The behavioural effects of iron 
 
Due to the essential role held by iron in the human body, numerous observational and 
randomised controlled trials (RCTs) have been conducted to explore the impact of iron and 
iron status on brain function, behaviour, mood and fatigue. As stated previously, infants and 
pregnant women are most at risk of ID; however, non-pregnant women of reproductive age 
are also at risk due to suboptimal iron consumption and menstrual blood losses, with >20 % 
experiencing ID during their lives (Harvey et al., 2005; Percy, Mansour, & Fraser, 2017). 
Consequently, the majority of iron supplementation research focusses upon infants and 
pregnant women due to the clinical nature and the previous notion that ID can only affect brain 
functioning during neurodevelopment (Beard, 1995; Hermoso et al., 2011). However, the 
brain’s plastic nature allows it to adapt both structurally and functionally beyond infancy, 
highlighting that an iron insult can detrimentally affect neural functioning at any time of life 
(Oberman & Pascual-Leone, 2013). The following sections will therefore review the current 
literature surrounding the behavioural effects of iron in infants, older children, pregnant women 
and non-pregnant women of reproductive age of varying iron status.  
 
1.5.1 The role of iron in mood 
 
Iron deficiency has previously been associated with mood disorders such as depression and 
anxiety. Depression is considered an affective disorder that is characterised by negative 
feelings affecting daily functioning; over 264 million people of all ages suffer from depression 
and it is currently the leading cause of disability worldwide (James et al., 2018), with incidence 
twice as common in women than in men (Ma, Xu, Wang, & Li, 2019). A possible mechanism 
responsible for this involves the serotonergic system. The serotonin receptor 5-HT1A 
modulates the release of serotonin to be cleared by serotonin transporters (SERT). Positron 
emission tomography scans of healthy women indicate a higher density of 5-HT1A receptors 
and a lower density of SERT in comparison to healthy men (Jovanovic et al., 2008). This is 
also demonstrated in those with depression as SERT are significantly decreased in depressed 
women whereas no significant differences are demonstrated between depressed and healthy 
men (Staley et al., 2006). As women are more at risk for ID than men, this highlights a potential 
role of iron in the aetiology of depression as IDA is associated with increased reports of 
depressive symptoms in women (Pamuk et al., 2015; Vahdat Shariatpanaahi et al., 2007), 
and to a lesser extent in men (Hidese, Saito, Asano, & Kunugi, 2018; Yi et al., 2011). Animal 
models have shown lower densities of SERTs in the striatum of iron deficient mice (Morse, 
Beard, Azar, & Jones, 1999), which may be responsible for a decreased serotonin uptake by 
brain synaptic vesicles that can however be corrected following iron supplementation 
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(Kaladhar & Narasinga Rao, 1982). Similarly, dysfunction of the dopaminergic system in ID 
increases extracellular dopamine and downregulates functions of the DAT and D2 receptor in 
the striatum (Erikson, Jones, & Beard, 2000), deficits of which predict reductions in striatal 
functional connectivity in depression (Hamilton et al., 2018). 
 
The prescription of antidepressants has more than doubled over a period of 13 years (Ilyas & 
Moncrieff, 2012), which has largely been driven by an increase in selective serotonin reuptake 
inhibitors (SSRIs) (Mars et al., 2017). Considerable efforts to clarify the role of iron in 
depression’s pathophysiology through dietary interventions have been made, given that 
nutritional interventions are considered inexpensive, safe, easier to administer and are 
generally accepted by patients in comparison to antidepressants (Bodnar & Wisner, 2005). In 
2017, the first nutritional guidelines to curb depression were published recommending a 
Mediterranean diet, rich in omega-3 fatty acids and avoiding processed foods (Opie et al., 
2017) following suggestions for nutritional medicine as a mainstream treatment in psychiatry 
(Sarris et al., 2015). Subsequently, a Mediterranean dietary intervention was associated with 
positive changes in depressive symptoms in adults with major depression (Opie, O'Neil, 
Jacka, Pizzinga, & Itsiopoulos, 2018). This has encouraged the development of a nutrient 
profiling system for depression; analysis revealed iron to be one of the 12 antidepressant 
nutrients related to the prevention and treatment of depression (LaChance & Ramsey, 2018).  
 
Antidepressants are considered the first-line treatment for women with moderate-to-severe 
postpartum depression (PPD) (Kim, Epperson, Weiss, & Wisner, 2014). Post-partum 
depression is a non-psychotic depressive episode that typically arises due to hormonal 
fluctuations following childbirth and the psychological adjustment to motherhood, affecting 
approximately 10-15 % of mothers annually (Anokye, Acheampong, Budu-Ainooson, Obeng, 
& Akwasi, 2018). There is evidence to suggest associations between PPD development and 
having ID with or without anaemia (Albacar et al., 2011; Corwin, Murray-Kolb, & Beard, 2003; 
Etebary, Nikseresht, Sadeghipour, & Zarrindast, 2010; Milman, 2011). A review of evidence 
linking anaemia and/or low ferritin to PPD revealed a higher risk of PPD in anaemic women 
and in those with low ferritin in the postpartum period rather than during pregnancy (Wassef, 
Nguyen, & St-Andre, 2019). By consequence, a decreased risk of PPD following postpartum 
iron supplementation was found, yet if iron supplementation was provided during pregnancy 
no protective effects were observed (Wassef et al., 2019). Potential mechanisms for an 
increased risk of PPD in postpartum women are reflected by changes in monoamine 
neurotransmitter concentrations compared to healthy controls; plasma and serum serotonin 
concentrations are significantly lower in postpartum women whilst noradrenaline is 
significantly higher (Xie, Xie, Krewski, & He, 2018; Yildiz et al., 2017). However, plasma and 
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serum concentrations may not reflect serotonin and noradrenaline levels in the brain. Further 
studies are required to elucidate the association between the risk of PPD in anaemic and iron 
deficient women during the postpartum period; however, a clear association between 
decreased iron levels and PPD presentation is evident. As women naturally suffer from 
detriments to the monoaminergic system in comparison to men, this may be exacerbated in a 
synergistic relationship between depressive and ID conditions; with evidence suggesting that 
PPD symptoms (depression, anxiety and stress) can be improved following iron 
supplementation (Beard et al., 2005; Sheikh et al., 2017; Wassef et al., 2019).  
 
Iron deficiency during pregnancy can be detrimental to foetal well-being. Low maternal iron 
stores are replicated in neonates due to a limited iron-acquisition capacity of the foetus to 
obtain a sufficient iron supply (Jaime-Perez, Herrera-Garza, & Gomez-Almaguer, 2005). 
Evidence suggests low serum ferritin concentrations can continue through to early childhood 
(Hay et al., 2007) with increased vulnerability to anaemia during the first year of life (Scholl, 
2011). Iron deficiency with and without anaemia is associated with increased fearfulness as a 
sign of anxious behaviours in infants, regardless of iron therapy administration (Lozoff, 
Brittenham, Viteri, & Urrutia, 1982). This has also been reflected in animal models with iron 
deficient rats demonstrating increased fearfulness and anxious behaviours in light/dark box 
and maze studies (Beard, Erikson, & Jones, 2002; Li et al., 2011). It is now of increasing 
concern that these mood alterations can persist into adulthood, despite prompt iron repletion 
during infancy (Kennedy, Wallin, Tran, & Georgieff, 2016). There is evidence to suggest that 
adolescents treated for severe, chronic ID in infancy were of more concern to parents and 
teachers through reports of increased symptoms of depression, anxiety, social and attentional 
problems (Lozoff, Jimenez, Hagen, Mollen, & Wolf, 2000). These mood deficits are also 
evident at a follow-up of 25 years from diagnosis, with poorer emotional health increasing 
negative emotions and feelings of dissociation and detachment via behavioural problems 
observed in adolescence (Lozoff et al., 2013). Concurrently, the diagnosis of IDA during 
childhood or adolescence increases the risk of mood disorders including anxiety and 
depression alongside a developmental delay, autism spectrum disorder and ADHD (Chen et 
al., 2013). The explanation behind iron deficits in infancy affecting adolescent and adult mood 
and behaviour is no doubt complex. However, a potential mechanism to account for these 
later differences emerges from the detrimental effects of ID upon the nervous system during 
neurodevelopment. As discussed in section 1.4, ID can impair myelination, neurotransmitter 
function and alter neurometabolism in areas of the brain such as the prefrontal cortex, striatum 
and hippocampus that undergo considerable maturation in the neonatal period. When such 
effects occur during neurodevelopment, it is postulated that they can elicit a cascading effect, 
disrupting fundamental neural processes and inducing the divergence of developmental 
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trajectories away from the norm (Lozoff et al., 2013). For example, the hippocampus is highly 
metabolically active in the early postnatal period and IDA animal models have demonstrated 
altered neural metabolic activity that persists into adulthood regardless of iron repletion 
(Carlson, Stead, Neal, Petryk, & Georgieff, 2007). This is reflected by differences in brain 
connectivity in adulthood. In comparison to healthy controls, former IDA young adults have 
decreased connectivity of the left posterior cingulate cortex (PCC) with posterior default mode 
network (DMN) regions (Algarin et al., 2017). This pattern of functional connectivity is also 
observed in major depressive disorder (Bluhm et al., 2009; Yang et al., 2016), Alzheimer’s 
disease (Chhatwal et al., 2013), ADHD (Castellanos et al., 2008) and social functioning in 
schizophrenia (Dodell-Feder, Delisi, & Hooker, 2014). Therefore, it would be reasonable to 
suggest that an iron-related insult during the neonatal period and infancy has potentially 
irreversible neurological effects regardless of blood and brain iron repletion later in life 
(Georgieff, 2011).  
 
Due to the overwhelming attention on PPD, maternal anaemia and the potential 
consequences upon infant neurodevelopment, minimal research has focussed upon the role 
of iron in mood regulation in non-pregnant women. Meta-analytic findings indicate an inverse 
association between dietary iron intake and risk of depression, however only amongst Asian 
populations of both genders (Li, Li, Song, & Zhang, 2017). Studies that have investigated 
women of reproductive age specifically have produced conflicting results. Two cross-sectional 
studies found that a higher frequency of depressive symptoms was only associated with low 
serum ferritin when women of reproductive age were also taking oral contraceptives (Fordy & 
Benton, 1994; Rangan, Blight, & Binns, 1998). However, current evidence suggests a lack of 
negative associations between oral contraceptives and depression (Toffol, Heikinheimo, 
Koponen, Luoto, & Partonen, 2012), although female adolescents may be more susceptible 
(Skovlund, Mørch, Kessing, & Lidegaard, 2016). Recent evidence suggests that the combined 
presentation of depressive symptoms and oral contraceptive use is only reported amongst 16-
year-old girls, which may impede quality of life and increase the risk of contraceptive non-
adherence (de Wit et al., 2020). Therefore, when disregarding oral contraceptive use and 
those < 20 years of age, it may be suggested that no observational relationship between iron 
haematological indices and depression exists in women of reproductive age. However, 
participants were not screened for inflammatory and blood disorders, the use of iron 
supplements or medications that could affect iron status biomarkers, all of which could inflate 
serum ferritin and inaccurately depict iron status (Namaste et al., 2017). When such factors 
are considered, the frequency of NAID is shown to be 15 % higher in female medical students 
classed as depressed (Vahdat Shariatpanaahi et al., 2007). To infer a role of iron in the 
aetiology of depression, iron supplementation RCTs measuring depression change scores 
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have been conducted. However, no associations have been found between improvements in 
iron status and depressive symptoms following oral iron supplementation over four (Verdon et 
al., 2003) or 12 weeks (Vaucher, Druais, Waldvogel, & Favrat, 2012). The main outcome of 
both studies was to assess the effect of iron supplementation upon fatigue and specifically 
recruited participants reporting considerable fatigue without obvious clinical causes. 
Subsequently, depression was assessed as a secondary outcome, giving rise to the 
suggestion that more comprehensive depressive scales may have yielded different results 
(Lomagno et al., 2014). As a decrease in anxiety levels was however observed following four 
weeks of iron supplementation (Verdon et al., 2003), this highlights the potential benefits of 
iron to non-pregnant women for improving indices of mood.  
 
Although complex, there is adequate evidence to suggest a role for iron in mood regulation 
amongst infants, children, adolescents, pregnant and non-pregnant women. However, despite 
non-pregnant women presenting with an increased risk of mood disorders and ID in 
comparison to men, a causal relationship between the two has yet to be established. This 
demographic is deserving of further cross-sectional studies and RCTs using non-clinical 
samples and validated, comprehensive mood scales to determine the potential mood 
enhancing effects of iron and to establish whether normalcy can be restored following iron 
repletion. 
 
1.5.2 The role of iron in fatigue and physical performance 
 
Reports of fatigue in general practice have consistently shown that women are more likely to 
report to their general practitioner for fatigue than men (Cullen, Kearney, & Bury, 2002; 
Engberg, Segerstedt, Waller, Wennberg, & Eliasson, 2017; Ridsdale et al., 1993). There is 
evidence to suggest that ID is associated with a higher prevalence of constant tiredness in 
comparison to those who are IS (Patterson, Brown, Powers, & Roberts, 2000). The role of iron 
in oxygen transport, detailed in section 1.4.3, is often postulated as a cause of fatigue 
symptoms due to the reduced delivery of oxygen to the tissues requiring it by consequence of 
a reduction in haemoglobin concentrations. However, this would only be the case when 
haemoglobin is reduced in IDA, whereas reductions in serum ferritin in NAID should not affect 
the oxygen-carrying capacity of erythrocytes directly. Studies have instead suggested that 
reduced ferritin in NAID rats is detrimental to mitochondrial oxidative enzyme activity, such as 
cytochrome C, reducing successful oxygen extraction and utilisation from haemoglobin, 
halting the production of ATP for energy metabolism and increasing ROS production to 
promote oxidative stress (Bahadir, Erduran, Değer, Birinci, & Ayar, 2018; Srinivasan & 
Avadhani, 2012). This provides further support for the U-shaped risk curve as iron overload is 
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also associated with increased ROS, which is detrimental to cellular vitality. To combat this, a 
change of fuel selection for skeletal muscle energy metabolism is postulated in order to limit 
processes with a high iron expenditure. A shift towards anaerobic metabolism is proposed as 
evidence suggests greater lactate dehydrogenase activity, skeletal muscle fibre alterations 
and a subsequent shift from oxidative metabolism to glycolysis in iron deficient rats in 
comparison to healthy controls (Henderson, Dallman, & Brooks, 1986; Ohlendieck, 2013). 
However, glycolysis is inferior to mitochondrial oxidative metabolism as only two ATP 
molecules are generated per glucose molecule compared to the 36 produced by oxidative 
metabolism (Yetkin-Arik et al., 2019). This therefore provides a mechanism for a reduced 
aerobic capacity in ID with and without anaemia.  
 
There is evidence to suggest that ID is more prevalent amongst athletes in comparison to 
more sedentary individuals, which has the potential to affect athletic performance due to 
impaired aerobic capacity and increased fatigue (Sinclair & Hinton, 2005). Female athletes 
are at an additional risk for ID with and without anaemia (Koehler et al., 2012; Sinclair & Hinton, 
2005), with an estimated prevalence of five to seven times higher than their male counterparts 
(DellaValle & Haas, 2011). Additionally, female athletes are at a heightened risk of NAID 
compared with female non-athletes (27 % vs. 13 %) (Ponorac et al., 2019). Explanations 
beyond those previously mentioned for women of reproductive age include increased blood 
loss through haematuria and the gastrointestinal tract; and intravascular haemolysis as a 
result of exercise intensity and the type of exercise (i.e., foot strike in runners, tissue pressure 
in strength training) (Beard & Tobin, 2000; Mairbäurl, 2013; McClung, Gaffney-Stomberg, & 
Lee, 2014). An increased erythrocyte turnover is shown in animal and human studies. 
Exercise-trained male rats with ID exhibit a higher erythrocyte turnover in comparison to non-
exercise trained rats (Tobin & Beard, 1989). This turnover is approximately 20 % faster in 
human female athletes than in non-athletes; regardless of exercise training category, 
erythrocyte turnover is also faster than in adult men (Ehn, Carlmark, & Hoglund, 1980). 
Despite this, an increased erythrocyte and haemoglobin concentration in comparison to 
sedentary individuals is observed (Mairbäurl, 2013). Female athletes also exhibit changes in 
iron absorption in response to inflammation. Skeletal muscles act as secretary organs during 
physical activity; responding to exercise by secreting pro-inflammatory myokines such as IL-
6 in an exponential fashion, which return to baseline concentrations following exercise 
cessation (Hojman et al., 2019). Acute exercise-induced inflammation upregulates expression 
of hepcidin, affecting efficient iron absorption in the gastrointestinal tract and enterocyte and 
macrophage iron export (McClung et al., 2014). This detrimentally affects iron status as there 
are inadequate amounts of iron to support physical functioning. A review of evidence to 
determine the effects of acute exercise on elevations in hepcidin demonstrated that a single 
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session of endurance exercise at a moderate-vigorous intensity augments hepcidin levels 
between 0 hours and 6 hours, with a peak concentration at approximately 3 hours post-
exercise (Domínguez et al., 2018). It is suggested that this timing is likely to coincide with an 
athlete’s meal consumption and so their dietary-derived iron intake is not as efficiently 
absorbed potentially explaining the prevalence of iron deficiency amongst this population 
(Peeling, 2010). However, it is suggested that iron status facilitates this hepcidin upregulation 
as serum ferritin < 30 µg/L is shown to blunt exercise-induced hepcidin (Peeling et al., 2014), 
and this is shown to increase following iron supplementation (Burden, Pollock, et al., 2015). 
Consequently, those considered at a sub-optimal iron status with sufficient haemoglobin 
concentrations and serum ferritin 30-50 µg/L may be most affected by exercise-induced 
hepcidin elevation due to the greater potential for hepcidin to suppress efficient iron absorption 
and utility, thus increasing the likelihood for ID presentation. Methods of increasing iron stores 
through dietary or supplementation means therefore often target female athletes to prevent 
ID-associated declines in sporting performance.  
 
A meta-analytic review of 17 published RCTs investigating the effects of iron supplementation 
on iron status and aerobic capacity of NAID endurance athletes found that iron treatment 
significantly improved serum ferritin, serum iron, transferrin saturation and haemoglobin in 
both male and female athletes (Burden, Morton, Richards, Whyte, & Pedlar, 2015). These 
effects were not only larger in female groups but were also present up to eight weeks following 
oral treatment cessation. Iron supplementation was also seen to moderately improve 
maximum oxygen capacity (VO2 max) in NAID female endurance athletes, which is in 
agreement with a further meta-analysis focussing on women of reproductive age regardless 
of iron status and athleticism (Pasricha, Low, Thompson, Farrell, & De-Regil, 2014). However, 
further meta-analytic reviews have found equivocal results that do not support iron 
supplementation consistently improving athletic performance in NAID male and female adults 
(Houston et al., 2018; Rubeor, Goojha, Manning, & White, 2018). Although Houston et al. 
(2018) found no significant improvements in objective physical capacity amongst adults 
regardless of athleticism, a serum ferritin cut off of ≤ 20 µg/L and below proved effective for 
improving performance following iron supplementation amongst NAID athletes (Rubeor et al., 
2018). Although serum ferritin concentrations for ID remain uncertain, the cut off of 20 µg/L 
sits between previous recommendations of < 15 µg/L and < 30 µg/L (Daru et al., 2017); 
reflecting the general recognition of ID from previous studies regarding female athletes often 
using serum ferritin cut offs between 12 and 23 µg/L (DellaValle, 2013). These findings provide 
support for the physical performance of trained and untrained NAID females being amenable 
to iron supplementation in a greater fashion than that of their male counterparts, especially at 
a serum ferritin threshold of ≤ 20 µg/L.  
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Fatigue is not only associated with a reduction in endurance aerobic capacity and physical 
performance. A reduction in physical parameters may present alongside central fatigue 
categorised by subjective feelings of lowered energy and motivation, which may instigate an 
increase in anxious and depressive mood depleting cognitive capacity and quality of life 
(Dziembowska, Kwapisz, Izdebski, & Żekanowska, 2019). The known dependency of iron in 
monoaminergic systems for neurotransmission, as discussed in section 1.4.5, may be critical 
to the presentation of fatigue-associated symptoms. The monoamine hypothesis of central 
fatigue suggests that an elevated ratio of serotonin to dopamine in the brain is associated with 
tiredness and lethargy, instigating fatigue onset, in comparison to a low ratio driving the 
opposite with increased arousal, motivation and feelings of reward (Davis & Bailey, 1997; 
Meeusen, Watson, Hasegawa, Roelands, & Piacentini, 2006). As ID is associated with 
increases in serotonin and decreases in dopamine, the central fatigue hypothesis acts as a 
possible explanation for the concurrent presentation of reduced subjective energy levels and 
cognitive capacity. A meta-analysis of cross-sectional studies demonstrated a significant 
association between NAID and subjective fatigue in populations screened for RCTs and those 
with diagnosed disorders, but not the general population (Yokoi & Konomi, 2017).  
 
Meta-analytic reviews have revealed significant therapeutic effects of iron supplementation in 
those presenting with fatigue and NAID (Houston et al., 2018; Yokoi & Konomi, 2017). 
Although neither review specifically focussed on women, all seven studies included across the 
meta-analyses investigated subjective fatigue in NAID menstruating women. Five were 
associated with a significant reduction in subjective measures of fatigue (Beutler, Larsh, & 
Gurney, 1960; Favrat et al., 2014; Krayenbuehl, Battegay, Breymann, Furrer, & Schulthess, 
2011; Vaucher et al., 2012; Verdon et al., 2003). A significant response to iron 
supplementation was discovered in all studies when serum ferritin was ≤ 50 µg/L; a much 
higher cut off in comparison to studies showing iron supplementation to significantly affect 
aerobic capacity and physical performance. However, these studies all recruited women 
whose primary concern was unexplained fatigue and so a stronger association between iron 
and fatigue improvements is to be expected in comparison to studies where participants do 
not self-report fatigue or reduced physical performance. Promising findings are demonstrated 
amongst NAID adolescent girls; intravenous iron improved subjective fatigue and quality of 
life without significant improvements in haemoglobin (Sharma, Stanek, Koch, Grooms, & 
O'Brien, 2016). This suggests that the mechanisms underpinning the beneficial effect of iron 
therapy on reducing fatigue are independent of the haematological functions as suggested by 
the monoamine hypothesis of central fatigue. It is therefore imperative that not only objective 
measures of physical performance are investigated in iron supplementation RCTs, but also 
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subjective measures of fatigue and energy. Further studies of the general population are also 
warranted.  
 
1.5.3 The role of iron in sleep quality 
 
The key role of iron for modulation of monoamines in the brain and the role of those 
monoamines in sleep physiology suggests a detrimental impact of ID upon sleep parameters. 
Subjective sleep quality is shown to significantly predict fatigue (Lavidor, Weller, & Babkoff, 
2003), quality of life (Marques, Meia-Via, da Silva, & Gomes, 2017), academic performance 
(El Hangouche et al., 2018; Maheshwari & Shaukat, 2019), and mood (Augner, 2011) in non-
clinical populations. Regardless of the presentation of depression and anxiety symptoms, IDA 
is shown to affect sleep quality with IDA patients exhibiting poorer sleep quality than healthy 
controls (Murat et al., 2015). Dopamine neuromodulation is fundamental to sleep-wake cycle 
regulation, encompassing modulation of REM sleep quality, quantity and timing (Dzirasa et 
al., 2006; Monti & Monti, 2007; Takeuchi et al., 2018). Sleep/wake disturbances are 
associated with dopamine losses (Murat et al., 2015) and, as discussed in section 1.4.5, 
decreased brain iron is directly tied to dopaminergic system dysfunction including D1 and D2 
receptor downregulation. This bolsters the idea that altered dopamine-related behaviours and 
dopaminergic system functioning in ID would affect sleep parameters.  
 
Iron deficiency-associated impairments in neuronal iron uptake can trigger the 
pathophysiology of restless leg syndrome (RLS) (Guo et al., 2017). A significant association 
between IDA and RLS presentation in women has been demonstrated (Telarović & Čondić, 
2019) and RLS patients have significantly reduced iron and serum ferritin concentrations in 
cerebrospinal fluid (Mizuno, Mihara, Miyaoka, Inagaki, & Horiguchi, 2005). This reduces 
available iron for dopaminergic system regulation potentially leading to the characteristic 
clinical feature of RLS, the irresistible urge to move the limbs whilst at rest that may only be 
relieved by movement. Poor sleep quality is therefore a serious consequence to RLS sufferers 
as a result of this (Bogan, 2006). Meta-analytic findings suggest that iron supplementation can 
improve RLS severity; however, subjective sleep quality did not significantly favour iron 
treatment (Trotti & Becker, 2019). Further RCTs are warranted to determine the impact of iron 
supplementation upon sleep quality.  
 
In addition to dopamine, serotonin, noradrenaline and GABA-ergic systems are dysregulated 
during ID; it is postulated that these alterations affect the neural mechanisms involved in sleep 
organisation to cause altered REM sleep transitions observed in former IDA children despite 
iron repletion (Peirano et al., 2010). Effective sleep is also essential for myelin maintenance 
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and turnover for healthy white matter and altered sleep patterns are evident in demyelinating 
diseases (de Vivo & Bellesi, 2019). Iron is also essential for myelination, though iron 
supplementation RCTs are limited to infant and child populations for determining the effect 
upon sleep quality. Children with autistic spectrum disorder (ASD) are a population at risk for 
ID who experience altered sleep patterns, which are shown to improve following iron 
supplementation (Dosman et al., 2007). Similarly, sleep quality and reduced night waking 
significantly improved in IDA children and adolescents with sleep-maintenance insomnia 
treated with iron (Mila et al., 2013). Non-anaemic iron deficiency is also associated with sleep 
disorders such as RLS, periodic leg movement disorder and restless sleep disorder (Munzer 
& Felt, 2017), symptoms of which improve following iron therapy (Simakajornboon et al., 
2003). Significant improvements in serum ferritin following iron supplementation are 
associated with sleep quality improvements in children with such conditions (DelRosso et al., 
2019). As NAID is most prevalent in women of reproductive age, and there is a higher 
prevalence of poor sleep quality in females than males (Fatima, Doi, Najman, & Mamun, 2016; 
Madrid-Valero, Martínez-Selva, Ribeiro do Couto, Sánchez-Romera, & Ordoñana, 2017), 
further iron supplementation RCTs are warranted to determine any beneficial effects upon 
sleep quality in this population.  
 
1.5.4 The role of iron in maintaining brain health across the lifespan 
 
1.5.4.1 The role of iron in neurodevelopment and infancy  
 
As early brain development is a highly metabolically taxing process, optimal brain 
development is reliant upon vital nutrients such as glucose, branched chain amino acids and 
iron for supporting effective cellular metabolism (Wullschleger, Loewith, & Hall, 2006). 
However, nutrition can be wilfully altered and may differ according to parental food habits and 
feeding strategies. As discussed in section 1.4, iron is essential for neurocognitive processes 
including neurotransmission and myelination. However, despite brain development continuing 
across the lifespan due to continued neural plasticity (Power & Schlaggar, 2017) it is argued 
that the opportunity to influence later function is far greater during early life than in adulthood 
(Georgieff, Brunette, & Tran, 2015). Reducing ID prevalence is therefore not only important 
because of its ubiquity worldwide, but also because of the potential long-term effect on 
neurocognitive functioning and behaviour.  
 
Infant ID may arise as a consequence of maternal anaemia because of the high requirements 
for iron by both mother and foetus (Harvey et al., 2013). Premature labour also increases risk 
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for ID as most foetal iron is obtained from the mother during the third trimester of pregnancy, 
which can result in iron stores reflective of a low birth weight (Moreno-Fernandez, Ochoa, 
Latunde-Dada, & Diaz-Castro, 2019). Similarly, infants subject to intrauterine growth 
restriction and infants born to mothers with diabetes or preeclampsia are at an increased risk 
of developing ID (Abu-Ouf & Jan, 2015; Coşkun, Bilgen, Özdemir, Şirikçi, & Özek, 2012; 
Verner et al., 2007). Systematic and meta-analytic reviews have found negative associations 
between maternal diabetes and infant’s cognitive and psychomotor development (Adane, 
Mishra, & Tooth, 2016; Camprubi Robles et al., 2015). There is also evidence to suggest that 
the children of mothers with preeclampsia and those affected by intrauterine growth restriction 
are at an increased risk of neurocognitive, behavioural and motor development deficits 
(Hartkopf et al., 2018; Korzeniewski et al., 2017; Nomura et al., 2017; Warshafsky, Pudwell, 
Walker, Wen, & Smith, 2016). However, such investigations have not considered the effect of 
consequent ID during development as a causal link for impaired cognitive and behavioural 
function.  
 
Iron deficiency and IDA in infancy is associated with dysfunction of cognitive, affective and 
motor domains in comparison to their IS counterparts (Beltran-Navarro, Matute, Vasquez-
Garibay, & Zarabozo, 2012; Carter et al., 2010). Infancy is considered a time of peak central 
nervous system formation of myelin, dendrites and synapses alongside hippocampal and 
cortical regional development (Lozoff et al., 2006). However, early life ID may encourage the 
prioritisation of available iron to red blood cells over the brain (Dallman, 1986). Animal models 
have highlighted the vulnerability of the hippocampus to early ID; a significant loss of 
cytochrome c oxidase activity in the hippocampus and the prefrontal cortex during 
foetal/neonatal ID (Bastian, von Hohenberg, Mickelson, Lanier, & Georgieff, 2016) is greatest 
during the early stages of dendrite maturation causing altered hippocampal dendritic growth 
(Bastian et al., 2016; de Deungria et al., 2000) that may persist from infancy through to puberty 
(Fretham, Carlson, & Georgieff, 2011). Such abnormalities may contribute to the memory and 
learning deficits attributed to early ID. Children born with low cord serum ferritin and chronic 
ID are shown to have lower scholastic performance (Tamura et al., 2002), frontostriatal-
mediated executive functions and recognition memory (Geng et al., 2015; Lukowski et al., 
2010), working memory and immediate and delayed recall memory (Riggins, Miller, Bauer, 
Georgieff, & Nelson, 2009). When provided with support, memory task deficits were improved 
indicating that alternate learning approaches may be enlisted by formerly ID children.  
 
Similarly, impaired myelination is a potential mechanism for motor deficits in early life as the 
corticospinal tract, responsible for signal communication between the motor and sensory 
regions of the cerebral cortex and the spinal cord, is not fully myelinated until aged 20-40 
 42 
months (Parazzini, Baldoli, Scotti, & Triulzi, 2002). As myelin is also necessary for 
communication with sensory cortical regions, it is vital for effective auditory and visual system 
functioning critical to social interaction and learning. Auditory brainstem responses (ABR) and 
visual evoked potential (VEP) latencies decrease through infancy to adulthood reflecting 
maturation of the CNS and increased myelination of the auditory and optic nerves (Algarín et 
al., 2003; Long, Wan, Roberts, & Corfas, 2018). Iron deficient anaemic infants however show 
longer ABR latencies relative to IS controls indicating slower auditory pathway transmission 
(Roncagliolo et al., 1998). However, NAID animal models have demonstrated a different 
mechanism; instead of myelination deficits, altered ABRs were a consequence of disrupted 
axonal maturation and development of the auditory nerve (Lee, Strathmann, Gelein, Walton, 
& Mayer-Pröschel, 2012). This is reflected in electrophysiological evidence that highlights the 
inability of ID infants to discriminate a novel from a familiar stimulus in the same manner as IS 
infants (Deregnier, Nelson, Thomas, Wewerka, & Georgieff, 2000; Siddappa et al., 2004). Iron 
is therefore key to successful auditory and visual systems, however not only during infancy. A 
follow-up study demonstrated consistently longer ABR and VEP latencies in formerly IDA 
children relative to IS controls (Algarín et al., 2003), providing support for a long-term effect of 
infant ID later in life.  
 
The long-term effects of ID during infancy are also reflected in cognitive function. Children 
diagnosed with severe IDA as infants demonstrated poorer intelligence and visual-motor 
performance at 5 years (Lozoff, Jimenez, & Wolf, 1991). Ten years following ID treatment, the 
same children attained significantly poorer arithmetic achievement, written expression, motor 
functioning, selective recall, spatial memory and were more likely to have either repeated a 
school year or to have received additional tutoring (Lozoff et al., 2000). Cognitive and motor 
functioning alterations were also coupled with affective domain changes in early adolescence; 
a greater prevalence of anxiety and depression symptoms were evident as well as 
externalising behavioural problems (Lozoff et al., 2000). In addition to iron-dependent CNS 
developmental processes previously discussed, affective and motor functioning alterations 
are consistent with changes in iron-dependent neurotransmitters such as dopamine and 
serotonin (section 1.4.5). When these children were followed-up to the age of 19 years, 
cognitive test scores remained significantly lower for those who had ID in infancy relative to 
those who were IS (Lozoff, Jimenez, & Smith, 2006). When combined with socio-economic 
status (SES), those with ID in lower-SES families were doubly burdened; initial cognitive 
scores in infancy were 10 points lower, which extended to 25 points by 19 years old (Lozoff et 
al., 2006). As ID disrupts and delays neurodevelopment, it is suggested to subsequently alter 
infant-caregiver interactions that may further compromise development (Lozoff et al., 2006). 
Therefore, when combined with a lower-SES background, where there are functionally 
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significant differences regarding educational attainment and future career opportunities, it 
seems reasonable to suggest ID-associated deficits would be exacerbated. When SES was 
controlled for at 25 years follow-up, a greater percentage of those who had chronic ID in 
infancy failed to complete secondary school or pursue further education in comparison to 
those who were IS via the indirect path of poorer cognitive functioning in early adolescence 
(Lozoff et al., 2013).  
 
Iron supplementation during infancy for prevention of ID in at risk populations has 
demonstrated benefits upon behaviour (Berglund et al., 2018; Berglund, Westrup, Hagglof, 
Hernell, & Domellof, 2013; Lozoff, Castillo, Clark, Smith, & Sturza, 2014), and psychomotor 
development (Angulo-Barroso et al., 2016; Chmielewska et al., 2019; Friel et al., 2003; Lind 
et al., 2004; Moffatt, Longstaffe, Besant, & Dureski, 1994; Stoltzfus et al., 2001). However, 
cognitive benefits from RCTs supplementing iron are much less pronounced. Benefits to 
information processing speed are demonstrated in well-nourished children (Lozoff et al., 2003) 
but have more recently been contradicted with no effects on neurodevelopment of well-
nourished children shown (Iglesias Vázquez et al., 2019). Overall neurodevelopmental 
benefits of iron supplementation are quashed by systematic and meta-analytic reviews failing 
to identify a clear benefit of iron supplementation on cognitive function in infancy following 
short-term ID prevention or treatment (Pasricha, Hayes, Kalumba, & Biggs, 2013; Sachdev, 
Gera, & Nestel, 2005; Szajewska, Ruszczynski, & Chmielewska, 2010; Thompson, Biggs, & 
Pasricha, 2013; Wang, Zhan, Gong, & Lee, 2013). Such disparity has also been shown 
following the long-term effects of iron supplementation on cognitive performance. Following 
ID correction during infancy, cognitive performance was similar at 5 years of age to those who 
were IS at baseline (Lozoff et al., 1991). However, regardless of initial iron status, iron 
supplementation administered in infancy did not lead to long-term cognitive performance 
improvements at 7-9 years of age (Pongcharoen et al., 2011), with one study discovering a 
worsened performance on tasks of executive function and fine motor function when compared 
with those who did not receive iron supplementation from 12-18 months of age (Murray-Kolb 
et al., 2012). This comparatively inferior cognitive performance was also seen at a follow-up 
of 10 (Lozoff, Castillo, Clark, & Smith, 2012) and 16 years of age (Gahagan, Delker, Blanco, 
Burrows, & Lozoff, 2019) following treatment with iron-fortified or low-iron formula. 
Additionally, both studies found that infants with high haemoglobin (> 128 g/L) displayed 
poorer cognitive and visual-motor integration if they had received an iron-fortified formula 
compared with those who were randomised to the low-iron formula, and those with a lower 
baseline haemoglobin (<105 g/L) demonstrated better cognitive and visual-motor outcomes. 
Animal models provide possible explanations for poorer neurodevelopmental outcomes; 
excess iron during infancy is postulated to be neurotoxic and thus detrimental for brain 
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development (Berggren et al., 2016; Fredriksson, Schröder, Eriksson, Izquierdo, & Archer, 
1999; Hare et al., 2015). The pro-oxidative consequences of excess iron are suggested to 
augment brain oxidative stress to decrease serotonin and dopamine whilst increasing the 
production of ROS and hydroxyl radicals following brain cell damage producing significant 
cognitive deficits (Yu, Feng, Shen, & Li, 2011).  
 
Together, the evidence regarding human and animal models supports the idea of long-term, 
irreversible neuropsychological alterations following early iron deficiency (Beard et al., 2006; 
Georgieff, 2011). Further research is suggested due to the heterogeneous nature of the 
populations, intervention duration, dosage and cognitive tests enlisted by previous RCTs 
(Larson, Phiri, & Pasricha, 2017). However, there are potential implications for an optimal 
amount of iron for supplementation and that supplementation during infancy should be 
individualised based on baseline iron measures to avoid the potentially detrimental effects of 
early iron exposure on brain development.  
 
1.5.4.2 The role of iron in children and adolescents 
 
Although pre-school infants and young children are at a greater risk of ID, global statistics 
indicate that approximately 25 % of older children (5-9 years) and adolescents (10-19 years) 
are affected by IDA (Global Burden of Disease Pediatrics et al., 2016). A systematic review 
demonstrated significant associations between poor cognitive, behavioural and psychomotor 
outcomes in infants, children and adolescents born to women who were ID and IDA during 
pregnancy (Iglesias, Canals, & Arija, 2018). Iron deficient anaemic children aged >2 years old 
are also shown to have cognitive function deficits and poorer scholastic achievements in 
comparison to IS children (Grantham-McGregor & Ani, 2001). Whilst IDA children demonstrate 
the poorest cognitive function, a dose-response relationship has been postulated between 
haemoglobin and cognitive function in NAID primary-school-aged children (average age 9.6 
years); language and arithmetic scores increased with haemoglobin concentrations, whilst this 
relationship was not shown in IS children (Sungthong, Mo-suwan, & Chongsuvivatwong, 
2002). More recent studies have also suggested primary-school-aged children with NAID to 
have poorer processing speeds and visual motor-coordination in comparison to healthy 
controls (Hamid Jan, Amal, Rohani, & Norimah, 2010). Optimising cognitive abilities in 
primary-school-aged children is shown to enhance cognitive capacities in later life (Ritchie, 
Bates, Der, Starr, & Deary, 2013) and it may therefore be imperative to investigate optimal 
iron status and supplementation methods beyond infancy and into childhood.  
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Iron supplementation significantly improved verbal and nonverbal learning and memory when 
children aged 6-11 years were IDA at baseline but not when NAID (Baumgartner et al., 2012). 
This is in line with evidence suggesting that IDA children are most likely to benefit from 
supplementation (Grantham-McGregor & Baker-Henningham, 2010). Systematic and meta-
analytic reviews support this as children >7 years of age responded to iron supplementation 
with an improved intelligence quotient (IQ) (Sachdev et al., 2005), as well as improved 
cognitive domains of attention and concentration (Falkingham et al., 2010), but only amongst 
those who were IDA at baseline. Similarly, systematic evidence of iron supplementation 
amongst primary school children aged 5-12 years indicates improved measures of attention, 
concentration and global cognition in comparison to placebo (Low, Farrell, Biggs, & Pasricha, 
2013). However, global cognition improvements were only exhibited for children who were 
IDA at baseline, as were improvements in IQ.  
 
Adolescence is usually associated with an increase in dietary intake to fulfil the energy 
requirements of accelerated growth and production of bone and muscle. Iron requirements 
dramatically increase to satisfy the haemoglobin demand for expansion of total blood volume, 
myoglobin for increases in lean body mass and the enzymes necessary for growth in both 
boys and girls (Beard, 2000; Mesias, Seiquer, & Navarro, 2013). Serum ferritin stores are 
anticipated to be redistributed for haemoglobin production, which increases the likelihood of 
NAID. This may be especially apparent amongst young males due to a greater incorporation 
of iron into erythrocytes to compensate for greater growth rates in comparison to young 
females (Mesias et al., 2013). However, menarche onset instigates an increase in iron 
requirements, and it is suggested that girls with menses are 2.57 times more likely to be iron 
deficient compared to girls prior to menarche onset across countries of varied economic 
stature (Moschonis et al., 2013). Menarche onset averages around 12.9 years of age, 
dependent upon ethnicity (Campbell, Mallappa, Wisniewski, & Silovsky, 2013) and 
menstruation for greater than three years is considered a risk factor for NAID (Sekhar, Murray-
Kolb, Kunselman, Weisman, & Paul, 2017). This coincides with a time of cognitively 
demanding school years and as iron plays a key role in neurodevelopment, its deficiency may 
impair and alter the typical neurodevelopmental trajectory associated with adolescence. 
Significant positive associations between serum ferritin, haemoglobin and academic 
achievement have been shown; IDA adolescent girls demonstrated poorer academic 
achievement in comparison to their IS peers (Soleimani & Abbaszadeh, 2011). Such findings 
have also been extended to IDA and NAID adolescent girls exhibiting poorer scholastic 
performance through lower arithmetic, IQ, verbal learning, attention, concentration, verbal 
memory and recognition scores as compared to their IS equivalents (Devaki, Chandra, & 
Geisser, 2009; More, Shivkumar, Gangane, & Shende, 2013; Mousa, Higazi, Saleh, & Ali, 
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2016). As has consistently been shown in younger children, IDA adolescent girls had the 
lowest cognitive scores whilst those who were IS performed best with NAID girls at an 
intermediate level between the two. Iron deficient anaemic adolescent girls are 1.73 times 
more likely than non-anaemic girls to have impaired cognitive function (Bahrami et al., 2019).  
 
A meta-analysis of iron supplementation in adolescents and young adults found evidence to 
support its use for improving measures of attention and concentration independent of baseline 
iron status, however further well-designed studies were called for (Falkingham et al., 2010). 
No effect on memory was found, however this may be due to the studies included not having 
useable data for the meta-analysis. Early iron intervention studies in pregnant adolescent girls 
from a low SES background identified improvements in short-term memory following iron 
supplementation of one month (Groner, Holtzman, Charney, & Mellits, 1986). The triple 
burden of adolescence, pregnancy and low SES increases the risk for ID, however ID 
prevalence at baseline was minimal. This high-risk demographic benefitted from iron 
supplementation regardless of baseline iron status, which highlights the potential for beneficial 
effects of iron interventions even when iron status is considered optimal. However, iron 
requirements during pregnancy increase from .08 mg/day in the first trimester to > 6 mg in the 
third (Bothwell, 2000). As this study recruited females during the first 16 weeks’ gestation, it 
may not accurately reflect the efficacy of iron supplementation for cognitive performance 
enhancement in pregnancy. Similar findings are demonstrated when recruiting non-pregnant 
adolescents based upon iron status parameters; NAID adolescent girls verbal learning and 
working memory improved following iron supplementation (Bruner, Joffe, Duggan, Casella, & 
Brandt, 1996; Lambert, Knaggs, Scragg, & Schaaf, 2002) as did short-term memory, long-
term memory and intelligence amongst NAID and IDA adolescent girls and boys (Devaki et 
al., 2009). Significant baseline differences existed with better cognitive performance reflecting 
iron sufficiency (IS>NAID>IDA), and although treatment groups’ cognitive scores were greater 
following iron supplementation, the initial differences persisted between iron status groups 
(Devaki et al., 2009). This may echo how neurocognitive systems are subject to a greater 
deficit as haematological indices of iron status deplete, which reflects a cognitive capacity that 
takes longer to correct with iron supplementation. Similarly, improvements to iron status and 
perceptual, attention and mnemonic abilities are shown following an iron-bio fortified millet 
intervention at much lower doses than oral iron supplementation forms (Scott et al., 2018).  
 
In contrast to RCTs conducted on cognition in infants, treatment of IDA in older children 
demonstrates a benefit to cognitive function. It is postulated that older children may respond 
differently to iron interventions due to the most critical neurodevelopmental stages having 
occurred in infancy. The advantageous effects of iron supplementation for correcting ID and 
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IDA in adolescents of both genders could be considered educationally advantageous. The 
consistent observational findings of ID diminishing scholastic performance and academic 
achievement combined with the consistent improvements to IQ, attention and memory 
following iron treatment highlight the importance of maintaining an optimal iron status for 
reaching cognitive heights during a period of intense scholastic demand.  
 
1.5.4.3 The role of iron in women of reproductive age 
 
Cognitive function is known to naturally decline with age across genders in healthy educated 
adults starting from their 20s and 30s (Salthouse, 2009). This decline is characterised by near 
linear declines in speed and accelerating declines in memory and reasoning, despite 
increases in vocabulary knowledge (Salthouse, 2019). Prevalence of anaemia in non-
pregnant women of reproductive age ranges from 9 % to 59 % with prevalence decreasing 
with economic and social advancements by country (Global Health Observatory, 2020). As 
>20 % of women experience ID during their reproductive years (Percy et al., 2017), the known 
cognitive impairments associated with its deficiency in infancy, childhood and adolescence 
have stimulated an accumulation of evidence regarding altered cognition and depleted iron 
status in this demographic also.  
 
A significant reduction in haemoglobin following 50 % energy restriction in dieting women of 
varied iron status who were obese is associated with poorer performance on a task of 
sustained attention (Kretsch, Fong, Green, & Johnson, 1998). Comparisons between IS and 
IDA males and females identified significant impairments of memory and IQ with declining iron 
status (Khedr et al., 2008). Positive associations are also shown in the absence of anaemia 
between body iron (the log ratio of sTfR to serum ferritin), serum ferritin and executive planning 
function amongst healthy female university students (Blanton, 2013; Blanton, Green, & 
Kretsch, 2013). Additionally, greater body iron and serum ferritin was associated with faster 
response times and improved memory strategy scores on a spatial working memory task 
(Blanton, 2013). Although lower body iron and ferritin was associated with better immediate 
free word recall, which is in agreement with an earlier study comparing low and normal ferritin 
groups (Fordy & Benton, 1994). These findings have been extended to a NAID female 
population using a higher-difficulty version of the executive function task (Scott & Murray-Kolb, 
2016). Iron status groups did not differ in attentional and executive function performance, 
however a faster planning time was associated with higher serum ferritin and, when age was 
added as a covariate, higher total body iron. Furthermore, increased body iron and serum 
ferritin were associated with a smaller change in planning time with increased task difficulty 
yet worse working memory performance. However, more recent evidence suggests that only 
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women with IDA exhibit poorer attentional task performance, whereas NAID is not associated 
with any cognitive differences compared to those who are IS (Cook et al., 2017). Although, 
NAID females are also shown to have a lower grade point average (GPA) as a measure of 
academic performance at university, in comparison to IS females (Scott, De Souza, Koehler, 
& Murray-Kolb, 2017). Together these findings demonstrate the potential benefit of iron for 
handling higher cognitive loads, although the role of NAID remains inconclusive.  
 
Recent systematic reviews have indicated benefits of iron supplementation on cognitive 
function; however, findings remain equivocal. The earliest meta-analytic review, regarding 
older children and women of reproductive age, highlighted improved measures of attention 
and concentration regardless of baseline iron status over intervention durations of 8-17 weeks; 
improvements in intelligence were only demonstrated when women were IDA at baseline over 
intervention durations of 13-29 weeks (Falkingham et al., 2010). When only investigating 
women of reproductive age, eight out of ten included studies reported cognitive improvements 
following iron supplementation over 4-20 weeks, though only four studies found that ID at 
baseline resulted in poorer cognitive performance (Greig, Patterson, Collins, & Chalmers, 
2013). Meta-analysis revealed that only arithmetic scores, as a measure of working memory, 
significantly improved after iron treatment. A subsequent systematic review corroborates and 
extends these findings; iron supplementation improves memory, specifically working memory, 
and intellectual ability regardless of baseline ID or IDA (Lomagno et al., 2014). Iron deficiency 
and IDA were however both shown to be detrimental to cognitive function. An updated 
systematic review of iron supplementation for cognitive and behavioural function in women of 
reproductive age is presented in Chapter 3 of this thesis.  
 
More recently, interest has grown regarding dietary interventions rather than conventional oral 
iron supplementation methods. When investigating the effect of naturally iron-rich beef 
lunches (~ 3.5 mg/lunch) in comparison to a control lunch, no significant differences in iron 
status were identified as both groups’ iron status improved. However, greater improvements 
in body iron were demonstrated in women whose body iron was lowest at baseline. Higher 
body iron and serum ferritin were associated with better planning speed and spatial working 
memory; these improvements were more pronounced following a serum ferritin response to 
intervention in comparison to non-responders (Blanton, 2013). The consumption of iron bio-
fortified beans (86.1 ppm) by NAID women corroborates and extends these findings (Murray-
Kolb et al., 2017). Significant treatment effects were found for speed of attention and speed, 
efficiency and specificity of memory, whilst a significant increase in serum ferritin was 
associated with quicker attention and memory task completion. Such studies provide growing 
evidence for benefits of iron at doses much lower than traditional supplementation methods. 
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Overall, observational investigations have identified that the importance of iron status for 
cognitive function is not limited to the developing brain. The iron intervention studies 
conducted thus far have largely supported this by demonstrating that the cognitive deficits 
associated with ID can be overcome in women of reproductive age. However, the number of 
studies specifically investigating iron supplementation that employ non-pregnant women of 
reproductive age remain scarce despite their risk for NAID and IDA (Percy et al., 2017; Soppi, 
2018). In conjunction with the natural age-related decline of cognitive function experienced 
during this time of life (Salthouse, 2009), ensuring iron sufficiency may be essential for 
maintaining optimal brain health in pre-menopausal women.  
 
1.5.4.4 The role of iron post-menopause and for neurodegeneration  
 
Women of reproductive age have lower haematological indices of iron compared to middle-
aged and elderly women (Cho et al., 2011). A population-based study corroborates this as 11 
% of women aged 20-49 present with ID in comparison to 5 % of women aged 50-69 years 
(Looker, Dallman, Carroll, Gunter, & Johnson, 1997). Longitudinal evidence has identified 
women having significantly lower serum ferritin and higher sTfR:serum ferritin concentrations 
during pre-menopause than post-menopause (Kim, Nan, Kong, & Harlow, 2012), presumably 
due to the cessation of menstrual bleeding. However, as women continue to age post-
menopause, anaemia frequency increases where by the age of 85 years, approximately 20 % 
are considered anaemic (Friedman et al., 2012). Although anaemia may not be due to ID; it 
becomes increasingly challenging to determine as we age due to age-related changes in 
haemoglobin, increases in serum ferritin due to chronic activation of inflammatory pathways 
and the potential effects of medications prescribed for age-related illnesses (Fairweather-Tait, 
Wawer, Gillings, Jennings, & Myint, 2014). Considering the growing ageing population, iron 
status and supplementation studies have grown in importance to ensure cognitive function 
stability and subsequent quality of life.  
 
Strong associations between anaemia and poorer cognitive and physical functions are shown 
amongst geriatric populations (Denny, Kuchibhatla, & Cohen, 2006), with global cognitive 
function and episodic memory being highlighted as susceptible (Qin et al., 2019). When 
specifically investigating ID, cognitive scores were significantly lower for those with ID and the 
prevalence of dementia was higher (Yavuz et al., 2012). Non-anaemic ID was associated with 
significantly lower cognitive scores in comparison to those who were IS indicating that the 
influence ID has on cognitive function may be independent of anaemia in the elderly also. Iron 
treatment for ID with and without anaemia in an elderly general population demonstrates 
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significant improvements in cognitive functions and daily functioning (Selvi Öztorun et al., 
2018). Considering the demographic was heavily populated with comorbidities, outcomes 
such as muscle weakness and motor function that are often affected as a result of such 
comorbidities were improved following iron treatment. The effects of ID with and without 
anaemia and the positive effects of iron treatment may therefore persist over the lifespan. 
However, it is essential that underlying causes are identified and treated prior to iron treatment 
administration due to the natural accumulation of iron in the brain with ageing.  
 
Brain iron dysregulation is observed in the ageing brain, observed as region-specific iron 
increases in the cerebral cortex, cerebellum, hippocampus, amygdala and basal ganglia white 
matter (Ashraf, Clark, & So, 2018). The accumulation of toxic levels of iron within these brain 
regions may cause cell death via apoptosis, autophagy or ferroptosis (Dixon et al., 2012) or 
proliferate a pro-inflammatory environment that together stimulate neurodegeneration, 
neuroinflammation, protein aggregation and neurobehavioural deficits observed in 
neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease (Ward, 
Zucca, Duyn, Crichton, & Zecca, 2014; Xu, Jia, Knutson, & Leeuwenburgh, 2012). However, 
the neurological detriments of high brain iron are not restricted to clinical populations. In 
healthy older individuals, higher hippocampal iron was associated with worse verbal working 
memory performance in men but not in women (Bartzokis et al., 2011). As women naturally 
have lower peripheral iron compared to men (Whitfield, Treloar, Zhu, Powell, & Martin, 2003), 
this may lead to reduced brain iron at older ages meaning that men may be more susceptible 
to neurodegeneration at earlier ages (Moisan et al., 2016; Ullah et al., 2019). Regardless of 
gender, iron accumulation in the putamen predicts greater rates of cognitive decline 
(Daugherty & Raz, 2016) as does striatal iron accumulation alongside changes in verbal 
working memory (Daugherty, Haacke, & Raz, 2015). Together, this evidence may suggest 
that iron supplementation is beneficial when ID with or without anaemia is being treated, 
however providing iron supplementation to the oldest populations presenting with 
neurodegenerative issues may exacerbate the effects of cognitive decline. It could be argued 
that iron supplementation is more beneficial for women pre-menopause and is more essential 
from infancy into the reproductive years to maintain long-term brain health.  
 
1.5.5 Summary of the behavioural effects of iron  
 
Research investigating the effects of iron on behavioural outcomes in both animals and 
humans has demonstrated that its deficiency leads to a variety of behavioural and cognitive 
impairments. Iron deficiency is associated with mood and behavioural disorders including 
depression, anxiety, autism and ADHD, as well as increased fatigue and poorer sleep quality. 
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However, iron supplementation trials in humans are less conclusive regarding ameliorating 
these associated impairments across the lifespan. The promising findings thus far warrant 
continued investigation as research has highlighted the importance of iron for optimal brain 
functioning across the lifespan. The critical involvement of iron for multiple aspects of 
neurodevelopment in infancy and childhood is well described alongside research supporting 
the importance of iron sufficiency during pregnancy for infant neurodevelopment. Furthermore, 
ID is shown to be detrimental to cognitive function at any time of life, including older age in the 
presence of comorbidities. However, iron also acts as a double-edged sword as its increased 
dysregulation with age can promote neurodegeneration. Iron is also important for cognition 
during early adulthood, specifically for non-pregnant women of reproductive age. 
Unfortunately, studies are limited within the research area as this demographic are overlooked 
in favour of those deemed at a higher risk of deficiency. Yet beyond infancy, neural structures 
are still amenable to an iron insult, which may be detrimental considering the suggestion that 
cognitive function naturally declines in the 20s and 30s. Within this sample, RCTs have 
identified benefits to treating ID-associated cognitive deficits and as women of reproductive 
age are at a prolonged risk of ID due to years of menstruation and the potential of pregnancy, 
they are at risk of ID with or without anaemia for a large proportion of their adult life. It is 
therefore imperative that nutritional iron intervention studies investigating a range of outcomes 
relating to brain health are furthered focussing on women of reproductive age.  
 
1.6 Previous limitations of randomised clinical trials  
 
There are many aspects to consider regarding iron supplements prior to commencing 
investigations of their use in human trials, most of these revolve around dosage and duration, 
which have consequences for absorption, tolerability and efficacy. Oral iron supplements are 
the gold-standard treatment for ID and are available as either solid or liquid preparations, with 
several variations. Ferrous salts, including ferrous fumarate, ferrous gluconate and specifically 
ferrous sulphate are the most common form of iron supplements currently in use in the United 
Kingdom and are considered the first-line treatment for IDA (Goddard, James, McIntyre, & 
Scott, 2011; Zariwala, Somavarapu, Farnaud, & Renshaw, 2013). However, efficient iron 
supplement absorption is a complicated process as it is amenable to considerable variability 
and is often associated with gastrointestinal side effects reducing tolerability and compliance 
(Tolkien, Stecher, Mander, Pereira, & Powell, 2015). Factors such as sample population, 
baseline iron status, dietary and lifestyle factors, dose, and study duration, all have the 
potential to affect the efficacy of iron supplementation, which makes it difficult to compare the 
findings from different studies due to heterogeneity surrounding the measurement of these 
factors. These factors are discussed below. 
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1.6.1 Sample population 
 
A large majority of previous iron supplementation research focusses heavily on either infants, 
children or pregnant women putting very little focus on healthy, non-pregnant women of 
reproductive age. This demographic is of particular interest as they are at a prolonged risk for 
ID due to physiological losses of iron posing demands on its effective absorption, which may 
be exacerbated by the quantity and quality of dietary iron intake. In Europe, 61-97 % of women 
of reproductive age have a dietary iron intake below the recommended daily allowance of 
14.8-16.0 mg/day (Milman, 2019). Consequently, the demand for iron may be greater than the 
quantity of iron acquired from the diet, increasing the likelihood of ID despite otherwise being 
healthy. Not only does this reiterate that ID is the most prevalent nutritional deficiency but also 
supports the notion of the general population of upper-middle and high-income countries being 
deficient in one or more vitamins and minerals (Kennedy, 2016; Kennedy & Haskell, 2011). 
Previous multivitamin intervention studies utilising a healthy, young female population have 
identified a significant attenuation of the negative effects on physical tiredness following a 
difficult multi-tasking cognitive battery alongside improvements in accuracy and speed of 
cognitive functioning (Haskell et al., 2010). Acute and chronic supplementation is also shown 
to modulate cerebral blood flow and metabolic parameters of energy expenditure during 
cognitive task performance (Kennedy et al., 2016). It is therefore suggested that both 
metabolism and brain function are receptive to micronutrient supplementation even when 
healthy adult females are assumed to have a sufficient nutritional status. As iron is essential 
for fundamental biological processes that affect psychological and physiological functioning, 
it is suggested that otherwise healthy females classed as iron deficient or those with an 
inadequate dietary iron intake regardless of iron status would both benefit from iron 
supplementation.  
 
Similarly, this population is subject to natural age-related cognitive decline beginning in their 
20s or 30s (Salthouse, 2009; Salthouse, 2019), which may be accompanied by age-related 
alterations in cerebral blood flow inciting a negative association between cerebral blood flow 
and task performance (Bertsch et al., 2009; Catchlove et al., 2018). Iron deficiency anaemia 
is associated with an increased cardiac workload, which is shown to invoke compensatory 
increases in cerebral blood flow to enhance cerebral oxygen delivery when haemoglobin is 
diminished in infancy (Aliefendioglu et al., 2007; Hare, 2004). However, serum ferritin is shown 
to moderate relationships between task difficulty and brain activity as measured by 
electroencephalography (EEG) in women of reproductive age with NAID (Wenger, DellaValle, 
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Murray-Kolb, & Haas, 2019). This suggests that brain function can still be affected prior to the 
development of IDA, which may exacerbate the natural age-related cognitive declines.  
 
Considering this, it is not solely IDA that is considered a clinical issue; statistics from the United 
States indicate that 3-5 % of non-pregnant women aged 16-49 have IDA whilst 11-20 % have 
NAID (Soppi, 2018; Umbreit, 2005). Similarly, although epidemiological data is scarce for this 
demographic in the United Kingdom, the prevalence of IDA is estimated to be 5 % whilst the 
prevalence of NAID may be up to 15 % (SACN, 2010; PHE, 2014). Non-anaemic ID arises in 
females when haemoglobin concentrations are normal (> 120 g/L) but ferritin stores are 
depleted. Symptoms remain the same as for IDA, however it poses a clinical challenge in 
comparison as there are no well-defined diagnostic criteria for a serum ferritin cut-off due to 
its APP properties. A serum ferritin cut-off of < 15 µg/L is a proposed indicator of ID in healthy 
female populations (Garcia-Casal, Pasricha, Martinez, Lopez-Perez, & Peña-Rosas, 2018); 
however, it is arguably too low as serum ferritin 15 - 30 µg/L (Pasricha et al., 2010) and 25 - 
40 µg/L (Hallberg et al., 1993) are shown to be highly suggestive of ID. Serum ferritin < 30 
µg/L is associated with increased diagnostic accuracy in comparison to a cut off of < 12 µg/L 
(Mast, Blinder, Gronowski, Chumley, & Scott, 1998), however it is also suggested to increase 
the occurrence of false-positive ID diagnoses (Daru et al., 2017). Together with the indication 
that mobilisation of iron stores and their subsequent depletion is reflected by serum ferritin 13-
20 µg/L (Langley-Evans, 2013), a cut-off of ≤ 20 µg/L should be considered when investigating 
NAID. There is promising evidence to suggest a causal role for iron in cognitive function 
concerning attention, memory and learning domains (Leonard, Chalmers, Collins, & 
Patterson, 2014; Murray-Kolb & Beard, 2007) and objective measures of athletic performance 
(Rubeor et al., 2018) when using a serum ferritin cut-off of ≤ 20 µg/L for NAID women of 
reproductive age. As a reduction in physical capacity often presents simultaneously alongside 
symptoms of central fatigue characterised by subjective feelings of reduced energy and 
motivation, which may instigate augmented anxious and depressive emotions that deplete 
quality of life and cognitive capacity (Dziembowska et al., 2019), further investigation of 
behavioural function at this serum ferritin cut-off is warranted.  
 
Overall, although reviews have highlighted the beneficial effect of iron supplementation for 
women of reproductive age, NAID is deserving of further investigation among this population 
using a serum ferritin cut-off of 20 µg/L. It is postulated that NAID women should still benefit 
from iron supplementation, as should those who do not consume sufficient dietary iron. 
 
1.6.2 Dosage and duration of iron supplementation 
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In NAID women, fractional absorption of iron is shown to be highest at lower doses of 40-80 
mg in comparison to higher doses of 160-240 mg, with consecutive-day and twice-daily dosing 
reducing iron bioavailability at high doses (Moretti et al., 2015). Although, alternate-day dosing 
of iron ranging from 100-200 mg is shown to optimise iron absorption in NAID and IDA women 
(Stoffel et al., 2017; Stoffel, Zeder, Brittenham, Moretti, & Zimmermann, 2019). A comparative 
study of iron doses has identified a 60 mg iron dose to be as effective as an 80 mg dose for 
improving iron status in NAID women with no significant difference in adverse events or 
compliance (Leonard et al., 2014). However, 60 mg is substantially greater than the 
recommended daily allowance (RDA) of 14.8-16 mg for non-pregnant, menstruating women 
(Milman, 2019), and greater than the tolerable upper level of iron intake of 40-45 mg based 
upon the prevention of gastrointestinal discomfort (Pra, Franke, Henriques, & Fenech, 2012). 
A systematic review highlighted a significant association between increased gastrointestinal 
side effects and iron doses exceeding 30 mg elemental iron (Low, Speedy, Styles, De-Regil, 
& Pasricha, 2016). Resolution of NAID has however been achieved after an 8-week 
intervention of 26 mg daily iron supplementation without the occurrence of adverse effects 
(D'Adamo, Novick, Feinberg, Dawson, & Miller, 2018). Although serum ferritin improved from 
baseline, this was only to a mean of 21.1 µg/L, which is only marginally above the 20 µg/L cut 
off for NAID classification. However, the 8-week intervention period was below the 
recommended duration of three to six months for iron supplementation to effectively restore 
iron levels (Baird-Gunning & Bromley, 2016), which may explain why the improvement in iron 
status was not pronounced. A lower dose supplement over a longer duration may therefore 
be more beneficial for achieving an optimal iron status and reducing adverse effects to ensure 
compliance. 
 
1.6.3 Increasing the absorption and tolerability of iron supplements 
 
Although oral iron supplementation is the gold-standard treatment for ID, specifically ferrous 
sulphate forms, its daily administration in a non-clinical population is associated with an 
increased risk of gastrointestinal side effects regardless of dose when compared to placebo 
or intravenous iron delivery, which lead to reductions in treatment compliance (Tolkien et al., 
2015). Intravenous iron however is only used under certain circumstances such as known iron 
malabsorption, cancers, chronic kidney disease, inflammatory bowel disease, pregnancy, an 
urgent need to raise haemoglobin concentrations and poor compliance due to intolerable side 
effects of oral iron (Gozzard, 2011; Singh, Fong, & Kuperan, 1998). Using intravenous iron in 
RCTs for non-clinical samples would lack ecological validity, therefore alternate oral forms of 
iron are deserving of investigation.  
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To improve iron supplementation tolerability, alternate preparations including polynuclear 
formulations based on the ferric iron form, such as iron hydroxide polymaltose complex (IPC) 
(Yasa, Agaoglu, & Unuvar, 2011), have been investigated. A meta-analysis highlighted oral 
IPC to be as effective as ferrous sulphate formulations for improving haemoglobin 
concentrations, whilst reducing the prevalence of adverse side effects (Toblli & Brignoli, 2007). 
A trial in adolescents of both sexes with varied iron status used oral IPC containing 100 mg 
elemental iron given six days a week for eight months; no adverse side effects were reported 
whilst concomitantly improving haematological parameters and cognitive and scholastic 
performance (Devaki et al., 2009). Iron sufficient, NAID and IDA groups all elicited significant 
increases in serum ferritin; however, IS adolescents who had higher initial haemoglobin 
concentrations compared to NAID and IDA adolescents had the highest gain of serum ferritin. 
These findings are corroborated by recent data that discovered no correlation between initial 
haemoglobin concentrations and increases in serum ferritin in IDA children administered oral 
IPC (Name, Vasconcelos, & Valzachi Rocha Maluf, 2018). It is suggested that oral IPC may 
therefore encourage the development of iron overload.  
 
Iron bis-glycinate chelate compounds are a suggested resolution to counteract the concerns 
associated with bivalent ferrous supplements and ferric IPC preparations. The bis-glycinate 
chelate consists of two heterocyclic rings (Figure 1.6) orientated at uniform tetrahedral angles 
in the least sterically hindered conformation possible (Ashmead, 2001). This conformation 
protects iron from interacting with dietary inhibitors including calcium, phytates and 
polyphenols to form insoluble compounds increasing the bioavailability of iron for absorption. 
The five-member rings infer a stronger stability constant than that of inhibitory ligands, which 
have the potential to displace the ferrous cation from the glycine ligand causing its 
disassociation in the gut (Ashmead, 2001). Additionally, the chelate has a low molecular 
weight of 204 daltons (Da); a value much lower than the upper limit of 1,000-1,500 Da for 
effective chelate absorption in humans (Ashmead, 2001; Kratzer, 2018). Although greater than 
ferrous sulphate (152 Da) (National Center for Biotechnology Information, 2019), the chelate 
is more likely to be successfully absorbed as ferrous sulphate is more susceptible to the 
detrimental impact of inhibitory ligands. Subsequently, iron bis-glycinate chelate is favoured 
over bivalent ferrous formulations for iron fortification food and drink strategies to combat ID. 
Studies have identified greater absorption of fortified iron from bis-glycinate chelate than 
ferrous sulphate in typically iron inhibiting mediums; fortified whole cow’s milk (Olivares et al., 
1997; Stekel et al., 1986; Torres, Lobo, Sato, & Queiroz Sde, 1996), polyphenol and phytate-
rich breakfasts (Layrisse et al., 2000), phytate-rich breads (Giorgini et al., 2001) and high-




Figure 1.6 Structural formation of iron bis-glycinate chelate (C4H8FeN2O4). The chelate consists of two, five-
member, heterocyclic rings comprising two bonds between the ferrous cation and the glycine molecules. The 
carboxyl group and the α-amino group of the glycine molecule bind the ferrous cation by an ionic bond and a 
coordinate covalent bond respectively (figure adapted from Ashmead, 2001). 
 
The structural formation of iron bis-glycinate is suggested to promote gastrointestinal 
tolerability as the amino acid ligand ring formation prevents the ferrous cation from interacting 
with the mucosal lining (Ashmead, 2001). The lower stability constant of ferrous sulphate is 
suggested to cause its dissociation in the gut to promote elemental iron release in the 
stomach, which initiates gastrointestinal irritation and subsequent side effects (Ashmead, 
2001). Human studies provide support for this concept; non-pregnant women of reproductive 
age with IS iron status demonstrated a significantly higher preference for iron bis-glycinate 
chelate over ferrous sulphate following trends for lower incidence of gastrointestinal adverse 
effects (Coplin, Schuette, Leichtmann, & Lashner, 1991) and significantly fewer reports of 
adverse effects (Fouad et al., 2013). This evidence suggesting superior bioavailability and 
tolerability of iron bis-glycinate has prompted its use as an alternative oral supplement for the 
treatment of IDA. Amongst pregnant women, lower doses of iron bis-glycinate have initiated 
significantly less pronounced pregnancy-associated decreases in iron status parameters 
(Szarfarc, de Cassana, Fujimori, Guerra-Shinohara, & de Oliveira, 2001), significantly lower 
gastrointestinal complaints (Milman, Jonsson, Dyre, Pedersen, & Larsen, 2014) and a 
significantly faster rise in haemoglobin (Abdel Moety et al., 2017) in comparison to ferrous 
salts. Iron bis-glycinate is also shown to improve haematological measures above the IDA cut-
off more efficiently than an equal dose of ferrous sulphate in the presence of significantly fewer 
reported side effects (Abbas, Abdelbadee, Alanwar, & Mostafa, 2019). For infants and 
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adolescents, lower (Bagna et al., 2018; Pineda, Ashmead, Perez, & Lemus, 1994) and equal 
doses (Pineda & Ashmead, 2001) of iron bis-glycinate chelate are shown to improve 
haemoglobin with similar efficacy but serum ferritin with greater efficacy than ferrous sulphate 
in the presence of fewer adverse effects. Iron bis-glycinate also demonstrates superior 
efficacy than oral IPC for treatment of IDA in children by increasing iron stores through 
absorption that is regulated by the demand for iron (Name et al., 2018). This corroborates 
previous findings of an inverse relationship between iron stores and the absorption of iron bis-
glycinate chelate (Bovell-Benjamin et al., 2000; Olivares et al., 1997). From these findings, 
there is support for iron bis-glycinate chelate supplementation to be of most benefit to a NAID 
population.  
 
1.6.3.1 Vitamin C co-supplementation  
 
Vitamin C, otherwise known as ascorbic acid, cannot be synthesised by the human body so 
must also be acquired from the diet (Hansen, Tveden-Nyborg, & Lykkesfeldt, 2014); however, 
the brain has the ability to recycle it to prevent the neurological symptoms associated with its 
deficiency, including severe fatigue, confusion, and depression (Caballero, Trugo, & Finglas, 
2003). In addition to its well-known anti-oxidant properties, vitamin C is vital for 
neuromodulation acting as a co-factor for acetylcholine, noradrenaline, dopamine and 
serotonin synthesis (Figueroa-Méndez & Rivas-Arancibia, 2015; Gupta, Tiwari, & Haria, 
2014); modulation of GABA-ergic systems and inhibition of N-methyl-D-aspartate receptors 
and L-arginine-nitric-oxide cyclic guanosine 3,5-monophosphate pathway (Covarrubias-Pinto, 
Acuna, Beltran, Torres-Diaz, & Castro, 2015); and inducing haem-oxygenase 1 expression 
(Gariballa, 2014). Dysfunction of these metabolic processes is linked to depression and 
anxiety, instilling the hypothesis of ascorbic acid having anti-depressant-like properties. High 
ascorbic acid status has been associated with improved mood (Prohan, Amani, Nematpour, 
Jomehzadeh, & Haghighizadeh, 2014; Pullar, Carr, Bozonet, & Vissers, 2018), further 
supported by intervention trials with oral vitamin C showing significantly reduced depressive, 
anxiety and fatigue symptoms following 500 mg/day supplemental (de Oliveira, de Souza, 
Motta, & Da-Silva, 2015) and 212 mg/day dietary vitamin C (Carr, Bozonet, Pullar, & Vissers, 
2013) over two and six weeks, respectively. Similarly, significant associations between plasma 
ascorbic acid and performance on tasks of attention, memory (working, recall and recognition), 
focus and decision speed have been identified (Travica et al., 2019), mechanisms for which 
include the known roles of acetylcholine and noradrenaline for attention, focus and memory 
performance (Klinkenberg, Sambeth, & Blokland, 2011); the impact of hippocampal and 
prefrontal cortex serotonergic neurons upon memory, decision making, and attention (Švob 
Štrac, Pivac, & Mück-Šeler, 2016); and the increased synthesis of energy through L-carnitine 
 58 
production allowing the optimal metabolic energy supply for peak cognitive performance 
(Owen & Sunram-Lea, 2011).  
 
Vitamin C is also capable of reducing ferric iron from the diet to ferrous iron but can also 
chelate ferrous iron to preserve its solubility and increase its uptake across the duodenum 
with a change in pH (Conrad & Schade, 1968). The addition of a vitamin C-rich fruit to a ferrous 
sulphate-fortified breakfast cereal significantly improved serum ferritin concentrations in 
women with serum ferritin ≤ 25 µg/L and haemoglobin ≥ 115 g/L (Beck, Conlon, Kruger, Coad, 
& Stonehouse, 2011). Consequently, combination therapy of iron supplements and vitamin C 
is often recommended for IDA treatment. However, despite the positive associations between 
cognition, mood, fatigue and vitamin C, iron and vitamin C co-supplementation has not been 
previously investigated with regards to the effects on cognitive and behavioural functions. 
Additionally, to our knowledge, co-supplementation of iron bis-glycinate and vitamin C has not 
previously been investigated.   
 
The efficacy of iron bis-glycinate chelate (15 µg/L) in an iron inhibiting medium like milk for 
improving iron status is deemed comparable to the co-fortification of ferrous sulphate and 
ascorbic acid (Olivares et al., 1997; Stekel et al., 1986). The structural configuration of the 
chelate protects against inhibitory compounds, whilst the addition of ascorbic acid (100 mg/L) 
is shown to further stimulate iron bis-glycinate absorption (15 µg/L) in an inhibitor-rich 
environment (Olivares et al., 1997). Although ferrous sulphate formulations are more 
amenable to the benefits of ascorbic acid (Olivares et al., 1997), such evidence indicates that 
the addition of ascorbic acid improves the already superior bioavailability of iron bis-glycinate 
chelate. In view of this, co-supplementing iron bis-glycinate chelate with ascorbic acid would 
not only benefit its absorption but would also reduce the impact of inhibitory compounds found 
in a normal dietary intake.  
 
1.6.4 Dietary and lifestyle factors 
 
As iron cannot be synthesised by the human body, all iron sources are acquired externally 
through the diet. Iron deficiency and IDA rates are highest in low-income developing countries 
primarily due to the combination of exposure to chronic infection and limited access to an iron-
rich diet (Prentice et al., 2017). Within upper-middle and high-income countries, ID remains 
the most prevalent nutritional deficiency by consequence of common lifestyle factors that 
increase deficiency occurrence, including dietary iron consumption and bioavailability, 
physical activity and menstrual blood loss.  
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Although possible to achieve optimal iron intake without consuming meat, review findings 
provide evidence for a positive association between animal flesh intake/day and iron status 
(Jackson, Williams, McEvoy, MacDonald-Wicks, & Patterson, 2016). Meta-analysis 
corroborated these findings by concluding that vegetarians have significantly lower serum 
ferritin concentrations compared to non-vegetarians subsequently increasing the risk for ID 
(Haider, Schwingshackl, Hoffmann, & Ekmekcioglu, 2018). This may be due to an increased 
consumption of phytate-rich grains and cereals, polyphenol-rich food and drink, and calcium-
rich dairy products that have inhibitory effects on non-haem bioavailability (Beck et al., 2014). 
Similarly, alternate nutritional deficiencies may contribute to cognitive limitations and affect the 
efficacy of iron supplementation. Iron and zinc share some absorptive and transport 
mechanisms so may compete for greater absorption, initiating redundancies in both minerals 
(Sandstrom, 2001). Iron supplementation can significantly reduce zinc absorption due to this 
competition (Kordas & Stoltzfus, 2004; Sandstrom, Davidsson, Cederblad, & Lonnerdal, 1985; 
Solomons & Jacob, 1981) and exacerbate the potential cognitive deficits associated with ID 
(de Moura et al., 2013; Stoecker et al., 2009). Therefore, it may be imperative to assess dietary 
iron intake and to monitor zinc levels across intervention periods. A greater risk for depressive 
and anxiety disorders is attributed to a lower consumption of iron-rich red meat independent 
of other dietary influences in a sample of adult women (Jacka et al., 2012) whilst vegetarian 
diets may influence mental well-being due to the loss of nutrients from excluded foods causing 
an elevation in depressive symptoms compared to omnivores (Baines, Powers, & Brown, 
2007; Forestell & Nezlek, 2018; Matta et al., 2018). As iron has a key role in monoaminergic 
neurotransmitter modulation, this may explain the prevalence of mood dysfunction associated 
with lower dietary iron intake. Additionally, as absorption of dietary iron can be impacted by 
multiple variables, dietary iron may have a direct effect upon psychological parameters that is 
independent of iron status; however, this potentially influential effect has not previously been 
considered.   
 
Iron deficiency may also arise following acute exercise-induced inflammation upregulating 
hepcidin expression, which diminishes effective iron absorption (McClung et al., 2014), as 
discussed in section 1.5.2. Despite an adequate daily dietary intake of iron, trained female 
endurance athletes exhibit significant hepcidin elevations with increases in training load that 
increase the risk for ID (Ishibashi, Maeda, Sumi, & Goto, 2017). A systematic review extended 
these findings to single acute bouts of endurance exercise between 30-120 minutes at 
moderate or high intensity facilitating the upregulation of hepcidin expression between 0 hours 
and 6 hours post-exercise, peaking at 3 hours which may coincide with high-iron meals being 
consumed and not effectively absorbed (Domínguez et al., 2018). For untrained women who 
partake in regular aerobic exercise, the efficacy of iron supplementation is diminished in 
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comparison to those who do not regularly exercise (Pompano & Haas, 2017). The 
aforementioned findings regarding athletes may therefore apply to physically active but 
untrained women in that iron absorption is reduced due to exercise-induced upregulation of 
hepcidin and an increased demand of iron for use in oxidative pathways (Buratti, Gammella, 
Rybinska, Cairo, & Recalcati, 2015). Alternatively, poorer physical performance is also 
associated with IDA and NAID amongst females (Brownlie IV, Utermohlen, Hinton, Giordano, 
& Haas, 2002; Brutsaert et al., 2003; Haas, Seymour, Hernandez, Dehaene, & Villalpando, 
2002; Haas & Brownlie IV, 2001; Hinton, Giordano, Brownlie, & Haas, 2000; Zhu & Haas, 
1998) alongside lower physical activity; NAID females spend more time in sedentary 
behaviours than those who are IS, which potentially contributes to body mass gain (Crouter, 
DellaValle, & Haas, 2012). Increased adipose tissue induces augmented pro-inflammatory 
cytokine and hepcidin production, which attenuates dietary iron absorption due to increased 
ferroportin degradation (Aigner, Feldman, & Datz, 2014; Tussing-Humphreys, Pusatcioglu, 
Nemeth, & Braunschweig, 2012). Obesity-associated systemic inflammation is more 
pronounced in females than males and this has been associated with poor cognitive 
performance (Cook et al., 2017; Gimeno, Marmot, & Singh-Manoux, 2008; Sweat et al., 2008), 
depression (Amiri, Behnezhad, & Nadinlui, 2018; de Wit et al., 2010; Evangelou et al., 2019), 
daytime sleepiness, sleep quality, and general fatigue thus influencing ratings of quality of life 
(Jarosz et al., 2014; Vgontzas et al., 1997). In the United Kingdom, 40 % of adult females are 
insufficiently active and exhibit lower levels of physical activity in comparison to males 
(Guthold, Stevens, Riley, & Bull, 2018). Failure to meet physical activity recommendations is 
associated with greater levels of fatigue in women; effects that are exacerbated by prolonged 
sedentary behaviours (Ellingson, Kuffel, Vack, & Cook, 2014). A systematic review concluded 
that physical activity has a positive effect on cognitive functioning (Cox et al., 2016) and mood 
(Rebar et al., 2015) in young to middle-aged adults due to modulation of monoaminergic 
neurotransmitters (Strasser & Fuchs, 2015), the production of which may be downregulated 
by ID (Beard & Connor, 2003). Yet, despite the influence of physical activity and obesity upon 
iron status, cognitive function, mood and fatigue, only one cross-sectional study assessing the 
impact of iron status on cognition has accounted for the confounding variability (Cook et al., 
2017), whilst no studies investigating mood and fatigue have done so. 
 
Blood loss through regular blood donation is a known risk factor for ID in both males and 
premenopausal women (Beck et al., 2014; Reddy, Shastry, Raturi, & Baliga B, 2020); 
however, women of reproductive age are at an additional risk for ID due to increased iron 
losses because of heavy menstrual bleeding (Johnson, Lang, Sturm, & O'Brien, 2016). 
Quantitative measures of menstrual blood loss have been shown to significantly predict iron 
status (Harvey et al., 2005), whilst subjective approaches have indicated significantly lower 
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serum ferritin concentrations for those with greater menstrual blood loss (Heath, Skeaff, 
Williams, & Gibson, 2001; Toxqui, Pérez-Granados, Blanco-Rojo, Wright, & Vaquero, 2014). 
Haemoglobin and serum ferritin concentrations are also lowest during menses and highest 
during the luteal phase of the menstrual cycle (Kim, Yetley, & Calvo, 1993). This suggests that 
physiological biomarkers of iron undergo cyclical variations, thus it is recommended to assess 
such biomarkers during the late luteal phase of the menstrual cycle for an accurate 
representation of iron status (Laine et al., 2016) as well as taking menstrual blood loss into 
consideration. Irrespective of ID, increased menstrual blood losses affect physical health, 
fatigue, well-being and productivity (Copher et al., 2012; Karlsson, Marions, & Edlund, 2014; 
Kim et al., 1993; Kocaoz, Cirpan, & Degirmencioglu, 2019; Wang et al., 2013), which instil an 
increased degree of limitations in physical, social and leisure activities affecting quality of life 
(Lukes, Baker, Eder, & Adomako, 2012). Despite such evidence, objective and subjective 
assessments of menstrual blood loss have not been considered when investigating the 
associations between iron status parameters and psychological function. Similarly, women’s 
serum ferritin concentrations are at their lowest between 25 and 35 years of age and are 
generally lower until post-menopause where they abruptly increase (Chełchowska, 
Laskowska-Klita, & Leibschang, 2007). When considered alongside the fact that cognitive 
function is known to naturally decline with age in healthy educated adults starting from their 
20s and 30s (Salthouse, 2009; Salthouse, 2019), it may be imperative to also consider age 




1.7 Rationale and aims of the thesis  
 
The foregoing literature review establishes the involvement of iron in numerous fundamental 
cellular processes, specifically regarding neurobiological functioning. As iron is only attainable 
through dietary sources, its involvement in these processes is considered essential for 
maintaining cellular homeostasis with both ID and overload having detrimental effects upon 
physiological and behavioural outcomes. As ID is the most prevalent nutritional deficiency 
worldwide, previous RCTs have focussed on its impact but are limited by methodological 
issues including classification of iron status, supplement dosage and duration as well as 
disregarding important factors such as supplement tolerability and bioavailability and lifestyle 
factors that can affect iron status regardless of iron supplementation.    
 
The evidence evaluated in the literature review highlights the need for further research 
investigating the effects of iron status and the effects of supplementation on women of 
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reproductive age as they are a population that has been largely overlooked in favour of those 
considered to be at a higher risk for ID. The combination of prolonged iron losses from 
menstruation, the potential for pregnancy associated iron losses and the likelihood of an 
inadequate dietary iron intake bolster the need for further investigations. As NAID is more 
prevalent among this population than IDA, NAID warrants further investigation. Serum ferritin-
dependent associations with fatigue are becoming increasingly apparent; however, findings 
remain equivocal regarding mood, wellbeing and cognition, whilst there is limited data 
available regarding sleep quality. Previous RCTs have shown promising effects of iron 
supplementation; however, should positive physiological or behavioural changes be observed 
in NAID women of reproductive age with a lower and more tolerable dose of iron then these 
results may offer insights into recognising and treating NAID before progression to IDA.   
 
Accordingly, the primary purpose of this thesis is to investigate iron status and the effects of 
iron bis-glycinate chelate and iron bis-glycinate chelate/vitamin C co-supplementation on 
cognitive function, subjective fatigue, mood and wellbeing in NAID menstruating women of 
reproductive age. Overall, this thesis intends to address the following aims: 
 
1. Investigate association of iron status, haemoglobin concentrations and serum ferritin 
concentrations with cognition, subjective mood, fatigue and wellbeing in menstruating 
women of reproductive age aged 18-49 years (Chapter 2). 
 
2. Systematically review current understanding of findings from RCTs investigating the 
effects of iron supplementation on cognition, subjective mood, fatigue and/or wellbeing 
in menstruating women of reproductive age aged 18-49 years (Chapter 3).  
 
3. Investigate the effect of iron bis-glycinate chelate and iron/vitamin C co-
supplementation on cognition, subjective mood, fatigue and wellbeing in menstruating 
women of reproductive age aged 18-49 years (Chapter 4).  
 
4. Investigate the effect of iron bis-glycinate chelate and iron/vitamin C co-
supplementation on cerebral blood flow and energy expenditure at rest and during 
cognitive demand in menstruating women of reproductive age aged 18-49 years 
(Chapter 5).   
 
The experimental investigations within this thesis will be the first employing both iron bis-
glycinate chelate alone and co-supplemented with vitamin C upon cognition, subjective mood, 
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fatigue and well-being. Additionally, assessing the effects of iron supplementation on cerebral 
blood flow is novel to the research area.  
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 THE ASSOCIATION OF IRON STATUS, HAEMOGLOBIN AND SERUM 
FERRITIN TO COGNITIVE FUNCTION, MOOD, FATIGUE AND WELL-BEING IN WOMEN 




Non-anaemic iron deficiency (NAID) is a clinical challenge worldwide for women of 
reproductive age. The psychological differences between women who are iron deficient 
anaemic (IDA) or iron sufficient (IS) are well established; IDA is associated with an increased 
likelihood of cognitive, emotional and behavioural dysfunction (Jáuregui-Lobera, 2014), 
however the differences between NAID and IS remain ambiguous. The functional role of iron 
for cognitive performance is often attributed to its essential role in meeting the metabolic 
demands of oligodendrocytes for axon myelination. Iron deficiency (ID) is postulated to induce 
myelin deficits across the lifespan (Oberman & Pascual-Leone, 2013) reducing neural 
information processing speeds, which are essential for maintaining attention, learning, 
memory and planning cognitive functions (Nickel & Gu, 2018). However, studies remain limited 
to the populations considered at a higher risk of ID such as infants, children and pregnant 
women whilst the prolonged risk to non-pregnant women of reproductive age due to years of 
menstruation and the possibility of pregnancy is often overlooked.  
 
Cross-sectional studies comparing the cognitive function of NAID and IS women of 
reproductive age have shown no significant differences across iron status groups for attention 
and executive function (Scott & Murray-Kolb, 2016). Similarly, previous iron intervention 
studies focussed upon group comparisons between NAID and IS women of reproductive age 
have found no significant differences in baseline cognitive performance (Leonard et al., 2014; 
Murray-Kolb & Beard, 2007). Those who are NAID and IS have demonstrated superior 
cognitive performance in comparison to those who are IDA (Murray-Kolb & Beard, 2007), in 
agreement with more recent evidence that identified no cognitive differences between NAID 
and IS women yet greater attentional task performance than IDA women (Cook et al., 2017). 
Despite this, NAID women are shown to have a lower grade point average (GPA) as a 
measure of academic performance in comparison to those who are IS (Scott et al., 2017). 
Overall, the findings are equivocal as to whether NAID infers cognitive dysfunction in 
comparison to IS women of reproductive age. 
 
In contrast, cross-sectional studies of women of reproductive age without anaemia that have 
instead investigated continuous markers of iron status have identified significant associations 
with cognitive function. Increased body iron and serum ferritin were associated with faster 
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executive function planning times and smaller changes in planning time with increased task 
difficulty (Blanton, 2013; Blanton et al., 2013; Scott & Murray-Kolb, 2016). However, findings 
are mixed regarding memory; both positive (Blanton et al., 2013) and negative associations 
(Scott & Murray-Kolb, 2016) of body iron and serum ferritin with working memory performance 
have been identified in addition to negative associations with immediate word recall (Blanton, 
2013). When compared to iron status group comparisons, investigating individual continuous 
markers of iron status highlights potential benefits of iron for handling higher cognitive loads, 
though further investigation is required to determine the direction of such associations across 
all cognitive domains.  
 
As stated in section 1.5.1, in addition to ID-associated cognitive deficits, women naturally 
suffer from detriments to the monoaminergic system in comparison to men (Jovanovic et al., 
2008; Staley et al., 2006) and are at a greater risk for ID. Iron may contribute to the aetiology 
of depression as indicated by the association of IDA with increased reports of depressive 
symptoms in women (Pamuk et al., 2015; Vahdat Shariatpanaahi et al., 2007). However, most 
cross-sectional studies within this area have focussed upon women with postpartum 
depression (Beard et al., 2005; Sheikh et al., 2017; Wassef et al., 2019) regardless of the 
prevalence of one in 20 non-pregnant women of reproductive age experiencing major 
depression (Guo, Robakis, Miller, & Butwick, 2018). Those that have investigated non-
pregnant women have shown equivocal results. The frequency of NAID is 15 % greater in 
women with depression and serum ferritin has been shown to be 11 µg/L lower in those with 
depressive symptoms compared to healthy women (Vahdat Shariatpanaahi et al., 2007). Yet 
recent evidence suggests no independent relationships between haemoglobin, serum ferritin 
and depression and that iron deficient serum ferritin (< 20 µg/L) is only associated with 
depressive symptoms when concomitant fatigue is reported (Price, Abernathy, Dobbs, & 
Gallaher, 2017). Such ambiguity highlights the need to further investigate a sample of non-
pregnant women of reproductive age.  
 
The role of haemoglobin for oxygen transport is often proposed as the main cause of fatigue 
onset in ID as reduced haemoglobin diminishes the amount of oxygen delivered to the tissues. 
However, as haemoglobin is unaffected in NAID, alternate mechanisms must be involved. As 
explained in section 1.5.2, ID is characterised by augmented serotonin and decreased 
dopamine, thus fulfilling the monoamine central fatigue hypothesis. Meta-analysis of cross-
sectional studies evinced significant associations between NAID and subjective fatigue in 
women of reproductive age but only in populations screened for randomised controlled trials 
recruiting participants with a primary concern of fatigue or with diagnosed disorders and not 
within the general population (Yokoi & Konomi, 2017) despite consistent reports of women 
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within the general population having higher fatigue scores than men (Cullen et al., 2002; 
Engberg et al., 2017; Ridsdale et al., 1993). A stronger association is to be expected when 
assessing a population who already recognise their fatigue and so further investigations are 
warranted amongst a general population of women of reproductive age.  
 
Although NAID is more common than IDA and is becoming more prevalent amongst women 
of reproductive age, no well-defined diagnostic criteria exist (Soppi, 2018). Such disparity 
across studies assessing cognitive and behavioural function may be a consequence of 
categorising based upon varied diagnostic criteria. Worldwide clinical guidelines suggest 
anaemia can be diagnosed in women of reproductive age when haemoglobin is <120 g/L and 
a serum ferritin cut-off of 15 µg/L is indicative of ID (World Health Organization, 2017), whilst 
clinical laboratories implement a reference range of 10-20 µg/L (Goodnough, Nemeth, & Ganz, 
2010). However, serum ferritin 15-30 µg/L is highly suggestive of ID (Pasricha et al., 2010) 
with diagnostic accuracy of serum ferritin increasing from 25 % to 92 % when changing from 
a cut-off of 12 µg/L to 30 µg/L respectively (Mast et al., 1998). Categorising participants into 
groups based upon inconsistent diagnostic criteria may conceal the impact of ID, especially 
effects that can be attributed to haemoglobin and serum ferritin amongst NAID populations. 
Equally, categorising continuous iron biomarkers into iron status groups may cause unequal 
sample sizes, loss of power and increased heterogeneity between the groups. This may 
explain the mixed findings regarding cognitive function across studies using a NAID population 
as when continuous iron biomarkers are assessed, potential benefits of iron for handling 
higher cognitive loads (Blanton, 2013; Blanton et al., 2013; Scott & Murray-Kolb, 2016) are 
observed.   
 
Additionally, the mixed findings regarding the impact of iron upon psychological parameters 
may be because of little consideration for certain lifestyle factors that increase ID occurrence 
including physical activity, body mass index (BMI), dietary iron consumption and menstrual 
blood loss as discussed in section 1.6.4. The evidence regarding how NAID affects cognitive 
and behavioural function is largely mixed. As no well-defined diagnostic criteria exist for NAID, 
grouping participants into iron status groups using various cut-offs for both serum ferritin and 
haemoglobin increases the heterogeneity within and across study samples. This implies the 
need to investigate the biomarkers of iron status as continuous variables to determine 
independent associations, in addition to the categorical iron status groupings. Additionally, 
physical activity, BMI, dietary iron, menstrual blood loss and age all have the potential to affect 
iron status biomarkers, as well as potentially having direct effects on cognitive function, mood, 
fatigue and well-being, yet there is a lack of control for such variables across previous studies. 
The present study therefore aims to investigate the associations of categorical iron status 
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groups, and continuous biomarkers of iron status haemoglobin and serum ferritin to 
psychological function in women of reproductive age, whilst controlling for the potential 
confounding effects of demographic and lifestyle factors.  
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2.2 Methods 
2.2.1 Design and ethics  
 
This study employed an observational, cross-sectional design. Ethical approval was gained 
from Northumbria University’s Psychology Department and the study was conducted 
according to the Declaration of Helsinki (1964). The study was registered on 




Four hundred and fourteen females aged 18-49 years were recruited. All participants were 
recruited via advertisement posters around Northumbria University and local businesses, 
advertisements on social media and intranet services or by emails sent to university staff and 
students as well as those on the Brain, Performance and Nutrition Research Centre’s 
(BPNRC) participant database. All participants therefore lived in the surrounding area of 
Newcastle-upon-Tyne. All participants enrolled were aged between 18-49 years, self-reported 
that they were in good health and had a BMI between 18.5 and 40 kg/m2. A wide BMI range 
was chosen to include participants that may have elevated hepcidin levels as a result of obese 
adipose tissue that may increase the risk of ID (Aigner et al., 2014; Tussing-Humphreys et al., 
2012). Participants were able to participate if they were proficient in English, a non-smoker, 
free from major illnesses, free from any blood disorders excluding anaemia and were not 
taking any prescription medications excluding the contraceptive pill. To ensure an accurate 
measure of iron status parameters, participants were excluded if they regularly used dietary 
or herbal supplements, had used iron supplements within the past four months or had donated 
more than 300 ml of blood within the past 3 months. Participants were only eligible to take part 
if the phlebotomist could obtain venous blood samples on the day of screening. An a priori 
power analysis was conducted to calculate the sample size based on a small-medium effect 
size (r = 0.2) observed in a previous observational study (Blanton et al., 2013). This indicated 
that a total sample of 193 participants was required to detect significant associations at an 
alpha level of 0.05 to achieve power of .80. In comparison to previous observational studies 
(Blanton et al., 2013; Cook et al., 2017; Scott et al., 2017; Scott & Murray-Kolb, 2016), the 
expected sample size was deemed sufficient. Additionally, as the current study was 
fundamental in recruiting participants into the study described in Chapter 4, participants 
continued to be recruited to the current study until the required sample size was achieved in 
the subsequent study.  
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2.2.3 Demographic/lifestyle measurements 
 
2.2.3.1 Caffeine consumption questionnaire (CCQ) (BPNRC, Northumbria University) 
 
The Caffeine Consumption Questionnaire (CCQ) is a questionnaire developed in-house to 
calculate participants’ estimated typical daily caffeine consumption (mg/day) (APPENDIX I). 
Participants are required to indicate the caffeinated products (fresh brewed coffee; instant 
coffee; decaffeinated coffee; black/green/white tea; decaffeinated black/green/white tea; 
cocoa drink; cola; Lucozade products; red bull; monster/relentless/rockstar; solid chocolate 
bar; square of solid chocolate), if any, that they would have at particular times of the day 
(breakfast; between breakfast and lunch; lunch; between lunch and dinner; dinner; after 
dinner) and the most applicable portion size of the product as indicated by picture graphics. 
Total caffeine consumption (mg/day) is calculated by totalling the caffeine contained in each 
of the indicated products. 
 
2.2.3.2 International physical activity questionnaire short form (IPAQ) (Craig et al., 
2003) 
 
The International Physical Activity Questionnaire (IPAQ) measures the types of intensity of 
physical activity that participants do as a part of their daily lives to give a metabolic (MET)-
minutes score. Participants are required to estimate how often during the last 7 days they have 
taken part in vigorous and moderate physical activities and walked for at least 10 minutes at 
a time. Continuous MET-minute/week scores are calculated by multiplying the average MET 
value of the activity (8, 4 and 3.3 for vigorous, moderate and walking activities respectively) 
by the number of activity minutes and days. The IPAQ is a reliable and valid measure of 
physical activity across multiple countries in comparison to other self-report measures (Craig 
et al., 2003).  
 
2.2.3.3 Menstrual cycle and blood loss questionnaire  
 
This questionnaire (APPENDIX II) was adapted from a published menstrual blood loss (MBL) 
questionnaire (Toxqui et al., 2014). Participants were required to detail whether they used 
hormonal contraceptive methods and whether they had had a period or withdrawal bleed in 
the last three months. Information was also gathered regarding the date of onset of their last 
menstrual bleed, usual number of days menstruation, estimated number of heavy blood loss 
days and the estimated date of onset of their next menstrual bleed. Additionally, participants 
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were required to specify the number and type of pads and/or tampons used during their 
heaviest blood loss day of their bleed, both during the day and night. Menstrual blood loss 
was estimated by multiplying the relative absorbance values of the different pads and tampons 
by the number of units used by the participant; a method deemed reliable (α = 0.83) for 
menstrual blood loss estimation (Toxqui et al., 2014). An MBL-score was then calculated 
taking into consideration the number of heavy days, number of days menstruation and the 
estimated MBL using the following formula in Figure 2.1:  
 
Figure 2.1 Formula used to create the MBL-score from the menstrual cycle and blood loss questionnaire (Toxqui 
et al., 2014). 
 
2.2.3.4 EPIC-Norfolk food frequency questionnaire (FFQ)  
 
The EPIC-Norfolk food frequency questionnaire (FFQ) consists of 130 food items, which 
participants had to select the most appropriate frequency of consumption over the last year 
ranging from ‘never or less than once/month’ to ‘6+ per day’. An additional six questions were 
asked regarding milk type and frequency, cereal type, fat for frying, fat for baking, and 
consumption of visible fat. The FFQ is processed by FETA software (Mulligan et al., 2014) to 
calculate a daily nutrient and food weight producing an output of 46 nutrients and 14 food 
groups consumed daily in mg and g, respectively. For the purpose of this thesis, dietary iron 
was the only nutrient utilised in analysis. Iron-relevant food groups, meat and meat products; 
fish and fish products; cereal and cereal products; nuts and seeds; and vegetables were used 
for demographic information. 
 
2.2.4 Computerised cognitive assessments 
 
The Computerised Mental Performance Assessment System (COMPASS, Northumbria 
University, Newcastle-upon-Tyne, UK) was used to administer all cognitive assessments and 
visual analogue scales across all studies included in the thesis. The tasks included are well-
validated and have previously demonstrated sensitivity to a range of acute and chronic 
nutritional interventions in healthy adults (Haskell-Ramsay et al., 2018; Kennedy et al., 2017; 
Stonehouse et al., 2013). Cognitive task responses were registered by Cedrus RB-530 
response pads with the exception of the word recall, serial subtractions and peg and ball, 
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which were instead recorded by pen and paper, keyboard entry and mouse clicks, 
respectively. The cognitive tasks are described below in order of presentation.  
 
2.2.4.1 Computerised location learning task (cLLT) 
 
Participants were shown a 5 x 5 grid containing pictures of objects and were asked to 
remember the location of the objects as accurately as possible. The presentation duration was 
15 seconds after which there was a 10 second gap before participants were required to 
relocate the objects to the correct location shown to them previously in an empty grid. There 
was no time limit for responding. This was repeated five times during the learning phase. For 
each of the five learning trials, a displacement score was calculated as the sum of the errors 
made for each object (calculated by counting the number of cells the object had to be moved 
both horizontally and vertically in order to be in the correct location). A total displacement score 
was calculated as the sum of the displacement scores on the five learning trials. A Learning 
Index was also calculated as the average relative difference in performance between trials 
(Kessels, Nys, Brands, van den Berg, & Van Zandvoort, 2006). The Learning Index equation 
can be visualised in Figure 2.2. 
 
Figure 2.2 Learning Index equation where the letters A-E are indicative of the displacement scores for the five 
location learning trials respectively (Kessels et al., 2006).   
 
2.2.4.2 Word presentation 
 
Participants were presented sequentially with 15 words selected at random from a large bank 
of words derived from the MRC Psycholinguistic Database (Fearnley, 1997) and matched for 
word length, frequency, familiarity and concreteness. Stimulus duration was one second, with 
an inter-stimulus duration of one second.  
 
2.2.4.3 Immediate word recall 
 
Immediately after the word presentation, participants were given 60 seconds to write down as 
many of the 15 words that they were presented with during the stimulus presentation period. 
The task is scored for number of words correctly recalled.   
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2.2.4.4 Picture presentation 
 
Participants were presented sequentially with 15 randomly selected photographic images to 
remember. Presentation was at a rate of one picture every three seconds, with a stimulus 
duration of one second.  
 
2.2.4.5 Numeric working memory 
 
A series of 5 digits from 1-9 were presented sequentially to the participant one at a time for 
them to memorise. Immediately following, 30 digits (15 targets and 15 distractors) were 
presented sequentially for the participant to indicate whether each digit was presented in the 
original series with a yes/no response. The task consists of 3 separate trials and outcomes 
are overall accuracy (% correct) and mean reaction time for correct responses (msec).   
 
2.2.4.6 Choice reaction time 
 
Arrows pointing either left or right appeared on the screen at irregular intervals ranging 
between 1 and 3 seconds. Participants were required to indicate the direction of the arrow as 
quickly as possible, whenever an arrow was displayed. Outcomes are accuracy (% correct) 
and reaction time for correct responses (msec). 
 
2.2.4.7 Digit vigilance 
 
A fixed digit ranging from 1-9 was presented on the right of the screen and a series of changing 
digits appeared on the left of the screen. Participants were required to respond with a single 
button press when both digits matched. Outcomes are accuracy (% correct), mean reaction 
time for correct responses (msec) and errors (number of false alarms).  
 
2.2.4.8 Serial subtraction tasks  
 
Computerised versions of the serial subtraction tasks were implemented using tests of 2-
minute duration. Participants were required to count backwards in threes or sevens from a 
given number as quickly and as accurately as possible using the number keys to enter each 
response. A random starting number between 800 and 999 was presented on the computer 
screen, which is cleared by the entry of the first response. In the case of an incorrect response, 
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subsequent responses are scored as correct in relation to the previous number. The task is 
scored for total number of responses and the number of errors.  
 
2.2.4.9 Rapid visual information processing (RVIP) 
 
The participant was required to monitor a continuous series of digits for targets of three 
consecutive odd or three consecutive even digits. The digits were presented at the rate of 100 
per minute and the participant responded to the detection of a target string by pressing the 
response button as quickly as possible. The task was continuous and lasted for 5 minutes, 
with 8 correct target strings presented in each minute. Outcomes are percentage of target 
strings correctly detected (% correct), average reaction time (msec) for correct detections, and 
number of false alarms. 
 
2.2.4.10 Visual analogue scales (VAS) 
 
Participants rated their current subjective ‘mental fatigue’ and ‘alertness’ states by placing an 
‘X’ on a 100 mm line with the end points labelled “not at all” (left hand end; 0) and “extremely” 
(right hand end; 100). 
 
2.2.4.11 Peg and ball 
 
Two configurations were shown on the screen. In each, there was a blue, green and red ball 
each on one of 3 pegs. The configuration at the top of the screen was the goal configuration 
and participants were required to arrange the balls on the starting configuration (shown in the 
centre of the screen) to match the position of balls in the goal configuration. Participants were 
required to complete the task in the least number of moves possible with difficulty increasing 
as the task progressed. Outcomes were number of errors, average thinking time (msec) and 
average completion time (msec). Five stimuli at each of the three levels (3, 4 and 5 moves) 




In this computerised version of the classic task, words describing one of four colours (‘RED’, 
‘YELLOW’, ‘GREEN’, ‘BLUE’) were presented in different coloured fonts in the centre of a 
computer screen. The participant was required to press one of four coloured response buttons 
in order to identify the font colour (e.g., if the word ‘GREEN’ was presented in a blue font, the 
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correct response would be to respond with the blue button). The presented words were either 
‘congruent’ (word and font are the same colour) or ‘incongruent’ (word and font are different 
colours) and were presented in a random order. Outcomes are for accuracy (% correct) and 
mean reaction time for correct responses (msec).  
 
2.2.4.13 Delayed word recall 
 
Following completion of all other tasks, participants were given 60 seconds to write down as 
many of the 15 words that they were presented with during the stimulus presentation period 
described in section 2.2.4.2. The task is scored for number of words correctly recalled.   
 
2.2.4.14 Delayed picture recognition 
 
Thirty pictures comprising of the same 15 pictures from the stimuli presentation, described in 
section 2.2.4.4, plus 15 distractor pictures were presented, with participants making a yes/no 
response indicating whether the picture was in the original set. Outcomes are accuracy (% 
correct) and reaction time for correct responses (msec). 
 
2.2.4.15 Delayed word recognition 
 
Thirty words comprising the 15 words presented during the stimuli presentation (section 
2.2.4.2) period plus 15 distractor words were presented, with the participant making a yes/no 
response indicating whether the word was in the original set. Outcomes are accuracy (% 
correct) and reaction time for correct responses (msec). 
 
2.2.4.16 Computerised location learning recall 
 
During the recall phase of the location learning task, which participants completed 
approximately 30 minutes after completion of the learning phase, participants were again 
asked to place the objects in the correction location on the empty grid as described in section 
2.2.4.1 with no further prompting. The delayed trial was scored for displacement and a delayed 
displacement score was subsequently calculated as the difference between the displacement 
score on the final learning trial and the delayed trial.  
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2.2.5 Cognitive domain data 
 
The thesis aimed to expand upon the findings of previous cross-sectional and intervention 
studies assessing cognitive performance in NAID women (Leonard et al., 2014; Murray-Kolb 
& Beard, 2007; Scott & Murray-Kolb, 2016) and therefore adopted the same paradigm as the 
intervention studies of assessing cognitive function by domain rather than by individual task 
outcomes to reduce the number of comparisons and for consistency throughout the thesis. 
Although it can be argued that reducing several cognitive outcomes to a single composite 
variable reduces the amount of information representing a single underlying construct 
(Schneider & Goldberg, 2020), cognitive composite measures are shown to improve the 
statistical power of analyses (Jacobs et al., 2020). Task assignment to cognitive domains was 
based upon a framework conceptualised in a literature review focussed upon the impact of 
breakfast consumption on cognitive function in adults (Galioto & Spitznagel, 2016) and by 
consulting alternate nutritional intervention studies that adopted a domain paradigm, which 
also used the same cognitive function assessment system (Haskell-Ramsay, Stuart, Okello, 
& Watson, 2017; Stonehouse et al., 2013). The chosen cognitive domains of attention, 
memory, learning and executive function were used throughout the thesis due to the cross-
sectional differences in these domains identified by iron status and their amenability to iron 
supplementation across iron status groups (Cook et al., 2017; Falkingham et al., 2010; Greig 
et al., 2013; Lomagno et al., 2014; Scott et al., 2017; Scott & Murray-Kolb, 2016). The cognitive 
domains were confirmed by factor analyses using principal components analysis with varimax 
rotation; a component was retained if its eigenvalue was greater than 1.0 (See Appendix III). 
Ten cognitive domains were identified: attention accuracy, attention speed, episodic memory 
accuracy, episodic memory speed, executive function accuracy, executive function speed, 
learning accuracy, working memory accuracy, and working memory speed.   
 
Cognitive domains were calculated by transforming individual task outcomes into standardised 
Z scores and grouping these scores into their respective cognitive domain, utilising the 
methodology previously advocated in nutritional intervention studies (Haskell-Ramsay et al., 
2017; Stonehouse et al., 2013). Prior to calculating accuracy and speed scores, each task 
was required to be represented by one score so that all tasks were weighted equally within 
the domain. Consequently, for those tasks that had both correct and error outcomes (Digit 
Vigilance, RVIP and Serial Subtractions) an overall accuracy score was created by subtracting 
the standardised error score from their respective accuracy/total score and dividing the total 
by 2. For cLLT, the standardised total displacement score was subtracted from the respective 
delayed recall score and added to the standardised learning index score. This total was 
divided by 3 to create a total cLLT score. Scores were then re-standardised to create a final 
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standardised cLLT accuracy score. For the Peg and Ball task thinking time and completion 
time were averaged to create a total Peg and Ball reaction time score, which was then 
standardised. The specific calculations for each domain are outlined below. 
 
2.2.5.1 Episodic memory  
 
The episodic memory data consisted of episodic memory accuracy and speed. These two 
domain outcomes were calculated in a similar manner using standardised scores of task 
outcomes representative of the domain.  
 
Episodic accuracy = (Zpicture recognition accuracy + Zword recognition accuracy + 
Zimmediate word recall correct + Zdelayed word recall correct) /4 
 
Episodic speed = (Zpicture recognition RT + Zword recognition RT) /2 
 
2.2.5.2 Working memory 
 
The working memory data consisted of working memory accuracy and speed. The working 
memory accuracy score was calculated using standardised task outcomes including 
accounting for errors (serial subtractions) as described above:  
 
Working memory accuracy = (Znumeric working memory accuracy + Zserial 3 
subtractions accuracy + Zserial 7 subtractions accuracy) /3 
 
The working memory speed score was calculated using the one standardised task outcome:  
 
Working memory speed = (Znumeric working memory RT) 
 
2.2.5.3 Executive function 
 
The executive function data consisted of executive function accuracy and speed. The 
executive function accuracy score was calculated using standardised task outcomes 
representative of the domain:  
 




The executive function speed score was calculated using standardised task outcomes 
accounting for multiple reaction time outcome measures (peg and ball) as described above: 
 




The attention data consisted of attention accuracy and speed. The attention accuracy score 
was calculated using standardised task outcomes accounting for errors (RVIP and digit 
vigilance) as previously described:  
 
Sustained attention accuracy = (ZRVIP accuracy + Zdigit vigilance accuracy) /2 
 
The attention speed score was calculated from standardised scores using the following 
formula: 
 




Learning comprised of the cLLT task, domain score was calculated as described in section 
2.2.5. 
 
cLLT = (ZDelayed Recall – ZTotal Displacement + ZLearning Index) /3 
 
2.2.6 Behavioural function assessments 
 
2.2.6.1 Profile of mood states (POMS) (McNair, 1992) 
 
The Profile of mood states (POMS) questionnaire comprises 65 adjectives rated on a 5-point 
scale of 0 (not at all) to 4 (extremely) for how the participant is feeling right now. Each item is 
consolidated into the sub-scales of tension-anxiety, depression-dejection, anger-hostility, 
vigour-activity, fatigue-inertia and confusion-bewilderment. A total ‘mood disturbance’ score 
(TMD) is obtained by subtracting the vigour-activity score from the sum of tension-anxiety, 
depression-dejection, anger-hostility, fatigue-inertia and confusion-bewilderment scores. For 
TMD, higher scores are indicative of greater mood disturbance. The POMS is widely used and 
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demonstrates internal consistency across subscales (α 0.63-0.96) (Curran, Andrykowski, & 
Studts, 1995).  
  
2.2.6.2 Piper fatigue scale (PFS) (Piper et al., 1998) 
 
The Piper fatigue scale (PFS) is a 22-item questionnaire assessing subjective feelings of 
fatigue. Questions are answered on a 1-10 scale. Each item is consolidated into the subscales 
of behavioural/severity, affective meaning, sensory, and cognitive/mood. A total fatigue score 
is computed as the average of all responses; higher scores are indicative of greater subjective 
fatigue. The PFS is widely used and validated in clinical populations in several languages 
(Cantarero-Villanueva et al., 2014; Jang, Kim, & Lee, 2017; Lundgren-Nilsson, Dencker, 
Jakobsson, Taft, & Tennant, 2014; Reeve et al., 2012) and has been validated within non-
clinical populations (Clark, Ashford, Burt, Aycock, & Kimble, 2006).  
 
2.2.6.3 Sleep condition indicator (SCI) (Espie et al., 2014) 
 
The Sleep condition indicator (SCI) is an 8-item questionnaire assessing sleep quality over 
the last month. Questions are answered on a 5-point scale (0-4) and a total SCI score is 
calculated by summing across all scale items. Total scores can range from 0 to 32; higher 
total scores are indicative of better sleep quality. The SCI also has a cut-off point for detecting 
clinically significant insomnia (scores ≤16). The SCI is a reliable measure of sleep quality (α 
≥.86) and has shown convergent validity with the validated Pittsburgh Sleep Quality Index and 
Insomnia Severity Index (Espie et al., 2014).  
 
2.2.6.4 Perceived stress scale (PSS) (Cohen, Kamarck, & Mermelstein, 1983) 
 
The Perceived stress scale (PSS) is a 10-item questionnaire assessing feelings and thoughts 
surrounding situations one may deem as stressful having occurred during the last month. 
Questions are answered on a 5-point scale of 0 (never) to 4 (very often) and a total PSS score 
is obtained by reversing responses to the four positively worded items (4, 5, 7 & 8) and then 
summing across all scale items. Total scores can range from 0 to 40; a higher total PSS score 
is indicative of higher perceived stress. The PSS is a widely used research questionnaire, 




2.2.6.5 Health outcomes SF-12 (Ware, Kosinski, & Keller, 1996) 
  
The SF-12 is a 12-item questionnaire used as a measure of generic health and well-being 
outcomes. The items consolidate into eight health domain outcome scales: physical 
functioning, role limitations due to physical health problems (role-physical), bodily pain, 
general health, vitality, social functioning, role limitations due to emotional problems (role-
emotional) and mental health. For physical functioning, role-physical, general health, vitality, 
social functioning, role-emotional and mental health domain scores, low scores are indicative 
of health disturbance whilst higher scores indicate little to no effect on health. Similarly, for 
bodily pain scores, lower scores are indicative of greater levels of pain affecting normal 
activities whilst higher scores indicate that pain does not affect activity. Two component 
summary measures are calculated by combining scores on the four relevant outcome scales; 
a ‘physical component’ summary (PCS) using physical functioning, role-physical, bodily pain 
and general health scores; a ‘mental component’ summary (MCS) using vitality, social 
functioning, role-emotional and mental health scores. Scores are calculated using the 
QualityMetric Health Outcomes™ Scoring System to accommodate norm-based 
standardisation of scale scores. Each health domain scale and component summary score 
have means of 50 and a standard deviation of 10 based upon the 2009 United States general 
population sample (Kosinski, Ware, Turner-Bowker, & Gandek, 2007). Therefore, scores 
greater or lesser than 50 are indicative of scores above or below the average, respectively. 
The SF-12 is a widely used alternative for the SF-36 Health Outcomes questionnaire and has 
been validated for use in several European countries (Gandek et al., 1998).  
 
2.2.6.6 NASA task load index (NASA-TLX) (Hart, 2006; Hart & Staveland, 1988) 
 
The NASA-TLX tool is a subjective workload assessment comprising 6-items. With 
permission, the standard pen and paper version was adapted for use on COMPASS through 
the use of a VAS. Following completion of the cognitive task battery, participants rated their 
subjective feelings of mental demand, physical demand, temporal demand, performance, 
effort and frustration. All scales were answered by placing an ‘X’ on a 100 mm line with the 
end points labelled “very low” (left hand end; 0) and “very high” (right hand end; 100) with the 
exception of the performance scale where end points were “perfect” (left hand; 0) and “failure” 
(right hand; 100). A total workload score following cognitive assessment is calculated using 
the average of all responses; higher scores are indicative of greater subjective workload. As 
advised, physical demand scores were not included in the total workload calculations due to 
a lack of relevance to the cognitive tasks employed.  
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The cognitive and behavioural assessments described in sections 2.2.4 and 2.2.6, 
respectively, are depicted in Figure 2.3 in order of presentation to participants.  
 
Figure 2.3 Schematic of the cognitive and mood assessments completed during study testing. SCI, sleep condition 
indicator; RVIP, Rapid visual information processing; VAS, visual analogue scales. 
 
2.2.7 Blood sampling and analysis 
 
For all studies throughout the thesis, blood samples collected by venepuncture and finger-
prick were necessary for participant enrolment and iron status determination. For iron 
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intervention studies, it is recommended to use haemoglobin and serum ferritin for accurate 
iron status determination (Joint World Health Organization/Centers for Disease & Prevention 
Technical Consultation on the Assessment of Iron Status at the Population Level, 2007). 
However, as serum ferritin is an acute phase reactant, it is recommended to also measure 




The finger-prick blood sample was used for the measurement of haemoglobin with the mobile 
HemoCue® Hb 201+ Analyser. The HemoCue® test method has shown good reproducibility 
for determining haemoglobin concentrations in capillary blood samples (da Silva Pereira et al., 
2020) and good within- and between-model reproducibility (Lin’s concordance correlation 
coefficient > 0.90 in all cases) for Hb201+ and Hb 301 instruments (Jain, Chowdhury & Jain, 
2018). Standardised capillary blood collection methods were followed; after sterilising the 
participant’s middle finger of their non-dominant hand, light pressure was applied towards the 
fingertip and a lancet was used to make a puncture. The first 2-3 drops of blood were wiped 
away with sterile gauze before collecting a large enough blood sample to fill the microcuvette 
in one continuous process. Excess blood was wiped from the microcuvette before placing into 
the analyser tray, which displayed the haemoglobin value in g/L. A cut-off of <120 g/L was 
used throughout the thesis to determine anaemia in accordance with worldwide guidelines 
(World Health Organization, 2011a).  
 
2.2.7.2 Serum ferritin  
 
For serum ferritin, blood samples were obtained via venepuncture into serum separator tube 
(SST) vacutainers (8.5 ml). Samples were inverted 6 times, refrigerated at 5 °C, and allowed 
to clot for at least 30 minutes before they could be processed within 2 hours of acquisition. 
Samples were centrifuged at 3000 rpm (x 1734 g) for 10 minutes at 4 °C. Following 
centrifugation, 1 ml of serum was transferred into two 1.5 ml Eppendorf tubes® and 
immediately frozen at -80 0C prior to analysis conducted by Newcastle Laboratories, 
Newcastle-upon-Tyne. 
 
Samples were analysed using the Roche ECLIA® electrochemiluminescence two-site 
sandwich immunoassay technology. The serum samples were aliquoted into false-bottomed 
tubes following receipt at the laboratory. During the first incubation of the serum samples, 
ferritin was combined with a biotinylated monoclonal ferritin-specific antibody and a 
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monoclonal ferritin-specific antibody labelled with a ruthenium complex to form a sandwich 
complex. During the second incubation following addition of streptavidin-coated 
microparticles, the complex binds to the solid phase via interaction of biotin and streptavidin. 
The reaction mixture was aspirated into the measuring cell where the microparticles were 
magnetically captured onto the surface of the electrode. Unbound substances were removed 
using Procell (Roche Diagnostics GmbH). A voltage was then applied to the electrode to 
induce chemiluminescent emission for measurement by a photomultiplier. Results were 
determined by measuring the electrochemiluminescence signal obtained from the reaction 
product of the sample against a calibration curve generated by a 2-point calibration and a 
master curve provided via the reagent barcode. This method of serum ferritin analysis has 
been assessed for within-run (4.8±2.3%; CI 3.88–5.72%) and between-run imprecision 
(6.9±2.6%; CI 5.70–8.14%); these values are comparable to alternate laboratory methods, 
which is indicative of comparable accuracy and performance across methods (Garcia-Casal 
et al., 2018). Final serum ferritin results were provided in µg/L.  
 
A cut-off of 20 µg/L was used for ID in line with previous nutritional intervention studies 
(Leonard et al., 2014) and evidence suggesting that a cut off of 30 µg/L is subject to risk of 
false-positives (Daru et al., 2017), whilst depletion of iron stores is reflected by levels between 
13-20 µg/L (Langley-Evans, 2013).  
 
2.2.7.3 C-reactive protein (CRP)1 
 
For CRP, blood samples were obtained via venepuncture into serum separator tube (SST) 
vacutainers (8.5 ml). Samples were inverted 6 times, refrigerated at 5 °C, and allowed to clot 
for at least 30 minutes before they could be processed within 2 hours of acquisition. Samples 
were centrifuged at 3000 rpm (x 1734 g) for 10 minutes at 4 °C. Following centrifugation, 1 ml 
of serum was transferred into two 1.5 ml Eppendorf tubes® and immediately frozen at -80 0C 
prior to analysis conducted by the Newcastle Laboratories, Newcastle-upon-Tyne. 
 
Samples were analysed by particle-enhanced immunoturbidimetric assay. CRP in the sample 






1 Serum samples were analysed for CRP after completion of data collection. Participants with CRP 
concentrations >10 mg/L were excluded from the per protocol population. 
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insoluble aggregates. The turbidometric absorbance of the aggregates is proportional to the 
CRP concentration in the samples. A serum CRP threshold of 3-10 mg/L is considered normal 
when interpreting micronutrient status (Joint World Health Organization/Centers for Disease 
& Prevention Technical Consultation on the Assessment of Iron Status at the Population Level, 
2007) whilst CRP concentrations >10 mg/L are indicative of marked elevation and are thus 
considered positive for infection, inflammation or tissue injury (Nehring, Goyal, Bansal, & 
Patel, 2020).   
 
 
2.2.7.4 Iron status parameters 
 
Upon gaining individual haemoglobin and serum ferritin concentrations, participants were 
assigned to one of four iron status groups; iron sufficient (haemoglobin ≥120 g/L and serum 
ferritin >20 µg/L), non-anaemic iron deficient (haemoglobin ≥120 g/L and serum ferritin ≤20 
µg/L); iron deficient anaemic (haemoglobin <120 g/L and serum ferritin ≤20 µg/L) or anaemic 




All study visits took place at Northumbria University’s Brain, Performance and Nutrition 
Research Centre (BPNRC). Potential participants were initially screened by the principal 
investigator over telephone or email to determine whether they were eligible to attend a full 
screening appointment. During this initial screening, menstrual cycle information was gathered 
so that those who had a regular menstrual cycle or withdrawal bleed attended the laboratory 
during the last week of their menstrual cycle’s luteal phase (approximately day 21-28 or 
equivalent), consistent with when haemoglobin and serum ferritin should be at their highest 
(Kim et al., 1993). Those using contraceptive methods that halted bleeds attended based on 
their and the researcher’s availability.  
 
Following successful screening, potential participants were invited for a full screening visit on 
site. The requirements of the study were discussed in line with the participant information 
sheet supplied to the participant prior to screening. Following written informed consent, 
demographic data was collected, and participants underwent a health screening and provided 
finger-prick and venous blood samples. The blood samples were used to determine 
haemoglobin, serum ferritin and CRP. CRP was measured as an inflammation-correction 
approach to account for falsely elevated serum ferritin due to infection and inflammation 
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(Suchdev et al., 2017). Participants were also required to complete lifestyle questionnaires 
regarding daily caffeine consumption, physical activity, food frequency intake and menstrual 
blood loss.  
 
Training on the computerised cognitive tasks was then completed to further confirm eligibility. 
The training session followed standard operating procedures designed to decrease the 
chance of learning effects during the main trials. Participants were required to complete three 
shortened versions of each task to gain familiarity, followed by two full-length versions. 
Following the shortened tasks, participant’s scores were compared to the shortened task 
norms for the researcher to provide performance feedback. This enabled participants to 
perform at their best during one of the full-length versions. Extra training was provided where 
necessary, however once participants completed the session to the required standards, they 
were eligible to be enrolled into the study.  
 
Before attending the testing session, participants were asked to fast for 12 hours, avoiding 
intake of all food and drink except water. Participants were also asked to avoid alcohol and 
the intake of ‘over the counter’ medication for 24 hours. Participants with natural or withdrawal 
bleeds were required to return for this session 7-14 days following bleed onset; due to 
menstrual cycle phase impacts on brain activation (Pletzer, Harris, Scheuringer, & Hidalgo-
Lopez, 2019) and emotion-related changes exhibited in the luteal phase and menses 
(Sundstrom Poromaa & Gingnell, 2014). Those without bleeds were required to attend 
approximately two weeks following their initial appointment to allow time for blood sample 
analysis. Upon confirmation of continued eligibility, participants completed the cognitive and 
mood assessments outlined in Figure 2.3, which took approximately forty-five minutes. Once 
all assessments were completed, participants were fully debriefed and were given their 
haemoglobin and serum ferritin results. Participant’s iron status was only disclosed to them 
following completion of the cognitive and mood assessments to avoid the potential influence 
this may have had on responses.  
 
2.2.9 Data cleaning  
 
Prior to conducting analyses, procedural deviations were checked to identify the per protocol 
population. The data were then investigated for anomalous and outlier data. Initially, raw data 
were inspected for any 0 values on cognitive assessments, which would be indicative of a 
failure to respond to task stimuli. All analyses were conducted using SPSS (Version 26) and 
boxplots were generated for individual variables to identify potential outliers. The boxplots 
visually depict the numerical data and skewness; the box represents the middle 50 % of values 
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and the whiskers depict the upper and lower 25 % of values. Five sample statistics (the 
minimum score, lower quartile, median, upper quartile and maximum score) provide additional 
information regarding the numerical distribution of data. Outliers beyond the minimum and 
maximum scores that are more than one and a half box lengths from either end of the box are 
denoted by a circle. Those beyond three box lengths from either end of the box are denoted 
with an asterisk to indicate an extreme outlier. Outliers marked with an asterisk were removed 
whilst those marked with a circle were removed if they were also noted as deviating from the 
normal distribution following inspection of residual plots and histograms. Any additional values 
identified as deviating from the normal distribution were also removed. Upon completion of 
these data cleaning procedures for each outcome variable, data analysis commenced.  
 
2.2.10 Statistical methods 
 
Data were analysed using regression models in SPSS (Version 26). The analysis was 
conducted in three phases to address the outcomes of interest. Initially, data were analysed 
using an enter method multiple regression. This was used to determine the contribution of 
age, physical activity, BMI, dietary iron and menstrual blood loss to predict iron status, 
haemoglobin and serum ferritin. Enter method multiple regression was then used to determine 
the extent to which age, physical activity, BMI, dietary iron and menstrual blood loss predict 
cognitive performance, subjective mood, fatigue, health and well-being. Years in education 
was also included as a predictor variable for the cognitive performance and workload 
regression models (Gallego, Barcos, Correa, Sánchez Espinosa, & Callejo, 2016; Lövdén, 
Fratiglioni, Glymour, Lindenberger, & Tucker-Drob, 2020; Weber & Skirbekk, 2014). If any of 
the demographic/lifestyle variables were found to have significantly predicted any of the 
outcome variables comprising cognitive performance, subjective mood, fatigue, health or well-
being, they were then included in an adjusted regression model alongside iron status or 
haemoglobin and ferritin. This was first used to determine whether iron status as a categorical 
factor could predict cognitive performance, subjective mood, fatigue, health or well-being 
whilst controlling for these variables. Secondly, it was used to determine whether haemoglobin 
and serum ferritin as continuous variables could predict cognitive performance, subjective 
mood, fatigue, health or well-being whilst controlling for these variables. If none of the 
demographic/lifestyle variables were able to significantly predict the outcome variables in the 







Of the 414 participants screened 379 were enrolled into the study. Eighteen participants were 
lost to follow-up and one participant was excluded as their serum ferritin sample had 
haemolysed meaning no reading could be obtained for iron status determination; 361 
participants subsequently completed the study. As the focus of the thesis is upon NAID, 
participants categorised as IDA (N = 38) and anaemic without ID (AWID) (N = 59) were 
excluded from the analyses. The per protocol analysis excluded thirteen participants for not 
complying with day of menstrual cycle requirements for either their screening or testing visit; 
four for elevated serum ferritin in the absence of inflammation (> 150 µg/L confers a risk of 
iron overload in the general population (World Health Organization, 2011b); four for 
haemoglobin outside of the normal range of 120-150 g/L (Lewis, Osei-Bimpong, & Bradshaw, 
2004); four for concomitant medication; three for elevated CRP (> 10 mg/L) and one for 
missing cognitive data. The final sample for data analysis was N = 235; 162 participants were 
IS (haemoglobin ≥120 g/L and serum ferritin >20 µg/L) and 73 were NAID (haemoglobin ≥120 
g/L and serum ferritin ≤20 µg/L). Participant disposition through the study can be found in 











Figure 2.4 Participant disposition through the trial, culminating in N = 235 of the 361 whom underwent testing. IS = iron sufficient; NAID = non-anaemic iron deficient; IDA = iron 
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Table 2.1 Participant demographic information and characteristics. Means and Std. Deviation (SD) are presented 




N Baseline Main effects 
 Mean SD F P 
Haemoglobin (g/L) 
NAID 73 126.15 6.32 
5.47 .020 
IS 162 128.29 6.56 
Serum ferritin (µg/L) 
NAID 73 14.53 4.57 
143.78 <.001 
IS 162 56.62 29.80 
Age (years) 
NAID 73 25.92 7.88 
3.33 .069 
IS 162 28.15 9.03 
Years in education 
NAID 72 16.58 2.63 
.535 .465 
IS 162 16.84 2.40 
BMI (kg/m2) 
NAID 73 23.99 3.72 
1.69 .195 
IS 162 24.70 3.95 
Systolic BP (mmHg) 
NAID 73 116.77 9.27 
.017 .895 
IS 161 116.57 11.53 
Diastolic BP (mmHg) 
NAID 73 77.30 6.72 
1.36 .245 
IS 161 78.60 8.36 
Menstrual blood loss score 
NAID 55 3.73 2.50 
1.76 .186 
IS 115 3.21 2.32 
Physical activity (MET minutes/week) 
NAID 71 3674.70* 2297.67 
6.07 .015 
IS 158 2939.88* 1962.16 
Cereals and cereal products (g/day) 
NAID 72 240.25 91.78 
.014 .905 
IS 160 238.21 131.27 
Dietary iron (mg/day) 
NAID 72 10.67 3.58 
.050 .824 
IS 160 10.79 3.59 
Fish and fish products (g/day) 
NAID 72 33.83 31.90 
.690 .407 
IS 160 40.33 62.82 
Meat and meat products (g/day) NAID 72 92.08 72.65 2.56 .111 
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IS 160 109.85 80.69 
Nuts and seeds (g/day) 
NAID 72 12.79 23.88 
.593 .442 
IS 160 10.32 21.97 
Vegetables (g/day) 
NAID 72 306.04 155.60 
.349 .555 
IS 160 321.68 198.79 
Alcohol consumption (units/day) 
NAID 73 0.78 0.85 
1.76 .186 
IS 162 0.99 1.18 
Caffeine consumption (mg/day) 
NAID 71 199.18 141.08 
.061 .805 
IS 160 204.52 155.74 
* = significant difference between iron status groups below p < .05. 
 
Due to the number of statistical analyses performed, only those which revealed significant 
models are reported throughout. Data are reported in full in Appendix IV.  
 
2.3.2 Demographic/lifestyle factor predictors of different measures of iron status, cognitive 
function, subjective mood, fatigue, health and well-being 
 
2.3.2.1 Iron status groups 
 




No significant contribution of the predictor variables was identified for haemoglobin.  
 
 
2.3.2.3 Serum ferritin  
 
A significant model was identified that accounted for 7% of the variance in serum [R2 = .068, 
F (5, 157) = 2.3, p = .047]. Menstrual blood loss scores made a significant negative 








Demographic/lifestyle predictors of cognitive function, subjective mood, fatigue and wellbeing 
are presented in Table 2.3.  
 
Table 2.2 Demographic/lifestyle factor predictors of cognitive function, subjective mood, fatigue, health and well-
being. R2 and β-weightings are presented from the models of best fit. All values are significant to p < .05 unless 
indicated.  
Psychological measures Predictor 
  




Years in education .067 .201 .039 
Executive Function 
Speed 
Age .079 .237 .050 
Attention Accuracy Age .068 .227 .046 
Learning BMI .061 -.174 -.028 
Subjective mood  
(PSS; SCI) 
Perceived Stress Menstrual blood loss .066 .164 .027 
Sleep Quality Menstrual blood loss .100* -.274 -.073 
Subjective fatigue  
(PFS; VAS) 
Behavioural-Severity Menstrual blood loss .042 .165 .026 
Affective-Meaning Menstrual blood loss .057 .179 .031 




BMI .075 -.189 -.034 
Physical activity .075 .163 .027 




2.3.3 Iron status and associations with cognitive function, subjective mood, fatigue, health 
and well-being  
 
2.3.3.1 Cognitive domains  
 
Neither the unadjusted nor adjusted models revealed any significant impact of iron status for 




Table 2.3 Cognitive task analysis outcomes for NAID and IS groups. Means and standard error (SE) are presented 
with R2, β-weightings and p values of the unadjusted or adjusted models for iron status2,3 
 
 
N    
 Mean SE R2 β p 
Episodic Accuracy 
NAID 73 0.02 0.08 
.000 -.017 .801 
IS 162 -0.01 0.06 
Episodic Speed 
NAID 73 0.04 0.11 
.001 -.023 .726 
IS 160 -0.00 0.07 
Working Memory Accuracy 
NAID 73 0.07 0.10 
.043 -.097 .134 
IS 162 -0.08 0.06 
Working Memory Speed 
NAID 72 -0.11 0.11 
.005 .072 .273 
IS 159 0.05 0.08 
Executive Function Accuracy 
NAID 73 -0.05 0.07 
.002 .047 .472 
IS 162 0.02 0.05 
Executive Function Speed 
NAID 73 -0.04 0.09 
.061 .014 .823 
IS 162 0.02 0.06 
Sustained Attention Accuracy 
NAID 73 0.04 0.10 
.048 -.089 .170 
IS 162 -0.08 0.07 
Sustained Attention Speed 
NAID 73 0.01 0.11 
.000 .019 .769 
IS 162 0.04 0.06 
Learning 
NAID 72 0.02 0.09 
.033 .000 .995 






2 Unadjusted models are presented for analysis outcomes that did not have any significant 
demographic/lifestyle predictors. Adjusted models are presented for analysis outcomes that did have 
significant demographic/lifestyle predictors from Table 2.3. 
3 For accuracy outcomes, positive values are indicative of better performance and negative values of 
worse performance. For speed outcomes, positive values are indicative of slower speed and positive 
values of slower speed. 
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Neither the unadjusted nor adjusted models revealed any significant impact of iron status for 
the POMS subscales (Table 2.5).   
 
Table 2.4 Subjective mood analysis (POMS) outcomes for NAID and IS groups. Means and standard error (SE) 
are presented with R2, β-weightings and p values of the unadjusted or adjusted models for iron status4 
 
 
N    
 Mean SE R2 β P 
Tension-Anxiety 
NAID 72 6.64 0.57 
.001 -.030 .646 
IS 158 6.32 0.39 
Depression-Dejection 
NAID 68 2.02 0.36 
.000 -.008 .911 
IS 151 1.97 0.24 
Anger-Hostility 
NAID 68 1.37 0.24 
.002 .041 .543 
IS 150 1.55 0.16 
Vigour-Activity 
NAID 72 13.01 0.74 
.000 -.008 .898 
IS 159 12.90 0.50 
Fatigue-Inertia 
NAID 72 7.04 0.61 
.000 .011 .868 
IS 159 7.16 0.41 
Confusion-Bewilderment 
NAID 72 9.18 0.60 
.000 -.019 .777 
IS 159 8.98 0.40 
Total Mood Disturbance 
NAID 65 9.29 2.14 
.000 .016 .812 








4 Unadjusted models are presented for analysis outcomes that did not have any significant 
demographic/lifestyle predictors. Adjusted models are presented for analysis outcomes that did have 
significant demographic/lifestyle predictors from Table 2.3. 
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2.3.3.2.2 PSS and SCI 
 
Neither the unadjusted nor adjusted models revealed any significant impact of iron status for 
ratings of perceived stress or sleep quality (Table 2.6).  
 
Table 2.5 Subjective mood analysis (PSS and SCI) outcomes for NAID and IS groups. Means and standard error 
(SE) are presented with R2, β-weightings and p values of the unadjusted or adjusted models for iron status5 
 
 
N    
 Mean SE R2 β P 
Perceived Stress 
NAID 55 19.25 0.92 
.034 -.059 .439 
IS 115 17.38 0.64 
Sleep Quality 
NAID 55 19.95 0.93 
.080 .051 .491 





No significant confounding variables were identified to impact ratings of total workload. The 
unadjusted model revealed no significant impact of iron status for ratings of total workload 
(Table 2.7).  
 
Table 2.6 Subjective mood analysis (NASA-TLX) outcomes for NAID and IS groups. Means and standard error 
(SE) are presented with R2, β-weightings and p values of the unadjusted or adjusted models for iron status6 
 
 
N    
 Mean SE R2 β P 
Total Workload 
NAID 72 53.10 1.45 
.015 .123 .064 








5,6 Unadjusted models are presented for analysis outcomes that did not have any significant 
demographic/lifestyle predictors. Adjusted models are presented for analysis outcomes that did have 
significant demographic/lifestyle predictors from Table 2.3. 
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2.3.3.3 Subjective fatigue (PFS and VAS) 
 
Neither the unadjusted nor adjusted models revealed any significant impact of iron status for 
ratings of subjective fatigue (Table 2.8).  
 
Table 2.7 Subjective fatigue analysis (PFS and VAS) outcomes for NAID and IS groups. Means and standard error 
(SE) are presented with R2, β-weightings and p values of the unadjusted or adjusted models for iron status7 
 
 
N    
 Mean SE R2 F P 
Behavioural-Severity  
NAID 55 3.66 0.27 
.032 -.031 .689 
IS 115 3.31 0.18 
Affective Meaning 
NAID 55 4.83 0.27 
.038 -.051 .503 
IS 115 4.78 0.19 
Sensory 
NAID 73 5.60 0.23 
.004 -.060 .361 
IS 162 5.35 0.15 
Cognition-Mood 
NAID 73 4.57 0.20 
.000 -.003 .964 
IS 162 4.56 0.13 
Total Fatigue 
NAID 55 4.64 0.23 
.003 -.051 .437 
IS 115 4.48 0.16 
Mental Fatigue 
NAID 73 59.60 2.11 
.004 .062 .343 
IS 162 62.02 1.42 
Alertness 
NAID 54 41.50 2.55 
.030 -.070 .364 











7 Unadjusted models are presented for analysis outcomes that did not have any significant 
demographic/lifestyle predictors. Adjusted models are presented for analysis outcomes that did have 
significant demographic/lifestyle predictors from Table 2.3. 
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Neither the unadjusted nor adjusted models revealed any significant impact of iron status for 
the SF-12 scales (Table 2.9).  
Table 2.8 Subjective wellbeing analysis (SF-12) outcomes for NAID and IS groups. Means and standard error (SE) 
are presented with R2, β-weightings and p values of the unadjusted or adjusted models for iron status8 
 
 
N    
 Mean SE R2 F P 
Physical Functioning  
NAID 73 54.59 0.73 
.007 -.085 .193 
IS 161 53.54 0.49 
Role-Physical 
NAID 73 51.72 0.82 
.000 .021 .745 
IS 161 52.05 0.56 
Bodily Pain 
NAID 73 54.15 0.81 
.005 -.072 .274 
IS 161 53.08 0.54 
General Health 
NAID 73 52.19 0.98 
.001 .026 .690 
IS 160 52.66 0.66 
Vitality 
NAID 70 49.33 0.98 
.068 .074 .266 
IS 153 50.75 0.66 
Social Functioning 
NAID 72 47.88 0.91 
.010 .101 .126 
IS 159 49.57 0.62 
Role-emotional 
NAID 73 42.33 1.21 
.006 .077 .238 
IS 161 44.05 0.81 
Mental health  
NAID 73 42.76 1.06 
.014 .117 .074 
IS 160 45.07 0.72 
PCS 
NAID 72 57.86 0.66 
.013 -.112 .091 
IS 157 56.51 0.45 
MCS 
NAID 71 41.54 1.13 
.013 .115 .083 






8 Unadjusted models are presented for analysis outcomes that did not have any significant 
demographic/lifestyle predictors. Adjusted models are presented for analysis outcomes that did have 
significant demographic/lifestyle predictors from Table 2.3. 
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2.3.4 Haemoglobin and serum ferritin associations with cognitive domains, subjective mood, 
fatigue, health and well-being 
 
 2.3.4.1 Cognitive domains 
 
Neither the unadjusted nor adjusted models revealed any significant impact of haemoglobin 
nor serum ferritin for the cognitive domain outcomes.   
 
 2.3.4.2 Subjective mood 
 
2.3.4.2.1 POMS  
 
Neither the unadjusted nor adjusted models revealed any significant impact of haemoglobin 
nor serum ferritin for the POMS subscales.   
 
2.3.4.2.2 PSS and SCI 
 
Neither the unadjusted nor adjusted models revealed any significant impact of haemoglobin 




No significant confounding variables were identified to impact ratings of total workload. The 
unadjusted model revealed no significant impact of haemoglobin nor serum ferritin for 
ratings of total workload.  
   
 2.3.4.3 Subjective fatigue (PFS)  
 
Neither the unadjusted or adjusted models revealed any significant impact of haemoglobin nor 
serum ferritin for ratings of subjective fatigue.  
 
 2.3.4.4 Subjective well-being (SF-12) 
 
For PCS and its components, a significant model was only identified for bodily pain. No 
confounding variables were identified to impact ratings of bodily pain. The unadjusted model 
significantly accounted for 2.6 % of the variance in bodily pain scores [R2 = .026, F (2, 231) = 
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3.06, p = .049]. However, neither haemoglobin (p = .099) nor serum ferritin significantly 
contributed to the regression (p = .178).  
 
A significant model was identified for MCS, for which no confounding variables were identified. 
The unadjusted model significantly accounted for 2.7 % of the variance in MCS [R2 = .027, F 
(2, 226) = 3.09, p = .047].  Serum ferritin made a significant positive contribution to the 
regression [β = .169, t (226) = 2.48, p = .014]. Haemoglobin did not significantly contribute to 
the regression (p = .621).  
 
Within MCS, role limitations due to emotional functioning was the only component for which a 
significant model was revealed. No confounding variables were identified to impact role 
limitations due to emotional functioning. The unadjusted model significantly accounted for 3.4 
% of the variance in emotional functioning scores [R2 = .034, F (2, 231) = 4.10, p = .018]. 
Serum ferritin made a significant positive contribution to the regression [β = .181, t (231) = 
2.70, p = .008]. Haemoglobin did not significantly contribute to the regression (p = .105).  
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2.4 Discussion  
 
Overall, the results from the current study revealed no significant associations between 
psychological function and categorical iron status. Higher serum ferritin concentrations were 
associated with better emotional functioning and higher mental component summary scores, 
indicating better mental functioning.  
 
With regards to serum ferritin, significant positive associations were identified with emotional 
functioning and MCS scores as indicators of health-related quality of life and well-being. 
Current knowledge surrounding the impact of iron status upon health and well-being is mixed 
as NAID women of reproductive age have previously exhibited significantly lower MCS scores 
than their IS counterparts (Patterson, Brown, & Roberts, 2001), yet further investigations failed 
to identify any significant differences in perceived health and well-being between NAID and IS 
women (Beck et al., 2012). In comparison, chi-square analysis revealed that NAID women 
were significantly more likely than their IS counterparts to score below average on MCS in the 
current study, and a specific role of serum ferritin in emotional functioning and mental health 
has been identified. A potential explanation for this may surround the dependence of 
monoamine synthesis, including dopamine, serotonin and noradrenaline, upon non-haem iron 
(Kim & Wessling-Resnick, 2014); a reduction in serum ferritin and thus reduced stored iron 
may cause emotional dysregulation and negative affectivity through feelings of depression 
(Vahdat Shariatpanaahi et al., 2007), anxiety (Lozoff et al., 2000), fatigue (Meeusen et al., 
2006) and aggression (Chester et al., 2016) that can profoundly affect individuals’ mental 
health and wellbeing (Ferreira et al., 2019). Although no associations were identified for these 
individual mood states in the current study, their combination may contribute to an overall 
representation of emotional functioning and mental health-related quality of life. Interpretation 
of such findings should however err on the side of caution as the contribution of serum ferritin 
for explaining indicators of health-related quality of life and well-being was very small. 
 
The current study identified no significant associations between cognitive function and 
categorical iron status, consistent with previous findings (Cook et al., 2017; Leonard et al., 
2014; Murray-Kolb & Beard, 2007; Scott & Murray-Kolb, 2016). When haematological 
parameters were treated as continuous variables, no significant associations with cognition 
were achieved in contrast to earlier findings (Blanton, 2013; Blanton et al., 2013; Scott & 
Murray-Kolb, 2016). Overall, these findings are suggestive of cognition not declining in the 
early stages of ID. It must be considered however that compensatory neural adaptations may 
be responsible for such findings. To meet the metabolic demands of increased neural activity 
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under normal conditions, cerebral blood flow (CBF) is augmented to supply the metabolic 
resources required to fulfil the demand for tissue oxygen and glucose (Kozberg & Hillman, 
2016; Vazquez, Masamoto, Fukuda, & Kim, 2010). As NAID is shown to impair cardiomyocyte 
contractility (Hoes et al., 2018), blood viscosity is subsequently increased (Broberg et al., 
2006; Khaled et al., 1998). To compensate for this action, vasodilation is increased, and it is 
only when this action is exhausted that CBF is impaired. Further investigation is thus 
warranted using neuroimaging techniques to determine whether there are significant 
differences in CBF between iron status groups.  
 
The null findings concerning the mood, fatigue, stress and sleep quality outcomes are 
suggestive of no behavioural differences between NAID and IS women of reproductive age. 
This contributes to the largely equivocal literature as although NAID is shown to be 15 % 
greater in women with depression compared to those without (Vahdat Shariatpanaahi et al., 
2007), independent associations between iron status parameters of haemoglobin and serum 
ferritin and depressive symptoms only present with a concomitant presentation of fatigue 
(Price et al., 2017). Though meta-analysis revealed that significant associations between 
NAID and fatigue were only identified in populations who reported with a primary concern of 
fatigue and not within the general population (Yokoi & Konomi, 2017), as in the current study. 
Further cross-sectional investigations are required to determine whether associations 
between NAID and behavioural function exist within the general population of women of 
reproductive age whilst taking the role of fatigue into account.  
 
The current study has highlighted the increased prevalence of NAID compared to IDA (22 % 
v 11.4 %, respectively) in a general population of women of reproductive age based in the 
United Kingdom, which is consistent with previous international epidemiological data (Soppi, 
2018; Umbreit, 2005). As the relationship between IDA and cognitive and behavioural 
dysfunction is already well-established (Jáuregui-Lobera, 2014) and the AWID group suggests 
anaemia to be independent of iron, excluding these two groups enabled an analysis and 
interpretation focussed specifically upon discovering the effects associated with the more 
prevalent NAID compared to their IS counterparts. Additionally, several limitations concerning 
previous cross-sectional investigations have been addressed including a thorough 
assessment of iron status by controlling for inflammation, categorising iron status based upon 
a more diagnostically accurate serum ferritin cut-off and considering the potentially 
confounding effects of several key variables. Analyses were adjusted to comprehensively 
account for variables with an established relationship to the cognition, mood, fatigue, and 
wellbeing outcomes to ensure the most accurate determination of the influence of iron status, 
haemoglobin, and serum ferritin on psychological function in women of reproductive age. 
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However, it is interesting to note that dietary iron did not significantly contribute to any of the 
haematological, cognitive, or behavioural outcomes. When compared to menstrual blood loss, 
which significantly contributed to serum ferritin concentrations and multiple mood and fatigue 
outcomes, the current study provides evidence to suggest that it may be more important to 
correct heavy menstrual blood loss than to increase dietary iron intake. Although causal 
evidence is required to confidently support these associations, they may have future 
implications in primary care. Overall, the current study is one of the first to provide insight into 
the associations between categorical iron status groups and psychological function, 
encompassing both cognitive and behavioural outcomes, and the relationships that can be 
individually attributed to haemoglobin and serum ferritin specifically amongst women of 
reproductive age from a general population sample.  
 
However, the cross-sectional nature of the study should not be overlooked as it does not allow 
an interpretation of cause and effect. Although controlling for potentially confounding variables 
reduces the amount of statistical noise, many genetic, socio-economic, and nutritional factors 
are shown to contribute to cognitive and behavioural function across the lifespan (Jirout et al., 
2019; Kim & Park, 2017). Attributing current psychological states to current iron status is thus 
difficult to explicitly deduce, especially when the contribution of each variable was nominally 
very small. Similarly, interpreting associations between iron parameters and psychological 
function is challenging as it is not possible to definitively state that peripheral iron status is 
reflective of brain iron content. Animal studies provide evidence for nutritional ID stimulating 
different brain areas to acquire a distinct capacity to store iron as ferritin decreases in the 
hippocampus but increases in the striatum (Pino et al., 2017). However, early ID is shown to 
invoke long-term irreversible psychological effects; IDA in infancy significantly diminishes 
cognitive functioning and mood regulation in childhood (Lozoff et al., 2000; Lozoff et al., 1991), 
adolescence (Lozoff et al., 2000) and early adulthood (Lozoff et al., 2006; Lozoff et al., 2013) 
regardless of iron repletion. Neuroimaging of animal brain tissue has shown how early-life ID 
reduces brain iron content and alters brain tissue composition despite iron repletion (Mudd et 
al., 2018). This suggests that participants categorised as IS may have included those at a 
psychological disadvantage due to irreversible neurological damage instigated during infant 
ID. It may be imperative for future research to consider screening participants based on 
medical history to account for diagnoses of early ID. Utilising neuroimaging techniques such 
as magnetic resonance imaging (MRI) will also bolster interpretations surrounding iron status 
and psychological function to ensure that they are specific to the brain. Additionally, although 
cyclic variations in haematological parameters were considered for an accurate assessment 
of iron status at blood sampling, the study may have included participants who could have 
been categorised as IS one week and NAID the next. Mean serum ferritin concentrations have 
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been found to be highest in the luteal phase of the menstrual cycle (24.0 µg/L) compared to 
during menses (17.2 µg/L) (Kim et al., 1993). Using a serum ferritin cut-off of 20 µg/L as in the 
current study means that some participants may have fluctuated between IS and NAID 
classifications within one menstrual cycle and therefore between screening and testing visits. 
It may be imperative for future research to include an additional ‘buffer’ iron status group 
between NAID and IS groups to take into consideration those who may fluctuate between iron 
status classifications. Similarly, although the reproducibility of the Hemocue® is considered 
good, single capillary samples may be open to error whenever individual-level estimates are 
required (Morris et al., 1999), which may have caused some inaccuracies in individual iron 
status group classifications. It may therefore be necessary to use replicate sampling for 
measurements of haemoglobin from capillary blood in future to minimise the possibility of iron 
status classification errors. Additionally, it would have been beneficial to measure participants’ 
copper status. Copper, as well as iron, is required for erythropoiesis; thus, its deficiency can 
cause an iron deficiency-like anaemia (Ha et al., 2016). Similarly, ceruloplasmin, a major 
copper carrying protein in the blood, acts as a ferroxidase to facilitate iron transport out of the 
cell into the circulation and to bind transferrin (Wazir & Ghobrial, 2017). Therefore, it is possible 
that the anaemic without iron deficiency group may have been a result of copper deficiency or 
that the IDA group were also deficient in copper. The interaction between copper and iron is 
also of interest as marginal copper deficiency is shown to greatly increase the effect of iron 
deficiency (Troost et al., 2003). This is especially true as all proteins involved in copper 
homeostasis are expressed in the brain, with key roles in antioxidant defence, energy 
metabolism, neurotransmitter synthesis, neuropeptide synthesis, as well as iron metabolism 
(Scheiber, Mercer & Dringen, 2014). Therefore, copper deficiency may also impact cognitive 
function, mood and fatigue in addition to the effect of iron deficiency. 
 
Despite these limitations, the present study has established novel evidence of a greater 
prevalence of NAID than IDA in women of reproductive age from the general population in the 
United Kingdom. The null findings concerning cognitive function support earlier findings that 
suggest no cognitive differences across categorical iron status groups. However, in addition 
to heterogeneity surrounding serum ferritin cut-offs for NAID classification that make 
comparisons between studies challenging, previous studies have not considered upper cut-
off levels for haemoglobin and serum ferritin. Consequently, iron status groupings are 
problematic as an IS population may include those with high haemoglobin and serum ferritin-
associated cognitive deficits (Agrawal et al., 2017; Shah et al., 2009) alongside those with an 
‘optimal’ iron status thus failing to capture meaningful and accurate relationships. The present 
study endeavoured to address this by implementing upper limits of haemoglobin and serum 
ferritin for inclusion in the per protocol population for analysis and investigating continuous 
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haematological markers of iron status. However, the fact that the significant positive 
associations of emotional functioning and MCS scores with serum ferritin did not carry over to 
iron status, supports the notion that the impact of serum ferritin may have been masked by 
categorisation, even in the absence of excess iron. It may therefore be imperative for future 
studies to focus upon establishing optimum haemoglobin and serum ferritin concentrations for 
cognitive and behavioural outcomes rather than comparing NAID and IS groups for non-
pregnant women of reproductive age.  
 
The positive associations identified between serum ferritin and mental health-related quality 
of life highlight the potential role of serum ferritin in emotional regulation. Moreover, the null 
findings concerning haemoglobin may indicate the greater significance of serum ferritin to a 
non-anaemic population. However, it is important to note the cross-sectional design of the 
study, the small contribution of the variables, and that findings are not specific to brain iron 
levels. Implementing a more rigorous screening of participants based upon medical history of 
iron status and applying neuroimaging techniques to assess brain iron levels and tissue 
morphology will advance this research area. Confirmation of any causative effects regarding 
iron status, haemoglobin and serum ferritin upon cognitive and behavioural outcomes is reliant 





 THE EFFECT OF IRON SUPPLEMENTATION ON COGNITION, SUBJECTIVE 





Iron deficiency (ID) remains the most prevalent nutrient deficiency worldwide and is the most 
significant contributor to anaemia onset (World Health Organization, 2008). Growing infants 
and young children have the highest rates for ID and iron deficiency anaemia (IDA) (Gupta, 
Perrine, Mei, & Scanlon, 2017) and have consequently been the focus of most of the research 
in this field. However, iron insufficiency is also common in women of reproductive age due to 
an increased maternal and placental-foetal demand for iron during pregnancy (Brannon & 
Taylor, 2017; Milman, Taylor, Merkel, & Brannon, 2017) as well as increased iron depletion 
during regular menstruation (Harvey et al., 2005). Young females in upper-middle and high-
income countries are at high risk for ID due to diets comprising an imbalance of dietary factors 
that inhibit iron absorption, such as consumption of phytates and polyphenols; and those that 
enhance it, such as ascorbic acid consumption (Beck et al., 2014). Restrictive dieting 
behaviours such as the avoidance of haem-rich meat also contribute to this insufficiency 
(Fayet, Flood, Petocz, & Samman, 2014; Young et al., 2018). Non-haematological 
consequences of ID include unexplained fatigue, impaired immune response, mood changes, 
modulation of energy metabolism and decreased cognitive performance (Beard, 2001; 
Murray-Kolb & Beard, 2007). Maternal ID in pregnancy can also reduce iron stores in the 
developing foetus causing neonatal ID (Rao & Georgieff, 2002). There is considerable 
evidence from animal models detailing the role of iron in neurodevelopment through its effects 
on cerebral energy metabolism (Dallman, 1986; Rao, Asha, Ramesh, & Rao, 2008; Ward et 
al., 2007), neurotransmitter synthesis (Beard & Connor, 2003; Unger et al., 2012; Youdim, 
Sills, Heydorn, Creed, & Jacobowitz, 1986), myelination (Badaracco, Siri, & Pasquini, 2010; 
Beard et al., 2003; Connor & Menzies, 1996) and neural network architecture (Brunette, Tran, 
Wobken, Carlson, & Georgieff, 2010; Greminger, Lee, Shrager, & Mayer-Proschel, 2014; 
Jorgenson, Wobken, & Georgieff, 2003). An iron insult early in life can therefore result in 
deficits to neurodevelopment, especially in the hippocampus, which is highly vulnerable to ID 
during infancy and is important for learning, memory and cognitive function (Radlowski & 
Johnson, 2013). This perhaps explains the relative abundance of research into the relationship 
between iron status and cognition in infants and children (Hermoso et al., 2011) in comparison 
to women of reproductive age. However, it is now recognised that the brain continues to adapt 
both functionally and structurally throughout the lifespan according to the changing 
environment (Oberman & Pascual-Leone, 2013), reflecting continued plasticity beyond early 
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development. These neurophysiological and neuroanatomical modifications are suggested to 
underpin the known shifts in cognition with age (Oberman & Pascual-Leone, 2013) leading to 
the possibility that changes in iron levels beyond infancy could stimulate such neural changes 
and subsequently modulate cognition at any time of life.  
 
Observational studies have provided evidence for a potential benefit of iron for handling higher 
cognitive loads in women of reproductive age (Blanton, 2013; Blanton et al., 2013; Cook et 
al., 2017; Scott et al., 2017; Scott & Murray-Kolb, 2016). Longitudinal studies have also 
highlighted associations between self-reported ID diagnosis and decreased general health 
and well-being alongside increased levels of subjective fatigue (Patterson et al., 2000). 
However, evidence for a causal link through the conduct of intervention studies remains 
sparse and results are often varied. Meta-analysis of the effects of iron supplementation, 
regardless of iron status group, suggests significant improvements to attention, concentration 
and intelligence yet no significant improvements to memory, when compared to baseline 
(Falkingham et al., 2010). However, these findings contrast with those of a subsequent meta-
analysis of the effects of iron supplementation, which is potentially due to the inclusion of both 
sexes aged six years and above in the former. When looking specifically at women of 
reproductive age, only improvements in ID participants’ arithmetic scores were shown (Greig 
et al., 2013). A subsequent systematic review, including only ID and IDA pre-menopausal 
women, similarly found significant improvements in working memory as well as intellectual 
ability following iron supplementation. However, the effect of iron supplementation for 
improving mood is unclear, possibly due to a range of mood measures used for assessment 
leading to differing results (Lomagno et al., 2014). Greig et al. (2013) also noted that results 
for mental health and fatigue varied following iron supplementation, which they attributed to 
varying study quality.  
 
The aim of this systematic review is to provide an updated overview of findings from 
randomised controlled trials investigating the effects of iron supplementation on cognition, 










This systematic review was conducted in accordance with Cochrane (Higgins & Green, 2011), 
and was reported according to PRISMA, guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009).  
 
3.2.1 Eligibility criteria 
 
Eligibility criteria were determined using the PICO (population, intervention, comparison and 
outcome) tool. Accordingly, the population included were required to be human females 
between the ages of 12 and 50 years of age. Participants were also required to give baseline 
and endpoint blood samples measuring at least haemoglobin (Hb) and serum ferritin (sft) 
levels to determine iron status. Studies that met the participant criteria and included the 
assessment of either cognition, mood, fatigue or well-being, alongside an iron intervention 
versus a control arm for any duration of time were considered. Iron supplementation had to 
be in the form of an oral or venous supplement; high-iron diets were only considered in studies 
where this was used in comparison to iron supplementation. Additionally, only studies 
originally written in English were considered.  
 
3.2.2 Outcome measures 
 
In addition to the broad term of cognition, cognitive domains deemed relevant for the review 
included attention, executive function, memory, and reaction time (Galioto & Spitznagel, 
2016). Cognitive tests must have been completed at baseline and at the end of the intervention 
period. Cognitive tests carried out mid-way through the intervention were also considered. 
Tests could be carried out by oral, written or computer test providing results were objective. 
Studies that assessed any domain of mood, well-being and fatigue through subjective self-
report measures were considered.  
 
3.2.3 Search strategy 
 
To ensure all possible relevant articles were obtained for review, two researchers (HA & CHR) 
independently followed the same search strategy and assessed articles in accordance with 
the inclusion criteria. Electronic searches were initially conducted in January 2018 and 
updated in July 2019. The review therefore covers all studies published from the earliest 
record to June 30th, 2019. To guarantee adequate coverage of the literature and to avoid 
database bias, multiple electronic databases were searched: Cochrane Library, PubMed and 
Web of Science. Following the initial search, reference lists from relevant retrieved articles 
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were manually reviewed. The reference lists from previous systematic and meta-analytic 
reviews relevant to iron interventions, cognition, and subjective mood, fatigue and well-being 
(Falkingham et al., 2010; Greig et al., 2013; Lomagno et al., 2014) were also searched for 
additional studies. Following a preliminary search to determine breadth of the research topic 
for review, the search term iron status was deemed appropriate to achieve the most relevant 
searching algorithms for the effect of iron supplementation on cognition, mood, fatigue and 
well-being. Each domain was searched for separately using Boolean terms as follows: ‘iron 
status AND…’ 1) cogniti*; 2) memory; 3) executive function; 4) reaction time; 5) attention; 6) 
mood; 7) well-being; 8) fatigue. The truncation symbol * used with cogniti allowed for a broader 
range of results, encompassing terms such as cognition, cognitive and cognitive function 
within one search to avoid missing relevant articles. Cogniti* and the specific cognitive 
domains were searched for individually to ensure accurate data capture of all relevant articles. 
For the mood and well-being searches, the MeSH term (“affect” [MeSH Terms] OR “affect” [All 
Fields]) would appear in the ‘Search details’ box, affecting the search output. This term was 
manually removed to ensure that all articles retrieved were of relevance to mood and well-
being. The ‘All fields’ search query was utilised for all searches to provide the best opportunity 
to retrieve all relevant articles.  
 
3.2.4 Study selection and data collection process 
 
Once retrieval of all articles was complete and duplicates were removed, all remaining articles 
were screened independently by the researchers to determine whether they met the inclusion 
criteria based upon title, abstract and key words. If eligibility was unclear from the title and 
abstract, background and methods were examined, and a full-text screen completed if 
necessary. Any disagreements on study inclusion and exclusion were resolved by discussion 
between the reviewers. Data was extracted from baseline and endpoint for all studies. 
Information regarding author and published year; study design; participant characteristics 
(mean age, sample size at baseline); intervention details (intervention type, dosage, 
frequency, duration); baseline iron status parameters and criteria of iron status; number of 
dropouts; and outcome measures were extracted.  
 
3.2.5 Risk of bias assessment 
 
The use of the Cochrane risk-of-bias tool facilitated a comprehensive assessment of risk of 
bias in studies included in the systematic review. Risk of bias was assessed independently by 
the researchers (HA & CHR) addressing seven specific domains (random sequence 
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generation, allocation concealment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective reporting and other) as either ‘high 



































3.3.1 Search results & study selection  
 
A total of 2731 articles were retrieved through the systematic database search; of these 1077 
were duplicates and thus removed. An additional five articles were retrieved through searching 
reference lists of previous systematic and meta-analytic reviews and articles identified through 
the database searches. The titles and abstracts of the remaining 1659 articles were screened 
for eligibility leading to the exclusion of a further 1635 articles. The main reasons for exclusion 
included: an inappropriate study population; animal studies; confounding disorders; no iron 
intervention; review paper; and no assessment of cognition/mood/fatigue/well-being. The full 
texts of the remaining 24 articles were read to determine inclusion; of these 11 were excluded. 
Three studies were excluded because high iron diets or iron bio-fortified foods were 
administered with no oral or venous iron supplement as a comparator (Blanton, 2013; Murray-
Kolb et al., 2017; Wenger et al., 2017). Two studies were excluded as they included male and 
female participants but did not split results by gender (Devaki et al., 2009; Woods et al., 2014). 
Two studies did not include controlled interventions (Khedr et al., 2008; Kretsch et al., 1998). 
The remaining studies were excluded for using a demographic of pregnant women (Groner et 
al., 1986), an inappropriate assessment of iron status (Elwood & Hughes, 1970), including 
participants aged up to 55 with no specification of menstruation status (Verdon et al., 2003) 
and for the full text being unavailable (Swain, Penland, Johnson, & Hunt, 2006).  A total of 13 







Figure 3.1 PRISMA study flow diagram for the systematic review 
 
3.3.2 Study characteristics 
 
Table 3.1 provides a summary of characteristics and findings of all included studies. Of the 
thirteen studies included all were randomised controlled trials (RCTs). Of the six studies 
primarily assessing cognition following iron intervention, four were conducted in high-income 
countries (Bruner et al., 1996; Lambert et al., 2002; Leonard et al., 2014; Murray-Kolb & Beard, 
2007) and two in upper-middle income countries (Beard et al., 2005; Rezaeian, Ghayour-
Mobarhan, Mazloum, Yavari, & Jafari, 2014). The seven studies primarily assessing either 
fatigue, mood or wellbeing were all conducted in high-income countries (Ballin et al., 1992; 
Favrat et al., 2014; Krayenbuehl et al., 2011; McArthur, Petocz, Caterson, & Samman, 2012; 
McClung et al., 2009; Patterson et al., 2001; Vaucher et al., 2012). One trial was considered 
to have a low risk of bias; the remainder were considered unclear overall due to unclear 
Records identified through 
database searching (n = 2731)
Additional records identified 
through other sources (n = 5)
Records after duplicates removed 
(n = 1659)
Titles screened (n = 1659)
Abstracts screened (n = 73)
Articles excluded (n = 49)
No intervention (n = 29)
Review paper (n = 9)
Food-derived supplement (n = 5)
No cognitive assessment (n = 3)
Clinical population (n = 2)
Male participants only (n = 1)
Full-text articles screened 
(n = 24)
Studies excluded (n = 11)
Food-derived supplement only (n = 3)
Results not split by gender (n = 2)
Not controlled interventions (n = 2)
Pregnant female demographic (n = 1)
Iron status not assessed (n = 1)
Abstract only (n = 1)
Participants aged 50+ and no exclusion for 
menopause (n = 1)
Studies included in systematic 
review 
(n = 13)
Records excluded (n = 1586)
Irrelevant topic (n = 850)
Inappropriate study population 
(n = 444)
Descriptive nutrition papers 
(n = 198)
Animal studies (n = 67)
Confounding disorders (n = 27)
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processes of random sequence allocation, allocation concealment, blinding of outcome 
assessment, outcome data completeness and access to protocols for assessments of 











Table 3.1 Characteristics of included studies 
 





Design Dose and 
type of iron 
Cognitive/mood tests Results 
Ballin et 
al., 1992 
59 adolescent girls, 
16-17 years, 0 
dropouts 
Any RCT, 8 
weeks 





Questionnaires not specified but 
included questions on lassitude, 
fatigue, ability to concentrate, mood, 
appetite, quality of sleep and a physical 
fitness test 
Iron treatment improved: 
subjective ability to concentrate 
and lassitude; mood for 
participants who were ID at 
baseline and became IS post-
dose. 
No significant reduction in fatigue 
after iron supplementation. 
Beard et 
al., 2005 
95 mothers 6-8 
weeks postpartum, 
18-30 years. 14 
dropouts 
Iron deficiency anaemia 
(Hb 90-11.5 g/L, and at 
least 2 of the following: 
MCV < 80 fL; TSAT < 
15 %, sft < 12 g/L.  
Iron sufficient (Hb > 135 
g/L; MCV > 80 fL; TSAT 




125 mg ferrous 
sulphate (plus 25 




Raven’s Coloured Progressive 
Matrices, Weschler’s Digit Symbol, 
Edinburgh Post-Natal Depression 
Scale (EPDS), Perceived Stress Scale, 
State-Trait Anxiety Inventory 
Iron treatment improved: digit 
symbol, intelligence, depressive 
symptoms and perceived stress. 
No improvement in anxiety. 
Positive correlation: intelligence 
and Hb at baseline. 
Positive correlation at follow-up: 
intelligence, Hb, MVC and TSAT; 
digit symbol and MCV; stress 
and Hb, MCV and TSAT; 
anxiety, Hb and MCV. 
Negative correlation at follow-up: 
depressive symptoms, Hb and 
MCV. 
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Bruner et al., 
1996 
81 females, 13-18 
years. 8 dropouts 
Non-anaemic iron 
deficient (sft 12 g/L, 
Hb >115 g/L (African 




1300 mg ferrous 
sulphate (260 mg 
elemental iron) 
 
650 mg twice daily 
Brief Test of Attention; 
Symbol Digit Modalities 
Test; Visual Search and 
Attention Test; Hopkins 
Verbal Learning Test 
(HVLT) 
Iron treatment improved: verbal working 
memory and verbal learning. No 
improvement in measures of attention. 
Positive correlation: change in sft and 
HVLT score. 








deficient (Hb 115 g/L, 
sft  50 g/L and TSAT 








infusion (1000 mg 
iron) 
Piper Fatigue Scale 
(PFS), SF-12, CDR 
system and Bond-Lader 
visual analogue scales 
Iron treatment improved: power of 
attention for those with baseline sft < 15 
g/L; PFS scores at 7-days follow-up 
and 8-weeks; subjective mental health 
quality and a numerical trend for quality 
of physical health. 
No significant effects on accuracy of 
attention. 
Positive correlation: sft and improved 
fatigue scores. 
No significant associations between 
improved haematological measures and 
cognitive improvements. 
Krayenbuehl 




years. 4 dropouts 
Non-anaemic iron 
deficient (sft  50 




up for 12 
weeks) 
200 mg intravenous 
iron (III) hydroxide 
sucrose 




Iron treatment improved: SPI scores; 
median BFI scores decreased, and SPI 
scores increased for those with serum 
ferritin <15g/L or transferrin saturation 
<20% at baseline median BFI scores 
significantly decreased. 
At follow up, significantly more of the 
iron treatment group reported perceived 





12.5-17.9 years. 5 
dropouts 
Non-anaemic iron 
deficiency (sft <12 g/L 
, Hb >120 g/l) 
RCT, 8 
weeks 
105 mg elemental iron 
as tablets 
Hopkins Verbal Learning 
Test (HVLT), Stroop 
Task, Visual Search, 
Reading Span Task 
Iron treatment improved: verbal working 
memory and recall of learnt words from 
the second half of the list. No 
improvements in measures of attention. 
Positive correlation: Hb and word recall; 
sft and reading span. 
Leonard et 
al., 2014 
32 females, 18-35 
years. 7 dropouts 
Non-anaemic iron 
deficiency (sft  20 
g/L, Hb >120 g/L) 
Iron sufficient (serum 




60 mg or 80 mg 
elemental iron as 
ferrous sulphate 
IntegNeuro battery Iron treatment improved: impulsivity. 
Serum ferritin response improved: 
impulsivity, sustained attention and 
recognition memory. 
Haemoglobin response improved: digit-




76 females, 18-35 
years, 11 
dropouts 
Any RCT, 12 
weeks 
300 mg ferrous 
gluconate and 200 mg 
ascorbic acid or pork 
meat diet (at least 3 
pork meat meals a 
week) 
SF-36 Iron supplementation improved: vitality 
Pork meat diet improved: bodily pain 
No significant association between 






15-25 years, 48 
dropouts 
Any RCT, 8 
weeks 
100 mg ferrous 
sulphate 
Two mile running time 
and Profile of Mood 
States 





35 years. 39 
dropouts 
Iron deficiency anaemia 
(Hb 105-119 g/L +  2 




160 mg ferrous 
sulphate (60 mg 
elemental iron) 
Cognitive Abilities Test, 
Shipley Institute of 
Living Scale 
Serum ferritin response improved: 
attention, memory and learning cognitive 
domains. 
Haemoglobin response improved: speed 
of task completion. 
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Non-anaemic iron 
deficiency (Hb  120 g/L 
+  2 abnormal iron 
status values 
Iron sufficient (Hb 120 
g/L +  1 abnormal iron 
status value) 
 
No significant correlation between size 








deficient (Hb 90 g/L, 
sft <15 g/L or sft 15-20 
g/L, plus two of the 
following: serum iron 
<10 mol/L, TIBC >68 
mol/L or TSAT <15 %) 
Iron sufficient (Hb 120 
g/L and sft >20 g/L) 
RCT, 12 
weeks 
350 mg ferrous 
sulphate or a high iron 
diet (2.25 mg 
absorbed iron per 
day) 
SF-36 and Piper Fatigue 
Scale (PFS) 
Iron supplementation improved: total 
PFS scores, behavioural/severity 
fatigue, affective meaning fatigue, and 
vitality 
High-iron diet improved: total PFS 
scores, sensory fatigue, vitality, and 
MCS scores 
No significant association between 
haematological measures and fatigue 
scores. 
Significantly lower vitality and mean 





18 years. 0 
dropouts 
Those who had Hb 
160 g/dL and RBC 
count 5.03 million/l 
were not included 
RCT, 16 
weeks 
50 mg ferrous 
sulphate twice a week 
Toulouse-Piéron test Iron treatment improved: attention span 
for those with IS and IDA status at 
baseline 
Positive correlation: Hb improvement 
and attention scores. 
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Hb, haemoglobin; IDA, iron deficient anaemic; IS, iron sufficient; MCV, mean corpuscular volume; RBC, red blood cell; RCT, randomised controlled trial; sft, serum ferritin; 


















50 years, 20 
dropouts 
Non-anaemic iron 
deficiency (Hb  12.0 
g/dL, sft < 50 g/L) 
RCT, 12 
weeks 
80 mg ferrous 
sulphate 




Assessment of Fatigue 
(MAF), SF-12 
Iron supplementation improved: CAPPS 
fatigue score, MAF global fatigue index 
and fatigue severity index, all 
independent of sft concentrations above 
or below 15g/L and transferrin 
saturation above or below 20%.  No 
significant improvements on measures 
of quality of life, depression or anxiety. 
Haemoglobin improvements were 
significantly more substantial for those 
with a baseline Hb <130 g/dL. 
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Table 3.2 Cochrane risk of bias summary 
+, low risk of bias; ?, unclear risk of bias.















Ballin et al., 1992 ? ? ? ? ? ? ? ? 
Beard et al., 2005 ? + ? + ? ? ? + 
Bruner et al., 1996 ? + ? + ? + ? + 
Favrat et al., 2014 ? + + + ? ? + + 
Krayenbuehl et al., 
2011 
? + ? + + + ? + 
Lambert et al., 
2002 
? ? ? + ? ? ? + 
Leonard et al., 
2014 
? + + + + + ? + 
McArthur et al., 
2012 
? + ? + ? ? ? + 
McClung et al., 
2009 
? ? ? + ? ? ? + 
Murray-Kolb and 
Beard, 2007 
? + + + + + ? + 
Patterson et al., 
2001 
? ? ? + ? + ? + 
Rezaeian et al., 
2014 
? ? + + + ? ? + 
Vaucher et al., 
2012 
+ + + + + + + + 
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3.3.3 Iron status and cognitive function 
 
Three studies found no differences in baseline cognitive function between differing iron status 
groups (Beard et al., 2005; Leonard et al., 2014; Rezaeian et al., 2014). One study found that 
iron sufficient (IS) women performed better on the cognitive tasks than those with non-
anaemic ID (NAID) or IDA; however, the difference was only significant between IS and IDA 
groups (Murray-Kolb & Beard, 2007). Additionally, IS and NAID women completed the 
cognitive tasks significantly faster than those with IDA. The remaining three studies only used 
NAID participants, so no baseline cognitive comparisons were made (Bruner et al., 1996; 
Favrat et al., 2014; Lambert et al., 2002). Of the seven studies that assessed cognitive function 
following iron supplementation, all found significant beneficial effects.  
 




Six studies assessed the effects of iron supplementation on attention (Bruner et al., 1996; 
Favrat et al., 2014; Lambert et al., 2002; Leonard et al., 2014; Murray-Kolb & Beard, 2007; 
Rezaeian et al., 2014) with mixed findings. Amongst females of varied iron status, post-
intervention attention scores were significantly higher than baseline following iron treatment 
and were significantly different from the control group (Rezaeian et al., 2014). Additionally, 
there was a positive correlation between haemoglobin and attention scores post-iron 
treatment. However, amongst NAID women attention domain change scores only trended 
towards being significantly higher (Leonard et al., 2014) or were numerically higher (Favrat et 
al., 2014) for iron treatment groups than placebo controls. Two further studies did not find any 
significant improvements in attention following supplementation (Bruner et al., 1996; Lambert 
et al., 2002). However, when participants were classified as ferritin or haemoglobin responders 
post-intervention, significant effects were found. Ferritin responders displayed significant 
improvements in attention domain scores (Leonard et al., 2014; Murray-Kolb & Beard, 2007), 
and an improvement in power of attention (Favrat et al., 2014). Haemoglobin responders 
showed significantly improved speed of attention task completion (Murray-Kolb & Beard, 
2007) and displayed improved accuracy on a task of attentional switching (Leonard et al., 
2014).  
 
3.3.4.2 Memory  
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Five studies assessed the effects of iron supplementation upon memory domains and all found 
significant improvements post-intervention (Beard et al., 2005; Bruner et al., 1996; Lambert et 
al., 2002; Leonard et al., 2014; Murray-Kolb & Beard, 2007). NAID women displayed a 
significant improvement in verbal working memory (Bruner et al., 1996; Lambert et al., 2002) 
and recognition memory change scores following iron treatment in comparison to placebo 
(Leonard et al., 2014). IDA mothers’ digit span scores also significantly improved post-iron 
treatment as a reflection of short-term memory (Beard et al., 2005). Improvements in serum 
ferritin drove the findings of two of these studies; a significant association between change in 
serum ferritin and improved reading span scores was shown (Lambert et al., 2002) and better 
recognition memory was observed for serum ferritin responders post-intervention (Leonard et 
al., 2014). Ferritin responders also demonstrated seven-fold improvements in the memory 
domain regardless of iron status at baseline in comparison to non-responders (Murray-Kolb & 
Beard, 2007). Similarly, there was a significant association between greater haemoglobin and 
better free recall of recently heard words as a measure of verbal working memory (Lambert et 
al., 2002). Haemoglobin responders were also able to complete memory tasks significantly 
faster (Murray-Kolb & Beard, 2007) and had a significantly greater improvement on digit span 




The only study to assess intelligence found a significant improvement in scores following a 6-
month iron intervention (Beard et al., 2005). Intelligence scores of IDA mothers were almost 
identical to those of IS control mothers post-intervention, whilst the placebo group exhibited 
no change. A significant positive correlation existed between intelligence scores and 
haemoglobin.   
 
3.3.4.4 Learning  
 
The three studies that assessed the effect of iron supplementation on measures of learning 
found significant improvements (Bruner et al., 1996; Lambert et al., 2002; Murray-Kolb & 
Beard, 2007). In comparison to placebo, iron supplementation caused significant learning 
effects on the Hopkins Verbal Learning Test (HVLT) overall total word recall (Bruner et al., 
1996) and significant improvements in words learnt from the second half of the list (Lambert 
et al., 2002). The former study found a significant positive correlation between change in 
serum ferritin and HVLT score post-intervention (Bruner et al., 1996). A five-fold improvement 
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in learning ability was also found for serum ferritin responders following supplementation 
(Murray-Kolb & Beard, 2007).  
 




Five studies assessed perceived levels of fatigue (Ballin et al., 1992; Favrat et al., 2014; 
Krayenbuehl et al., 2011; Patterson et al., 2001; Vaucher et al., 2012) and four found 
significant improvements post-intervention (Favrat et al., 2014; Krayenbuehl et al., 2011; 
Patterson et al., 2001; Vaucher et al., 2012). Two studies assessed fatigue of NAID women 
using the Piper Fatigue Scale (PFS) (Favrat et al., 2014; Patterson et al., 2001). Total PFS 
scores significantly improved following oral and dietary iron interventions (Patterson et al., 
2001), however the intravenous iron study extended this finding to all PFS subscales and 
found a significant correlation between increased serum ferritin and an improved fatigue score 
(Favrat et al., 2014). Another intravenous iron study of NAID women found no significant 
difference between treatment groups’ severity of fatigue scores post-intervention but did find 
significant improvements in perceived fatigue change (Krayenbuehl et al., 2011). However, 
those with substantially depleted iron stores at baseline (serum ferritin <15 µg/L) showed 
significantly improved fatigue severity and fatigue change scores in comparison to placebo 
controls. A further study indicated that significant improvements in global fatigue and fatigue 
severity indices post-intervention were independent of baseline ferritin concentrations above 
or below 15 µg/L (Vaucher et al., 2012). Two studies followed-up their participants for eight 
(Favrat et al., 2014) or twelve weeks after intervention (Krayenbuehl et al., 2011) and found 
greater significant reductions in fatigue reported by the iron group. One study did not find any 
significant benefits of iron supplementation on fatigue yet found a significant improvement in 
lassitude; of those who reported improved lassitude, 65 % were iron deficient at baseline and 
were IS post-intervention (Ballin et al., 1992).  
 
3.3.5.2 Mood and wellbeing 
 
Quality of life, general health and well-being were assessed by two versions of the Self-
Reported Health Questionnaire; SF12 (Favrat et al., 2014; Vaucher et al., 2012) and SF36 
(McArthur et al., 2012; Patterson et al., 2001). Intravenous iron supplementation significantly 
improved NAID women’s mental health quality (mental component score; MCS) whilst a 
numerical trend existed for subjective quality of physical health (Favrat et al., 2014). No 
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significant improvements in quality of life were exhibited in NAID women following oral 
supplementation (Vaucher et al., 2012). The SF36 was used by the two studies that included 
both an oral iron supplement and a high-iron diet (McArthur et al., 2012; Patterson et al., 2001). 
MCS numerically increased post-intervention for both treatment groups in the initial study, but 
this increase was only significant for the dietary intervention group (Patterson et al., 2001). 
The latter study found no significant MCS improvements following either intervention 
(McArthur et al., 2012). Vitality scores improved post-intervention in both studies; the initial 
study found that both NAID treatment groups showed significantly improved vitality scores 
from baseline to no longer be significantly lower than the IS control group at endpoint 
(Patterson et al., 2001) but vitality scores only significantly improved from baseline for the oral 
iron supplement group in the latter (McArthur et al., 2012).  
 
Four studies broadly measured aspects of mood (Ballin et al., 1992; Beard et al., 2005; 
McClung et al., 2009; Vaucher et al., 2012) and all but one (Vaucher et al., 2012) found 
significant improvements following iron supplementation. Iron supplementation during eight 
weeks’ basic combat training in female military soldiers significantly improved feelings of 
vigour from baseline in comparison to placebo (McClung et al., 2009). Another 8-week 
intervention found significant improvements in mood; more so for those who had been ID at 
baseline and became IS post-intervention (Ballin et al., 1992). However, mood was not 
categorised into subscales and it is not clear how and what domains of mood were subjectively 
assessed. Iron supplementation significantly improved depressive symptoms of IDA 
postpartum mothers by 25 % in comparison to the placebo group (Beard et al., 2005). A 
significant negative correlation was found between depression scores and haemoglobin whilst 
significant positive correlations were found between perceived stress and haemoglobin. 
Perceived stress significantly increased from baseline in the placebo and control groups, yet 
numerically decreased in the iron group but did not reach significance. Iron supplementation 
did not significantly affect anxiety levels; this is in agreement with a study on menstruating 













This systematic review aimed to synthesise and critically analyse the existing literature relating 
to the effect of iron supplementation upon cognition, mood, fatigue and/or well-being in women 
of reproductive age. 
 
3.4.1 Cognitive function 
 
Four studies found significant improvements in measures of attention (Favrat et al., 2014; 
Leonard et al., 2014; Murray-Kolb & Beard, 2007; Rezaeian et al., 2014). Two studies 
exhibited significant improvements in short term memory (Beard et al., 2005; Leonard et al., 
2014) and one in recognition memory (Leonard et al., 2014). Furthermore, three studies 
demonstrated improvements in both working memory and learning ability (Bruner et al., 1996; 
Lambert et al., 2002; Murray-Kolb & Beard, 2007). Only one study found a significant 
improvement in intelligence (Beard et al., 2005). Overall, the results suggest that following 
iron supplementation improvements can be made upon cognitive functioning including 
attention, memory, and learning domains. Previous reviews have reported evidence for 
improvements in attention (Falkingham et al., 2010) and memory (Greig et al., 2013; Lomagno 
et al., 2014) following iron supplementation. Although there was evidence of improvements in 
intelligence from one study, this does not provide sufficient evidence in determining its impact. 
This is in contrast to previous systematic and meta-analytic reviews that have suggested 
evidence for iron supplementation improving intelligence in older children and pre-menopausal 
women (Falkingham et al., 2010) and pre-menopausal women alone (Lomagno et al., 2014).  
 
Observational studies have also provided evidence to further support a role for iron in cognitive 
function. Correlations have been found between iron status and spatial ability (Foley, Hay, & 
Mitchell, 1986), attention and memory (Fordy & Benton, 1994). More recently, positive 
associations have been observed between body iron, serum ferritin and executive planning 
function in healthy, non-anaemic women of reproductive age (Blanton et al., 2013). These 
observational findings were replicated and extended in a subsequent dietary iron intervention 
study (Blanton, 2013). Despite no significant improvements in iron status parameters, higher 
body iron and serum ferritin were associated with significantly increased planning speed, 
spatial working memory and attention. These findings were corroborated by further 
observational results demonstrating that although iron status groups did not differ in attentional 
and executive function performance, higher serum ferritin and, when age was added as a 
covariate, higher total body iron were associated with improved planning speed (Scott & 
Murray-Kolb, 2016). With increasing task difficulty, change in planning speed was found to 
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diminish depending upon serum ferritin and total body iron concentrations; iron status could 
be accountable for more efficient management of difficult cognitive loads (Scott & Murray-
Kolb, 2016). This review highlighted that significant ferritin and haemoglobin responses to 
supplementation improved attentional task performance. However, one study noted the 
marked increase of attention scores in comparison to haemoglobin concentrations (95 % vs 
10 % increase) stimulating the suggestion that attentional improvements were a result of 
neurotransmitter pathway modulation rather than increased haemoglobin production and 
subsequent brain oxidation (Rezaeian et al., 2014). Similarly, increased iron status 
parameters may be indicative of oligodendrocytes obtaining a sufficient supply of iron to meet 
their metabolic needs for myelination thus increasing information processing speeds (Connor 
& Menzies, 1996). The two studies that did not find significant improvements to attention 
following iron supplementation suggested that the measures may not have been sensitive 
enough with ceiling effects evident (Bruner et al., 1996) or that findings may be a consequence 
of the multi-faceted nature of attention and its central role within working memory processing 
resources (Lambert et al., 2002). It is postulated that working memory improvements rely 
heavily upon attention-based processes; thus, the improvements in working memory 
demonstrated in these two studies may be a consequence of iron being used by attentional 
networks for a more efficient retrieval of working memory (Feng, Pratt, & Spence, 2012).  
 
The current systematic literature review suggests evidence for memory, particularly working 
memory and short-term memory, improvements following iron supplementation in NAID and 
IDA women. Dopamine-dependent pathways are altered in NAID and IDA in children and 
young adults (Ferreira et al., 2019; Lozoff, 2011) and have been shown to return to normal 
following iron repletion in animal models (Nelson et al., 1997). Dopamine projections in the 
prefrontal cortex and hippocampus are essential for regulation of working memory through 
neuronal activity during task performance and for memory consolidation when learning, 
respectively (LaLumiere, 2014). Improvements in iron status following supplementation may 
facilitate dopamine regulation within these brain regions and subsequently improve memory 
performance. However, further investigation of this in human adults is warranted as a better 
iron status has previously been associated with worse performance on working memory tasks 
(Scott & Murray-Kolb, 2016). There is evidence to suggest that this may be by consequence 
of competition within an intact hippocampal system (Fretham et al., 2011), in comparison to 
ID-induced hippocampal memory abnormalities that may result in hippocampal avoidance and 
easier access and increased dominance of prefrontal systems necessary for superior task 





Of the five studies that assessed fatigue following iron supplementation, four found significant 
positive effects post-intervention. All studies suggested a relationship between ID and 
increased fatigue levels. A previous meta-analytic review of NAID women included three of 
the studies included in this review (Favrat et al., 2014; Krayenbuehl et al., 2011; Vaucher et 
al., 2012); all found significant treatment effects of iron supplementation on subjective fatigue 
(Yokoi & Konomi, 2017). The additional study included in this review that found a significant 
improvement in fatigue following iron supplementation also investigated NAID women, 
bolstering the suggestion that iron supplementation has a serum ferritin-dependent effect upon 
fatigue (Patterson et al., 2001). As haemoglobin is not affected in NAID, it is postulated that 
serum ferritin deficits cause diminished activity of iron-dependent oxidative enzymes and 
respiratory proteins, reducing the extraction and utilisation of oxygen-bound haemoglobin 
evoking subjective and objective indications of fatigue (Bahadir et al., 2018). Similarly, fatigue 
onset is associated with an elevated serotonin to dopamine ratio in the brain (Davis & Bailey, 
1997; Meeusen et al., 2006); monoamine dysfunction is also associated with iron deficiency 
presentation. The only study not to find a significant improvement in fatigue had no eligibility 
criteria regarding iron status resulting in unequal numbers of iron status within and between 
treatment groups (Ballin et al., 1992), which may have contributed to the lack of significant 
findings. A causal link between IDA and increased subjective fatigue is well established, whilst 
this link amongst NAID women is becoming increasingly acknowledged (Dziembowska et al., 
2019; Houston et al., 2018).  
 
These findings are in accordance with meta-analytic results suggesting a benefit of iron 
supplementation for improving physical exercise performance in women of reproductive age 
(Pasricha et al., 2014) and NAID female athletes (Burden et al., 2015). A recent meta-analysis 
however found that physical performance only improved when a serum ferritin cut-off of ≤ 20 
µg/L and below was used (Rubeor et al., 2018), contrary to the studies assessing subjective 
fatigue in this review. This suggests that subjective fatigue is responsive to iron 
supplementation at higher serum ferritin concentrations, whilst physical performance may only 
be amenable at lower levels. 
 
3.4.3 Mood and wellbeing  
 
The effect of iron supplementation on improving aspects of mood and wellbeing appears to 
be far more complex. Of the seven studies assessing mood and wellbeing, six found significant 
effects; however, these are somewhat divergent. Quality of life, as assessed by the SF-12, 
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improved following an intravenous iron supplement (Favrat et al., 2014) but not following oral 
iron supplementation (Vaucher et al., 2012). A single total dose of intravenous iron is shown 
to be as beneficial as a daily oral iron supplementation (Iyoke et al., 2017), and the same dose 
of intravenous iron given daily is more effective than daily oral iron (Bhavi & Jaju, 2017). This 
would give support to a beneficial effect of intravenous iron over daily oral iron for improved 
perceived health and well-being, however further investigation is warranted. Mental health, as 
assessed by the SF-36, significantly improved following a dietary intervention of lean beef or 
lamb (Patterson et al., 2001) but not following a dietary pork intervention (McArthur et al., 
2012). Although all are classed as red meat, unprocessed beef and lamb have a higher mean 
iron content than pork with only beef qualifying as a source of iron in accordance with 
European regulations (Cashman & Hayes, 2017). Dietary pork was able to maintain 
haemoglobin concentrations to the same extent as supplemental iron; however, serum ferritin 
only increased following supplemental iron (McArthur et al., 2012). This may explain why 
improvements in vitality were only significant when either a beef-rich diet or an oral iron 
supplement was consumed, coupled with significant improvements in haemoglobin and serum 
ferritin.   
 
A significant improvement in depressive symptoms was only found amongst IDA postpartum 
mothers (Beard et al., 2005). Low ferritin and/or IDA is identified as a risk factor for postpartum 
depression (PPD) occurrence (Wassef et al., 2019). Postpartum iron supplementation 
significantly improves PPD symptoms over six weeks (Sheikh et al., 2017) and is shown to 
reduce PPD risk, however no protective effects are observed when iron is administered during 
pregnancy (Wassef et al., 2019). Monoaminergic systems involved in mood regulation are 
dysregulated during iron deficiency (Kim & Wessling-Resnick, 2014) and amongst postpartum 
women (Xie et al., 2018; Yildiz et al., 2017); the combined effect may subsequently exacerbate 
depressive symptoms. However, no significant improvements in depressive or anxiety 
symptoms were shown in NAID women in this review (McClung et al., 2009; Vaucher et al., 
2012). A relationship between depression and low serum ferritin concentrations, in non-
anaemic women has been observed previously. In comparison to healthy females, serum 
ferritin was significantly lower in individuals with depression; this was reflected by a 
significantly higher frequency of ID (<15 µg/L) in females with depression (Vahdat 
Shariatpanaahi et al., 2007). Depressive symptoms may not have improved in these 
intervention studies due to a higher serum ferritin at baseline; the first study had no inclusion 
criteria for serum ferritin (McClung et al., 2009) whilst the latter used a higher cut-off of < 50 
µg/L resulting in only 32.4 % of the iron treatment group having serum ferritin < 15 µg/L 
(Vaucher et al., 2012). Further investigation is warranted focussing upon NAID women, to 
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determine whether depressive symptoms can successfully be ameliorated in this 
demographic. 
 
3.4.4 Evaluation  
 
This systematic review has expanded upon previous reviews regarding the impact of iron 
supplementation upon cognition in women of reproductive age. Yet it is the first to focus on 
RCTs of mood, fatigue and well-being regardless of whether cognition was also being 
measured. Subsequently, this allowed the inclusion of an additional five studies and a more 
thorough discussion of the literature was possible. Similarly, the review has expanded 
knowledge in the field for women of reproductive age specifically, avoiding including studies 
in infants and children (Falkingham et al., 2010), and has focussed on iron supplementation 
alone rather than additional nutritional supplementation types (Lomagno et al., 2014). The 
search was not limited by date as all studies published and recorded from Cochrane Library, 
Web of Science and PubMed were included from the earliest date to the current year.   
 
However, there are several factors that must be taken into consideration when basing 
conclusions on the results of this review. Firstly, heterogeneity surrounding the methods 
chosen to assess and categorise participants into iron status groups was evident. To not be 
considered anaemic, it is recommended that haemoglobin concentrations are ≥120 g/L (World 
Health Organization, 2011b); the studies included in this review that consider NAID to include 
those with a haemoglobin concentration >90 g/L are possibly open to misinterpretation (Favrat 
et al., 2014; Patterson et al., 2001). Similarly, serum ferritin cut-offs for ID vary between 
organisations and laboratories worldwide (Daru et al., 2017). In this review, serum ferritin 
ranged from <12 to ≤50 µg/L for NAID classification. Identifying a cut-off for serum ferritin 
reflective of depleted iron stores remains challenging due to its acute-phase protein (APP) 
properties; consequently, there are no well-defined diagnostic criteria (Namaste et al., 2017; 
Soppi, 2018). Subsequently, serum ferritin concentrations can be elevated following an 
inflammatory response to microbial invasion, tissue injury, chronic or autoimmune diseases 
(Northrop-Clewes, 2008), which can lead to an inaccurate calculation of iron stores. Obesity 
and exercise-associated inflammation are also shown to stimulate reactive oxygen species 
production, which prompts increases in hepcidin production to cause degradation of the 
transmembrane protein ferroportin instigating reduced iron absorption (Aigner et al., 2014; 
Domínguez et al., 2018; Gaffney-Stomberg & McClung, 2012). It is recommended that other 
APPs, such as C-reaction protein and alpha-1-glycoprotein, are controlled for to determine 
whether an acute phase response is present and reduce diagnostic inaccuracies (Suchdev et 
al., 2017). However, seven of the 13 studies included studies did not control for the potential 
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effect of inflammation (Ballin et al., 1992; Bruner et al., 1996; Lambert et al., 2002; McArthur 
et al., 2012; McClung et al., 2009; Patterson et al., 2001; Rezaeian et al., 2014). Concurrently, 
although the majority of the included studies controlled for chronic and autoimmune diseases, 
the same cannot be said for body mass index (BMI) or physical activity.  
 
There was also a lack of consistency regarding supplementation duration, method of 
administration and dosage. The intervention period ranged from two weeks to 6 months 
despite the recommended supplementation duration being 12 to 24 weeks to restore and 
improve iron status (Baird-Gunning & Bromley, 2016). Consequently, half of the studies 
included in this review would not fulfil this criterion. Similarly, administration of the supplement 
varied; eleven studies administered iron orally (9 ferrous sulphate; 1 ferrous gluconate; 1 iron 
polystyrene sulphonate) whilst two used intravenous iron. Despite oral iron, specifically ferrous 
sulphate, being the gold-standard treatment for ID (Santiago, 2012), its daily administration to 
a non-clinical population is associated with an increased risk of gastrointestinal side effects 
when compared to placebo or intravenous iron delivery (Tolkien et al., 2015). This encourages 
reductions in treatment compliance, though associated adverse effects and compliance were 
not consistently documented in the included studies of this review increasing the difficulty of 
determining the tolerability of the interventions.  
 
Iron supplement dosage also varied across the studies, from 37.4 mg-260 mg elemental iron. 
A comparative study included in this review identified an elemental 60 mg iron dose to be as 
effective as an 80 mg dose for improving iron status in NAID women with no significant 
difference in adverse events or compliance (Leonard et al., 2014). However, 60 mg is, 
substantially greater than the recommended daily allowance of 14.8-16.0 mg/day for non-
pregnant, menstruating women (Milman, 2019), and greater than the tolerable upper level of 
iron intake of 40-45 mg for gastrointestinal discomfort prevention (Pra et al., 2012). Resolution 
of NAID has been achieved after an 8-week intervention of 26 mg daily iron supplementation 
without the occurrence of adverse effects (D'Adamo et al., 2018). A lower dose supplement 
administered over a longer duration may be more beneficial for achieving an optimal iron 
status and reducing adverse effects. 
 
Dietary iron intake at baseline was considered by less than half of the studies included in this 
review. Although possible to achieve optimal iron intake without consuming meat, both haem 
iron and non-haem iron are positively associated with serum ferritin concentrations in healthy 
young women, with haem iron exhibiting a stronger association (Young et al., 2018). Red 
meat-rich diets may therefore be of increased value to maintaining optimal iron status. These 
findings are echoed by positive associations between consumption of animal flesh foods and 
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iron status (Jackson et al., 2016) and meta-analytic findings suggesting vegetarians have 
significantly lower serum ferritin compared to non-vegetarians and are subsequently more 
susceptible to ID (Haider et al., 2018). Higher serum ferritin concentrations are also associated 
with tertiary education (Young et al., 2018), which may be a consequence of increased health 
awareness and desire for greater diet quality, especially when following a diet low in haem 
iron. A higher quality diet is associated with a greater executive functioning (Cohen, Gorski, 
Gruber, Kurdziel, & Rimm, 2016) and a reduced prevalence of depressive and anxiety 
symptoms in women (Gibson-Smith, Bot, Brouwer, Visser, & Penninx, 2018; Quehl, Haines, 
Lewis, & Buchholz, 2017; Sakai, Murakami, Kobayashi, Suga, & Sasaki, 2017), bolstering the 
need to assess not only dietary iron intake but also overall diet quality.  
 
Similarly, there was a lack of control for the menstrual cycle prior to haematological testing, 
group allocation and randomisation. Women of reproductive age are at a greater risk of ID 
due to increased iron losses as a result of menstrual bleeding (Johnson et al., 2016). 
Quantitative measures of menstrual blood loss have proven to significantly predict iron status 
(Harvey et al., 2005), whilst subjective approaches have identified significantly lower serum 
ferritin concentrations for those with greater menstrual blood loss (Heath et al., 2001; Toxqui 
et al., 2014). It is therefore important to take menstrual blood loss into consideration when 
assessing iron status and methods of combating ID. Similarly, no studies controlled for where 
participants were in their menstrual cycle prior to collecting haematological samples. 
Haemoglobin and serum ferritin are at their lowest during menses and at their highest during 
the luteal phase of the menstrual cycle (Kim et al., 1993). It is thus recommended that iron 
biomarkers should be assessed during the late luteal phase of the menstrual cycle for accurate 




Overall, there is evidence to suggest that iron supplementation can improve cognitive function, 
particularly attention, memory and learning, in addition to subjective fatigue in menstruating 
women of reproductive age. However, the impact of iron on subjective mood and well-being 
appears much more complex, which may be due to the heterogeneity surrounding intervention 
routes of administration, intervention doses and the methods chosen to assess and categorise 
participants into iron status groups across the included studies. Further research including 
assessments of response to iron supplementation and controlling for confounding variables of 
dietary iron intake, BMI, physical activity, menstrual cycle and blood loss are needed to confirm 
and extend these results.  
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 EFFICACY EVALUATION OF 16 WEEKS’ DIETARY SUPPLEMENTATION 





The systematic review reported in Chapter 3 indicated significant benefits of iron 
supplementation for improving iron status, cognitive function, mood, fatigue and well-being in 
non-pregnant women of reproductive age. However, not all iron RCTs have considered 
baseline iron status (Ballin et al., 1992; McArthur et al., 2012; McClung et al., 2009). 
Concerning NAID, significant improvements to iron status, measures of memory (Bruner et 
al., 1996; Lambert et al., 2002; Leonard et al., 2014; Murray-Kolb & Beard, 2007), attention 
(Favrat et al., 2014; Leonard et al., 2014; Murray-Kolb & Beard, 2007), learning (Bruner et al., 
1996; Murray-Kolb & Beard, 2007), fatigue (Favrat et al., 2014; Krayenbuehl et al., 2011; 
Patterson et al., 2001; Vaucher et al., 2012) and well-being (Favrat et al., 2014; Patterson et 
al., 2001) following iron supplementation in NAID women of reproductive age have been 
observed, inferring a causal relationship between iron and psychological functioning. 
However, it is noteworthy that the cut-offs for NAID varied across the included studies; serum 
ferritin ranged from < 12 to < 50 µg/L whilst haemoglobin ranged from > 90 to ≥ 120 g/L. 
Worldwide clinical guidelines propose a haemoglobin concentration of ≥ 120 g/L to signify non-
anaemia in women (World Health Organization, 2011a), which suggests the studies 
classifying NAID using haemoglobin < 120 g/L (Favrat et al., 2014; Patterson et al., 2001) may 
be misrepresenting IDA as NAID. Consequently, studies only including NAID women may be 
limited to a small proportion of the population with low serum ferritin or could have included 
participants with serum ferritin concentrations greater than those considered reflective of ID. 
Similarly, IS groups could encompass participants with performance deficits associated with 
high haemoglobin or serum ferritin, which could lead to inaccuracies in comparisons of iron 
supplementation between NAID and IS women. To address this issue, it may be important to 
recruit women of reproductive age into iron supplementation RCTs based on NAID and IS iron 
status to ensure a range of iron status across non-anaemic women in the absence of excess 
iron, while controlling for baseline serum ferritin concentration. As haemoglobin is positively 
associated with folate due to its involvement in the formation of iron-containing haem (Elema, 
Yimam, Waka, & Olana, 2018; Koury & Ponka, 2004), serum ferritin (a measure of iron stores) 
is required to determine iron status, especially amongst a non-anaemic population. Controlling 
for baseline serum ferritin, alongside CRP to account for its APP properties, would allow for 
the impact of baseline iron status on any treatment effects to be accounted for whilst 
overcoming the problems associated with iron status group categorisations.  
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The RCTs that have used a cut off of ≤ 20 µg/L for NAID in studies recruiting both NAID and 
IS women (Leonard et al., 2014; Murray-Kolb & Beard, 2007) both administered oral ferrous 
sulphate, the gold-standard iron preparation for IDA treatment (Cook, 2005; Santiago, 2012; 
Tolkien et al., 2015), for 16 weeks, which is within the recommended 12 to 24 weeks required 
to significantly replenish iron stores in the brain (Baird-Gunning & Bromley, 2016). However, 
both administered elemental iron doses (60-80 mg) much greater than the recommended daily 
allowance of 14.8-16.0 mg for non-pregnant, menstruating women (Milman, 2019), and 
greater than the tolerable upper level of iron intake of 40-45 mg based upon the prevention of 
gastrointestinal discomfort (Pra et al., 2012). Additionally, iron doses exceeding 30 mg are 
shown to increase the likelihood of gastrointestinal discomfort (Low et al., 2016), whilst meta-
analysis suggests that ferrous sulphate causes significant gastrointestinal side-effects 
amongst adults (Tolkien et al., 2015) such as nausea, vomiting, abdominal discomfort, 
constipation and dark-coloured stools (Johnson-Wimbley & Graham, 2011). Consequently, 
adherence to treatment protocols is often affected as once haemoglobin concentrations are 
improved or corrected after four weeks, iron supplementation must continue for approximately 
three months to replenish serum ferritin (Alleyne, Horne, & Miller, 2008; Goddard et al., 2011). 
Of the two comparable RCTs from the systematic review, one reported analogous side effects 
and compliance between treatment and placebo groups (Leonard et al., 2014), however such 
findings were not reported in the other (Murray-Kolb & Beard, 2007). Following this, 
investigations of alternate sources of iron at doses below 30 mg have been trialled; 26 mg of 
elemental iron cultured from yeast led to significant increases in serum ferritin concentrations 
in NAID women of reproductive age without adverse effect presentation (D'Adamo et al., 
2018). It is thus imperative to investigate lower and more tolerable doses of iron to determine 
whether they too can improve psychological functioning yet in a more efficient manner than 
higher doses of elemental iron from ferrous formulations.  
 
Another option to reduce adverse effects of ferrous formulations is to use a different iron 
preparation. As described in section 1.6.3, iron bis-glycinate has a heterocyclic ring structure, 
which infers a stronger stability constant than that of inhibitory ligands and prevents the ferrous 
cation from interacting with the gastric mucosal lining. This leads to augmented iron 
bioavailability for absorption and improved gastrointestinal tolerability in comparison to ferrous 
formulations (Ashmead, 2001). Consequently, IS non-pregnant women of reproductive age 
show a significantly greater preference for iron bis-glycinate over ferrous sulphate following 
trends for lower incidence of gastrointestinal adverse effects (Coplin et al., 1991) and 
significantly fewer reports of adverse effects (Fouad et al., 2013). This promising evidence has 
prompted its use as an alternative oral supplement for IDA treatment. Research has targeted 
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populations of infants, young children and adolescents due to the increased demand for iron 
and increased risk of IDA during these stages of life. A dose-response study that focused on 
IDA treatment in adolescents discovered that 30 mg iron bis-glycinate chelate was as effective 
as 120 mg ferrous sulphate in improving iron status (Oscar Pineda et al., 1994). Increased 
bioavailability of the chelate was associated with greater efficacy for increasing serum ferritin 
concentrations at 60 mg and 120 mg in comparison to 120 mg ferrous sulphate. Similarly, 
fewer gastric complaints were reported in all iron bis-glycinate groups with no complaints 
reported by the 30 mg group. For IDA treatment in infants, equal doses of iron bis-glycinate 
and ferrous sulphate (5 mg/kg/day) significantly increased haemoglobin after 28 days, 
however iron bis-glycinate resulted in a significantly greater increase in serum ferritin (Pineda 
& Ashmead, 2001); the bioavailability of iron bis-glycinate was 3.4 times higher than ferrous 
sulphate. Lower doses of iron bis-glycinate chelate (0.75 mg/kg/day) have also demonstrated 
an efficacy comparable to a four-time greater dose of ferrous sulphate in new-born children 
(Bagna et al., 2018) for IDA prevention. Additionally, the efficacy of iron bis-glycinate for IDA 
treatment in children has been compared to polymaltose iron (Name et al., 2018), which has 
similarly enhanced bioavailability and tolerability compared to ferrous formulations (Jacobs, 
Wood, & Bird, 2000; Jacobs, Wormald, & Gregory, 1979; Ortiz et al., 2011; Saha, Pandhi, 
Gopalan, Malhotra, & Saha, 2007; Toblli & Brignoli, 2007; Yasa et al., 2011). Following a 45-
day intervention, both treatments (3 mg/kg/day) led to significantly improved haemoglobin 
concentrations. However, only iron bis-glycinate prompted significantly increased serum 
ferritin concentrations, which highlights the greater efficacy of the compound for replenishing 
iron stores at low doses and over a short intervention duration (Name et al., 2018). Such 
findings demonstrate the superiority of iron bis-glycinate chelate over ferrous sulphate 
formulations and polymaltose iron for IDA resolution with improved tolerability. 
 
Due to the marked increase in serum ferritin associated with iron bis-glycinate treatment, 
investigations of its efficacy have extended to children who are NAID to further knowledge on 
the prevention of IDA. An inverse relationship between serum ferritin and the absorption of 
iron bis-glycinate chelate has been observed (Bovell-Benjamin et al., 2000; Olivares et al., 
1997). A 12-week intervention with 30 mg/day iron bis-glycinate chelate or ferrous sulphate in 
children with normal-range haemoglobin and serum ferritin <12 ug/L found a significant 
improvement in serum ferritin for both treatment groups (Duque et al., 2014). Iron bis-glycinate 
was more efficient than ferrous sulphate for sustaining serum ferritin 6 months after 
supplementation. It is postulated that the persistence of this effect is because of the ability to 




One other approach to overcoming absorption issues associated with ferrous salts has been 
to co-supplement with ascorbic acid (Vitamin C), which is shown to enhance the absorptive 
properties of ferrous formulations and accelerate improvements to iron status (Chiamchanya, 
2013). Ferrous formulations combined with ascorbic acid have been compared to iron bis-
glycinate chelates for IDA management during pregnancy. A 100 mg dose of iron bis-glycinate 
significantly improved haemoglobin from baseline after 14 and 28 days; this improvement was 
also significantly greater at day 28 compared with that of ferrous ascorbate treatment (Kamdi 
& Palkar, 2015). For serum ferritin, significant improvements were evident after 14 and 28 
days in both treatment groups but improvements were significantly greater at both time points 
for iron bis-glycinate. This demonstrates the higher bioavailability and efficacy of the bis-
glycinate chelate over a ferrous formulation for the management of IDA in pregnant women, 
even when the ferrous salt is combined with an enhancer of iron absorption like ascorbic acid. 
Despite the greater dose in comparison to previous studies, 28 days of treatment did not 
restore haemoglobin concentrations to non-anaemic classification warranting extended 
intervention durations. To date, however, no iron supplementation studies have investigated 
the co-supplementation of iron bis-glycinate and ascorbic acid. Considering the beneficial 
effect ascorbic acid has on iron bis-glycinate absorption in an iron inhibitor-rich environment 
(Olivares et al., 1997), it is imperative to investigate whether such co-supplementation would 
improve the already superior bioavailability of iron bis-glycinate supplements to subsequently 
improve iron status further.  
 
Largely, although NAID is more prevalent amongst women of reproductive age than IDA, 
comparatively less is known about the effects of iron supplementation in NAID women. 
Previous iron RCTs in NAID women of reproductive age have adopted varying cut-off levels 
for serum ferritin, resulting in studies that have either only focussed on a small proportion of 
the population who have very low serum ferritin or have considered NAID at cut-offs greater 
than levels considered reflective of ID. To address this, investigations of a range of NAID and 
IS women of reproductive age are warranted that take baseline serum ferritin into account 
when assessing treatment effects. Additionally, it appears that the designs of the RCTs 
conducted so far could be improved by supplementing with a low-dose iron bis-glycinate 
chelate following observed improvements to bioavailability, efficacy, tolerability and 
subsequent compliance compared to ferrous formulations. Despite the advantages of iron bis-
glycinate, no studies to date have investigated its administration for improving iron status in 
non-pregnant women of reproductive age with NAID. The inverse relationship between iron 
bis-glycinate chelate absorption and serum ferritin suggests the potential of iron bis-glycinate 
to be of most benefit to a NAID population. To date, iron bis-glycinate chelate has not been 
investigated to assess cognitive and mood parameters. It would be valuable to determine 
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whether the improvements to psychological and physiological function highlighted in the 
preceding chapter’s systematic review, are replicated or extended because of the increased 
bioavailability and tolerability of low doses of iron bis-glycinate chelate. Additionally, the 
increased absorption of iron by co-supplementation of iron bis-glycinate chelate and ascorbic 
acid warrants investigation to determine whether it will be more advantageous to psychological 
and physiological health than iron bis-glycinate alone. The present study therefore aims to 
build upon the methodologies of previous RCTs to compare the effects of low-dose iron bis-
glycinate and iron bis-glycinate plus ascorbic acid treatments on cognitive function, mood, 
fatigue and well-being. The present study will investigate the effects of 16 weeks 
supplementation with either 28 mg/d of iron bis-glycinate chelate alone, 28 mg/d iron bis-
glycinate chelate plus 240 mg ascorbic acid or matched placebo in women of reproductive 
age upon the same cognitive, mood, fatigue and wellbeing measures assessed in Chapter 2.  
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4.2 Methods 
4.2.1 Design & ethics 
 
This study employed a randomised, placebo-controlled, double-blind, stratified groups design, 
with participants randomly assigned to one of three treatment groups (placebo, iron, iron and 
vitamin C; see section 4.2.3). The study received ethical approval from Northumbria 
University’s Psychology Department and was conducted according to the Declaration of 





One hundred and fifty-one females aged 18-49 years were recruited into the study following 
completion of the study that formed the basis of Chapter 2 and who met the inclusion criteria 
described in section 2.2.29. In addition, participants reported themselves to not have any food 
allergies or sensitivities relevant to the interventional product and had a haemoglobin 
concentration ≥120 g/L. An a priori power analysis was conducted to calculate the sample size 
based upon a mixed measures ANCOVA-F test with medium effect size (f = 0.25) using G 
Power 3.1.9.2. This indicated that a total sample of 141 participants with 47 participants per 
treatment arm was required to detect a significant difference at an alpha level of 0.05 between 
groups to achieve power of .75. All participants were non-anaemic and were randomised into 
each treatment arm by stratified sampling to ensure a range of NAID and IS participants across 
treatments. To account for potential dropouts, the total sample size was increased to a total 




All participants were randomly assigned to either placebo, 28 mg/day iron bis-glycinate 
chelate, or 28 mg/day iron bis-glycinate chelate plus 240 mg vitamin C within their stratified 
groups of IS or NAID. The manufacturer (Bayer HealthCare – Consumer Care, Basel, 






9 A visual representation of the participant disposition throughout the studies that comprise this thesis 
can be found in Appendix V. 
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were delivered to the lab in boxes organised by treatment code. The lead researcher had no 
access to identification materials associating these letters to the respective treatment.  A 
stratified randomisation schedule was created by the second supervisor using 
randomization.com. Treatment bottles within each box were relabelled with a treatment 
randomisation number that corresponded to their iron status stratification group (IS 101-178; 
NAID 201-273) according to the randomisation schedule, assigning each participant to an A, 
B or C treatment. Upon completion, the principal supervisor ensured that the treatment bottles 
in the A, B and C boxes corresponded with the randomisation schedule. Treatment bottles 
were assigned to participants in sequential order stratified by iron status group. Treatments 
were oblong tablets identical in appearance to ensure participants and the research team 
remained blind to which treatment had been dispensed. Upon completion of all analyses in 
the thesis, the lead researcher and principal supervisor were unblinded to allow data 
interpretation with the knowledge of which treatment corresponded to the A, B and C codes.  
 
Participants were randomly allocated to a single treatment for the duration of the study 
according to a randomisation schedule. Treatments were provided in two bottles of 63 tablets 
to be consumed once per day for 16 weeks. The treatment duration mimicked the protocols of 
previous iron intervention studies (Leonard et al., 2014; Murray-Kolb & Beard, 2007) following 
evidence of a reduced rate of iron recovery in the brain in comparison to the liver following 
treatment in animal models (Youdim et al., 1989). To combat the known increased risk of 
gastrointestinal side effects associated with traditional ferrous formulations of iron 
supplements that reduce tolerability and successful iron absorption, the active treatments 
comprised iron bis-glycinate chelate as the source of iron. Participants were instructed to 
commence taking their treatment the morning following randomisation with a glass of water 
and to avoid co-ingesting with milk, coffee, tea or orange juice due to the known respective 
reducing and enhancing absorptive properties. This was especially important due to one of 
the active treatments co-supplementing iron with vitamin C. Participants were advised to take 
their treatment immediately upon wakening and to avoid food or drink for one hour after. The 
final tablet was ingested the morning before participant’s final testing visit (Week 16) to 
conclude the supplementation period.  
 
4.2.4 Demographic/lifestyle questionnaires 
 
The current study utilised the same demographic/lifestyle questionnaires of caffeine 
consumption, physical activity, subjective nutrient and food group frequencies and menstrual 
blood loss outlined in section 2.2.3.    
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4.2.5 Cognitive and behavioural function assessment battery 
 
The current study utilised the same cognitive and behavioural function assessment battery 
outlined in sections 2.2.4 and 2.2.6. 
 
4.2.6 Treatment guess questionnaire and compliance  
 
Upon completion of the study, participants were provided with a treatment guess questionnaire 
(APPENDIX VI). This required participants to choose between whether they believed they had 
been randomised to an active or placebo treatment for the duration of the study and to provide 
a reason for this choice. A chi-square test was used to analyse the correct and incorrect 
responses given by treatment group for confirmation of the blinding procedure.  
 
A treatment compliance percentage was calculated upon study completion to ensure 
appropriate treatment consumption by participants in accordance with the study protocol. This 
percentage was calculated by counting the number of returned tablets and comparing it to the 
number of tablets that should have been consumed based on the number of days between 
the first and final study visits for each participant.   
 
4.2.7 Blood sampling  
 
In addition to the samples outlined in section 2.2.7, additional venous samples were collected 
for vitamin C and zinc. During the screening visit for the study described in Chapter 2, baseline 
venous samples were obtained, with post-dose samples obtained during the Week 16 
assessment. Any samples obtained from participants who were not enrolled in the current 
study were destroyed.  
 
4.2.7.1 Vitamin C 
 
Biological analysis of plasma vitamin C is considered the most reliable measure of vitamin C 
status (Dehghan, Akhtar-Danesh, McMillan, & Thabane, 2007; Travica et al., 2017). 
International population studies have established vitamin C status limits; deficiency (<11 
µmol/L), depletion or marginally deficient (11 - 28 µmol/L), adequate (28 - 40 µmol/L) and 




Blood samples were obtained via venepuncture into lithium heparin vacutainers (4 ml). 
Samples were inverted 8 - 10 times, refrigerated at 5 °C, and processed within 2 hours of 
acquisition. The plasma was separated in a refrigerated centrifuge (4 °C, 10 minutes, 1200 
rpm/277 x g) after which, 0.5 ml of plasma was transferred into two 1.5 ml Eppendorf tubes® 
in addition to an equal volume of 10 % metaphosphoric acid for stability as a protein-free acid 
supernatant (Lykkesfeldt, 2002). The sample was centrifuged again under the same 
conditions and immediately frozen at -80 0C prior to high performance liquid chromatography 
(HPLC) analysis conducted on-site.  
 
Following the procedure of Robitaille and Hoffer (2016), samples were thawed over ice and 
50 µL of plasma was placed in 1 ml plastic Eppendorf tubes®. To prepare the samples for 
analysis, an equal volume of 5 mmol/L tris(2-carboxy ethyl) phosphine hydrochloride (TCEP) 
in water was added and the sample allowed to react for 20 minutes at room temperature before 
centrifuging (4 °C, 5 minutes, 16000 x g). The supernatant was kept on ice and transferred 
into autosampler vials and injected immediately onto the HPLC column. The sample injection 
volume was 20 µL and samples were maintained at a temperature of 4 °C.  
 
The analysis was carried out using an Agilent 1260 Infinity modular HPLC system equipped 
with a multi-wavelength detector set to 245 nm. The column was a Thermo Hypersil BDS C18 
(150 x 4.6 mm, 5 µm) maintained at a temperature of 25 °C. The mobile phase was 1.8 mM 
sulphuric acid (aq.) and the flow rate was 1 mL/min. Total run time was 10 minutes and the 
retention time of the vitamin C peak was 2.5 minutes. Each sample run through the HPLC 
system included a plasma quality control sample to ensure internal batch precision following 
the standard curve developed using a peak areas linear regression from six ascorbic acid 
standards ranging from 0 to 100 µmol/L. The assay is a highly sensitive and reproducible 
HPLC method for the determination of ascorbic acid concentrations in human plasma 




Zinc was measured to monitor levels across the intervention period in response to iron 
supplementation as zinc shares some of its absorptive and transport mechanisms with iron, 
which may promote competition between the minerals (Sandstrom, 2001). Biological analysis 
of plasma or serum zinc concentrations is the most widely used measure of zinc status 
(Wieringa, Dijkhuizen, Fiorentino, Laillou, & Berger, 2015). For women of reproductive age (18 
- 49 years) cut offs for zinc deficiency are dependent on fasting and time of day; <10.7 mol/L 
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(morning, fasting), <10.1 mol/L (morning, non-fasting) and 9 mol/L (afternoon, non-fasting) 
(Grønli, Kvamme, Friborg, & Wynn, 2013; Wieringa et al., 2015).  
 
Blood samples were obtained via venepuncture into Trace Element Serum (TE) vacutainers 
(6 ml). Samples were inverted 8-10 times, refrigerated at 5 °C, and allowed to clot for at least 
30 minutes before they could be processed within 4 hours of acquisition. Samples were 
centrifuged at 3000 rpm (1734 x g) for 10 minutes at 4 °C. Following centrifugation, 1 ml of 
plasma was poured off into two 1.5 ml Eppendorf tubes® and immediately frozen at -80 0C 
prior to analysis conducted by Newcastle Laboratories, Newcastle-upon-Tyne.  
 
Samples were analysed by inductively coupled plasma-mass spectroscopy (ICP-MS) in 
collision mode. ICP-MS is a multi-element analytical technique capable of trace level 
elemental analysis. For zinc (m/z 66) isotope measurements, serum samples are diluted with 
Butan-1-ol and diluent containing yttrium for internal standardisation. Liquid samples are 
introduced into the ICP through a nebulizer and spray chamber carried by a flowing argon 
stream. By coupling radio-frequency power into flowing argon, plasma is created in which the 
predominant species are positive argon ions and electrons and has a temperature of 6,000-
8,000 °C. The sample passes through a region of the plasma and the thermal energy atomizes 
the sample and then ionizes the atoms. The ions, along with the argon, enter the mass 
spectrometer through an interface that separates the ICP (at atmospheric pressure) from the 
mass spectrometer (vacuum). The ions pass through a focusing region and then the universal 
reaction cell. Analysis of zinc is in Kinetic Energy Discrimination Mode (KED) with helium as 
the collision gas. The ions pass through the quadrupole mass filter, and finally are counted in 
rapid sequence at the detector allowing individual isotopes of zinc to be determined. The 
quadrupole is sequentially scanned to specific mass to charge ratio of each analyte and 
intensity is detected with a pulse detector. Electrical signals resulting from the detection of 
ions are processed into digital information that is used to indicate first the intensity of the ions 




The procedure outlined in section 2.2.8 was followed for all participants enrolled. Prior to their 
testing assessment for the study described in Chapter 2, participants eligible for the current 
study were informed of their eligibility and sent all study information. Following completion of 
the procedure outlined in section 2.2.8, the requirements of the study were discussed in line 
with the participant information sheet supplied to the participant prior to screening. Following 
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informed consent, participants received the first bottle of their allocated treatment along with 
instructions on how to take them and to commence supplementation the following morning. 
Participants were provided with a treatment diary (APPENDIX VII) to log the time and date of 
ingested tablets, to note any missed tablets, any concomitant medications and any adverse 
events they may have experienced during the supplementation period. 
   
Participants returned to the lab during week 8 to collect the final bottle of their allocated 
treatment. During this visit, participants returned their diary and any remaining tablets so that 
treatment compliance could be calculated, and any concomitant medications and adverse 
events noted in the Case Report Form (CRF). A new diary was provided to participants to 
complete in an identical manner for weeks 8 - 16 of the supplementation period.  
 
The week 16 assessment followed the same protocol as the baseline assessment with the 
exception of the return of their diary and all remaining tablets, the completion of the 
demographic/lifestyle questionnaires (excluding the food frequency questionnaire) initially 
completed at screening for the study described in Chapter 2, and a treatment guess 
questionnaire. Participants were asked if they had significantly changed their dietary habits 
over the supplementation period (e.g., adopted a vegan diet), which was noted down as a 
procedural deviation if so. Venous and finger-prick blood samples were obtained at week 16 
to determine a profile of iron, vitamin C, zinc and oestrogen (not analysed due to COVID-19) 
status. Upon completion of the final testing assessment, participants were fully debriefed.    
 
4.2.9 Data cleaning 
 
One hundred and fifty-one participants were enrolled into the study of which 135 completed 
all requirements. Of the 16 participants who did not complete the study; seven were lost to 
follow up; three withdrew due to time commitments; two withdrew due to self-reported lack of 
compliance; two withdrew as they believed they were taking placebo; one withdrew due to 
gastrointestinal upset and one withdrew due to falling pregnant. Of those who completed the 
study, 70 were IS and 65 NAID at baseline. The per-protocol analysis excluded six participants 
for a treatment compliance below 80 %; five for elevated CRP (>10 mg/L); three for donating 
blood the week prior to their final testing visit; one for elevated serum ferritin in the absence of 
inflammation (>150 µg/L confers a risk of iron overload in the general population (World Health 
Organization, 2011b)) and one for haemoglobin above the normal range of 120-150 g/L (Lewis 
et al., 2004).  
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Prior to conducting the analyses, the data cleaning procedures detailed in section 2.2.9 were 
followed for the removal of anomalous and outlier data. Data were cleaned by stratification 
group so that any expected differences between iron status and treatment groups were 
accounted for. Additionally, normality of data distribution was checked by plotting residual 
change scores and producing histograms for inspection. Residual change scores that deviated 
from the normal distribution were removed. Upon completion of these procedures for each 
outcome variable assessed, data analysis commenced. 
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4.2.10 Statistical methods 
 
Baseline differences across treatment groups were investigated using one-way ANOVAs. 
Analysis across baseline and post-dose was then conducted in two phases via linear mixed 
models using the MIXED procedure in SPSS. Linear mixed models were used instead of 
ANCOVAs as they are more advantageous for longitudinal datasets, including the ability to 
account for missing data points often encountered and the ability to model non-linear, 
individual characteristics (Krueger & Tian, 2004). The main effect of treatment group (placebo, 
iron, iron and vitamin C) was analysed. Treatment was included as a fixed factor in the model 
and respective baseline values were entered as a covariate. Additionally, baseline serum 
ferritin was included as a covariate to account for the impact of baseline iron status on any 
treatment effects. All post-hoc analyses compare both active treatments to placebo only and 







The population for analysis consisted of 63 IS and 56 NAID participants. Participant disposition 
















Figure 4.1 Participant disposition through the trial. Figure depicts the final disposition of participants throughout the study, culminating in N = 119 of the 151 randomised. IS = 
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Table 4.1 Participant demographic information and baseline characteristics. Means and Std. Deviation (SD) are 
presented with F and p values of the main effects from the one-way ANOVAs conducted on the baseline data by 
treatment group 
 
N Baseline Main effects 
 Mean SD F p 
Haemoglobin (g/L) 
Placebo 39 126.92 6.51   
Iron 38 127.74 6.39 1.80 .170 
Iron + Vit C 42 125.10 6.35   
Serum ferritin (µg/L) 
Placebo 39 37.90 30.83   
Iron 38 34.61 28.81 .594 .554 
Iron + Vit C 42 31.26 22.19   
Vitamin C (µmol/L) 






Iron 26 17.02 7.39 
Iron + Vit C 37 16.96 5.24 
Zinc (µmol/L) 
Placebo 26 10.72 1.45   
Iron 23 10.60 1.67 .293 .747 
Iron + Vit C 30 10.93 1.70   
Age (years) 
Placebo 39 27.79 8.86   
Iron 38 27.74 8.82 .543 .582 
Iron + Vit C 42 26.10 7.41   
Years in education 






Iron 38 16.47 2.18 
Iron + Vit C 42 16.79 2.51 
BMI (kg/m2) 






Iron 38 24.62 3.94 
Iron + Vit C 42 24.57 3.21 
Systolic BP (mmHg) 
Placebo 39 114.82 10.83 
1.08 .344 Iron 38 118.38 11.73 
Iron + Vit C 42 116.48 9.40 
Diastolic BP (mmHg) 
Placebo 39 76.67 7.25 
1.15 .319 Iron 38 78.89 7.19 
Iron + Vit C 42 78.77 7.45 
Menstrual blood loss score10 
Placebo 30 2.58 1.47 
4.40 .015 Iron 30 4.30* 2.88 
Iron + Vit C 33 3.56 2.23 
Physical activity (MET minutes) 
Placebo 38 3025.28 1504.66 
1.96 .145 






10 Menstrual blood loss was only calculated for those with a menstrual cycle; hence the reduced N. Higher scores 
are indicative of increased menstrual blood loss.   
 144 
Iron + Vit C 38 3540.81 2543.17 
Cereals and cereal products (g/day) 





Iron 38 244.71 139.79 
Iron + Vit C 42 220.91 81.67 
Dietary iron (mg/day) 
Placebo 39 10.95 3.65   
Iron 38 10.81 4.20 .044 .957 
Iron + Vit C 42 10.71 3.30   
Fish and fish products (g/day) 
Placebo 39 43.13 44.18 
.869 .422 Iron 38 37.28 38.03 
Iron + Vit C 42 32.08 30.23 
Meat and meat products (g/day) 






Iron 38 96.23 70.68 
Iron + Vit C 42 93.58 70.33 
Nuts and seeds (g/day) 
Placebo 39 12.39 20.67 
.028 .972 Iron 38 11.18 16.19 
Iron + Vit C 42 11.77 28.06 
Vegetables (g/day) 
Placebo 39 306.82 180.05 
.261 .771 Iron 38 335.04 169.29 
Iron + Vit C 42 319.43 165.30 
 
Alcohol consumption (units/day) 
Placebo 39 1.04 1.21 
.316 .730 Iron 38 0.86 0.84 
Iron + Vit C 42 0.93 0.97 
Caffeine consumption (mg/day) 
Placebo 38 192.74 163.14 
.617 .541 Iron  38 219.12 182.28 
Iron + Vit C 42 180.29 128.42 
 * = significant difference between the placebo and active treatment group below p < .05 
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4.3.2 Treatment effects 
 
4.3.2.1 Demographic/lifestyle variables 
 
A significant effect of treatment for menstrual blood loss was identified [F (2, 68) = 3.39, p = 
.039]. Post hoc comparisons revealed significantly greater menstrual blood loss scores for the 
placebo group (3.30) than the iron and vitamin C group (2.43; p = .030), however no significant 
difference was identified between the iron (3.05; p = .740) and placebo groups (Table 4.2). 
However, this should be interpreted with caution due to not all participants having a menstrual 
cycle and changes in menstruation status from baseline to post-dose.  
 
The analysis identified no significant effects of treatment for BMI or physical activity.  
 
Table 4.2 Demographic/lifestyle variable outcomes for placebo, iron and iron and vitamin C treatment groups. 
Baseline raw scores and post-dose estimated marginal means and standard error (SE) are presented with F and 
p values of the main treatment effects from the linear mixed models  
 
 Baseline Post-dose  Main Effects 
n Mean SE Mean SE df F p 
Menstrual blood loss 
Placebo 25 2.58 0.27 3.30 0.24    
Iron 24 4.04 0.47 3.05 0.25 2, 68 3.39 .039 
Iron + Vit C 24 3.56 0.39 2.43* 0.24    
BMI 
Placebo 32 23.75 0.54 24.54 0.13    
Iron 34 24.62 0.64 24.50 0.12 2, 99 .319 .728 
Iron + Vit C 37 24.57 0.49 24.41 0.12    
Physical activity (IPAQ) 
Placebo 36 3025.28 312.90 3019.67 332.92    
Iron 37 3824.47 317.10 3267.99 328.78 2, 107 .147 .864 
Iron + Vit C 39 3292.34 301.23 3192.19 319.56    
* = significant difference between placebo and active treatment group below p < .05. 
 
 
4.3.2.2 Cognitive domain analysis 
 
The analysis identified no significant effects of treatment for cognitive domain performance. 
See Table 4.3 for baseline and post-dose means and standard error (See Appendix VIII for 
outputs). 
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Table 4.3 Cognitive task analysis outcomes11 for placebo, iron and iron and vitamin C treatment groups. Baseline 
raw scores and post-dose estimated marginal means and standard error (SE) are presented with F and p values 
of the main treatment effects from the linear mixed models 
 
 Baseline Post-dose Main Effects 
n Mean SE Mean SE df F p 
Episodic Memory Accuracy 
Placebo 39 0.03 0.12 -0.04 0.09 
2, 114 .782 .460 Iron  38 -0.17 0.10 -0.09 0.09 
Iron + Vit C 42 0.06 0.11 0.07 0.09 
Episodic Memory Speed 
Placebo 38 0.14 0.15 -0.05 0.10 
2, 110 .683 .507 Iron  36 0.03 0.16 0.04 0.10 
Iron + Vit C 41 -0.03 0.14 -0.12 0.09 
Executive Function Accuracy 
Placebo 39 -0.04 0.11 0.06 0.11 
2, 114 .352 .704 Iron  38 0.09 0.10 0.03 0.11 
Iron + Vit C 41 -0.05 0.10 -0.06 0.10 
Executive Function Speed 
Placebo 39 -0.03 0.11 0.06 0.09 
2, 114 .735 .482 Iron  37 0.13 0.11 0.06 0.09 
Iron + Vit C 41 -0.05 0.13 -0.07 0.09 
Working Memory Accuracy 
Placebo 39 0.02 0.13 -0.01 0.10 
2, 113 .424 .655 Iron  38 -0.19 0.14 0.02 0.10 
Iron + Vit C 42 0.13 0.10 -0.11 0.10 
Working Memory Speed 
Placebo 37 0.16 0.16 0.01 0.11 
2, 99 .079 .924 Iron  37 0.01 0.16 -0.04 0.12 
Iron + Vit C 41 -0.14 0.16 -0.05 0.11 
Sustained Attention 
Accuracy 
Placebo 39 0.04 0.13 -0.19 0.12 
2, 113 1.58 .210 Iron  37 -0.03 0.15 0.00 0.12 
Iron + Vit C 42 -0.07 0.12 0.09 0.11 
Sustained Attention Speed 
Placebo 39 -0.04 0.14 0.12 0.08 
2, 113 2.12 .125 Iron  37 0.11 0.15 -0.11 0.09 
Iron + Vit C 42 -0.00 0.13 0.09 0.08 
Learning 
Placebo 38 0.12a 0.12 0.10 0.11 
2, 105 
  
Iron  35 -0.27ab 0.14 -0.18 0.11 2.49 .087 
Iron + Vit C 37 0.14b 0.08 0.15 0.11   
a = significant difference between the placebo and an active treatment group at baseline below p < .05; b = 








11 For accuracy outcomes, positive values are indicative of better performance and negative values of 
worse performance. For speed outcomes, positive values are indicative of slower speed and positive 
values of slower speed.  
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4.3.2.3 Subjective Mood Analysis 
 
4.3.2.3.1 POMS  
 
A significant effect of treatment for depression-dejection scores was identified [F (2, 96) = 
5.27, p = .007]. Post hoc comparisons revealed significantly higher ratings of depression-
dejection in the placebo group (2.37) compared to the iron group (0.79; p = .004) and a trend 
towards significantly higher ratings compared to the iron and vitamin C group (1.38; p = .071) 
(Figure 4.2). See Table 4.4 for baseline and post-dose means and standard error. 
 
Additionally, a significant effect of treatment for total mood disturbance was identified [F (2, 
89) = 3.21, p = .045]. Post hoc comparisons revealed significantly higher ratings of total mood 
disturbance in the placebo group (12.44) compared to the iron group (4.39; p = .048) and a 
trend towards significantly higher ratings compared to the iron and vitamin C group (5.36; p = 
.079) (Figure 4.2).  
 












Figure 4.2 Estimated marginal means and standard error (SE) for post-dose values of depression-dejection (top) 







































































Table 4.4 Subjective mood analysis (POMS) outcomes for placebo, iron and iron and vitamin C treatment groups. 
Baseline raw scores and post-dose estimated marginal means and standard error (SE) are presented with F and 
p values of the main treatment effects from the linear mixed models 
 
 Baseline Post-dose Main Effects 
n Mean SE Mean SE df F p 
Tension-Anxiety 
Placebo 34 5.44 0.57 5.13 0.60 
2, 99 
  
Iron 32 5.00 0.55 5.01 0.62 .619 .541 
Iron + Vit C 38 5.05 0.43 4.28 0.57   
Depression-Dejection 
Placebo 34 1.81 0.35 2.37 0.34 
2, 96 
  
Iron 29 2.42 0.55 0.79* 0.37 5.27 .007 
Iron + Vit C 38 1.10 0.38 1.38T 0.32   
Anger-Hostility 
Placebo 33 1.86 0.39 1.56 0.31 
2, 97 
  
Iron 33 1.66 0.32 0.96 0.31 1.38 .257 
Iron + Vit C 36 1.25 0.29 0.91 0.30   
Vigour-Activity 
Placebo 36 12.39 0.96 12.46 0.73 
2, 107 
  
Iron 37 13.03 1.05 13.84 0.72 .947 .391 
Iron + Vit C 39 12.49 0.96 12.96 0.70   
Fatigue-Inertia 
Placebo 37 6.84 0.79 6.98 0.57 
2, 107 
  
Iron 35 7.63 1.05 5.65 0.59 1.79 .172 
Iron + Vit C 40 6.17 0.64 5.67 0.55   
Confusion-Bewilderment 
Placebo 35 8.57 0.73 8.41 0.53 
2, 103 
  
Iron 35 9.28 1.01 7.53 0.53 1.44 .241 
Iron + Vit C 38 7.49 0.58 7.19 0.51   
Total Mood Disturbance 
Placebo 31 10.47 2.52 12.44 2.44 
2, 89 
  
Iron 29 7.77 3.61 4.39* 2.52 3.21 .045 
Iron + Vit C 34 6.92 2.10 5.36T 2.34   
* = significant difference between placebo and active treatment group below p < .05; T = trend towards a significant 


















4.3.2.3.2 PSS and SCI  
 
The analysis identified no significant effects of treatment for perceived stress or subjective 
sleep quality. See Table 4.5 for baseline and post-dose means and standard error. 
 
Table 4.5 Subjective mood analysis (PSS and SCI) for placebo, iron and iron and vitamin C treatment groups. 
Baseline raw scores and post-dose estimated marginal means and standard error (SE) are presented with F and 
p values of the main treatment effects from the linear mixed models  
 
 Baseline Post-dose Main Effects 
n Mean SE Mean SE df F p 
Perceived Stress 
Placebo 39 19.74 1.00 19.09 0.78    
Iron 36 22.11 1.13 19.79 0.81 2, 110 .318 .728 
Iron + Vit C 40 19.12 1.25 19.90 0.76    
Sleep Quality 
Placebo 39 19.46 1.14 20.05 0.87    
Iron 36 17.94 1.41 18.94 0.89 2, 108 .400 .672 




The analysis identified no significant effects of treatment for subjective workload. See Table 
4.6 for baseline and post-dose means and standard error. 
 
Table 4.6 Subjective workload analysis (NASA-TLX) outcomes for placebo, iron and iron and vitamin C treatment 
groups. Baseline and post-dose estimated marginal means and standard error (SE) are presented with F and p 
values of the main treatment effects from the linear mixed models 
 
 Baseline Post-dose  Main Effects 
n Mean SE Mean SE df F p 
Total Workload 
Placebo 38 52.83 2.13 52.23 1.81    
Iron 38 56.52 1.83 50.53 1.80 2, 111 .332 .718 




4.3.2.4 Subjective fatigue (PFS and VAS) 
 
The analysis identified no significant effects of treatment for subjective fatigue. See Table 4.7 
for baseline and post-dose means and standard error. 
 
Table 4.7 Subjective fatigue analysis (PFS and VAS) outcomes for placebo, iron and iron and vitamin C treatment 
groups. Baseline raw scores and post-dose estimated marginal means and standard error (SE) are presented with 
F and p values of the main treatment effects from the linear mixed models 
 
 Baseline Post-dose Main Effects 
n Mean SE Mean SE df F p 
Behavioural-Severity 
Placebo 37 3.13 0.31 2.79 0.23 
2, 108 
  
Iron 37 3.59 0.34 2.19 0.23 .179 .172 
Iron + Vit C 39 3.08 0.29 2.59 0.22   
Affective Meaning 
Placebo 39 4.69 0.33 4.31 0.34 
2, 113 
  
Iron 38 4.94 0.36 3.61 0.34 2.32 .103 
Iron + Vit C 41 4.87 0.31 4.61 0.33   
Sensory 
Placebo 38 5.48 0.33 5.08 0.30 
2, 113 
  
Iron 38 5.48 0.33 4.09 0.30 2.72 .070 
Iron + Vit C 42 5.70 0.26 4.65 0.29   
Cognition-Mood 
Placebo 38 4.66 0.30 4.19 0.23 
2, 111 
  
Iron 37 4.51 0.28 3.59 0.23 1.79 .171 
Iron + Vit C 41 4.54 0.23 3.98 0.22   
Total Fatigue 
Placebo 38 4.43 0.29 3.97 0.24 
2, 113 
  
Iron 38 4.61 0.29 3.33 0.24 2.38 .097 
Iron + Vit C 42 4.48 0.23 3.97 0.23   
Mental Fatigue 
Placebo 35 58.14 2.69 58.65 2.95 
2, 107 
  
Iron 36 59.18 2.87 56.21 2.89 .502 .607 
Iron + Vit C 41 62.10 2.29 54.62 2.73   
Alertness 
Placebo 35 42.08 2.84 41.82 3.08 
2, 109 
  
Iron 38 38.39 2.70 48.67 2.95 1.73 .183 
Iron + Vit C 41 42.00 2.33 42.05 2.84   
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4.3.2.5 Subjective wellbeing (SF-12) 
 
A significant effect of treatment for physical component scores was identified [F (2, 112) = 
5.78, p = .004]. Post hoc comparisons revealed significantly lower scores in the iron group 
(56.27) compared to the placebo group (58.52; p = .012), however no significant difference for 
the iron and vitamin C group (58.67; p = .977) compared to placebo (Figure 4.3). See Table 
4.8 for baseline and post-dose means and standard error. 
 
Figure 4.3 Estimated marginal means and standard error (SE) for post-dose values of physical component scores 
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Table 4.8 Subjective wellbeing (SF12) analysis outcomes for placebo, iron and iron and vitamin C treatment 
groups. Baseline raw scores and post-dose estimated marginal means and standard error (SE) are presented with 
F and p values of the main treatment effects from the linear mixed models  
  Baseline Post-dose Main Effects 
 n Mean SE Mean SE df F p 
Physical Functioning 
Placebo 39 55.24 0.84 55.80 0.41  
1.20 .306 Iron 36 54.78 0.66 55.74 0.43 2, 111 
Iron + Vit C 41 54.44 1.06 56.54 0.40  
Role-Physical 
Placebo 39 53.01 0.97 54.53 0.60    
Iron 37 51.67 1.21 54.36 0.62 2, 111 .596 .553 
Iron + Vit C 40 54.24 0.79 55.25 0.60    
Bodily Pain 
Placebo 39 53.34 1.14 55.06 0.71    
Iron 37 54.17 0.99 53.14 0.72 2, 112 2.93 .058 
Iron + Vit C 41 54.94 0.78 55.39 0.69    
General Health 
Placebo 38 53.56 1.27 54.63 0.97    
Iron 38 52.15 1.43 54.80 0.98 2, 113 1.03 .362 
Iron + Vit C 42 54.80 0.81 53.05 0.93    
Vitality  
Placebo 38 49.59 1.33 50.88 1.04    
Iron 38 48.81 1.32 52.52 1.04 2, 113 1.63 .201 
Iron + Vit C 42 51.41 1.25 49.93 1.00    
Social Functioning 
Placebo 38 49.18 1.35 50.28 1.05    
Iron 38 47.54 1.34 51.66 1.05 2, 113 .905 .407 
Iron + Vit C 42 51.40 1.17 52.18 1.01    
Role- emotional 
Placebo 39 46.29a 1.18 46.57 1.35    
Iron 38 40.69ab 1.91 48.46 1.40 2, 114 .726 .486 
Iron + Vit C 42 47.12b 1.63 46.26 1.31    
Mental health 
Placebo 38 46.09 1.14 45.03 1.24    
Iron 38 42.77 1.31 47.82 1.25 2, 113 1.24 .293 
Iron + Vit C 42 46.18 1.23 46.41 1.18    
PCS 
Placebo 38 56.80 0.84 58.52 0.57    
Iron 38 57.84 0.87 56.27* 0.57 2, 112 5.78 0.04 
Iron + Vit C 41 57.56 0.77 58.67 0.55    
MCS 
Placebo 38 44.18 1.22 43.92 1.27    
Iron 38 39.76b 1.58 47.64 1.29 2, 113 2.35 .100 
Iron + Vit C 42 45.50b 1.54 44.57 1.22    
* = significant difference between placebo group and an active treatment group below p < .05; a = significant 
difference between the placebo and an active treatment group at baseline below p < .05; b = significant difference 








4.3.2.6 Biochemical analysis 
 
A significant effect of treatment for haemoglobin was identified [F (2, 114) = 3.95, p = .022]. 
Post hoc analyses revealed significantly higher levels of haemoglobin in the iron and vitamin 
C group (133.07; p = .023) and a trend towards significantly higher levels in the iron group 
(132.45; p = .050) compared to the placebo group (127.15) (Figure 4.4). 
 
A significant effect of treatment for serum ferritin was also identified [F (2, 109) = 9.19, p < 
.001]. Post hoc analyses revealed significantly greater serum ferritin concentrations for both 
the iron group (54.69; p = .004) and the iron and vitamin C group (59.00; p < .001) compared 
to the placebo group (38.80) (Figure 4.4).  
 
Additionally, a significant effect of treatment for vitamin C was identified [F (2, 52) = 6.67, p = 
.003]. However, post-hoc comparisons revealed no significant differences between the iron 
group (9.32; p = .075) or the iron and vitamin C group (17.35; p = .354) compared to the 
placebo group (14.56).  
 
The analysis identified no significant effects of treatment for zinc levels.  
 
















Figure 4.4 Estimated marginal means and standard error (SE) for post-dose values of haemoglobin (top) and 




























































Table 4.9 Biochemical analysis outcomes for placebo, iron and iron and vitamin C treatment groups. Baseline raw 
scores and post-dose estimated marginal means and standard error (SE) are presented with F and p values of the 
main treatment effects from the linear mixed models 
 
 Baseline Post-dose  Main Effects 
n Mean SE Mean SE df F p 
Haemoglobin (g/L) 
Placebo 39 126.92 1.04 127.15 1.64    
Iron 38 127.74 1.04 132.45T 1.67 2, 114 3.95 .022 
Iron + Vit C 42 125.10 0.98 133.07* 1.60    
Serum ferritin (µg/L) 
Placebo 37 37.90 4.94 38.80 4.39    
Iron 37 34.61 4.67 54.69* 4.25 2, 109 9.19 < .001 
Iron + Vit C 39 31.26 3.42 59.00** 3.62    
Vitamin C (µmol/L) 
Placebo 17 15.95 1.14 14.56 1.73    
Iron 15 17.02 1.45 9.32T 1.87 2, 52 6.66 .003 
Iron + Vit C 25 16.96 0.86 17.35 1.39    
Zinc (µmol/L) 
Placebo 15 10.72 0.29 12.69 0.42    
Iron 9 10.60 0.35 12.21 0.54 2, 34 .715 .496 
Iron + Vit C 15 10.93 0.31 13.03 0.42    
* significant difference between placebo group and an active treatment group below p < .05; ** significant difference 
between placebo group and an active treatment group below p < .001; T trend towards a significant difference 
between placebo group and an active treatment group below p < .10.  
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4.3.3 Compliance and adverse events 
 
Two participants did not return their unused treatments. For the remaining participants, 
compliance was observed to be excellent in all three groups (101 % Placebo; 100 % Iron; 100 
% Iron & Vit C) with a one-way ANOVA identifying no significant difference for compliance 
percentage by treatment group [F (2, 116) = .274, p = .761]. Sixty-four percent of participants 
in the placebo group believed that had received placebo compared to 45 % and 44 % of 
participants in the iron and iron and vitamin C groups, respectively. Chi-squared analysis 
confirmed this to be a non-significant difference [2 (2) = .794, p = .672]. 
 
A chi-square test was conducted on the adverse events reported in response to treatment 
guess and revealed no significant association between treatment and adverse event reporting 
[2 (2) = 3.35, p = .187]. See Table 4.10. 
 
Table 4.10 Frequency of adverse events reported via treatment diary over the 16-week intervention period by 
treatment group 








Migraine Nosebleed Total 
Placebo 32 5 2 1 0 2 0 42 
Iron 26 4 2 0 0 0 1 33 






Overall, it was found that both iron alone and iron and vitamin C supplementation were 
effective for improving iron status parameters. Compared to placebo, iron and vitamin C 
significantly improved haemoglobin and serum ferritin concentrations whilst iron alone only 
significantly improved serum ferritin concentrations. Iron alone significantly reduced PCS 
compared to placebo, indicating lower physical health. Nevertheless, supplementation with 
iron alone significantly reduced ratings of depression-dejection and total mood disturbance 
compared to placebo. Furthermore, the iron and vitamin C treatment significantly reduced 
menstrual blood loss scores compared to placebo. No significant effects of treatment 
compared to placebo were identified for cognitive domain performance, subjective workload, 
perceived stress, sleep quality, subjective fatigue, and vitamin C or zinc levels.   
 
The current study did however find that iron treatment alone significantly reduced ratings of 
depression and total mood disturbance, whilst this effect trended numerically for iron and 
vitamin C supplementation. This is suggestive of a causal role of iron in mood regulation in 
non-anaemic women of reproductive age. These findings expand on those from previous 
RCTs that did not find significant improvements in depressive mood following higher iron 
doses in NAID women of reproductive age who presented with considerable fatigue (Vaucher 
et al., 2012; Verdon et al., 2003). This is indicative of a role for low dose iron in improving 
mood in the general population using a standardised and validated measure of mood. 
Additionally, as no treatment effects were observed for measures of fatigue, the previous 
suggestion that effects on depression were indirect effects of concomitant fatigue (Price et al., 
2017) is not supported. This elucidates a potentially causal role of functional iron in 
dopaminergic activity as deficits in dopamine are associated with reduced D2 receptors that 
predict presentation of depression (Hamilton et al., 2018), However, deficits in dopamine and 
D2 receptors are also predictive of fatigue (Meeusen et al., 2006), stress (Campus et al., 2017) 
and aggressive behaviour (Chester et al., 2016), for which no effects of iron treatment were 
found. Iron treatment alone also unexpectedly engendered a reduction in PCS as a measure 
of physical health despite no significant differences in reports of adverse events between 
active treatment groups. These findings are inconsistent with previous findings associating 
iron treatment with improved physical performance and quality of life (Favrat et al., 2014; 
Rubeor et al., 2018), and no effects at all upon PCS (Patterson et al., 2001). Further research 
is therefore required to understand the potential underlying mechanisms behind such findings.   
 
The current study unexpectedly identified no significant effects of treatment on cognitive 
function. Previous iron RCTs in non-anaemic women of reproductive age have found positive 
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treatment effects of iron on cognitive function at much higher doses of iron (60 – 260 mg 
elemental iron) from ferrous formulations (Bruner et al., 1996; Lambert et al., 2002; Leonard 
et al., 2014). This leads to the suggestion that the low dose of iron used in this study may not 
have been sufficient to elicit a cognitive change. However, examining the data by treatment 
group does not account for individual variation in response to treatment, which may lead to 
inaccurate conclusions regarding the true impact of iron supplementation (Murray-Kolb & 
Beard, 2007). This is especially appropriate as the study observed some significant 
improvements to haemoglobin and serum ferritin concentrations in the placebo group that 
were not associated with elevated CRP and vice versa for both iron treatment groups.  
 
Although not significantly different, the observed numerical supremacy of iron and vitamin C 
compared to iron alone for improving iron status parameters and increasing the likelihood of 
serum ferritin and haemoglobin responders is consistent with suggestions of the ability of 
vitamin C to improve the bioavailability and absorption of iron (Chiamchanya, 2013). The 
lowered menstrual blood loss scores in the iron and vitamin C treatment group compared to 
placebo may have led to the superior iron status in this group; however, reduced menstrual 
blood loss may also be a consequence of such improvements to iron status. Menstrual blood 
loss is shown to significantly predict iron status (Harvey et al., 2005; Kocaoz et al., 2019) 
though previous investigations have found that iron supplementation with 60 mg elemental 
iron weekly or for the first four days of the menstrual cycle does not improve menstrual blood 
loss in IDA women of reproductive age (Bani et al., 2014). However, a multivitamin and mineral 
formula containing iron, vitamin C, essential amino acids and B-vitamins administered daily 
for 28 days to anaemic, menstruating women caused significant reductions in menstrual blood 
loss (Cornelli & Belcaro, 2015). The current study has extended these findings to a non-
anaemic population and has reduced the number of confounding minerals and vitamins to 
infer a more specific causal relationship between iron and menstrual blood loss. This indicates 
the possibility of a beneficial cycle of improved iron status following iron and vitamin C co-
supplementation leading to reduced menstrual blood flow, subsequently leading to further 
improved iron status. It is interesting to note though, that the efficacy of iron and vitamin C for 
improving iron status compared to placebo is not coupled with behavioural improvements to 
cognition, mood, or wellbeing. The recommended daily allowance of vitamin C for women of 
reproductive age in the United Kingdom is 40 mg (PHE, 2016) and supplementation with doses 
greater than the RDA are associated with pro-oxidant activity (Fisher & Naughton, 2004). It is 
reasonable to suggest that although iron and vitamin C co-supplementation is effectively 
increasing iron status, it may be doing so at the expense of increased oxidative stress, which 
may dampen the beneficial effects experienced with iron alone. Although, co-supplementation 
of iron and vitamin C is shown to have similar antioxidant properties in comparison to iron 
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alone in non-anaemic female adolescents (Khoshfetrat et al., 2013). Further investigation is 
thus warranted to infer a causal effect as no measures of oxidative stress were explored in 
this study. However, it must also be considered that baseline vitamin C concentrations across 
all treatment groups would be classed as depleted or marginally depleted on average 
according to the status limits described previously in section 4.2.7.1. Yet, following 
supplementation with a dose of vitamin C where plasma saturation is to be expected (Levine 
et al., 2001) there was no significant improvement in vitamin C status. Although standardised 
methods were used for vitamin C analysis with quality control measures, these unexpected 
findings must be interpreted with caution.  
 
Overall, the current study addressed several limitations concerning previous RCTs including 
supplement dose and duration, controlling for inflammation, haematological sample and 
menstrual cycle timing and the previous lack of consideration for supplement bioavailability 
and tolerability. Consequently, the current study is the first to employ a low dose iron bis-
glycinate chelate treatment that allowed for the comparison of potentially separate effects of 
iron alone or co-supplemented with iron enhancing vitamin C. Biochemical analyses revealed 
that the low dose was capable of improving both haemoglobin and serum ferritin from baseline, 
which demonstrates superior efficacy compared to higher doses that have only caused 
significant improvements in serum ferritin concentrations (Leonard, Chalmers, Collins, & 
Patterson, 2014; Murray-Kolb & Beard, 2007). This was also achieved in the absence of 
significantly greater numbers of reported adverse events compared to placebo and no 
significant differences in treatment compliance. Such findings provide further support for the 
tolerability of the iron bis-glycinate formulation. Conversely, numerically greater adverse 
events were reported in the placebo group compared to active treatment groups. However, an 
increase in the reporting of side effects may be a consequence of negative expectations held 
by participants of ferrous iron supplements (Tolkien et al., 2015). Negative expectations are 
often stimulated following the discussion of potential side effects, which may then reduce 
treatment efficacy, increase reports of side effects and exaggerate feelings of worry and 
concern (Barsky, 2017; Petrie & Rief, 2019); this is a phenomenon known as the nocebo 
effect. This may explain why there was no significant difference across all three treatment 
groups. In addition, compliance was simply calculated by pill counting, which cannot account 
for participants potentially discarding tablets to give the impression of adherence to treatment 
protocols (Jimmy & Jose, 2011; Pullar, Kumar, Tindall, & Feely, 1989) to cause overestimates 
of compliance.  
 
Conversely, a potential limitation of the current study concerns baseline and post-dose blood 
samples collected under different conditions. Baseline samples were collected in the afternoon 
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in a non-fasted state whilst post-dose samples were collected in the morning in a fasted state. 
Haemoglobin concentrations are subject to significant postprandial reductions when 
compared to 12-hours fasted (Kościelniak, Charchut, Wójcik, Sztefko, & Tomasik, 2017; Lippi 
et al., 2010), which may confound the haematological findings. Similarly, as stated in section 
4.2.7.2, zinc levels are subject to diurnal variation. Future research should ensure consistency 
across blood samples to account for within-day variation of haemoglobin and zinc. It must also 
be considered that the combination of nutritional education and supplement provision is shown 
to promote healthier eating habits and lifestyles amongst female populations in developed 
nations (Lua & Wan Putri Elena, 2012). As participants in the current study were informed of 
their iron status prior to starting treatment, this information may have prompted a conscious 
or sub-conscious change in dietary habits. Although at the post-dose assessment participants 
were asked if they had made any changes to their diet, it is possible that they may not actively 
recognised the change. Completion of the FFQ at the end of the intervention may have been 
able to accurately capture this information; however, smartphone applications are 
progressively being developed to improve the reporting of dietary intake and are widely 
accepted with respect to participant usability (Ferrara, Kim, Lin, Hua, & Seto, 2019). Future 
RCTs should consider the potential role of smartphone applications for monitoring dietary 
habits across long-term nutritional intervention studies. Additionally, future RCTs should 
consider utilising objective measures of physical activity, not only for assessing changes in 
physical activity level due to discrepancies between self-reported activity and objectively 
measured reports (Nelson, Taylor, & Vella, 2019), but to determine when participants 
exercised in comparison to when they took their treatment. As a single bout of endurance 
exercise at a moderate-vigorous intensity augments hepcidin levels between 0- and 6-hours 
post-exercise (Domínguez et al., 2018), this may coincide with iron supplement administration 
and reduce its efficacious absorption. Collecting additional data on participants during the 
intervention period would allow further refinement surrounding the chronic effects of iron 
supplementation.  
 
Regarding the population sampled, future research should consider the influence of medical 
history and genetic influences. Early iron deficiency invokes long-term irreversible neurological 
effects that are not amenable to iron supplementation (Lozoff et al., 2006). It may therefore be 
imperative for future research to consider screening participants based on medical history to 
account for diagnoses of early iron deficiency. Additionally, iron status is not only influenced 
by environmental and physiological factors; serum transferrin genetic variants reduce iron 
transport to the tissues increasing the risk for iron deficiency (Blanco-Rojo et al., 2011). Iron 
intervention studies have observed significant increases in iron status in iron deficient women 
of reproductive age, except for those with the minor allele of single nucleotide polymorphism 
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rs3811647 (Blanco-Rojo et al., 2010). Both global and European prevalence of this rs3811647 
polymorphism is estimated at 34 % ("rs3811647 RefSNP Report - dbSNP - NCBI", 2020); of 
the 56 NAID women included in the analyses for the current study, ~ 19 women may have had 
the polymorphism. Such genetic polymorphisms surrounding iron metabolism demonstrate 
significant associations with decreased serum ferritin (Ji, Flower, Hyland, Saiepour, & Faddy, 
2018; Sørensen et al., 2012), thus greater iron doses may be required to elicit psychological 
and physiological benefits. This suggests the potential for incorporating nutrigenomics into 
future iron RCTs to further clarify the benefits of iron supplementation in women of 
reproductive age.  
 
The findings of the current study provide novel evidence of the efficacy of a low dose iron bis-
glycinate chelate supplement for significantly improving iron status, highlighting the absorptive 
and tolerability benefits associated with the bis-glycinate formulation regardless of vitamin C 
co-supplementation. However, the lack of findings regarding cognitive and behavioural 
function imply that the iron dose may indeed be too small compared to previous iron RCTs to 
have an effect in non-anaemic women of reproductive age. Future iron RCTs focussing on 
NAID women of reproductive age should consider lower doses of vitamin C, objective 
measures of physical activity, medical history, genotypes, time of blood sampling and 
monitoring dietary habits over the intervention period. Overall, the findings suggest that 16 
weeks supplementation of iron bis-glycinate chelate is effective for improving iron status, 
depression, total mood disturbance and menstrual blood loss with minimal associated adverse 




 THE EFFECT OF IRON BIS-GLYCINATE CHELATE AND VITAMIN C CO-
SUPPLEMENTATION ON CEREBRAL BLOOD FLOW AND ENERGY METABOLISM AT 




To produce a change in cognitive and behavioural functioning, a change in neural function is 
required to drive this action. In the adult brain, increases in neural activity evoke increases in 
the demand for delivery and consumption of metabolic resources, namely oxygen and 
glucose, for ATP production (Vazquez et al., 2010). Consequently, cerebral blood flow (CBF) 
is readily augmented to satisfy the demand for tissue oxygen; a mechanism referred to as 
neurovascular coupling (Kozberg & Hillman, 2016). However, a paradoxical relationship exists 
as the delivery of oxygen through increased CBF exceeds the cerebral metabolic rate of 
oxygen and ATP consumption (Leithner & Royl, 2014; Uludag et al., 2004). It is proposed that 
although the CBF response to neural activation may not be wholly necessary, it has evolved 
to protect brain function and thus cognitive performance during oxygen-limiting states 
(Leithner & Royl, 2014). This is especially true as although the brain only comprises a small 
fraction of human total body mass, it is the largest source of energy consumption with neurons 
consuming 75 to 80 % of energy produced in the brain (Hyder, Rothman, & Bennett, 2013). 
Brain imaging techniques rely on measuring cerebral haemoglobin and the diminished 
oxygen-carrying capacity of erythrocytes in IDA because of reduced systemic haemoglobin 
may lead to the assumption of IDA-associated reductions in cerebral haemoglobin. However, 
anaemic hypoxia is induced in IDA, which evokes increases in cardiac workload to ensure 
delivery of oxygen to the tissues (Pereira & Sarnak, 2003). In IDA infants, this adaptation is 
shown to contribute to increasing CBF velocities alongside increases in nitric oxide for 
augmented vasodilation as a neuroprotective compensatory mechanism to ensure sufficient 
oxygen delivery for neuronal activity (Aliefendioglu et al., 2007; Hare, 2004). However, 
independent of haemoglobin concentrations, NAID impairs cardiomyocyte function by 
provoking a hypoxic response that causes mitochondrial dysfunction (Hoes et al., 2018); this 
infers a reduction in ATP and an impaired ability of cardiomyocytes to contract and relax. 
Concurrently, NAID is associated with an increased blood viscosity (Broberg et al., 2006; 
Khaled et al., 1998) potentially because of iron deficiency-associated thrombocytosis and red 
blood cell aggregation (Evstatiev et al., 2014; Khaled et al., 1998), and is accompanied by 
symptoms such as irritability, headaches and exercise intolerance (Fairbank, 2001). However, 
despite these observed effects of iron on cerebrovascular parameters, studies investigating 
the effects of iron status on CBF are limited to IDA infants (Aliefendioglu et al., 2007), whilst 
the effects of iron supplementation on CBF are yet to be investigated in any population.  
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Few studies have investigated the impact of iron on functional outcomes of neural activity and 
changes in cognitive functioning. Observational studies using electroencephalography (EEG) 
have identified impairments to N200 and P300 event-related potential (ERP) latencies and 
P200 and P300 ERP amplitudes in IDA men and women in comparison to their IS counterparts 
(Khedr et al., 2008). Shorter ERP latencies and increased ERP amplitudes are associated 
with superior cognitive performance (Sur & Sinha, 2009) and as P300 latency and amplitude 
were in turn, negatively and positively associated with haemoglobin, serum ferritin and total 
IQ, a role for iron in brain function may be inferred. Similarly, over half of IDA participants had 
abnormal EEG findings, which may be indicative of iron’s key role in axonal growth and 
synaptogenesis causing brain activity alterations (Beard, 2003). These findings have been 
extended to a NAID population of women of reproductive age where lower levels of serum 
ferritin were predictive of smaller increases in θ- and γ-band power from baseline (Wenger, 
DellaValle, et al., 2019), indicative of a lesser ability to adapt to increases in cognitive demand 
(Fairclough, Venables, & Tattersall, 2005) and to modulate visual information processing and 
attentional perceptual mechanisms (Müller, Gruber, & Keil, 2000), respectively. Metabolic 
outcomes were also assessed by indirect calorimetry; a non-invasive technique that measures 
expired pulmonary air to determine oxygen uptake and carbon dioxide production. This 
provides an estimate of whole-body energy metabolism that is sufficiently sensitive to detect 
subtle differences in cognitive tasks requiring identical response demands (Al-Naher, 
Schlaghecken, Barber, & Kumar, 2016). Non-anaemic iron deficiency was shown to impair 
energy expenditure with lower levels of serum ferritin predicting smaller increases in 
respiratory rate, heart rate and energy expended with increased cognitive demand (Wenger, 
DellaValle, et al., 2019). Serum ferritin and haemoglobin were identified to moderate the 
relationship between cognitive demand and brain activity and brain activity and energy 
expended, respectively (Wenger, DellaValle, et al., 2019). Diminished brain activity is a 
proposed consequence of iron deficiency disrupting neurotransmitter regulation through 
inefficient energy metabolism in the brain following iron deficiency-induced mitochondrial 
dysfunction (Rao et al., 2003), potentially reducing the ability to handle higher cognitive loads. 
Similarly, mitochondrial dysfunction not only reduces aerobic respiration and ATP generation 
but infers a reduction in haem for oxygen transport (Paul et al., 2017) thus reducing the 
metabolic resources available to support the increases in brain activity following increased 
cognitive demand. Though, as this was a population of NAID women with non-anaemic 
haemoglobin concentrations, the effects due to haemoglobin are thought to be indicative of 
the status of an individual’s energetic reserves and the level of energetic resources needed to 
support increases in cognitive demand (Wenger, DellaValle, et al., 2019). However, as the 
measures previously used for oxygen consumption are not specific to the brain, further 
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refinement is required to be able to associate changes in cognitive function and energy 
expenditure specifically to the brain.    
 
Investigations of changes in systemic iron and functional outcomes to infer a causal 
relationship are similarly limited. Brain activity and cognitive performance have been assessed 
in women of reproductive age with serum ferritin < 20 µg/L administered iron bio-fortified beans 
for 18 weeks. A significantly greater change in α-band power and γ-band power across tasks 
of attention and visual memory, respectively, were exhibited by the iron bio-fortified group 
compared to the control group (Wenger, Rhoten, et al., 2019). However, participant’s 
haemoglobin was > 90 g/L, resulting in a combined sample of both IDA and NAID participants 
according to worldwide haematological guidelines (World Health Organization, 2011a). This 
restricts the specificity of the findings, making inferences regarding the effect of iron 
supplementation upon brain activity in NAID difficult. Iron supplementation is also shown to 
benefit physical energetic efficiency and aerobic capacity of NAID female athletes (Burden, 
Morton, et al., 2015; Fiddler, Seymour, Hernandez-Cordero, Campos, & Haas, 2019), however 
metabolic measures have not been used to determine the impact of iron supplementation on 
NAID women of reproductive age from the general population during cognitive demand. The 
use of indirect calorimetry for assessing the metabolic consequences of nutritional 
supplements during cognitive demand is relatively novel, however acute multi-micronutrient 
supplementation in healthy women of reproductive age caused a dose-dependent increase in 
total energy expenditure and fat oxidation during cognitive task performance of graded 
difficulty whilst chronic supplementation over 8 weeks sustained the increase in total energy 
expenditure only (Kennedy et al., 2016). Acute and chronic (28 days) supplementation of a 
similar multi-micronutrient supplement also resulted in increased total energy expenditure for 
both males and females compared to placebo during cognitive demand (Dodd et al., 2020). 
However, the former study also utilised continuous-wave near infrared spectroscopy (CW-
NIRS) to assess changes in cerebral metabolic activity during cognitive performance to 
quantify the capacity of multi-micronutrients to modulate whole body metabolism and 
metabolic substrate utilisation. After an acute dose of the multi-micronutrient supplement, total 
haemoglobin and oxygenated haemoglobin were increased throughout the post-dose 
cognitive tasks; an augmented haemodynamic response may be a consequence of improving 
neurovascular coupling to direct cerebral blood flow to sites of neural activity. However, CW-
NIRS is limited to only assessing relative changes in cerebral haemodynamics and cannot 
determine absolute, quantifiable concentrations of haemoglobin as it assumes a homogenous 
degree of light scatter amongst the tissues (Jones, Chiesa, Chaturvedi, & Hughes, 2016). The 
CW-NIRS relative change data is baseline-adjusted to the concentration immediately prior to 
the first data point in the recording session. Therefore, CW-NIRS data is unable to quantify 
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gross changes in haemodynamic parameters that occur between two separate recording 
sessions over a chronic time-period. To provide a more accurate measure, previous studies 
utilising the CW-NIRS have adopted an approach that subjects the data to a second baseline 
adjustment by creating ‘change from baseline’ data using resting CW-NIRS data collected 
prior to the consumption of nutritional supplements on each day of data capture (Kennedy et 
al., 2016; Wightman et al., 2015). However, frequency domain NIRS (FD-NIRS) can determine 
absolute optical path-length travelled by the light to provide absolute concentrations of 
haemoglobin and brain tissue oxygen saturation (Jones et al., 2016). The two NIRS systems 
have demonstrated good agreement with one another, with no significant differences 
observed when monitoring cerebral haemodynamics and oxygenation (Davies et al., 2017; 
Fantini & Sassaroli, 2020). As this is a novel area in the field of iron deficiency and 
supplementation research, utilising both NIRS techniques would offer advantages for 
assessing the cerebral haemodynamics associated with iron status and supplementation to 
further knowledge regarding energy metabolism and neural activity. Utilising FD-NIRS will 
allow for the quantification of absolute concentrations of haemoglobin at rest to determine 
chronic changes following iron supplementation, in addition to any differences in absolute 
values between iron status groups at baseline. Any significant differences in absolute values 
can then be considered when analysing relative changes in cerebral haemodynamics during 
cognitive demand. It is essential to assess metabolic parameters alongside this as measuring 
cerebral haemodynamic responses alone only reflects cerebral metabolic activity and does 
not quantify the extent of energy expenditure change during cognitive performance (Al-Naher 
et al., 2016).   
 
Overall, there is evidence to suggest adverse effects of low iron status, including NAID, on 
measures of cerebral blood flow, energy metabolism and cognitive function. However, to date, 
no study has investigated such measures simultaneously in a NAID population. Additionally, 
the parallel effects of iron supplementation on cerebral haemodynamics and energy 
metabolism to examine the capability of iron to modulate whole body energy expenditure and 
utilisation of metabolic substrates during increasing neural demand have not been 
investigated. Therefore, the present study aims to investigate the effects of 16-weeks 
supplementation with either 28 mg/d of iron bis-glycinate alone, iron bis-glycinate plus 240 mg 
ascorbic acid or matched placebo on energy metabolism and absolute and relative changes 
in cerebral haemodynamics during rest and increased cognitive demand in NAID and IS 






5.2.1 Design & ethics 
 
This study employed a randomised, placebo-controlled, double-blind, stratified groups design, 
with participants randomly assigned to one of three treatment groups (section 4.2.3). The 
study received ethical approval from Northumbria University’s Psychology Department and 
was conducted according to the Declaration of Helsinki (1964). The study was registered on 




Seventy-eight female volunteers aged 18-49 were recruited into the study as a sub-sample of 
those already enrolled into the study described in Chapter 4 and met the inclusion criteria 
outlined in sections 2.2.2 and 4.2.212. Of the seventy-eight enrolled into the study, seventy 
completed all requirements. This sample size was related to the calculation conducted for the 
study described in Chapter 4 and powered for the observation of significant effects on brain 
activity and energy expenditure following the significant effects observed with EEG and 
indirect calorimetry (ICa) in a previous RCTs (Wenger, DellaValle, et al., 2019; Wenger, 
Rhoten, et al., 2019).  
 
5.2.3 Physiological measures 
 
5.2.3.1 Near-Infrared Spectroscopy (NIRS) 
 
NIRS is a non-invasive optical imaging technique, considered an appropriate alternative for 
functional magnetic resonance imaging (fMRI) due to its comparatively inexpensive cost, 
portability, ease of use and applicability with other physiological measures and amongst 
populations with a limited tolerance for a claustrophobic environment as in fMRI (Minati, 
Visani, Dowell, Medford, & Critchley, 2011). The data extracted from NIRS strongly correlate 






12 A visual representation of the participant disposition throughout the studies that comprise this thesis 
can be found in Appendix V. 
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Culver, Thompson, & Boas, 2002) and successively this correlation prevails during cognitive 




Figure 5.1 Demonstration of the typical banana-shaped curves of infrared light produced by NIRS at differing 
source-detector distances. Short separation channels of 1 cm may not allow light to sufficiently penetrate the 
superficial layers of the prefrontal cortex. Increasing this to 4 cm can increase light penetration to deeper layers of 
the prefrontal cortex (Rupawala, Dehghani, Lucas, Tino, & Cruse, 2018).  
 
Through exploiting the differing photon absorption properties of oxygenated and 
deoxygenated haemoglobin chromophores, NIRS is able to quantify tissue oxygen status. 
Visible light (450-700 nm) cannot penetrate human tissue further than approximately 1 cm, 
however wavelengths along the near-infrared spectrum (700-1000 nm) can penetrate through 
both tissue and bone by depths of up to 8 cm for absorption by haemoglobin chromophores 
in the tissues (Pellicer & Bravo, 2011). NIRS technology was used in this study for measures 
of cerebral blood flow in the prefrontal cortex using a transmitter-receiver optode system. 
Infrared light is emitted from the transmitter optode following a curved pathway through the 
tissue of the prefrontal cortex (Figure 5.1); the light is either reflected at optical surfaces, 
scattered at certain tissue components or absorbed by haemoglobin chromophores. The 
oxygenation status of haemoglobin causes a change in the resultant spectrum, which is 
returned to the receiver optode (Scheeren, Schober, & Schwarte, 2012) to provide 
measurements of oxygenated haemoglobin (oxy-Hb), deoxygenated haemoglobin (deoxy-Hb) 
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and total haemoglobin (total-Hb). Cerebral blood haemodynamics were measured by two 
NIRS systems outlined below: 
 
5.2.3.1.1 Continuous Wave Near-Infrared Spectroscopy (CW-NIRS) 
 
The continuous wave Oxymon system (Artinis Medical Systems B.V.) was employed to 
measure relative changes in concentrations of haemoglobin in the prefrontal cortex through 
the absorption of infrared light. The CW-NIRS system functions by emitting light continuously 
at a constant amplitude, measuring only the amplitude of light decay (Strangman, Boas, & 
Sutton, 2002). Upon return to the receiver, the light decay denotes changes in regional 
cerebral blood flow by measuring change in cerebral haemoglobin (Hoshi, 2007). 
Concentration changes of oxy-Hb, deoxy-Hb and total-Hb are quantified using the modified 
Beer-Lambert Law (Kocsis, Herman, & Eke, 2006), with respect to an initial baseline value 
arbitrarily set to zero, adjusting the differential path length to the participant’s age using the 
proprietorial software to account for the additional distance travelled by the infrared light due 
to scattering (Duncan et al., 1996; Duncan et al., 1995; Pellicer & Bravo, 2011).  
 
Light was emitted at 764 and 858 nm and data collection recorded at a time resolution of 10 
Hz. A 2-channel configuration was used (2 transmitter-receiver optode pairs) via a standard 
optode holder headband that ensured a distance of 4 cm between the transmitter and receiver 
optodes within each pair and their positioning over the left and right hemispheres of the 
prefrontal cortex corresponding to Fp1 and Fp2 electroencephalogram (EEG) positions of the 
international 10-20 system. To account for potential motion artefacts during data collection, 
individual tasks were separated by rest periods to endorse this as a time to change posture 
rather than during the tasks. Markers were inserted throughout the NIRS recording to time-
stamp specific epochs corresponding to individual tasks and their repetitions. Therefore, only 
NIRS data collected during task completion was analysed. All quantities were measured as 
concentration change in micromoles per litre (µmol/L).  
 
5.2.3.1.2 Frequency Domain Near Infrared Spectroscopy (FD-NIRS) 
 
Progressing from CW-NIRS, FD-NIRS systems can determine absolute optical path travelled 
by the light to provide absolute concentrations of haemoglobin (Jones et al., 2016). This is 
determined by recording the intensity of light attenuation reflected onto the tissues and phase 
shift. Analysis of the latter allows for an accurate quantification of the total distance travelled 
and the subsequent degree of light scatter through the tissue (Lange & Tachtsidis, 2019). The 
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FD-NIRS systems have therefore progressed from the relative values of the CW-NIRS to 
delivering absolute values for oxy-Hb, deoxy-Hb, total-Hb and brain tissue oxygen saturation 
percentage (Ox%). The two systems have demonstrated good agreement with one another, 
with no significant differences observed when monitoring cerebral tissue saturation during 
increases of experimentally induced hypoxia (Davies et al., 2017).  
 
The OxiplexTS Frequency-Domain Near-Infrared Tissue Oximeter (ISS, Inc., Champaign, IL, 
USA) was the dual-channel FD-NIRS system used. The instrument comprises two flexible 
sensors made of polyurethane rubber, within which optical fibre laser diodes are embedded 
and glued in pairs to four prisms (eight fibres per channel) located at 2.0-, 2.5-, 3.0- and 3.5 
cm respectively from the detector bundle. Of the eight fibres per channel, four emit 
wavelengths of 690 nm and four emit wavelengths of 830 nm modulated at a frequency of 110 
MHz. Individual right-hand and left-hand sensors were positioned on the participants’ forehead 
so that the bottom edge was level with the top of the eyebrows and that the middle edges 
touched at the midline of the forehead. The sensors were secured in place by Velcro straps 
and a self-adhering bandage. Data was collected at 5 Hz and quantities measured in micro 
molars (µM). 
  
5.2.3.2 Indirect calorimetry (ICa) 
 
Oxygen uptake and carbon dioxide production from expired pulmonary air were measured 
using a portable high-resolution spiroergometry system using breath-by-breath technology 
(Metalyzer 3B, Cortex, Leipzing, Germany) in conjunction with the MetaSoft Studio software. 
The ICa system provides a non-invasive, functional analysis of whole-body energy 
expenditure and fuel substrate utilisation at rest and during cognitive activity, through the 
quantification of inhaled oxygen and exhaled carbon dioxide. In healthy participants, ICa 
demonstrates real-time metabolic comparisons during simple cognitive task performance 
through significantly greater energy expenditure during task performance in comparison to 
rest phases (Al-Naher et al., 2016). The use of ICa in nutritional intervention studies is 
relatively novel, however recent studies provide support for its application as a sensitive 
technique for monitoring changes in metabolic parameters following nutritional supplement 
administration (Dodd et al., 2020; Eschle, Goodall, Kennedy, & Wightman, 2019; Kennedy et 
al., 2016).  
 
During the sampling period, participants were fitted with a mask that covered the mouth and 
nose; this was connected to the Metalyzer via falconia tubing allowing for pulmonary gas 
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analysis. Standard formulae (Frayn, 1983) were used to calculate total energy expenditure 
(TotalEE), respiratory exchange ratio (RER), fat oxidation (FatOx) and carbohydrate oxidation 
(CHOx) from the data.  
 
5.2.4 Cognitive Tasks 
 
The following tasks were completed in the current study: 
 
5.2.4.1 Serial Threes Subtraction Task  
 
One minute of the same task outlined in section 2.2.4.8. 
 
5.2.4.2 Serial Sevens Subtraction Task  
 
One minute of the same task outlined in section 2.2.4.8. 
 
5.2.4.3 Rapid Visual Information Processing Task (RVIP) 
 
One minute of the same task outlined in section 2.2.4.9. 
 
5.2.4.4 Visual analogue scales (VAS) 
 
Participants rated their current subjective ‘mental fatigue’ and ‘alertness’ states by placing an 
‘X’ on a 100 mm line with the end points labelled “not at all” (left hand end; 0) and “extremely” 




The procedures outlined in sections 2.2.8 and 4.2.8 were followed for all participants enrolled 
in the current study. When participants were informed of their eligibility for the study described 
in Chapter 4, they were also offered to partake in an additional assessment of cerebral blood 
flow and energy metabolism. Following completion of the procedure outlined in 4.2.8, the 
principal investigator discussed the requirements of the additional assessment in line with the 
participant information sheet previously supplied to the participant. Following informed 
consent, the FD-NIRS sensors were connected to the participant’s forehead for a baseline 5-
minute rest measurement, whilst watching a non-stimulating video. Upon completion, the FD-
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NIRS was removed and participants were then connected to the ICa system via facemask, 
which was adjusted to ensure there were no gaps allowing air to escape through anywhere 
but the analysis turbine. The CW-NIRS headband was then positioned on the participant’s 
forehead. When proper functioning of both ICa and CW-NIRS systems were confirmed, 
participants sat for a further 5-minute resting baseline measurement whilst watching a 
continuation of the same non-stimulating video. This was followed by the completion of a 1-
minute serial 3 subtraction task and a rating of mental fatigue and alertness, followed by a 1-
minute rest. This was repeated three times before a 2-minute resting period. The same 
procedure was then repeated for the serial 7 subtraction and RVIP tasks (see Figure 5.2 for 
schematic depicting the cognitive battery and physiological measurements). Upon completion, 
participants were disconnected from the ICa and CW-NIRS systems and provided with their 
first bottle of allocated treatment, instructions on how to take them and a diary as detailed in 
section 4.2.8.  
 
The Week 8 and 16 testing visits followed the same procedures outlined in section 4.2.8. 
However, following completion of the lifestyle, cognitive and mood assessments for the study 
described in Chapter 4 at week 16, the same protocol as the baseline assessment for the 








Figure 5.2 Schematic of the baseline and Week 16 assessments. Each task was completed three times for a 
duration of 1 minute, followed by a rating of mental fatigue and alertness and then a 1-minute rest before the next 
repetition of the same task. Upon completion of three repetitions of the same task, a 2-minute resting period was 
given prior to beginning the next series of tasks. 3s, serial 3 subtractions; 7s, serial 7 subtractions; RVIP, rapid 
visual information processing; VAS, visual analogue scales. 
 
5.2.6 Data cleaning 
 
Seventy participants completed all requirements of the study. Of the eight who did not 
complete the study; four were lost to follow-up; two withdrew due to time commitments; one 
withdrew due to self-reported lack of compliance; and one withdrew due to pregnancy. Of 
those who completed the study, 35 participants were IS and 35 were NAID at baseline. The 
per-protocol analysis excluded three participants for elevated CRP (>10 mg/L); two for a 
treatment compliance below 80 %; one for elevated serum ferritin in the absence of 
inflammation (> 150 µg/L confers a risk of iron overload in the general population (World 
Health Organization, 2011b)) and one for haemoglobin outside of the normal range of 120-




Prior to conducting the analyses, the physiological and cognitive raw data was extracted and 
cleaned following the same procedures outlined in section 2.2.9 and 4.2.9 for the removal of 
anomalous and outlier data. One data set was removed from FD-NIRS analyses due to 
missing post-dose performance data following equipment malfunction. One data set was 
removed from CW-NIRS analyses due to missing baseline performance data following data 
catchment errors. One data set was removed from ICa analyses due to missing baseline data 
following data catchment errors. One data set was also removed from the cognitive and 
behavioural data analyses due to missing baseline performance data following data catchment 
errors. The final data sets for all physiological, cognitive and behavioural analyses each 
consisted of a sample of N = 62.  
 
5.2.7 Statistical methods 
 
Baseline differences across iron status and treatment groups were investigated using one-
way ANOVAs. Subsequently, data were analysed using linear mixed models. Separate linear 
mixed models were conducted for each outcome to investigate main effects of treatment 
(placebo, iron, iron and vitamin C), with treatment appearing as a fixed factor in the models.  
 
5.2.7.1 Near-Infrared Spectroscopy (NIRS) data 
 
The Frequency Domain NIRS (FD-NIRS) raw data [oxygen saturation % (Ox%), total 
haemoglobin (THb), oxygenated haemoglobin (Hb02) and deoxygenated haemoglobin (Hb)] 
were extracted and averaged over the 5-minute resting period. To investigate the main effect 
of treatment, treatment group (placebo, iron, iron and vitamin C) was included as a fixed factor 
in the models and respective baseline average values were entered as a covariate. In the first 
instance, FD-NIRS data were analysed with hemisphere as a factor (left, right). As no 
treatment-related effects of hemisphere were found, the data was averaged across the 
hemispheres for analysis. Additionally, baseline serum ferritin was included as a covariate in 
the model to account for the effect of baseline iron status on any treatment effects.  
 
All Continuous Wave NIRS (CW-NIRS) [oxygenated haemoglobin (Hb02); deoxygenated 
haemoglobin (Hb) and total haemoglobin (THb)] raw data were converted to change from 
baseline (the baseline being the average of the 5-minute resting CW-NIRS baseline) and 
averaged into epochs (10 readings per second averaged into task specific lengths). As with 
the FD-NIRS, CW-NIRS data were initially analysed with hemisphere (left, right) as a factor 
but as no effects were found, averages across the hemisphere were used for analysis. The 
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covariance matrix structure was selected based on the structure that produced the lowest 
Schwarz’s Bayesian Information Criterion (BIC) to indicate the best fitting model for the data 
(Mohammed, Naugler, & Far, 2015). Consequently, an autoregressive covariance structure 
was used for all models. To investigate the main effect of treatment, fixed effects appearing in 
the models consisted of treatment group (placebo, iron, iron and vitamin C) and epoch (1-9). 
Subject was also included in all models as a random factor and baseline average values and 
serum ferritin were included as covariates.  
 
5.2.7.2 Indirect Calorimetry (ICa) data 
 
The ICa raw data [carbohydrate oxidation (CHOx); fat oxidation (FatOx); respiratory exchange 
ratio (RER) and total energy expenditure (TotalEE)] were extracted and divided into resting 
and active periods. The resting data was averaged over the 5-minute rest and analysed using 
the same linear mixed model procedure described previously. To investigate the main effect 
of treatment, treatment group (placebo, iron, iron and vitamin C) was included as a fixed factor 
in the models and respective baseline average values were entered as a covariate. Serum 
ferritin was also included as a covariate to account for the effect of baseline iron status on any 
treatment effects.  
 
Active ICa data was averaged into epochs (1 reading per second averaged into task specific 
lengths). The data were analysed using the same linear mixed model procedure described 
previously with CHOx, RER and TotalEE using an autoregressive covariance structure and 
FatOX using an identity covariance structure. To investigate the main effect of treatment, fixed 
effects appearing in the models consisted of treatment group (placebo, iron, iron and vitamin 
C) and epoch (1-9). Subject was included in all models as a random factor and respective 
baseline average values were entered as a covariate. Serum ferritin was also included as a 
covariate to account for the effect of baseline iron status on any treatment effects. 
 
5.2.7.3 Cognitive data 
 
The cognitive data consisted of the baseline and post-dose total responses for the serial 3 and 
7 subtractions, serial 3 errors and serial 7 errors, RVIP accuracy %, RVIP correct reaction 
time (msec) and RVIP false alarms from all 3 repetitions of the associated tasks. The data 
were analysed using the same linear mixed model procedure described previously with an 
identity covariance structure for all models. To investigate the main effect of treatment, fixed 
effects appearing in the models consisted of treatment group (placebo, iron, iron and vitamin 
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C) and repetition (1-3). Subject was included in the models as a random factor and respective 
baseline scores were entered as a covariate. Serum ferritin was also included as a covariate 
to account for the effect of baseline iron status on any treatment effects.  
 
5.2.7.4 Subjective mental fatigue and alertness  
 
The subjective mental fatigue and alertness data consisted of the baseline and post-dose 
ratings from all 3 repetitions of the serial 3 subtractions, serial 7 subtractions and RVIP tasks.  
The data were analysed using the same linear mixed model procedure described previously 
with all models using an autoregressive covariance structure. To investigate the main effect 
of treatment, fixed effects appearing in the models consisted of treatment group (placebo, iron, 
iron and vitamin C) and epoch (1-9). Subject was included in all models as a random factor 
and respective baseline ratings were entered as a covariate. Serum ferritin was also included 








The population for analysis consisted of 31 participants in the IS group and 32 in the NAID 
group. Participant disposition through the trial can be found in Figure 5.3 and participant 
demographics for all who completed the study within each treatment group can be found in 




Figure 5.3 Participant disposition throughout the trial. Figure depicts the final disposition of participants throughout the study, culminating in N = 63 of the 78 randomised. IS = 










Lost to follow up n = 2
Pregnancy n = 1
Self-reported poor 
compliance n = 1
NAID
N = 12
Elevated CRP n = 1
Poor compliance n = 1
Analysed
N = 8







Elevated CRP n = 1







Lost to follow up n = 1









Elevated Hb n= 1
Analysed
N = 12
Time commitments n = 1Discontinued
Excluded
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Table 5.1 Participant demographic information and baseline characteristics. Means and Std. Deviation (SD) are 




N Baseline Main effect 
 Mean SD F p 
Haemoglobin (g/L) 
Placebo 19 126.05 4.56 
2.93 .061 Iron 22 127.86 5.77 
Iron + Vit C 22 123.95 5.57 
Serum ferritin (µg/L) 
Placebo 19 38.42 30.24 
.420 .659 Iron 22 34.18 28.72 
Iron + Vit C 22 30.68 21.63 
Vitamin C (µmol/L) 
Placebo 12 16.31 11.77 
.505 .607 Iron 14 19.81 12.96 
Iron + Vit C 20 16.79 5.62 
Zinc (µmol/L) 
Placebo 13 10.84 1.90 
.024 .976 Iron 15 10.68 1.98 
Iron + Vit C 13 10.78 2.00 
Age (years) 
Placebo 19 27.21 7.86 
.452 .638 Iron 22 28.91 10.26 
Iron + Vit C 22 26.55 6.86 
Years in education 
Placebo 19 17.84 3.58 
1.43 .248 Iron 22 16.27 2.10 
Iron + Vit C 22 16.95 3.12 
BMI (kg/m2) 
Placebo 19 23.13 3.13 
1.85 .166 Iron 22 24.74 4.26 
Iron + Vit C 22 25.25 3.36 
Systolic BP (mmHg) 
Placebo 19 112.84 10.90 
2.86 .065 Iron 22 120.66 11.76 
Iron + Vit C 22 117.41 8.47 
Diastolic BP (mmHg) 
Placebo 19 76.08 7.38 
1.37 .261 Iron 22 79.59 8.24 
Iron + Vit C 22 79.59 7.45 
Menstrual blood 
loss score13 
Placebo 15 2.45 1.31 
5.27 .009 Iron 18 5.03* 2.89 
Iron + Vit C 17 4.22 2.28 
Physical activity 
(MET minutes)  
Placebo 19 3079.26 1652.37 
1.43 .249 






13 Menstrual blood loss was only calculated for those with a menstrual cycle; hence the reduced N. Higher scores 
are indicative of increased menstrual blood loss.    
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Iron + Vit C 22 3354.93 2119.42 
Cereals and cereal 
products (g/day) 
Placebo 19 249.72 99.60 
.704 .499 Iron 22 231.00 119.52 
Iron + Vit C 22 213.12 70.46 
Dietary iron (mg/day) 
Placebo 19 10.87 3.30 
.132 .877 Iron 22 10.45 3.05 
Iron + Vit C 22 10.87 3.07 
Fish and fish 
products (g/day) 
Placebo 19 31.28 27.04 
.019 .981 Iron 22 31.84 28.10 
Iron + Vit C 22 30.20 30.04 
Meat and meat 
products (g/day) 
Placebo 19 110.87 63.88 
1.69 .193 Iron 22 82.90 45.34 
Iron + Vit C 22 82.82 56.95 
Nuts and seeds 
(g/day) 
Placebo 19 16.18 28.42 
1.50 .231 Iron 22 9.61 13.19 
Iron + Vit C 22 6.56 7.58 
Vegetables (g/day) 
Placebo 19 276.60 164.57 
.917 .405 Iron 22 323.54 160.39 
Iron + Vit C 22 350.94 199.82 
Alcohol consumption 
(units/day) 
Placebo 19 0.94 1.35 
.089 .915 Iron 22 0.86 0.95 




Placebo 18 182.82 145.03 
.703 .499 Iron 22 248.56 212.07 
Iron + Vit C 22 218.91 153.13 
* = significant difference between placebo and active treatment group below p < .05 
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5.3.2 Baseline comparisons across iron status groups 
 
5.3.2.1 Resting FD-NIRS 
 
No significant differences were identified across iron status groups. See Table 5.2 for means 
and standard deviations. 
 
Table 5.2 Resting FD-NIRS analysis outcomes for non-anaemic iron deficient (NAID) and iron sufficient (IS) iron 
status groups. Baseline mean scores and standard deviation (SD) are presented with F and p values for the 
separate one-way ANOVAs conducted on the baseline data by iron status group.   
 
 Baseline Main effect 
n Mean SD F p 
Ox (%) 
NAID 31 66.61 5.07 
.061 .806 
IS 28 66.33 3.41 
THb (µM) 
NAID 31 39.85 7.27 
.207 .651 
IS 30 40.71 7.56 
HbO2 (µM) 
NAID 29 26.01 5.15 
.000 .990 
IS 31 25.99 5.52 
Hb (µM) 
NAID 31 13.25 3.02 
.041 .840 
IS 28 13.40 2.45 
Ox, oxygen saturation; THb, total haemoglobin; HbO2, oxygenated haemoglobin; Hb, deoxygenated haemoglobin. 
 
 
5.3.2.2 Active CW-NIRS 
 
A significant effect of baseline iron status was identified for total Hb [F (1, 58.85) = 4.54, p = 
.037]. Participants who were NAID had higher total Hb levels (1.37) than IS participants (0.62) 











Table 5.3 Active CW-NIRS analysis outcomes for non-anaemic iron deficient (NAID) and iron sufficient (IS) iron 
status groups by epoch. Baseline mean scores and standard error (SE) are presented with F and p values of the 
main and interaction effects.  
 
 Baseline  Main effect 
n Mean SE  F p 
Oxy-Hb 
(µmol/L) 
NAID 29 1.61 0.27 Iron status 1.77 .188 
IS 28 1.08 0.29 Iron status*epoch 1.28 .252 
Deoxy-Hb 
(µmol/L) 
NAID 26 -0.20 0.10 Iron status 2.09 .154 
IS 28 -0.41 0.10 Iron status*epoch .781 .620 
Total Hb 
(µmol/L) 
NAID 29 1.37* 0.25 Iron status 4.54 .037 
IS 30 0.62* 0.25 Iron status*epoch 1.30 .247 
* = significant difference between baseline iron status groups below p < .05. 
Oxy-Hb, oxygenated haemoglobin; deoxy-Hb, deoxygenated haemoglobin; total Hb, total haemoglobin.  
 
5.3.2.3 Resting ICa 
 
No significant differences were identified across iron status groups. See Table 5.4. 
 
Table 5.4 Resting ICa analysis outcomes for non-anaemic iron deficient (NAID) and iron sufficient (IS) iron status 
groups. Baseline mean scores and standard deviation (SD) are presented with F and p values for the separate 
one-way ANOVAs conducted on the baseline data by iron status group.   
 
 Baseline Main effect 
n Mean SD F p 
CHOx (g) 
NAID 31 0.10 0.04 
.029 .865 
IS 31 0.10 0.06 
FatOx (g) 
NAID 31 0.05 0.02 
926 .340 
IS 31 0.06 0.02 
RER 
NAID 31 0.83 0.04 
.677 .414 
IS 31 0.82 0.05 
TotalEE (kcal) 
NAID 30 0.88 0.17 
.065 799 
IS 31 0.89 0.21 
CHOx, carbohydrate oxygenation; FatOx, fat oxidation; RER, respiratory exchange ratio; totalEE, total energy 
expenditure. 
 
5.3.2.4 Active ICa 
 






Table 5.5 Active ICa analysis outcomes for non-anaemic iron deficient (NAID) and iron sufficient (IS) iron status 
groups by epoch. Baseline mean scores and standard error (SE) are presented with F and p values of the main 
and interaction effects.  
 
 Baseline  Main effect 
n Mean SE  F p 
CHOx (g) 
NAID 31 0.12 0.01 Iron status .379 .541 
IS 31 0.11 0.01 Iron status*epoch .519 .842 
FatOx (g) 
NAID 31 0.05 0.00 Iron status .341 .561 
IS 31 0.05 0.00 Iron status*epoch .554 .815 
RER 
NAID 31 0.84 0.00 Iron status .433 .513 
IS 31 0.83 0.00 Iron status*epoch .649 .736 
TotalEE (kcal) 
NAID 30 0.91 0.01 Iron status .045 .832 
IS 31 0.90 0.01 Iron status*epoch .709 .684 
CHOx, carbohydrate oxygenation; FatOx, fat oxidation; RER, respiratory exchange ratio; totalEE, total energy 
expenditure. 
 
5.3.2.5 Cognitive performance 
 
No significant differences were identified across iron status groups. See Table 5.6. 
 
Table 5.6 Cognitive performance analysis outcomes for non-anaemic iron deficient (NAID) and iron sufficient (IS) 
iron status groups by repetition. Baseline mean scores and standard error (SE) are presented with F and p 
values of the main and interaction effects.  
 
 Baseline  Main effect 
n Mean SE  F p 
SS3 total 
responses 
NAID 30 19.03 1.08 Iron status .033 .857 
IS 31 19.31 1.10 Iron status*rep .114 .893 
SS3 errors 
NAID 30 0.72 0.14 Iron status 3.11 .083 
IS 31 1.06 0.14 Iron status*rep .736 .481 
SS7 total 
responses 
NAID 31 12.39 0.77 Iron status .501 .482 
IS 31 13.17 0.80 Iron status*rep 2.09 .129 
SS7 errors 
NAID 31 1.11 0.14 Iron status .366 .547 
IS 31 0.98 0.15 Iron status*rep 2.86 .062 
RVIP accuracy 
% 
NAID 31 74.14 3.06 Iron status .002 .966 
IS 30 74.33 3.26 Iron status*rep .386 .681 
RVIP correct 
RT (msec) 
NAID 31 491.85 9.41 Iron status 1.35 .250 
IS 30 475.83 10.07 Iron status*rep 1.84 .164 
RVIP false 
alarms 
NAID 31 0.35 0.09 Iron status .854 .360 
IS 30 0.47 0.10 Iron status*rep .311 .733 
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5.3.2.6 Mental fatigue and alertness VAS 
 
No significant differences were identified across iron status groups. See Table 5.7. 
 
Table 5.7 Mental fatigue and alertness VAS analysis outcomes for non-anaemic iron deficient (NAID) and iron 
sufficient (IS) iron status groups. Baseline mean scores and standard error (SE) are presented with F and p values 
of the main and interaction effects.  
 
 Baseline  Main effect 
n Mean SE  F p 
Mental fatigue 
NAID 30 40.02 3.21 Iron status .309 .580 
IS 30 37.46 3.31 Iron status*epoch .612 .767 
Alertness 
NAID 30 44.92 3.26 Iron status .975 .327 
IS 30 40.30 3.36 Iron status*epoch .468 .878 
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5.3.3 Baseline comparisons across treatment groups 
 
5.3.3.1 Resting FD-NIRS 
 
No significant differences were identified across treatment groups at baseline.  
 
5.3.3.2 Active CW-NIRS 
 
No significant differences were identified across treatment groups at baseline.  
 
5.3.3.3 Resting ICa 
 
A significant difference in baseline total energy expenditure was identified [F (2, 57) = 3.48, p 
= .038]. Post hoc comparisons revealed significantly lower energy expended by the placebo 
group (0.79) than the iron and vitamin C group (0.95; p = .036).  
 
5.3.3.4 Active ICa 
 
A significant treatment x epoch interaction was identified for carbohydrate oxidation [F (16, 
245.68) = 1.70, p = .047]. Post hoc comparisons indicated that the iron group had significantly 
higher carbohydrate oxidation (0.12) than the placebo group (0.07; p = .035) during epoch 9 
(RVIP repetition 3) at baseline.  
 
A significant treatment x epoch interaction was identified for total energy expenditure [F (16, 
249.14) = 2.21, p = .006]. Post hoc comparisons indicated that the iron group had significantly 
higher total energy expenditure levels than the placebo group during epochs 2 (serial 3’s 
repetition 2) and 6 (serial 7s repetition 3) (p < .05). Additionally, the iron and iron and vitamin 
C groups both had significantly higher total energy expenditure levels than the placebo group 
during epoch 9 (RVIP repetition 3) (p < .05).  
 
5.3.3.5 Cognitive performance 
 
A significant treatment x repetition interaction was identified for RVIP accuracy [F (4, 100.98) 
= 3.00, p = .022]. However, post hoc comparisons revealed no significant differences between 
treatment groups across epochs. 
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5.3.3.6 Mental fatigue and alertness VAS 
 
No significant differences were identified across treatment groups at baseline.  
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5.3.4 Treatment effects 
 
5.3.4.1 Resting FD-NIRS 
 
The analysis revealed no significant main effects of treatment. See Table 5.8. 
 
Table 5.8 Resting FD-NIRS analysis outcomes for placebo, iron and vitamin C and iron only treatment groups. 
Baseline raw scores, week 16 estimated marginal means and standard error (SE) are presented with F and p 
values of the main effects of treatment from the linear mixed models.  
 
 Baseline Post-dose Treatment main effect 
n Mean SE Mean SE F p 
Ox (%) 
Placebo 15 67.09 0.96 65.91 0.65 
.664 .520 Iron 18 66.50 0.89 66.71 0.56 
Iron + Vit C 20 66.00 1.06 66.87 0.59 
THb (µM) 
Placebo 17 39.77 1.74 39.47 0.92 
.380 .686 Iron 18 40.52 1.68 40.59 0.90 
Iron + Vit C 18 40.47 1.55 39.95 0.90 
Hb02 
(µM) 
Placebo 16 25.07 1.03 25.34 0.88 
.892 .416 Iron 19 26.01 1.36 26.92 0.79 
Iron + Vit C 20 26.78 1.13 26.06 0.81 
Hb (µM) 
Placebo 17 12.81 0.65 13.96 0.34 
.667 .518 Iron 19 13.42 0.05 13.46 0.32 
Iron + Vit C 20 13.64 0.69 13.52 0.31 
Ox, oxygen saturation; THb, total haemoglobin; HbO2, oxygenated haemoglobin; Hb, deoxygenated haemoglobin. 
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5.3.4.2 Active CW-NIRS 
 
The analysis revealed no significant main or interaction effects of treatment. See Table 5.9. 
 
Table 5.9 Active CW-NIRS analysis outcomes for placebo, iron and vitamin C and iron only treatment groups by 
epoch. Baseline raw scores, week 16 estimated marginal means and standard error (SE) are presented with F and 
p values of the main and interaction effects from the linear mixed models. 
 
 Baseline Post-dose Main effects 
N Mean SE Mean SE  F p 
Oxy-Hb 
(µmol/L) 
Placebo 17 1.35 0.15 1.30 0.24 Treatment .426 .655 
Iron 17 0.99 0.10 0.99 0.24 Epoch .844 .565 
Iron + Vit C 17 1.71 0.12 1.10 0.24 Treatment*Epoch .655 .836 
De-oxy Hb 
(µmol/L) 
Placebo 15 -0.20 0.04 -0.28 0.09 Treatment .074 .929 
Iron 14 -0.31 0.05 -0.33 0.09 Epoch 3.35 .001 
Iron + Vit C 16 -0.39 0.04 -0.30 0.10 Treatment*Epoch 1.24 .237 
Total-Hb 
(µmol/L) 
Placebo 16 0.81 0.13 1.05 0.20 Treatment 1.65 .202 
Iron 17 0.67 0.09 0.54 0.20 Epoch 2.25 .026 
Iron + Vit C 17 1.39 0.11 0.72 0.19 Treatment*Epoch .996 .463 
 Oxy-Hb, oxygenated haemoglobin; deoxy-Hb, deoxygenated haemoglobin; total Hb, total haemoglobin. 
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5.3.4.3 Resting ICa 
 
The analysis revealed no significant main effects of treatment. See Table 5.10. 
 
Table 5.10 Resting ICa analysis outcomes for placebo, iron and vitamin C and iron only treatment groups. Baseline 
raw scores, week 16 estimated marginal means and standard error (SE) are presented with F and p values of the 
main effects of treatment are presented from the linear mixed models.  
 
 Baseline Post-dose Treatment main effect 
n Mean SE Mean SE F p 
CHOx (g) 
Placebo 19 0.08 0.01 0.09 0.01 
.174 .841 Iron 20 0.11 0.01 0.10 0.01 
Iron + Vit C 22 0.11 0.01 0.11 0.01 
FatOx (g) 
Placebo 18 0.05 0.00 0.07 0.01 
.671 .515 Iron 21 0.05 0.00 0.06 0.01 
Iron + Vit C 21 0.06 0.00 0.06 0.01 
RER 
Placebo 19 0.81 0.01 0.81 0.02 
.377 .688 Iron 21 0.83 0.01 0.83 0.01 
Iron + Vit C 22 0.82 0.01 0.82 0.01 
TotalEE 
(kcal) 
Placebo 17 0.79 0.05 0.99 0.05 
.430 .653 Iron 21 0.90 0.03 0.97 0.04 
Iron + Vit C 21 0.95 0.04 0.93 0.04 




5.3.4.4 Active ICa 
 
The analysis revealed no significant main or interaction effects of treatment.  
See Table 5.11. 
 
Table 5.11 Active ICa analysis outcomes for placebo, iron and vitamin C and iron only treatment groups by epoch. 
Baseline raw scores, week 16 estimated marginal means and standard error (SE) are presented with F and p 
values of the main and interaction effects of treatment from the linear mixed models. 
 
 Baseline Post-dose Main effects 
n Mean SE Mean SE  F p 
CHOx (g) 
Placebo 19 0.10 0.00 0.12 0.01 Treatment .943 .395 
Iron 21 0.13 0.00 0.15 0.01 Epoch 9.02 <.001 
Iron + Vit C 22 0.11 0.00 0.13 0.01 Treatment*Epoch .740 .751 
FatOx (g) 
Placebo 19 0.04 0.00 0.05 0.01 Treatment .389 .679 
Iron 21 0.05 0.00 0.05 0.01 Epoch 1.13 .341 
Iron + Vit C 22 0.05 0.00 0.05 0.01 Treatment*Epoch .395 .984 
RER 
Placebo 19 0.84 0.00 0.84 0.01 Treatment .830 .441 
Iron 21 0.84 0.00 0.86 0.01 Epoch 5.79 <.001 
Iron + Vit C 22 0.83 0.00 0.84 0.01 Treatment*Epoch .643 .847 
TotalEE 
(kcal) 
Placebo 19 0.84 0.02 0.98 0.04 Treatment .196 .823 
Iron 21 0.83 0.00 1.00 0.04 Epoch 6.93 <.001 
Iron + Vit C 22 0.90 0.01 0.96 0.04 Treatment*Epoch .857 .620 
CHOx, carbohydrate oxygenation; FatOx, fat oxidation; RER, respiratory exchange ratio; totalEE, total energy 
expenditure. 
 
5.3.4.5 Cognitive performance 
 
A significant effect of treatment for serial 3 subtraction errors was identified [F (2, 49.60) = 
3.25, p = .047]. However, post hoc comparisons revealed no significant differences between 
the iron group (1.14; p =.984) and the iron and vitamin C group (0.68; p = .057) compared to 
the placebo group (1.17).  
 
A significant effect of treatment for serial 7 subtraction errors was also identified [F (2, 50.71) 
= 4.27, p = .019]. Post hoc comparisons revealed significantly fewer errors made by the iron 
and vitamin C group (0.70) compared to the placebo group (1.30; p = .014), however no 
significant difference for the iron group (1.12; p = .642) compared to placebo (Figure 5.4). 
 





Figure 5.4 Estimated marginal means and standard error (SE) for post-dose values of serial 7 subtraction errors 
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Table 5.12 Cognitive performance analysis outcomes for placebo, iron and vitamin C and iron only treatment 
groups by repetition. Baseline raw scores, week 16 estimated marginal means and standard error (SE) are 
presented with F and p values of the main and interaction effects from the linear mixed models. 
 
 Baseline Post-dose Main effects 
n Mean SE Mean SE  F p 
SS3 total 
responses 
Placebo 19 19.22 0.77 19.42 0.67 Treatment 1.83 .177 
Iron 22 18.90 0.87 21.12 0.62 Repetition .916 .404 
Iron + 
Vit C 
20 18.50 0.67 20.70 0.66 Treatment*Repetition .543 .705 
SS3 errors 
Placebo 19 0.84 0.14 1.17T 0.16 Treatment 3.25 .047 
Iron 22 0.86 0.15 1.14 0.14 Repetition .313 .732 
Iron + 
Vit C 
20 0.98 0.17 0.68T 0.15 Treatment*Repetition .285 .887 
SS7 total 
responses 
Placebo 19 12.75 0.59 13.26 0.37 Treatment .709 .497 
Iron 22 13.69 0.67 13.76 0.34 Repetition 5.24 .007 
Iron + 
Vit C 
21 12.42 0.45 13.79 0.34 Treatment*Repetition .229 .992 
SS7 errors 
Placebo 19 0.82 0.13 1.30* 0.16 Treatment 4.27 .019 
Iron 22 1.26 0.16 1.12 0.14 Repetition .127 .881 
Iron + 
Vit C 
21 0.98 0.15 0.70* 0.15 Treatment*Repetition 1.81 .133 
RVIP 
accuracy % 
Placebo 19 78.70 2.49 70.37 3.09 Treatment 1.24 .299 
Iron 22 72.71 2.86 75.60 3.13 Repetition 1.03 .361 
Iron + 
Vit C 




Placebo 19 480.07 11.67 487.96 9.12 Treatment .700 .502 
Iron 22 474.72 7.16 473.13 8.67 Repetition 1.01 .370 
Iron + 
Vit C 
20 498.11 7.79 480.82 9.26 Treatment*Repetition .763 .552 
RVIP false 
alarms 
Placebo 19 0.26 0.07 0.56 0.11 Treatment 1.02 .370 
Iron 22 0.43 0.10 0.35 0.10 Repetition .254 .776 
Iron + 
Vit C 
20 0.46 0.09 0.45 0.11 Treatment*Repetition .195 .940 
* = significant difference between placebo and active treatment group below p < .05; T = trend towards a significant 




5.3.4.6 Mental fatigue and alertness VAS 
 
The analysis revealed no significant main or interaction effects of treatment. See Table 5.13. 
 
Table 5.13 Mental fatigue and alertness VAS analysis outcomes for placebo, iron and vitamin C and iron only 
treatment groups by task and by repetition. Baseline raw scores, week 16 estimated marginal means and standard 
error (SE) are presented with F and p values of the main and interaction effects from the linear mixed models. 
 
 Baseline Post-dose Main effects 
n Mean SE Mean SE  F p 
Mental fatigue 
Placebo 18 38.67 1.64 37.59 3.13 Treatment .328 .722 
Iron 21 43.62 1.52 40.73 2.89 Epoch 5.72 <.001 
Iron + Vit C 19 34.27 1.55 38.04 3.07 Treatment*Epoch .699 .794 
Alertness 
Placebo 18 40.12 1.50 43.76 2.62 Treatment .188 .829 
Iron 21 48.62 1.65 45.35 2.43 Epoch 4.48 <.001 





Two participants did not return their unused treatments. For the remaining participants, 
compliance was observed to be very good in all three groups (102 % Placebo; 102 % Iron; 
101 % Iron and Vitamin C) with a one-way ANOVA identifying no significant difference for 
compliance percentage by treatment group [F (2, 58) = .002, p = .998]. Fifty-eight percent of 
participants in the placebo group believed that had received placebo compared to 46 % and 
41 % of participants in the iron and iron and vitamin C groups, respectively. Chi-squared 





The current study was the first to assess the parallel effects of iron supplementation on 
cerebral haemodynamics and energy metabolism in a sample of NAID and IS women of 
reproductive age. Overall, the only baseline difference between iron status groups was an 
increased total haemoglobin concentration during cognitive demand for NAID participants 
compared to IS participants. Following 16-weeks supplementation, iron and vitamin C 
treatment caused a significant decrease in serial 7 subtraction errors compared to placebo, 
whilst this only trended towards a significant decrease for serial 3 subtractions. Finally, no 
significant effects of treatment were identified for cerebral blood flow parameters, ICa 
parameters or ratings of mental fatigue and alertness.  
 
Concerning the significant baseline difference in total haemoglobin during cognitive demand 
between NAID and IS women, the finding may be useful for explaining the similarity found 
across these iron status groups for cognitive function, as shown in the previous chapters also. 
The observed increase in total haemoglobin for the NAID group may be a consequence of 
neurovascular coupling augmenting CBF to satisfy the demand for tissue oxygen following 
increased neural activity under cognitive demand. As NAID is associated with increased blood 
viscosity (Broberg et al., 2006; Khaled et al., 1998), vasodilation may increase as a 
compensatory mechanism as shown in carotid occlusion of rats (Lenz et al., 2000) and nitric 
oxide production may increase to allow this to occur in the same manner as in IDA female 
adolescents (Choi et al., 2002). This action may therefore be enhanced during cognitive 
demand compared to their IS counterparts to achieve the same cognitive performance. As 
NAID participants can achieve the same standard of performance, this may explain why there 
is also no significant difference between subjective ratings of mental fatigue and alertness 
either given the well-established relationship between cognition and mood (Baune, Fuhr, Air, 
& Hering, 2014). The current study has refined previous cross-sectional findings that obtained 
indirect estimates of brain energy through simultaneous EEG and ICa (Wenger, DellaValle, et 
al., 2019) by using NIRS to attribute changes in oxygen consumption specifically to the 
prefrontal cortex amongst NAID and IS women of reproductive age. However, contrary to such 
findings (Wenger, DellaValle, et al., 2019), metabolic measures of energy expenditure did not 
differ between the iron status groups. This may be attributed to the increased delivery of 
oxygen to the brain for use as a metabolic resource to fulfil the demands of increased neural 
activity. The study described in Chapter 2 however elucidated the issues surrounding 
heterogeneity when categorising continuous iron status biomarkers into iron status groups, 
which make comparisons between studies difficult.  
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Treatment effects were limited in the current study as the only significant effect pertained to a 
reduction in errors made on the serial 7 subtraction task and a trend for the same effect on 
the serial 3 subtraction task for the iron and vitamin C group. Iron supplementation (>100 mg 
elemental iron) has previously demonstrated significant improvements to working memory 
after 8-weeks in NAID women (Bruner et al., 1996; Lambert et al., 2002), however the current 
study extends these findings to iron and vitamin C supplementation rather than iron alone in 
a sample of NAID and IS women. Increased absorption and bioavailability of iron following co-
supplementation with vitamin C may increase the amount of iron available for dopamine 
synthesis and D2 receptor functioning; processes that are critical for modulating cognitive 
functions within the prefrontal cortex, such as working memory (Naef et al., 2017). The low 
dose of iron used in the current study may have not been sufficient alone to stimulate such 
effects upon the dopaminergic system to observe changes in working memory accuracy. 
Although, systemic changes in iron biomarkers may not necessarily reflect changes in brain 
iron. Therefore, using fMRI for estimates of brain iron in future studies should aid in providing 
a more accurate interpretation of these findings. It should also be noted that the current study 
was not powered to detect cognitive effects and interpretations should be approached with 
caution. 
 
Despite an improvement in working memory accuracy shown following supplementation with 
iron and vitamin C, this effect was not mirrored by changes in cerebral haemodynamics or 
energy expenditure. There is evidence to suggest that haemoglobin is involved in the normal 
physiology of the brain as it is present in dopaminergic neurons, cortical and hippocampal 
astrocytes and oligodendrocytes for a role in mitochondrial oxidative phosphorylation (Biagioli 
et al., 2009). Consequently, only measuring two channels across a small area of the prefrontal 
cortex in the current study limits knowledge regarding changes in cerebral haemoglobin in 
other areas of the brain. Haemoglobin may have increased in alternate areas of the brain to 
facilitate a lessened requirement for the breakdown of energy-rich fatty acids as a metabolic 
resource as the energy yielded from oxidative phosphorylation of glucose is used more 
efficiently at rest and during cognitive demand; this may then explain the null findings 
regarding cerebral haemodynamics. Haemoglobin is however shown to modulate the 
relationship between electrical brain activity and energy expenditure (Wenger, DellaValle, et 
al., 2019). If cerebral haemoglobin is increased in alternate areas of the brain as proposed 
here, future studies may benefit from utilising a multi-channel functional NIRS-EEG monitoring 
system (Chiarelli, Zappasodi, Di Pompeo, & Merla, 2017; Kassab et al., 2018) to determine 
the impact of iron supplementation upon neuronal electrical activity in addition to cerebral 
haemodynamics across multiple brain regions. Previous iron intervention studies regarding 
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NAID in female athletes (Dellavalle & Haas, 2014; Hinton & Sinclair, 2007) and non-athletes 
(Fiddler et al., 2019; LaManca & Haymes, 1993; McClung et al., 2009; Zhu & Haas, 1998) 
have observed significant benefits of iron supplementation for reducing energy expenditure 
and subsequently improving energetic efficiency. It must however be considered that the use 
of indirect calorimetry for assessing metabolic consequences of nutritional supplements is 
relatively novel and consequently further research within the field is required. 
 
The current study was one of the first to investigate the parallel effects of iron status and 
changes in systemic iron upon functional outcomes of cognition, cerebral haemodynamics and 
whole-body energy metabolism following iron supplementation in a sample of NAID and IS 
women of reproductive age. Specifically, the employment of both FD-NIRS and CW-NIRS 
technology was novel to the research area and offered potential to gain insight into the 
biological processes that may underpin functional differences between iron status groups. 
However, a potential limitation of the study surrounds the cognitive tasks and their duration. 
The cognitive demand battery of serial 3 and 7 subtractions and RVIP is validated in literature 
having demonstrated sensitivity to several nutritional interventions (Kennedy et al., 2018; 
Kennedy, Wightman, Khan, Grothe, & Jackson, 2019; Wightman et al., 2018) including multi-
vitamins and minerals (Kennedy et al., 2008; Kennedy et al., 2010), however this is when 
administered as a 10-minute battery of two minutes for each serial subtraction task and five 
minutes of RVIP. It is possible that the one-minute duration for each of the tasks was not 
sufficient to elicit changes in CBF in response to iron supplementation or changes in iron 
status. Additionally, the cognitive demand battery is designed to be repeated six times in 
immediate succession, accumulating to 60 minutes of cognitive demand (Kennedy & Scholey, 
2004). Altogether, the shorter task durations and fewer battery repetitions may have resulted 
in a lack of cumulative demand. Similarly, the one-minute rest periods provided between each 
task repetition may not have been sufficient to allow cerebral haemodynamic responses to 
return to resting levels as there is evidence suggestive of the neurovascular coupling response 
remaining elevated for ∼ 60 seconds following stimulation (Allen, Pasley, Duong, & Freeman, 
2007). Consequently, cerebral responses induced following one repetition of the tasks may 
not have returned to resting levels before starting the next task repetition; a longer rest 
between repetitions, such as the 2-minutes employed when transitioning between tasks, may 
have been more appropriate to avoid crossover between tasks. Furthermore, the fact that 
significant treatment effects were identified for the serial subtractions but not for the RVIP task 
may suggest that only the serial subtraction tasks were amenable to iron supplementation. 
Although, optimal working memory performance is dependent upon an efficient mechanism of 
filtering irrelevant information through neural suppression to prevent overloading working 
memory capacity (Zanto & Gazzaley, 2009). Consequently, in line with the systematic review 
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described in Chapter 3 and the study described in Chapter 4 that identified no treatment effects 
on attention, attentional networks may already be working in an efficient manner in non-
anaemic women; however, working memory systems may be using attentional networks more 
effectively in response to iron supplementation. Future research should consider employing 
working memory cognitive analogues to a treadmill test whereby the same tasks increase with 
difficulty in a similar manner to a previous investigation focussed upon cognitive performance, 
brain activity and energy expenditure (Wenger, DellaValle, et al., 2019). This is especially 
important as cognitive performance is facilitated by a brain-state coupled to expectations of 
the difficulty of an upcoming cognitive challenge (de Dreu, Schouwenaars, Rutten, Ramsey, 
& Jansma, 2019). As functional NIRS is limited by penetration depth that restricts detection of 
neural activity only from the cerebral cortex, brain areas such as the hippocampus cannot be 
detected. Future research could instead employ fMRI to detect hippocampal activity; however, 
there is evidence of associations of cortical regions such as the dorsolateral prefrontal cortex 
and ventrolateral prefrontal cortex, temporal and parietal cortices with successful memory 
encoding and retrieval (Glahn et al., 2010; Sperling, 2007; Sperling et al., 2002) in addition to 
the hippocampus that are detectable by functional NIRS (Jahani et al., 2017). It may therefore 
be possible for future research to employ either fMRI or multi-channel NIRS to detect 
haemodynamic changes related to working memory and episodic memory function.  
 
The findings from the current study provide novel evidence of a low dose iron bis-glycinate 
chelate co-supplemented with vitamin C for significantly reducing the number of errors made 
on a serial subtractions task as a measure of working memory, whilst having no effects on 
cerebral haemodynamics or energy metabolism, compared to placebo. However, future 
studies powered to detect cognitive effects that use fMRI or multi-channel NIRS should be 
used to confidently interpret effects and attribute changes in systemic iron to changes in brain 
iron. Although no significant changes in cerebral haemodynamic response were observed 
following the intervention period, the greater levels of total haemoglobin in the prefrontal cortex 
demonstrated by NAID women during cognitive demand at baseline compared to their IS 
counterparts is a novel contribution to the research area. Further investigations should 
consider employing simultaneous measures of EEG, multi-channel NIRS and ICa in addition 
to administering a working memory task battery of incremental difficulty for longer durations 
with longer rest periods between task repetitions to minimise crossover effects between the 
tasks.  
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Chapter 6 GENERAL DISCUSSION 
 
6.1 Summary of objectives 
 
The aims of this thesis were to investigate the effects of iron status and the effects of 
supplementation with iron bis-glycinate chelate and iron/vitamin C on cognitive function, 
subjective mood, fatigue, wellbeing, and cerebral blood flow and energy metabolism in NAID 
and IS women of reproductive age. Investigating this population was in response to women of 
reproductive age largely being overlooked in favour of those considered to be at a greater risk 
for ID despite women’s prolonged risk for ID across their reproductive years. Specifically, 
NAID is more prevalent than IDA among this population (Soppi, 2018; Umbreit, 2005) and few 
studies had directly compared associations between NAID and IS status groups concerning 
cognitive and behavioural function (Cook et al., 2017; Leonard et al., 2014; Murray-Kolb & 
Beard, 2007; Scott et al., 2017; Scott & Murray-Kolb, 2016). Moreover, as such studies 
categorise continuous iron biomarkers into iron status groups based upon different diagnostic 
criteria, heterogeneity is increased within and across samples, which may conceal the impact 
of ID. This is further complicated by the fact that other studies have employed continuous iron 
biomarkers to assess iron status (Blanton et al., 2013; Scott & Murray-Kolb, 2016). 
Additionally, previous cross-sectional investigations failed to account for the potential of 
physical activity, BMI, dietary iron and menstrual blood loss to confound measures of iron 
status, cognition and behavioural function. As numerous factors can determine human 
psychological function, it is essential to reduce the amount of noise when carrying out research 
at an observational level.  
 
Previous RCTs of iron supplementation in women of reproductive age were similarly limited 
concerning NAID and heterogeneity surrounding the cut-offs used for NAID. Attempts to 
improve the efficacy, tolerability and subsequent compliance throughout the intervention 
periods were lacking as no supplements were considered other than ferrous formulations. 
Additionally, dosage of elemental iron has consistently been administered at doses much 
greater than the recommended daily supplementation dosage for non-pregnant, menstruating 
women and greater than the tolerable upper level of iron intake for gastrointestinal discomfort 
prevention. Consequently, a low dose iron bis-glycinate chelate either administered alone or 
co-supplemented with vitamin C was employed for the RCTs in this thesis in an effort to 
improve supplement bioavailability and tolerability and subsequently psychological and 
physiological outcomes. Iron bis-glycinate was chosen specifically due to the inverse 
relationship identified between its absorption and serum ferritin (Bovell-Benjamin et al., 2000; 
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Olivares et al., 1997), which suggested that its administration would be most beneficial to a 
NAID population compared with alternate iron preparations.  
 
Considering the few cross-sectional and RCTs focussed on otherwise healthy, NAID women 
of reproductive age, further investigation was warranted to address the limitations associated 
and to expand the field of research. To address this, Chapter 2 aimed to investigate the 
associations of categorical NAID and IS status groups, and continuous iron status biomarkers 
haemoglobin and serum ferritin to cognitive and behavioural function, whilst controlling for the 
potential confounding effects of demographic and lifestyle factors. Chapter 3 aimed to 
systematically review the findings from RCTs investigating the effects of iron supplementation 
on cognition, mood, fatigue and/or well-being in menstruating, women of reproductive age. 
Chapter 4 comprised the first RCT of iron bis-glycinate chelate and its co-supplementation 
with vitamin C aimed at investigating the effect on iron status, cognitive function, subjective 
mood, fatigue and wellbeing in NAID and IS women of reproductive age. Finally, Chapter 5 
comprised the first investigation of the effects of iron status and iron bis-glycinate chelate and 
its co-supplementation with vitamin C on cerebral haemodynamics and energy metabolism at 
rest and during cognitive demand in NAID and IS women of reproductive age.  
 
6.2 Iron status, iron supplementation and brain function 
 
6.2.1 Cognitive function  
 
6.2.1.1 Iron status and cognitive function  
 
Concerning the impact of categorical iron status on cognitive function, previous investigations 
have largely found no distinguishable difference in cognition between NAID and IS women 
(Cook et al., 2017; Leonard et al., 2014; Murray-Kolb & Beard, 2007; Scott & Murray-Kolb, 
2016) despite NAID women performing worse academically compared to their IS counterparts 
(Scott et al., 2017). Consistent with such findings, the study presented in Chapter 2 found no 
associations between categorical iron status and cognitive function. When haematological 
parameters were treated as continuous variables, no significant associations with cognition 
were achieved in contrast to earlier findings (Blanton, 2013; Blanton et al., 2013; Scott & 
Murray-Kolb, 2016). Similarly, no differences in cognitive performance were found between 
iron status groups in the study described in Chapter 5. Overall, these findings are suggestive 
of cognition not declining in the early stages of ID. 
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6.2.1.2 Iron supplementation and cognitive function  
 
The intervention study described in Chapter 4 aimed to build upon the findings from Chapter 
2 to further investigate the relationship between iron and cognitive function and to determine 
whether iron and vitamin C co-supplementation would be more beneficial to cognition than 
iron alone. However, no significant effects upon cognitive function were identified. As previous 
iron RCTs in non-anaemic women of reproductive age have found positive treatment effects 
of iron on cognitive function at much higher doses of iron (60 – 260 mg elemental iron) from 
ferrous formulations (Bruner et al., 1996; Lambert et al., 2002; Leonard et al., 2014), this leads 
to the suggestion that the low dose of iron used in this study may not have been sufficient to 
elicit a cognitive change. However, the systematic review described in Chapter 3 highlighted 
the importance of accounting for individual variations in response to treatment to avoid making 
inaccurate conclusions regarding the actual impact of iron supplementation. This may 
therefore be an opportunity for further research and post-hoc analyses to determine whether 
significant changes in iron status biomarkers following supplementation result in changes in 
cognitive performance.    
 
In Chapter 5, however, a significant reduction in errors on the serial 7 subtraction task and a 
trend for the same effect on the serial 3 subtraction task for the iron and vitamin C treatment 
group was discovered. This corroborated findings from previous intervention studies that 
observed significant improvements to working memory using much greater doses of elemental 
iron in NAID women (Bruner et al., 1996; Lambert et al., 2002). The positive effect of treatment 
is the first evidence of a low dose of iron co-supplemented with vitamin C improving cognitive 
performance in a sample of NAID and IS women. This may suggest that the increased 
bioavailability and absorption of iron when co-supplemented with vitamin C compared to iron 
alone allows for augmented availability of iron for dopamine synthesis and proper D2 receptor 
functioning, which is required for modulation of working memory performance (Naef et al., 
2017). However, the study described in Chapter 5 was not powered to detect cognitive effects 
and as such these interpretations should be approached with caution.  
 
Overall, the findings observed throughout this thesis suggest that cognitive function does not 
decline in the early stages of ID and a low dose of iron supplemented over 16 weeks is not 
sufficient to influence cognitive function. To improve understanding, focus should be shifted 
to establishing optimal haemoglobin and serum ferritin concentrations for cognitive outcomes 
rather than comparing NAID and IS categorical groups of women of reproductive age to avoid 
heterogeneity. Although a significant benefit of iron and vitamin C was observed in Chapter 5 
for cognitive function, the thesis has also highlighted the potential importance of accounting 
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for individual variations in iron status parameters in response to treatment, which is deserving 
of exploration. 
 
6.2.2 Mood & Well-being 
 
Assessing the impact of iron status and iron supplementation on mood and well-being 
measures was an important aspect of this thesis due to the conflicting evidence previously 
presented. Chapter 2 observed no significant associations between iron status, mood and 
well-being, which is suggestive of no behavioural differences between NAID and IS women of 
reproductive age. A potential explanation for this may surround testing a sample from the 
general population who were otherwise healthy. Although there is evidence to suggest NAID 
is 15 % greater in women with depression compared to those without (Vahdat Shariatpanaahi 
et al., 2007), this is thwarted by the increased prevalence of mood disorders in populations 
from conflict-affected low-income countries as included in the study (Charlson et al., 2019). 
The studies that comprised this thesis however excluded those diagnosed with mood 
disorders, which limits the findings related to depression. More recent evidence from the 
United States however suggests that iron deficiency (serum ferritin < 20 µg/L) is only 
associated with depressive symptoms when concomitant fatigue is reported (Price et al., 
2017). Consequently, independent positive associations were only identified between serum 
ferritin and emotional functioning and mental component summary scores as indicators of 
health-related quality of life. As monoamines depend upon non-haem iron for effective 
synthesis (Kim & Wessling-Resnick, 2014), a reduction in non-haem in the form of serum 
ferritin may infer emotional dysregulation through mood disturbances that are not easily 
detected in a non-clinical sample. As no individual associations were observed across mood 
measures, it may be the combination of such factors that contribute to the overall 
representation of emotional functioning and mental health-related quality of life in the general 
population.  
 
The study described in Chapter 4, however, suggested a causal role of iron treatment alone 
in the aetiology of ratings of depression and total mood disturbance. Previous RCTs of iron 
supplementation have not observed improvements in depressive mood following higher doses 
of iron in NAID women of reproductive age who presented with concomitant fatigue at baseline 
(Vaucher et al., 2012; Verdon et al., 2003). The findings from this chapter may therefore imply 
that mood is amenable to a much lower dose of iron in the general population regardless of 
the presentation of considerable fatigue at baseline. The presentation of this effect may have 
also been a consequence of controlling for menstrual cycle; ensuring participants who 
experienced natural, or withdrawal bleeds attended their baseline and post-dose assessments 
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7 to 14 days following bleed onset. Controlling for the potential impact of menstrual cycle on 
brain activation (Pletzer et al., 2019) and emotion-related changes exhibited in the luteal 
phase and menses (Sundstrom Poromaa & Gingnell, 2014) may have reduced noise in this 
domain to allow for the detection of this effect. In contrast to this, iron treatment alone caused 
a reduction in PCS as a measure of physical health, which was inconsistent with previous 
RCTs that identified significant improvements to quality of life and physical performance 
following iron treatment (Burden, Pollock, et al., 2015; Favrat et al., 2014; McArthur et al., 
2012; Patterson et al., 2001; Rubeor et al., 2018). Overall, the thesis has highlighted the 
benefit of iron for mood regulation in women of reproductive age from the general population 
and that further research is required to elucidate the relationship between iron treatment and 




Iron deficiency is most attributed with non-haematological symptoms of weakness and fatigue, 
following greater reports of constant tiredness compared to those who are IS (Patterson et al., 
2000). However, RCTs have largely focussed on NAID female athletes for investigations of 
fatigue due to their additional risk of ID with and without anaemia and its potential impact upon 
athletic performance through impaired aerobic capacity and increased fatigue (DellaValle & 
Haas, 2011; Koehler et al., 2012; Sinclair & Hinton, 2005). However, ID-associated fatigue is 
not limited to its impact on physical athletic performance as subjective fatigue may also 
present categorised by feelings of lowered energy and motivation that may subsequently 
increase anxious and depressive symptoms to deplete quality of life and cognitive capacity 
(Dziembowska et al., 2019). Chapter 2 of this thesis, however, failed to show any significant 
associations of iron status group, haemoglobin or serum ferritin to any of the subjective fatigue 
outcomes. This is consistent with findings from a meta-analysis of cross-sectional studies that 
failed to find associations between NAID and subjective fatigue in the general population; 
significant associations were only identified amongst populations with diagnosed disorders 
(Yokoi & Konomi, 2017). Subjective central fatigue is hypothesised to be a consequence of 
an elevated ratio of serotonin to dopamine, as observed in ID (Kim & Wessling-Resnick, 2014; 
Meeusen et al., 2006). As no individual associations were observed across mood and fatigue 
measures in Chapter 2, it may be that associations are not detectable in a non-clinical sample. 
Although their combination may affect an individuals’ mental health and wellbeing through 
emotional dysregulation as previously evidenced (Ferreira et al., 2019) and as shown through 
the positive association of quality of life to serum ferritin in Chapter 2, which again may aid in 
explaining the Chapter 2 findings regarding fatigue, mood and wellbeing.   
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The systematic review presented in Chapter 3 highlighted a significant effect of iron 
supplementation for reducing fatigue in NAID women indicating a serum ferritin-dependent 
effect upon fatigue symptoms. However, the studies were subject to heterogeneity regarding 
the haemoglobin and serum ferritin concentration cut-offs used for classifying NAID, which left 
the findings open to bias. Using a serum ferritin cut-off of ≤ 20 µg/L proved most effective for 
improving athletic performance (Rubeor et al., 2018), and as a reduction in physical capacity 
often presents simultaneously with symptoms of central fatigue (Dziembowska et al., 2019) it 
was hypothesised that improvements to subjective fatigue may present following 
supplementation. However, no significant treatment effects were identified in Chapter 4 
regarding subjective fatigue or sleep quality. Previous iron RCTs that have found significant 
effects of iron supplementation for reducing fatigue, have however used intravenous iron or 
much higher doses of ferrous oral formulations in clinical populations of women (Favrat et al., 
2014; Krayenbuehl et al., 2011; Vaucher et al., 2012); the low dose of iron used in this study 
may have not been enough to initiate a significant improvement in the general population. 
Overall, the thesis has identified that fatigue may not be present in the early stages of ID, and 
that a low dose of iron is not sufficient to have a positive effect upon fatigue in a general 
population of non-anaemic women of reproductive age. 
 
6.2.4 Cerebral haemodynamics 
 
The study presented in Chapter 5 of this thesis was the first to employ NIRS to investigate 
cerebral haemodynamics across baseline iron status groups and to explore any changes in 
CBF following iron supplementation. Total haemoglobin concentrations during cognitive 
demand were significantly increased in NAID women compared to IS women. When 
considered alongside the cognitive findings in this Chapter and in Chapter 2 of no significant 
decline in cognitive performance in the early stages of ID, this may suggest augmented CBF 
acts as a compensatory mechanism for NAID women to achieve the same cognitive 
performance as those who are IS. Blood viscosity is increased in NAID due to impaired 
cardiomyocyte function following hypoxia-induced mitochondrial dysfunction (Broberg et al., 
2006; Khaled et al., 1998), which stimulates increases in vasodilation as a compensatory 
mechanism (Lenz et al., 2000); this action may therefore be intensified during cognitive 
demand to satisfy the increased demand for oxygen in response to increased neural activity. 
However, this compensatory effect may have long-term effects; increased blood viscosity is 
associated with increased morbidity and mortality of several cardiovascular and 
cerebrovascular diseases (Naghedi-Baghdar et al., 2018), which may be exacerbated upon 
exhaustion of compensatory vasodilation mechanisms. Therefore, although this 
compensatory effect may be beneficial to NAID women in the short-term, the potential long-
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term detriments it holds provide support for NAID being a clinical challenge in need of more 
recognition.  
 
Conversely, no significant treatment effects on CBF were established following 16-weeks iron 
supplementation, indicative of CBF not being amenable to improvements in iron status 
parameters. Restoring iron levels through iron supplementation is shown to improve 
cardiomyocyte function (Hoes et al., 2018) and blood flow regulation (Halis et al., 2009) in vitro 
and in children, respectively. As this was the first study to examine the effects of iron 
supplementation upon CBF, the null findings are difficult to interpret and are thus deserving of 
further investigation, especially as only two-channels across the prefrontal cortex were 
measured. Employing multi-channel functional NIRS systems in future would enable a greater 
understanding of the effects of iron supplementation on CBF across multiple brain regions to 
avoid making inaccurate conclusions.  
 
Overall, although no significant changes in cerebral haemodynamic response were revealed 
following 16-weeks iron supplementation, the thesis is the first to identify significant 
differences in CBF between iron status groups. The greater total haemoglobin concentrations 
in the prefrontal cortex exhibited by NAID women during cognitive demand compared to IS 
women provides novel insight into how compensatory mechanisms may be involved in 
ensuring maintenance of cognitive and behavioural function in the early stages of ID.  
 
6.2.5 Energy metabolism 
 
An additional aim of Chapter 5 was to investigate the effects of 16-weeks iron supplementation 
on energy metabolism during rest and cognitive demand in NAID and IS women of 
reproductive age. This was following evidence suggesting ID impairs energy metabolism with 
serum ferritin positively predicting respiratory rate, heart rate and energy expended as 
cognitive demand increases (Wenger, Rhoten, et al., 2019). However, no significant 
differences in measures of energy metabolism were observed between iron status groups in 
Chapter 5. Energy expenditure is though consistently observed to be higher during the luteal 
phase of the menstrual cycle (Benton, Hutchins, & Dawes, 2020; Zhang et al., 2020), which 
has not previously been controlled for. The null findings here may therefore have been due to 
a reduction in noise following controlling for where women were in their menstrual cycle for 
baseline and post-dose assessments. Although, when considered alongside the difference in 
total haemoglobin between iron status groups, the null findings may be attributable to the 
augmented delivery of oxygen to the brain for NAID women to fulfil the demands of increased 
neural activity to achieve the same performance as IS women. Therefore, the use of metabolic 
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resources and energy expended may not differ between iron status groups, however NAID 
women have more metabolic resources made available to ensure the same cognitive and 
behavioural outcomes are met. However, following the intervention period, no significant 
effects upon energy metabolism were found in contrast to previous iron RCTs (Fiddler et al., 
2019; LaManca & Haymes, 1993; McClung et al., 2009; Y. I. Zhu & Haas, 1998); iron 
supplementation significantly reduced energy expenditure and improved energetic efficiency. 
To further elucidate the relationships between iron supplementation and energy metabolism, 
adopting an approach utilising a multi-channel functional NIRS-EEG system simultaneously 
with ICa may be beneficial to determine the links between neural electrical activity, cerebral 
haemodynamics and energy metabolism in response to improvements in iron status 
parameters across multiple brain regions.  
 
Overall, this thesis included the first investigation of the impact of iron supplementation upon 
energy metabolism at rest and during cognitive demand in NAID and IS women of reproductive 
age. Although no significant effects were observed across iron status groups, when 
considered alongside the cerebral haemodynamics results, the null findings may be 
attributable to the augmented delivery of oxygen to the brain for NAID women to fulfil the 
demands of increased neural activity to achieve the same performance as IS women. As the 
use of indirect calorimetry is relatively novel in the field of nutritional interventions, further 
research is required in order to determine how iron supplementation may impact energy 
metabolism in non-anaemic women of reproductive age.  
 
6.3 Iron bis-glycinate chelate and vitamin C  
 
The intervention studies conducted throughout this thesis comprised the first investigations of 
an iron bis-glycinate chelate compound upon cognitive, behavioural, cerebral haemodynamic 
and energy metabolism outcomes. This was following evidence that its supplementation would 
allow for a more efficacious improvement of haematological measures of iron status due to 
increased bioavailability and tolerability (Coplin et al., 1991; Fouad et al., 2013), especially 
amongst a NAID population (Bovell-Benjamin et al., 2000; Olivares et al., 1997). The addition 
of vitamin C was also investigated as although ferrous formulations of iron supplements are 
more amenable to the associated benefits of vitamin C, its addition to iron bis-glycinate 
formulas is shown to improve the already superior efficacy (Olivares et al., 1997). The effects 
upon iron status that were observed in Chapter 4 were comparable as although the iron and 
vitamin C group had significantly higher haemoglobin and serum ferritin compared to placebo, 
no significant differences were identified between iron treatment groups despite numerically 
larger values for the iron and vitamin C group (APPENDIX IX). This was however the first 
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investigation of the effects of a low-dose iron bis-glycinate formula for improving iron status in 
NAID and IS women of reproductive age and has therefore demonstrated its ability to 
significantly improve iron status parameters compared to placebo with minimal associated 
adverse events. The findings revealed no significant benefit of co-supplementing with vitamin 
C, which is consistent with the biochemical analysis identifying no significant improvement in 
vitamin C levels for the iron and vitamin C group. A potential explanation for this could pertain 
to the 240 mg dose of vitamin C co-supplemented; the vitamin C RDA for women of 
reproductive age in the United Kingdom is 40 mg (PHE, 2016) and supplementation doses 
exceeding the RDA are associated with pro-oxidant activity (Fisher & Naughton, 2004), which 
may lead to poorer bioavailability and increased vitamin C excretion. Although the iron and 
vitamin C supplement was numerically superior for improving measures of iron status, the null 
findings between active treatments may be a consequence of the vitamin C dose increasing 
oxidative stress to diminish its absorptive capabilities. Iron and vitamin C co-supplementation 
at greater doses has been shown to have similar antioxidant properties compared to iron alone 
in NAID female adolescents (Khoshfetrat et al., 2013), therefore the oxidant properties of iron 
bis-glycinate co-supplemented with vitamin C require investigation. As ferrous formulations 
are far more amenable to the absorptive benefits of vitamin C, it may be beneficial for further 
research to measure markers of oxidative stress and to compare co-supplementation of iron 
and vitamin C from bis-glycinate chelate and ferrous formulations to determine the efficacy of 
vitamin C across supplementation methods. Overall, this thesis has provided the first evidence 
of the ability of iron bis-glycinate chelate to improve iron status in NAID and IS women of 
reproductive age with minimal associated adverse events. Although the iron and vitamin C 
group numerically had greater haemoglobin and serum ferritin concentrations, there was no 




The studies that comprise this thesis have addressed multiple limitations associated with 
previous cross-sectional studies and RCTs, specifically surrounding accurate determinations 
of iron status, the consideration of confounding variables, supplement bioavailability and 
tolerability. Additionally, the employment of novel methodologies to the research area, such 
as FD-NIRS and CW-NIRS, provided insight into the biological processes that may underpin 
the functional differences between iron status groups observed in this thesis and previous 
research. However, as discussed throughout the previous chapters, it is essential to consider 





Firstly, a potential issue that was overlooked in this thesis was the lack of accountability for 
medical history regarding iron status. There is extensive evidence suggesting that early-life 
IDA causes irreversible impairments to cognitive function and mood regulation that persist 
through to childhood (Lozoff et al., 2000; Lozoff et al., 1991), adolescence (Lozoff et al., 2000) 
and early adulthood (Lozoff et al., 2006; Lozoff et al., 2013) regardless of iron repletion 
following diagnosis. Animal model systems have identified alterations to monoamine 
neurotransmitter metabolism, energy metabolism, myelination (Beard & Connor, 2003; 
Dallman, 1986; Youdim & Green, 1978), brain iron content and brain tissue composition (Mudd 
et al., 2018) to be responsible for such irreversible psychological effects. Considering the 
Chapter 2 study, the lack of consideration for early-life ID highlights the possibility of including 
those classified as IS who were at a psychological disadvantage due to the neurological 
impairments instigated as a consequence of early-life ID. Similarly, as such psychological and 
physiological impairments are not amenable to iron supplementation, this may have also 
carried over to the RCTs reported in Chapters 4 and 5 and confound treatment effects. It may 
be imperative for future investigations of iron status and iron supplementation on cognitive 
and behavioural function to screen participants for a medical history of early-life ID and to 
consider excluding them on this basis to account for any neurological deficits that may 
confound findings.   
 
Another methodological consideration concerns the assessment of iron status from just 
haemoglobin and serum ferritin. Although, the complication of concomitant inflammation for 
an accurate assessment of ID was addressed by measuring CRP, NAID is also hallmarked by 
concomitant decreases in serum iron, transferrin saturation and hepcidin and increases in total 
iron-binding capacity and soluble transferrin receptors (sTfR) (Sheikh et al., 2017). To 
determine iron status within intervention studies, serum ferritin and haemoglobin are 
considered sufficient for accurate assessments (Joint World Health Organization/Centers for 
Disease & Prevention Technical Consultation on the Assessment of Iron Status at the 
Population Level, 2007). However, more recently iron status assessments have used a model 
of total body iron stores, which uses the log ratio of sTfR to serum ferritin to assess the full 
range of iron status from severe deficiency to overload (Pfeiffer & Looker, 2017). It provides a 
quantitative estimate as a continuous variable of the functional deficit to be corrected before 
iron can begin to accumulate in the body iron stores in iron deficient individuals or the size of 
the body iron stores when iron is present within it for those considered IS (Pfeiffer & Looker, 
2017). The model has been indirectly validated by providing accurate estimations of the 
prevalence of ID by demographic (Cook, Boy, Flowers, & Daroca Mdel, 2005; Cook, Flowers, 
& Skikne, 2003; Cook, Skikne, Lynch, & Reusser, 1986), and successfully examining 
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prevalence of and changes in low body iron stores in response to oral iron supplementation 
(Cable et al., 2016; Cook et al., 2003). It is therefore recommended to measure iron stores for 
ID in populations more accurately than serum ferritin alone (Northrop-Clewes & Thurnham, 
2013). Total body iron has already been used to determine iron status in both cross-sectional 
(Blanton et al., 2013; Cook et al., 2017; Scott et al., 2017; Scott & Murray-Kolb, 2016) and 
dietary iron intervention studies regarding cognitive function (Blanton, 2013; Wenger et al., 
2017; Wenger, Rhoten, et al., 2019), which have been referred to throughout this thesis. 
Future cross-sectional studies and RCTs of iron bis-glycinate chelate amongst women of 
reproductive age should consider using the total body iron model for iron status determination.   
 
Another potential issue that arises throughout the studies concerns the reliance on subjective 
measures of behaviour that could instead be measured objectively. Subjective assessments 
of physical activity were collected to determine baseline and post-dose levels of physical 
activity, however self-reported moderate to vigorous physical activity is often over-reported 
and sedentary time under-reported when results from the IPAQ are compared to an objective 
measure (Nelson et al., 2019). This may have led to inaccuracies in the confounding variables 
assessed in Chapter 2 as well as the effect of iron supplementation and significant responses 
to iron treatment upon physical activity in Chapter 4. Objective measurements of physical 
activity would also allow assessments of when participants exercised compared to when they 
consumed their treatment. Acute bouts of exercise at a moderate to vigorous intensity are 
evidenced to augment hepcidin levels from 0 to 6 hours post-exercise, peaking at 3 hours 
(Domínguez et al., 2018). This affects iron absorption in the gastrointestinal tract especially 
as this may coincide with iron supplement administration, thus reducing its efficacy. 
Additionally, serum ferritin concentrations < 30 µg/L are evidenced to blunt exercise-induced 
hepcidin increases (Peeling et al., 2014); iron supplementation increases the likelihood of 
hepcidin upregulation (Burden, Pollock, et al., 2015). Therefore, IS participants randomised to 
an iron treatment group with sub-optimal serum ferritin between 30-50 µg/L consuming their 
treatment during periods of exercise-induced hepcidin elevations may have inadvertently 
suppressed effective iron supplement absorption. Although no perfect tool exists for a truly 
accurate examination of physical activity, a systematic literature review highlights the lower 
levels of variability observed for validity and reliability when objective accelerometers are used 
compared to subjective measures specific to the behaviours of interest (Dowd et al., 2018). 
Future RCTs should therefore consider incorporating accelerometers that can specifically 
monitor timing and intensity of exercise, the data for which could be used alongside the 
electronic compliance applications previously discussed. Similarly, the subjective assessment 
of food frequency by FFQ is open to reporting bias as it requires participants to recall all foods 
and drinks consumed and in what quantity over the past year. This may have also led to 
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erroneous conclusions regarding dietary iron as a confounding variable in the study described 
in Chapter 2. Efforts have been made to shift from traditional pencil-and-paper based FFQs 
to 24-hour computer- or web-based applications to improve the accuracy of dietary recall by 
improving portion size estimation and minimising forgotten food items (Jobarteh et al., 2020). 
Additionally, smartphone applications have been created that are designed for participants to 
upload images of foods and meals eaten to; these can be used as a stand-alone assessment 
method or to enhance traditional self-report FFQ methods by reducing recall bias (Gemming, 
Utter, & Ni Mhurchu, 2015). Participant feedback of such smartphone applications has shown 
high levels of acceptance with respect to usability (Ferrara et al., 2019) and a significant 
preference for their use compared to completing 24-hour dietary recalls (Ambrosini, Hurworth, 
Giglia, Trapp, & Strauss, 2018). Future RCTs should consider the potential role of smartphone 
applications for monitoring dietary habits across long-term nutritional intervention studies. 
 
Lastly, iron is a vital component in various metabolic processes in the human body but is also 
a micronutrient required by all living organisms promoting competition for iron for both the 
maintenance of human health and indigenous microbial populations. Evidence from animal 
studies suggests that Lactobacillus species possess an iron-dependent mechanism that 
inhibits iron absorption; the gut microbiota produces microbial metabolites 1,3-
diaminopropane (DAP) and reuterin that suppress the role of the transcription factor hypoxia-
inducible factor 2α (HIF-2α) for intestinal iron absorption and increasing serum ferritin (Das et 
al., 2020). Therefore, iron supplement absorption may be diminished in those with a gut 
microbiome rich in these metabolites compared to those without. Additionally, studies in iron 
deficient menstruating women have identified genetic variations in the transferrin gene 
(rs3811647) that present a reduction in iron transport to the tissues causing an increased risk 
for ID (Blanco-Rojo et al., 2011) with significant associations demonstrated between the minor 
allele of rs3811647 and decreased serum ferritin (Ji et al., 2018; Sørensen et al., 2012). Iron 
deficient women of reproductive age who present with the rs3811647 SNP do not significantly 
respond to dietary iron interventions by means of improving iron status (Blanco-Rojo et al., 
2010). Adopting a metabolomics and nutrigenomics approach may be beneficial for future 
research to examine differences across baseline iron status groups for determining whether 
there are microbial or genomic differences that predispose an individual to ID and whether this 
can predict how an individual responds to iron supplementation.  
 
 
6.5 Future research 
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Upon starting this thesis, research investigating the impact of iron status and iron 
supplementation on cognitive and behavioural function was limited in women of reproductive 
age, especially that concerning NAID. However, for the research field to progress it is essential 
to address the aforementioned limitations. Therefore, future research should consider 
screening for early-life IDA diagnoses, genetic polymorphisms and microbial metabolites to 
account for predispositions for diminished cognitive, behavioural and iron status responses; 
dietary habits and physical activity timing and intensity; and measuring sTfR in addition to 
haemoglobin and serum ferritin for the calculation of total body iron to increase the accuracy 
of iron status assessments. Despite the limitations discussed, the studies that comprise this 
thesis have contributed to the research field through investigation of a novel low-dose iron 
supplement and represent the first investigations of the parallel effects of iron status and 
supplementation upon cerebral haemodynamics and energy metabolism. Accordingly, there 
are several interesting findings that could be investigated further in future.  
 
The results presented in Chapter 2 suggest that cognitive function does not decline in the 
early stages of ID that has previously been identified (Rebecca L. Cook et al., 2017). However, 
the significant improvement in working memory accuracy following iron treatment identified in 
Chapter 5 implies a potential role of iron in cognitive processing. To investigate these findings 
further, it would be appropriate to employ fMRI or multi-channel NIRS to determine whether 
differences in brain region activation exist during completion of working memory tasks 
between iron status groups and in response to iron supplementation. Additionally, to 
specifically determine whether deficits in brain iron exist across iron status groups it may be 
beneficial to employ quantitative magnetic susceptibility (QMS) as an in vivo indicator of brain 
iron content. This methodology has previously been used to confirm brain ID in restless leg 
syndrome patients compared to healthy controls (Li et al., 2016) and has demonstrated high 
specificity and sensitivity for identifying tissue iron content in cerebral grey matter regions 
(Langkammer et al., 2012; Lim et al., 2013; Zheng, Nichol, Liu, Cheng, & Haacke, 2013). It 
has also demonstrated superior efficacy for quantifying iron levels in clinical samples where 
changes in brain iron levels are commonly observed (Du et al., 2016; Langkammer et al., 
2013). Using QMS would allow associations to be made between peripheral iron status and 
brain iron for a more accurate interpretation of psychological function.  
 
However, the findings from the study described in Chapter 2 also suggest positive 
associations between serum ferritin and emotional functioning, yet this was not echoed in the 
findings of categorical iron status. This supports the notion that categorical iron status groups 
can be problematic and mask underlying relationships, even in the absence of excess iron. It 
may therefore be imperative for future studies to focus upon establishing optimum 
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haemoglobin and serum ferritin concentrations for cognitive and behavioural outcomes rather 
than comparing NAID and IS groups for non-pregnant women of reproductive age. This could 
involve splitting haemoglobin and serum ferritin concentrations into quantiles as in previous 
population studies (Murray-Kolb & Beard, 2007; Su et al., 2016), to determine optimal 
concentrations of haemoglobin and serum ferritin for optimal cognitive and behavioural 
performance. Assessing by quantile may also be more appropriate than using a fixed serum 
ferritin cut-off point for iron status classification considering participants whose serum ferritin 
may fluctuate between iron status groups across the menstrual cycle. 
 
The findings from Chapter 4 pertaining to the low-dose iron bis-glycinate chelate formulation 
significantly improving haemoglobin and serum ferritin with minimal associated side effects 
are promising considering the evidence suggesting its conformation promotes increased iron 
bioavailability and supplement tolerability (Ashmead, 2001). Oral iron supplements are often 
attributed to adverse events due to a large proportion remaining unabsorbed and entering the 
colon. This may be a consequence of supplements altering the composition of the gut 
microbiota due to increased competition between the human host, intestinal microbes and 
microorganisms for iron sources (Constante, Fragoso, Lupien-Meilleur, Calvé, & Santos, 
2017). Iron-fortification RCTs in African children have identified iron administration to 
adversely affect the gut microbiome by producing a more pathogenic gut microbiota profile 
and reducing beneficial commensal levels, which is associated with increased intestinal 
inflammation (Jaeggi et al., 2015; Zimmermann et al., 2010). Similarly, oral iron supplements 
are evidenced to contribute to exacerbated dysbiosis, intestinal inflammation and mucosal 
damage through increased oxidative stress in samples with inflammatory bowel diseases 
(IBD) (Carrier, Aghdassi, Cullen, & Allard, 2002; Seril et al., 2002). However, although gut iron 
concentrations may detrimentally influence microbiota composition, investigations concerning 
the chemical form of iron in murine models of IBD have identified iron bis-glycinate to have a 
protective role compared to alternate formulations; this was attributed to the type of iron 
compound administered causing significantly different clustering of microbiota communities 
(Constante et al., 2017). Gastrointestinal dysfunction seen in IBD and irritable bowel syndrome 
is frequently accompanied by comorbid psychiatric conditions (Mayer, 2000a, 2000b), which 
is postulated to be a consequence of disrupted communication across the gut-brain axis that 
modulates gastrointestinal and central nervous system functioning (Mayer, Tillisch, & Gupta, 
2015). Considering the role of the microbiota as a key regulator of the gut-brain axis (Cryan 
et al., 2019), it seems reasonable to suggest that the beneficial effect of iron bis-glycinate 
formulations upon the microbiota may also affect cognitive and behavioural function. However, 
the influence of iron supplementation and iron bis-glycinate specifically on the gut microbiota 
in non-clinical adult samples from the general population remains unclear and under-explored. 
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The measurement of microbial communities from faecal samples pre- and post- iron bis-
glycinate supplementation would allow further exploration of the potential mechanisms that 
underpin cognitive and behavioural function.  
 
Finally, the null findings presented in Chapter 5 concerning cerebral haemodynamics and 
energy metabolism following iron supplementation are deserving of further investigation to 
progress the field. As haemoglobin is shown to moderate the relationship between electrical 
brain activity and energy expenditure and serum ferritin moderates the relationship between 
electrical brain activity and cognitive performance (Wenger, DellaValle, et al., 2019), 
employing EEG technology simultaneously with multichannel NIRS or fMRI may be a future 
avenue to consider. To invoke CBF effects however, it may be necessary to employ tasks of 
a longer duration than one-minute and to provide longer rest periods between task repetitions 
to account for prolonged elevations of the neurovascular coupling response following cognitive 
stimulation (Allen et al., 2007). As working memory tasks were the only cognitive tasks to have 
shown an effect following supplementation in this thesis, this may provide insight into the type 
of tasks that should be focussed on in future studies. As similar studies have found significant 
effects when a cognitive analogue to a treadmill test was employed (Wenger, DellaValle, et 
al., 2019), working memory tasks of increasing difficulty should be considered for future iron 
RCTs that aim to assess neural electrical activity, cerebral haemodynamics and energy 
metabolism in response to cognitive demand.  
 
6.6 General conclusions 
 
The aim of this thesis was to investigate the effects of iron status and co-supplementation of 
iron bis-glycinate chelate and vitamin C on cognitive function, subjective mood, fatigue, 
wellbeing, and cerebral blood flow and energy metabolism in NAID and IS women of 
reproductive age. The study presented in Chapter 2 revealed the first evidence of the 
increased prevalence of NAID compared to IDA in a general population of women of 
reproductive age from the United Kingdom, consistent with international epidemiological data 
(Soppi, 2018; Umbreit, 2005) and local estimates (SACN, 2010; PHE, 2014). The findings also 
provide support for cognitive function not declining in the early stages of ID in women of 
reproductive age, bolstering previous suggestions that only IDA may be detrimental when 
potentially confounding factors are considered (Cook et al., 2017). However, Chapter 2 
highlighted how categorising women into iron status groups is problematic as associations 
present by continuous haematological parameters did not carry over to categorical iron status 
groups. It may be beneficial to shift focus from comparing NAID and IS groups of non-pregnant 
women of reproductive age, to establishing their optimum haemoglobin and serum ferritin 
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concentrations for cognitive and behavioural outcomes. The positive associations identified 
between serum ferritin and mental health-related quality of life are consistent with the known 
role of serum ferritin for emotional regulation (Kim & Wessling-Resnick, 2014; Perlman, Luna, 
Hein, & Huppert, 2014). Further investigation is however still required to account for early 
diagnoses of ID in infancy that may affect cognitive and behavioural findings, and employing 
neuroimaging methods to assess brain iron levels, neural activity, and tissue morphology to 
confirm theories regarding compensatory mechanisms associated with NAID.  
 
The Chapter 3 systematic review provided an updated overview of findings from RCTs 
investigating how iron supplementation affects cognition, mood, fatigue and/or well-being in 
women of reproductive age of varied baseline iron status. Significant improvements to 
attention, memory, learning, fatigue, mood and well-being were observed, however the review 
highlighted a lack of consideration for supplement dose, duration, bioavailability and 
tolerability. Consequently, Chapter 4 investigated the effects of 16 weeks low-dose iron bis-
glycinate and iron bis-glycinate co-supplemented with vitamin C in women of reproductive age 
upon the same cognitive and behavioural outcomes assessed in Chapter 2. The findings 
provide novel evidence of the efficacy of a low-dose iron bis-glycinate chelate supplement for 
significantly improving haemoglobin when co-supplemented with vitamin C, and serum ferritin 
when administered alone or with vitamin C. However, no significant benefit of co-
supplementation with vitamin C compared to iron alone was identified. The main effects of 
treatment were inconsistent; compared to placebo, iron alone significantly reduced PCS, 
indicating lower physical health, yet also significantly reduced ratings of depression-dejection 
and total mood disturbance. Furthermore, the iron and vitamin C treatment significantly 
reduced menstrual blood loss scores compared to placebo. However, in contrast to the 
Chapter 3 systematic review, no treatment effects were found for cognitive, fatigue or 
wellbeing outcomes indicating that a low dose of iron was perhaps not sufficient to elicit such 
changes in a general population sample of non-anaemic women of reproductive age. 
Nonetheless, the findings from Chapter 4 are the first concerning the effects of a low-dose 
iron bis-glycinate formula for improving iron status in NAID and IS women of reproductive age 
and has therefore demonstrated its ability to significantly improve iron status parameters 
compared to placebo with minimal associated adverse events. 
 
The study presented in Chapter 5 is the first to investigate the parallel effects of iron 
supplementation on cerebral haemodynamics and energy metabolism in a sample of NAID 
and IS women of reproductive age. The study identified novel evidence of greater levels of 
total haemoglobin in the prefrontal cortex for NAID women during cognitive demand compared 
to IS women, which may act as a compensatory mechanism to enable the same standard of 
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cognitive performance across iron status groups. However, no significant effects upon 
cerebral haemodynamics or energy metabolism were found following the intervention period 
despite a significant improvement in the number of errors made on a task of working memory 
for the iron and vitamin C group. Considering this was the only cognitive finding through this 
thesis, future research should consider administering a working memory task battery of 
incremental difficulty for longer durations with longer rest periods between task repetitions to 
minimise crossover effects between the tasks. Further investigations with methodologies that 
are capable of monitoring brain activity and brain iron content, such as EEG, fMRI, multi-
channel NIRS and QMS, should be considered simultaneously with ICa to elucidate a greater 
understanding of the mechanisms that underpin the effects discussed.  
 
In summary, the findings of the thesis are suggestive of cognitive function not declining in the 
early stages of ID and provide novel insight into how this may be a consequence of increased 
compensatory CBF to ensure maintenance of cognitive and behavioural function in women of 
reproductive age. Iron bis-glycinate has shown positive evidence for improving iron status at 
low doses, however there is no significant benefit of vitamin C co-supplementation. Iron 
treatment alone should be considered beneficial for improving measures of depression and 
total mood disturbance, but research is required to investigate further the unexpected finding 
regarding reduced PCS. However, it is essential to reduce the noise associated with iron 
status classifications and to investigate the mechanisms that underpin the observed effects of 
iron on cognitive function, mood, fatigue, well-being, CBF and energy metabolism in women 
of reproductive age. Altogether, the findings have offered an intriguing insight into the role of 
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APPENDIX I: Caffeine consumption questionnaire (CCQ) (BPNRC, Northumbria University) 
 
Subject ID : _______ Inits : ________ Visit : _______ Date : _________      Caffeine Consumption Questionnaire 
 











   
 
      
 
Coffee 
Cola, mixed cola beverages (no 
orangeade/lemonade) 
Solid chocolate 
bar e.g. Dairy 
Milk 
    
 
   








hite  tea 
D
ecaffeinated  Black, green, 
w
hite  tea 
Cocoa drink 
Cola, m
ixed cola beverages 





















Solid Chocolate Bar 






























    
  
      
 
              
 
          
lunch                                       
Between lunch 
and dinner 
    
  
      
 
              
 
          
Dinner                                       
After dinner     
  
      
 
              
 
          
TOTAL   
  
   
 
       
 
     
Please indicate what you would have on a typical day:  
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APPENDIX II: Menstrual cycle and blood loss questionnaire 
 
Menstrual Cycle Questionnaire 
 
Have you used hormonal contraception in the last 3 months?  
 
□ Yes…  
 □ Combined pill   
 
 □ Progesterone-only pill (POP) 
 
 □ Contraceptive injection 
 
 □ Contraceptive implant 
 
 □ Intrauterine device (IUD) 
 











Date of onset of your last period (day/month/year): ______________________ 
 
Usual n.o. days menstruation +/- how many days: ______________________ 
 
Estimated number of heavy blood loss days during menstruation: __________________ 
 
Indicate the number and type of pads and/or tampons used at heaviest blood loss day of 
menstruation, both during the day and night: 
 
 Number of pads Number of tampons 
 Mini Normal Super Night/Superplus Light Normal Super Night/Superplus 
Day          
Night         
 




APPENDIX III: Principle component analysis for cognitive outcomes 
 
Component 
Initial Eigenvalues* KMO and Bartlett's Test 
N Eigenvalue* % of Variance Cumulative % KMO Approx. Chi-Square df sig 
Episodic Accuracy 230 2.201 55.033 55.033 0.671 264.648 6 <0.001 









Extraction Method: Principal Component 
Analysis. 



















Initial Eigenvalues* KMO and Bartlett's Test 
N Eigenvalue* % of Variance Cumulative % KMO Approx. Chi-Square df sig 
Episodic Speed 230 1.565 78.253 78.253 0.5 87.499 1 <0.001 




Component Matrixa Component 1 
ZPic_Rec_Correct_RT 0.885 
ZWord_Rec_Correct_RT 0.885 
Extraction Method: Principal Component 
Analysis. 





















Initial Eigenvalues* KMO and Bartlett's Test 
N Eigenvalue* % of Variance Cumulative % KMO Approx. Chi-Square df sig 
Working Memory Accuracy 218 1.649 54.98 54.98 0.571 76.613 3 <0.001 









Extraction Method: Principal Component 
Analysis. 

















Initial Eigenvalues* KMO and Bartlett's Test 
N Eigenvalue* % of Variance Cumulative % KMO Approx. Chi-Square df sig 
Attention Accuracy 213 1.341 67.068 67.068 0.500 26.080 1 <0.001 




Component Matrixa Component 1 
ZZDigVigAcc_err 0.819 
ZZRVIPAcc_FA 0.819 
Extraction Method: Principal Component 
Analysis. 





















Initial Eigenvalues* KMO and Bartlett's Test 
N Eigenvalue* % of Variance Cumulative % KMO Approx. Chi-Square df sig 
Attention Speed 217 1.348 67.403 67.402 .500 27.182 1 <0.001 




Component Matrixa Component 1 
ZDigVig_Correct_RT 0.821 
ZRVIP_Correct_RT 0.821 
Extraction Method: Principal Component Analysis. 






















Initial Eigenvalues* KMO and Bartlett's Test 
N Eigenvalue* % of Variance Cumulative % KMO Approx. Chi-Square df sig 
Executive Function Accuracy 228 1.391 46.358 46.358 0.534 29.521 3 <0.001 









Extraction Method: Principal Component 
Analysis. 



















Initial Eigenvalues* KMO and Bartlett's Test 
N Eigenvalue* % of Variance Cumulative % KMO Approx. Chi-Square df sig 
Executive Function Speed 228 1.615 53.841 53.841 0.569 69.377 3 <0.001 










Extraction Method: Principal Component 
Analysis. 




APPENDIX IV: Chapter 2 data 
 
Predictors of iron status  
 
Correlations 
 Iron_status Age BMI IPAQ MCQ Iron 
Pearson Correlation Iron_status 1.000 .119 .085 -.163 -.102 .015 
Age .119 1.000 .255 -.140 -.037 .068 
BMI .085 .255 1.000 -.068 .053 .021 
IPAQ -.163 -.140 -.068 1.000 .105 .125 
MCQ -.102 -.037 .053 .105 1.000 .078 
Iron .015 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Iron_status . .035 .098 .007 .093 .412 
Age .035 . .000 .018 .317 .152 
BMI .098 .000 . .156 .248 .378 
IPAQ .007 .018 .156 . .091 .032 
MCQ .093 .317 .248 .091 . .157 
Iron .412 .152 .378 .032 .157 . 
N Iron_status 235 235 235 225 170 230 
Age 235 235 235 225 170 230 
BMI 235 235 235 225 170 230 
IPAQ 225 225 225 225 163 221 
MCQ 170 170 170 163 170 167 




Model Variables Entered 
Variables 
Removed Method 




a. Dependent Variable: Iron_status 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .217a .047 .017 .460 .047 1.554 5 157 .176 .092 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Age 
b. Dependent Variable: Iron_status 
 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 1.642 5 .328 1.554 .176b 
Residual 33.197 157 .211   
Total 34.839 162    
a. Dependent Variable: Iron_status 









Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) .515 .267  1.927 .056      
Age .004 .004 .078 .958 .339 .119 .076 .075 .912 1.097 
BMI .007 .010 .059 .734 .464 .085 .058 .057 .930 1.076 
IPAQ -3.154E-5 .000 -.142 -1.785 .076 -.163 -.141 -.139 .953 1.050 
MCQ -.017 .015 -.090 -1.141 .256 -.102 -.091 -.089 .979 1.021 
Iron .004 .010 .033 .418 .676 .015 .033 .033 .972 1.028 
a. Dependent Variable: Iron_status 
Coefficient Correlationsa 
Model Iron BMI MCQ IPAQ Age 
1 Correlations Iron 1.000 -.003 -.068 -.129 -.085 
BMI -.003 1.000 -.068 .040 -.249 
MCQ -.068 -.068 1.000 -.093 .044 
IPAQ -.129 .040 -.093 1.000 .132 
Age -.085 -.249 .044 .132 1.000 
Covariances Iron .000 -3.220E-7 -1.067E-5 -2.336E-8 -3.782E-6 
BMI -3.220E-7 9.293E-5 -9.974E-6 6.859E-9 -1.040E-5 
MCQ -1.067E-5 -9.974E-6 .000 -2.527E-8 2.934E-6 
IPAQ -2.336E-8 6.859E-9 -2.527E-8 3.121E-10 1.009E-8 
Age -3.782E-6 -1.040E-5 2.934E-6 1.009E-8 1.877E-5 
a. Dependent Variable: Iron_status 
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Collinearity Diagnosticsa 
Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Age BMI IPAQ MCQ Iron 
1 1 5.294 1.000 .00 .00 .00 .01 .01 .00 
2 .288 4.286 .00 .01 .00 .12 .92 .01 
3 .272 4.413 .00 .05 .00 .75 .05 .01 
4 .086 7.825 .00 .25 .01 .05 .00 .79 
5 .048 10.524 .07 .70 .15 .04 .03 .15 
6 .011 21.610 .92 .00 .84 .03 .00 .05 















Predictors of haemoglobin (SPSS output) 
 
Correlations 
 Haemoglobin Age BMI IPAQ MCQ Iron 
Pearson Correlation Haemoglobin 1.000 -.085 .127 -.021 -.002 .032 
Age -.085 1.000 .255 -.140 -.037 .068 
BMI .127 .255 1.000 -.068 .053 .021 
IPAQ -.021 -.140 -.068 1.000 .105 .125 
MCQ -.002 -.037 .053 .105 1.000 .078 
Iron .032 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Haemoglobin . .098 .026 .374 .488 .312 
Age .098 . .000 .018 .317 .152 
BMI .026 .000 . .156 .248 .378 
IPAQ .374 .018 .156 . .091 .032 
MCQ .488 .317 .248 .091 . .157 
Iron .312 .152 .378 .032 .157 . 
N Haemoglobin 235 235 235 225 170 230 
Age 235 235 235 225 170 230 
BMI 235 235 235 225 170 230 
IPAQ 225 225 225 225 163 221 
MCQ 170 170 170 163 170 167 





Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
IPAQ, Ageb 
. Enter 
a. Dependent Variable: Haemoglobin 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .184a .034 .003 6.542 .034 1.097 5 157 .364 1.871 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Age 
b. Dependent Variable: Haemoglobin 
 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 234.641 5 46.928 1.097 .364b 
Residual 6718.238 157 42.791   
Total 6952.879 162    
a. Dependent Variable: Haemoglobin 










Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 123.425 3.803  32.452 .000      
Age -.100 .062 -.133 -1.625 .106 -.085 -.129 -.127 .912 1.097 
BMI .268 .137 .159 1.955 .052 .127 .154 .153 .930 1.076 
IPAQ .000 .000 -.033 -.413 .680 -.021 -.033 -.032 .953 1.050 
MCQ -.043 .218 -.016 -.196 .845 -.002 -.016 -.015 .979 1.021 
Iron .080 .146 .044 .549 .584 .032 .044 .043 .972 1.028 
a. Dependent Variable: Haemoglobin 
 
Coefficient Correlationsa 
Model Iron BMI MCQ IPAQ Age 
1 Correlations Iron 1.000 -.003 -.068 -.129 -.085 
BMI -.003 1.000 -.068 .040 -.249 
MCQ -.068 -.068 1.000 -.093 .044 
IPAQ -.129 .040 -.093 1.000 .132 
Age -.085 -.249 .044 .132 1.000 
Covariances Iron .021 -6.516E-5 -.002 -4.727E-6 -.001 
BMI -6.516E-5 .019 -.002 1.388E-6 -.002 
MCQ -.002 -.002 .047 -5.115E-6 .001 
IPAQ -4.727E-6 1.388E-6 -5.115E-6 6.316E-8 2.042E-6 
Age -.001 -.002 .001 2.042E-6 .004 
a. Dependent Variable: Haemoglobin 
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Collinearity Diagnosticsa 
Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Age BMI IPAQ MCQ Iron 
1 1 5.294 1.000 .00 .00 .00 .01 .01 .00 
2 .288 4.286 .00 .01 .00 .12 .92 .01 
3 .272 4.413 .00 .05 .00 .75 .05 .01 
4 .086 7.825 .00 .25 .01 .05 .00 .79 
5 .048 10.524 .07 .70 .15 .04 .03 .15 
6 .011 21.610 .92 .00 .84 .03 .00 .05 



















Predictors of serum ferritin (SPSS output) 
 
Correlations 
 Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Ferritin 1.000 .181 .104 -.091 -.173 -.031 
Age .181 1.000 .255 -.140 -.037 .068 
BMI .104 .255 1.000 -.068 .053 .021 
IPAQ -.091 -.140 -.068 1.000 .105 .125 
MCQ -.173 -.037 .053 .105 1.000 .078 
Iron -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Ferritin . .003 .055 .087 .012 .322 
Age .003 . .000 .018 .317 .152 
BMI .055 .000 . .156 .248 .378 
IPAQ .087 .018 .156 . .091 .032 
MCQ .012 .317 .248 .091 . .157 
Iron .322 .152 .378 .032 .157 . 
N Ferritin 235 235 235 225 170 230 
Age 235 235 235 225 170 230 
BMI 235 235 235 225 170 230 
IPAQ 225 225 225 225 163 221 
MCQ 170 170 170 163 170 167 






Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
IPAQ, Ageb 
. Enter 
a. Dependent Variable: Ferritin 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .261a .068 .039 30.977 .068 2.301 5 157 .047 1.416 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Age 
b. Dependent Variable: Ferritin 
 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 11038.449 5 2207.690 2.301 .047b 
Residual 150650.207 157 959.555   
Total 161688.656 162    
a. Dependent Variable: Ferritin 









Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 25.954 18.010  1.441 .152      
Age .551 .292 .152 1.887 .061 .181 .149 .145 .912 1.097 
BMI .582 .649 .072 .896 .372 .104 .071 .069 .930 1.076 
IPAQ -.001 .001 -.044 -.563 .574 -.091 -.045 -.043 .953 1.050 
MCQ -2.181 1.032 -.165 -2.114 .036 -.173 -.166 -.163 .979 1.021 
Iron -.212 .690 -.024 -.307 .759 -.031 -.025 -.024 .972 1.028 
a. Dependent Variable: Ferritin 
 
Coefficient Correlationsa 
Model Iron BMI MCQ IPAQ Age 
1 Correlations Iron 1.000 -.003 -.068 -.129 -.085 
BMI -.003 1.000 -.068 .040 -.249 
MCQ -.068 -.068 1.000 -.093 .044 
IPAQ -.129 .040 -.093 1.000 .132 
Age -.085 -.249 .044 .132 1.000 
Covariances Iron .476 -.001 -.048 .000 -.017 
BMI -.001 .422 -.045 3.113E-5 -.047 
MCQ -.048 -.045 1.064 .000 .013 
IPAQ .000 3.113E-5 .000 1.416E-6 4.579E-5 
Age -.017 -.047 .013 4.579E-5 .085 
a. Dependent Variable: Ferritin 
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Collinearity Diagnosticsa 
Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Age BMI IPAQ MCQ Iron 
1 1 5.294 1.000 .00 .00 .00 .01 .01 .00 
2 .288 4.286 .00 .01 .00 .12 .92 .01 
3 .272 4.413 .00 .05 .00 .75 .05 .01 
4 .086 7.825 .00 .25 .01 .05 .00 .79 
5 .048 10.524 .07 .70 .15 .04 .03 .15 
6 .011 21.610 .92 .00 .84 .03 .00 .05 

























cy Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation Episodic_Accuracy 1.000 -.051 -.037 .100 -.104 -.060 .121 .029 .064 
Haemoglobin -.051 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin -.037 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE .100 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age -.104 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI -.060 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ .121 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ .029 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron .064 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Episodic_Accuracy . .217 .287 .063 .056 .179 .035 .355 .167 
Haemoglobin .217 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .287 .000 . .033 .003 .055 .087 .012 .322 
YIE .063 .284 .033 . .040 .244 .207 .391 .030 
Age .056 .098 .003 .040 . .000 .018 .317 .152 
BMI .179 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .035 .374 .087 .207 .018 .156 . .091 .032 
MCQ .355 .488 .012 .391 .317 .248 .091 . .157 
Iron .167 .312 .322 .030 .152 .378 .032 .157 . 
N Episodic_Accuracy 235 235 235 234 235 235 225 170 230 
Haemoglobin 235 235 235 234 235 235 225 170 230 
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Ferritin 235 235 235 234 235 235 225 170 230 
YIE 234 234 234 234 234 234 224 169 229 
Age 235 235 235 234 235 235 225 170 230 
BMI 235 235 235 234 235 235 225 170 230 
IPAQ 225 225 225 224 225 225 225 163 221 
MCQ 170 170 170 169 170 170 163 170 167 
Iron 230 230 230 229 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: Episodic_Accuracy 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .204a .042 -.008 .71490 .042 .839 8 154 .570 1.624 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 






Model Sum of Squares df Mean Square F Sig. 
1 Regression 3.429 8 .429 .839 .570b 
Residual 78.707 154 .511   
Total 82.137 162    
a. Dependent Variable: Episodic_Accuracy 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) .295 1.256  .235 .815      
Haemoglobin -.006 .009 -.051 -.605 .546 -.051 -.049 -.048 .889 1.125 
Ferritin -6.738E-5 .002 -.003 -.035 .972 -.037 -.003 -.003 .849 1.178 
YIE .032 .023 .112 1.384 .168 .100 .111 .109 .955 1.048 
Age -.008 .007 -.102 -1.200 .232 -.104 -.096 -.095 .862 1.161 
BMI -.005 .015 -.027 -.329 .743 -.060 -.026 -.026 .906 1.103 
IPAQ 3.473E-5 .000 .102 1.261 .209 .121 .101 .099 .948 1.055 
MCQ .004 .024 .014 .172 .864 .029 .014 .014 .951 1.051 
Iron .009 .016 .045 .560 .577 .064 .045 .044 .952 1.050 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 














 Episodic_Speed Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation Episodic_Speed 1.000 -.018 -.067 -.007 .158 .080 -.037 -.024 .113 
Haemoglobin -.018 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin -.067 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE -.007 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age .158 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI .080 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ -.037 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ -.024 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron .113 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Episodic_Speed . .393 .155 .455 .008 .113 .289 .377 .045 
Haemoglobin .393 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .155 .000 . .033 .003 .055 .087 .012 .322 
YIE .455 .284 .033 . .040 .244 .207 .391 .030 
Age .008 .098 .003 .040 . .000 .018 .317 .152 
BMI .113 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .289 .374 .087 .207 .018 .156 . .091 .032 
MCQ .377 .488 .012 .391 .317 .248 .091 . .157 
Iron .045 .312 .322 .030 .152 .378 .032 .157 . 
N Episodic_Speed 233 233 233 232 233 233 223 169 229 
Haemoglobin 233 235 235 234 235 235 225 170 230 
Ferritin 233 235 235 234 235 235 225 170 230 
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YIE 232 234 234 234 234 234 224 169 229 
Age 233 235 235 234 235 235 225 170 230 
BMI 233 235 235 234 235 235 225 170 230 
IPAQ 223 225 225 224 225 225 225 163 221 
MCQ 169 170 170 169 170 170 163 170 167 
Iron 229 230 230 229 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: Episodic_Speed 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .224a .050 .001 .91521 .050 1.016 8 154 .426 2.099 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 




Model Sum of Squares df Mean Square F Sig. 
1 Regression 6.810 8 .851 1.016 .426b 
Residual 128.991 154 .838   
Total 135.801 162    
a. Dependent Variable: Episodic_Speed 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) -.787 1.608  -.489 .625      
Haemoglobin .002 .012 .011 .133 .895 -.018 .011 .010 .889 1.125 
Ferritin -.003 .002 -.107 -1.253 .212 -.067 -.100 -.098 .849 1.178 
YIE -.011 .030 -.030 -.379 .705 -.007 -.031 -.030 .955 1.048 
Age .016 .009 .155 1.835 .068 .158 .146 .144 .862 1.161 
BMI .012 .019 .049 .598 .551 .080 .048 .047 .906 1.103 
IPAQ -1.413E-5 .000 -.032 -.401 .689 -.037 -.032 -.031 .948 1.055 
MCQ -.017 .031 -.045 -.563 .574 -.024 -.045 -.044 .951 1.051 
Iron .028 .021 .109 1.352 .179 .113 .108 .106 .952 1.050 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 




























ry_Accuracy Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation Working_Memory_Accurac
y 
1.000 .061 -.048 .184 .006 -.088 .087 .041 .059 
Haemoglobin .061 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin -.048 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE .184 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age .006 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI -.088 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ .087 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ .041 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron .059 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Working_Memory_Accurac
y 
. .174 .231 .002 .462 .090 .098 .299 .187 
Haemoglobin .174 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .231 .000 . .033 .003 .055 .087 .012 .322 
YIE .002 .284 .033 . .040 .244 .207 .391 .030 
Age .462 .098 .003 .040 . .000 .018 .317 .152 
BMI .090 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .098 .374 .087 .207 .018 .156 . .091 .032 
MCQ .299 .488 .012 .391 .317 .248 .091 . .157 




235 235 235 234 235 235 225 170 230 
Haemoglobin 235 235 235 234 235 235 225 170 230 
Ferritin 235 235 235 234 235 235 225 170 230 
YIE 234 234 234 234 234 234 224 169 229 
Age 235 235 235 234 235 235 225 170 230 
BMI 235 235 235 234 235 235 225 170 230 
IPAQ 225 225 225 224 225 225 225 163 221 
MCQ 170 170 170 169 170 170 163 170 167 
Iron 230 230 230 229 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: Working_Memory_Accuracy 








Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .259a .067 .019 .78956 .067 1.388 8 154 .206 1.765 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 
b. Dependent Variable: Working_Memory_Accuracy 
 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 6.920 8 .865 1.388 .206b 
Residual 96.005 154 .623   
Total 102.925 162    
a. Dependent Variable: Working_Memory_Accuracy 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) -2.479 1.388  -1.787 .076      
Haemoglobin .013 .010 .111 1.339 .183 .061 .107 .104 .889 1.125 
Ferritin -.002 .002 -.085 -1.007 .316 -.048 -.081 -.078 .849 1.178 
YIE .065 .026 .201 2.525 .013 .184 .199 .196 .955 1.048 
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Age .004 .008 .048 .575 .566 .006 .046 .045 .862 1.161 
BMI -.023 .017 -.110 -1.350 .179 -.088 -.108 -.105 .906 1.103 
IPAQ 3.305E-5 .000 .087 1.087 .279 .087 .087 .085 .948 1.055 
MCQ .009 .027 .028 .350 .727 .041 .028 .027 .951 1.051 
Iron .003 .018 .014 .171 .864 .059 .014 .013 .952 1.050 
a. Dependent Variable: Working_Memory_Accuracy 
 
Collinearity Diagnosticsa 
Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 

















ry_Speed Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation Working_Memory_Speed 1.000 -.017 -.068 -.079 .097 -.041 -.013 .114 .087 
Haemoglobin -.017 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin -.068 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE -.079 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age .097 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI -.041 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ -.013 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ .114 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron .087 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Working_Memory_Speed . .401 .152 .117 .070 .267 .425 .072 .097 
Haemoglobin .401 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .152 .000 . .033 .003 .055 .087 .012 .322 
YIE .117 .284 .033 . .040 .244 .207 .391 .030 
Age .070 .098 .003 .040 . .000 .018 .317 .152 
BMI .267 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .425 .374 .087 .207 .018 .156 . .091 .032 
MCQ .072 .488 .012 .391 .317 .248 .091 . .157 
Iron .097 .312 .322 .030 .152 .378 .032 .157 . 
N Working_Memory_Speed 231 231 231 230 231 231 221 166 226 
Haemoglobin 231 235 235 234 235 235 225 170 230 
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Ferritin 231 235 235 234 235 235 225 170 230 
YIE 230 234 234 234 234 234 224 169 229 
Age 231 235 235 234 235 235 225 170 230 
BMI 231 235 235 234 235 235 225 170 230 
IPAQ 221 225 225 224 225 225 225 163 221 
MCQ 166 170 170 169 170 170 163 170 167 
Iron 226 230 230 229 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: Working_Memory_Speed 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .217a .047 -.003 .99945 .047 .949 8 154 .478 1.932 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 




Model Sum of Squares df Mean Square F Sig. 
1 Regression 7.584 8 .948 .949 .478b 
Residual 153.830 154 .999   
Total 161.414 162    
a. Dependent Variable: Working_Memory_Speed 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) .171 1.756  .097 .923      
Haemoglobin .002 .013 .013 .150 .881 -.017 .012 .012 .889 1.125 
Ferritin -.002 .003 -.058 -.676 .500 -.068 -.054 -.053 .849 1.178 
YIE -.038 .033 -.093 -1.156 .250 -.079 -.093 -.091 .955 1.048 
Age .015 .010 .133 1.565 .120 .097 .125 .123 .862 1.161 
BMI -.019 .021 -.076 -.917 .361 -.041 -.074 -.072 .906 1.103 
IPAQ -1.489E-5 .000 -.031 -.387 .700 -.013 -.031 -.030 .948 1.055 
MCQ .045 .034 .108 1.334 .184 .114 .107 .105 .951 1.051 
Iron .023 .022 .084 1.041 .300 .087 .084 .082 .952 1.050 







Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 


















acy Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation Attention_Accuracy 1.000 .007 -.008 .136 .201 .017 .016 .005 -.037 
Haemoglobin .007 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin -.008 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE .136 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age .201 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI .017 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ .016 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ .005 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron -.037 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Attention_Accuracy . .459 .453 .019 .001 .395 .404 .474 .289 
Haemoglobin .459 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .453 .000 . .033 .003 .055 .087 .012 .322 
YIE .019 .284 .033 . .040 .244 .207 .391 .030 
Age .001 .098 .003 .040 . .000 .018 .317 .152 
BMI .395 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .404 .374 .087 .207 .018 .156 . .091 .032 
MCQ .474 .488 .012 .391 .317 .248 .091 . .157 
Iron .289 .312 .322 .030 .152 .378 .032 .157 . 
N Attention_Accuracy 235 235 235 234 235 235 225 170 230 
Haemoglobin 235 235 235 234 235 235 225 170 230 
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Ferritin 235 235 235 234 235 235 225 170 230 
YIE 234 234 234 234 234 234 224 169 229 
Age 235 235 235 234 235 235 225 170 230 
BMI 235 235 235 234 235 235 225 170 230 
IPAQ 225 225 225 224 225 225 225 163 221 
MCQ 170 170 170 169 170 170 163 170 167 
Iron 230 230 230 229 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: Attention_Accuracy 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .261a .068 .020 .88784 .068 1.409 8 154 .197 1.825 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 
b. Dependent Variable: Attention_Accuracy 
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ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 8.883 8 1.110 1.409 .197b 
Residual 121.393 154 .788   
Total 130.276 162    
a. Dependent Variable: Attention_Accuracy 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) -2.086 1.560  -1.337 .183      
Haemoglobin .008 .011 .059 .713 .477 .007 .057 .055 .889 1.125 
Ferritin -.002 .002 -.072 -.857 .393 -.008 -.069 -.067 .849 1.178 
YIE .049 .029 .136 1.705 .090 .136 .136 .133 .955 1.048 
Age .023 .009 .227 2.713 .007 .201 .214 .211 .862 1.161 
BMI -.010 .019 -.041 -.507 .613 .017 -.041 -.039 .906 1.103 
IPAQ 2.430E-5 .000 .057 .711 .478 .016 .057 .055 .948 1.055 
MCQ .002 .030 .006 .080 .937 .005 .006 .006 .951 1.051 
Iron -.020 .020 -.080 -1.006 .316 -.037 -.081 -.078 .952 1.050 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 













 Attention_Speed Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation Attention_Speed 1.000 .020 -.012 -.089 -.027 -.034 .069 -.023 .100 
Haemoglobin .020 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin -.012 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE -.089 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age -.027 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI -.034 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ .069 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ -.023 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron .100 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Attention_Speed . .379 .425 .088 .340 .301 .150 .385 .066 
Haemoglobin .379 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .425 .000 . .033 .003 .055 .087 .012 .322 
YIE .088 .284 .033 . .040 .244 .207 .391 .030 
Age .340 .098 .003 .040 . .000 .018 .317 .152 
BMI .301 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .150 .374 .087 .207 .018 .156 . .091 .032 
MCQ .385 .488 .012 .391 .317 .248 .091 . .157 
Iron .066 .312 .322 .030 .152 .378 .032 .157 . 
N Attention_Speed 235 235 235 234 235 235 225 170 230 
Haemoglobin 235 235 235 234 235 235 225 170 230 
Ferritin 235 235 235 234 235 235 225 170 230 
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YIE 234 234 234 234 234 234 224 169 229 
Age 235 235 235 234 235 235 225 170 230 
BMI 235 235 235 234 235 235 225 170 230 
IPAQ 225 225 225 224 225 225 225 163 221 
MCQ 170 170 170 169 170 170 163 170 167 
Iron 230 230 230 229 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: Attention_Speed 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .160a .025 -.025 .86163 .025 .503 8 154 .853 1.839 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 




Model Sum of Squares df Mean Square F Sig. 
1 Regression 2.986 8 .373 .503 .853b 
Residual 114.329 154 .742   
Total 117.315 162    
a. Dependent Variable: Attention_Speed 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) .191 1.514  .126 .900      
Haemoglobin .002 .011 .016 .193 .847 .020 .016 .015 .889 1.125 
Ferritin 3.276E-5 .002 .001 .014 .989 -.012 .001 .001 .849 1.178 
YIE -.034 .028 -.098 -1.199 .233 -.089 -.096 -.095 .955 1.048 
Age -.001 .008 -.009 -.111 .912 -.027 -.009 -.009 .862 1.161 
BMI -.006 .018 -.026 -.316 .753 -.034 -.025 -.025 .906 1.103 
IPAQ 2.101E-5 .000 .052 .633 .528 .069 .051 .050 .948 1.055 
MCQ -.013 .029 -.037 -.458 .648 -.023 -.037 -.036 .951 1.051 
Iron .026 .019 .109 1.337 .183 .100 .107 .106 .952 1.050 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 















 CLLT Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation CLLT 1.000 .054 -.033 .055 -.138 -.182 .042 .070 -.036 
Haemoglobin .054 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin -.033 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE .055 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age -.138 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI -.182 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ .042 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ .070 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron -.036 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) CLLT . .207 .310 .202 .018 .003 .269 .186 .296 
Haemoglobin .207 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .310 .000 . .033 .003 .055 .087 .012 .322 
YIE .202 .284 .033 . .040 .244 .207 .391 .030 
Age .018 .098 .003 .040 . .000 .018 .317 .152 
BMI .003 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .269 .374 .087 .207 .018 .156 . .091 .032 
MCQ .186 .488 .012 .391 .317 .248 .091 . .157 
Iron .296 .312 .322 .030 .152 .378 .032 .157 . 
N CLLT 230 230 230 229 230 230 220 167 225 
Haemoglobin 230 235 235 234 235 235 225 170 230 
Ferritin 230 235 235 234 235 235 225 170 230 
YIE 229 234 234 234 234 234 224 169 229 
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Age 230 235 235 234 235 235 225 170 230 
BMI 230 235 235 234 235 235 225 170 230 
IPAQ 220 225 225 224 225 225 225 163 221 
MCQ 167 170 170 169 170 170 163 170 167 
Iron 225 230 230 229 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: CLLT 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .247a .061 .012 .75300 .061 1.249 8 154 .274 2.000 
 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 




Model Sum of Squares df Mean Square F Sig. 
1 Regression 5.667 8 .708 1.249 .274b 
Residual 87.318 154 .567   
Total 92.985 162    
a. Dependent Variable: CLLT 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) -.558 1.323  -.422 .674      
Haemoglobin .009 .010 .079 .952 .343 .054 .076 .074 .889 1.125 
Ferritin .000 .002 -.016 -.194 .846 -.033 -.016 -.015 .849 1.178 
YIE .027 .025 .087 1.088 .278 .055 .087 .085 .955 1.048 
Age -.007 .007 -.085 -1.012 .313 -.138 -.081 -.079 .862 1.161 
BMI -.034 .016 -.174 -2.119 .036 -.182 -.168 -.165 .906 1.103 
IPAQ 7.618E-6 .000 .021 .263 .793 .042 .021 .021 .948 1.055 
MCQ .024 .025 .077 .956 .341 .070 .077 .075 .951 1.051 
Iron -.010 .017 -.049 -.612 .541 -.036 -.049 -.048 .952 1.050 







Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 

















tion_Accuracy Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation Executive_Function_Accura
cy 
1.000 .098 .019 -.022 -.037 .002 -.059 .063 .014 
Haemoglobin .098 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin .019 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE -.022 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age -.037 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI .002 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ -.059 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ .063 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron .014 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Executive_Function_Accura
cy 
. .067 .385 .367 .287 .489 .187 .208 .418 
Haemoglobin .067 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .385 .000 . .033 .003 .055 .087 .012 .322 
YIE .367 .284 .033 . .040 .244 .207 .391 .030 
Age .287 .098 .003 .040 . .000 .018 .317 .152 
BMI .489 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .187 .374 .087 .207 .018 .156 . .091 .032 
MCQ .208 .488 .012 .391 .317 .248 .091 . .157 




235 235 235 234 235 235 225 170 230 
Haemoglobin 235 235 235 234 235 235 225 170 230 
Ferritin 235 235 235 234 235 235 225 170 230 
YIE 234 234 234 234 234 234 224 169 229 
Age 235 235 235 234 235 235 225 170 230 
BMI 235 235 235 234 235 235 225 170 230 
IPAQ 225 225 225 224 225 225 225 163 221 
MCQ 170 170 170 169 170 170 163 170 167 
Iron 230 230 230 229 230 230 221 167 230 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: Executive_Function_Accuracy 
b. All requested variables entered. 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .141a .020 -.031 .68017 .020 .391 8 154 .924 1.966 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 




Model Sum of Squares df Mean Square F Sig. 
1 Regression 1.446 8 .181 .391 .924b 
Residual 71.244 154 .463   
Total 72.690 162    
a. Dependent Variable: Executive_Function_Accuracy 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) -1.015 1.195  -.849 .397      
Haemoglobin .009 .009 .091 1.071 .286 .098 .086 .085 .889 1.125 
Ferritin .000 .002 .012 .136 .892 .019 .011 .011 .849 1.178 
YIE -.006 .022 -.021 -.254 .800 -.022 -.020 -.020 .955 1.048 
Age -.003 .007 -.035 -.413 .680 -.037 -.033 -.033 .862 1.161 
BMI -.002 .014 -.010 -.119 .906 .002 -.010 -.009 .906 1.103 
IPAQ -2.337E-5 .000 -.073 -.892 .374 -.059 -.072 -.071 .948 1.055 
MCQ .020 .023 .070 .855 .394 .063 .069 .068 .951 1.051 
Iron .004 .015 .020 .244 .807 .014 .020 .020 .952 1.050 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 















tion_Speed Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation Executive_Function_Speed 1.000 .037 .050 -.026 .247 .141 -.011 .048 .072 
Haemoglobin .037 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin .050 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE -.026 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age .247 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI .141 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ -.011 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ .048 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron .072 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Executive_Function_Speed . .284 .223 .346 .000 .015 .437 .265 .140 
Haemoglobin .284 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .223 .000 . .033 .003 .055 .087 .012 .322 
YIE .346 .284 .033 . .040 .244 .207 .391 .030 
Age .000 .098 .003 .040 . .000 .018 .317 .152 
BMI .015 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .437 .374 .087 .207 .018 .156 . .091 .032 
MCQ .265 .488 .012 .391 .317 .248 .091 . .157 
Iron .140 .312 .322 .030 .152 .378 .032 .157 . 
N Executive_Function_Speed 235 235 235 234 235 235 225 170 230 
Haemoglobin 235 235 235 234 235 235 225 170 230 
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Ferritin 235 235 235 234 235 235 225 170 230 
YIE 234 234 234 234 234 234 224 169 229 
Age 235 235 235 234 235 235 225 170 230 
BMI 235 235 235 234 235 235 225 170 230 
IPAQ 225 225 225 224 225 225 225 163 221 
MCQ 170 170 170 169 170 170 163 170 167 
Iron 230 230 230 229 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: Executive_Function_Speed 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .280a .079 .031 .72139 .079 1.642 8 154 .117 1.877 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 





Model Sum of Squares df Mean Square F Sig. 
1 Regression 6.837 8 .855 1.642 .117b 
Residual 80.142 154 .520   
Total 86.980 162    
a. Dependent Variable: Executive_Function_Speed 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) -1.385 1.268  -1.092 .276      
Haemoglobin .005 .009 .043 .519 .604 .037 .042 .040 .889 1.125 
Ferritin .000 .002 .007 .080 .936 .050 .006 .006 .849 1.178 
YIE -.018 .023 -.061 -.771 .442 -.026 -.062 -.060 .955 1.048 
Age .020 .007 .237 2.843 .005 .247 .223 .220 .862 1.161 
BMI .014 .015 .075 .921 .358 .141 .074 .071 .906 1.103 
IPAQ 4.856E-6 .000 .014 .175 .861 -.011 .014 .014 .948 1.055 
MCQ .015 .024 .047 .597 .551 .048 .048 .046 .951 1.051 
Iron .011 .016 .055 .693 .490 .072 .056 .054 .952 1.050 







Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 



















 Tension-Anxiety Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Tension-Anxiety 1.000 .088 .000 -.071 -.053 .080 .024 -.019 
Haemoglobin .088 1.000 .272 -.076 .141 -.012 .015 .054 
Ferritin .000 .272 1.000 .198 .103 -.075 -.169 -.022 
Age -.071 -.076 .198 1.000 .271 -.151 -.036 .050 
BMI -.053 .141 .103 .271 1.000 -.069 .049 .021 
IPAQ .080 -.012 -.075 -.151 -.069 1.000 .077 .100 
MCQ .024 .015 -.169 -.036 .049 .077 1.000 .045 
Iron -.019 .054 -.022 .050 .021 .100 .045 1.000 
Sig. (1-tailed) Tension-Anxiety . .091 .500 .142 .210 .118 .379 .387 
Haemoglobin .091 . .000 .126 .016 .431 .425 .211 
Ferritin .500 .000 . .001 .060 .132 .014 .371 
Age .142 .126 .001 . .000 .012 .323 .226 
BMI .210 .016 .060 .000 . .152 .263 .376 
IPAQ .118 .431 .132 .012 .152 . .167 .071 
MCQ .379 .425 .014 .323 .263 .167 . .283 
Iron .387 .211 .371 .226 .376 .071 .283 . 
N Tension-Anxiety 230 230 230 230 230 220 167 225 
Haemoglobin 230 231 231 231 231 221 168 226 
Ferritin 230 231 231 231 231 221 168 226 
Age 230 231 231 231 231 221 168 226 
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BMI 230 231 231 231 231 221 168 226 
IPAQ 220 221 221 221 221 221 161 217 
MCQ 167 168 168 168 168 161 168 165 
Iron 225 226 226 226 226 217 165 226 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Tension-Anxiety 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .144a .021 -.024 4.888 .021 .464 7 153 .860 2.046 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Haemoglobin, Age, Ferritin 







Model Sum of Squares df Mean Square F Sig. 
1 Regression 77.546 7 11.078 .464 .860b 
Residual 3654.920 153 23.888   
Total 3732.466 160    
a. Dependent Variable: Tension-Anxiety 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) -.784 8.150  -.096 .924      
Haemoglobin .072 .063 .097 1.135 .258 .088 .091 .091 .878 1.138 
Ferritin -.001 .013 -.006 -.068 .946 .000 -.006 -.005 .848 1.179 
Age -.020 .049 -.035 -.405 .686 -.071 -.033 -.032 .851 1.175 
BMI -.065 .105 -.052 -.617 .538 -.053 -.050 -.049 .896 1.116 
IPAQ .000 .000 .074 .902 .369 .080 .073 .072 .959 1.043 
MCQ .038 .167 .019 .228 .820 .024 .018 .018 .958 1.043 
Iron -.041 .110 -.030 -.370 .712 -.019 -.030 -.030 .979 1.022 







Model Iron BMI MCQ IPAQ Haemoglobin Age Ferritin 
1 Correlations Iron 1.000 .001 -.031 -.107 -.069 -.077 .041 
BMI .001 1.000 -.064 .030 -.156 -.271 -.013 
MCQ -.031 -.064 1.000 -.064 -.052 .005 .173 
IPAQ -.107 .030 -.064 1.000 .017 .133 .025 
Haemoglobin -.069 -.156 -.052 .017 1.000 .178 -.295 
Age -.077 -.271 .005 .133 .178 1.000 -.209 
Ferritin .041 -.013 .173 .025 -.295 -.209 1.000 
Covariances Iron .012 1.147E-5 -.001 -2.221E-6 .000 .000 6.113E-5 
BMI 1.147E-5 .011 -.001 5.995E-7 -.001 -.001 -1.767E-5 
MCQ -.001 -.001 .028 -2.029E-6 -.001 3.718E-5 .000 
IPAQ -2.221E-6 5.995E-7 -2.029E-6 3.581E-8 2.000E-7 1.228E-6 6.286E-8 
Haemoglobin .000 -.001 -.001 2.000E-7 .004 .001 .000 
Age .000 -.001 3.718E-5 1.228E-6 .001 .002 .000 
Ferritin 6.113E-5 -1.767E-5 .000 6.286E-8 .000 .000 .000 












Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.946 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .407 4.129 .00 .00 .38 .00 .00 .07 .27 .00 
3 .288 4.910 .00 .00 .01 .00 .00 .66 .34 .00 
4 .202 5.859 .00 .00 .49 .03 .01 .16 .36 .05 
5 .085 9.016 .00 .00 .04 .26 .01 .03 .00 .73 
6 .055 11.288 .01 .01 .00 .63 .06 .05 .03 .19 
7 .015 21.468 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 77.200 .97 .97 .07 .05 .00 .00 .00 .00 












Dejection Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Depression-Dejection 1.000 -.023 .023 -.055 -.143 .042 -.004 .040 
Haemoglobin -.023 1.000 .272 -.076 .141 -.012 .015 .054 
Ferritin .023 .272 1.000 .198 .103 -.075 -.169 -.022 
Age -.055 -.076 .198 1.000 .271 -.151 -.036 .050 
BMI -.143 .141 .103 .271 1.000 -.069 .049 .021 
IPAQ .042 -.012 -.075 -.151 -.069 1.000 .077 .100 
MCQ -.004 .015 -.169 -.036 .049 .077 1.000 .045 
Iron .040 .054 -.022 .050 .021 .100 .045 1.000 
Sig. (1-tailed) Depression-Dejection . .366 .365 .209 .017 .270 .480 .279 
Haemoglobin .366 . .000 .126 .016 .431 .425 .211 
Ferritin .365 .000 . .001 .060 .132 .014 .371 
Age .209 .126 .001 . .000 .012 .323 .226 
BMI .017 .016 .060 .000 . .152 .263 .376 
IPAQ .270 .431 .132 .012 .152 . .167 .071 
MCQ .480 .425 .014 .323 .263 .167 . .283 
Iron .279 .211 .371 .226 .376 .071 .283 . 
N Depression-Dejection 219 219 219 219 219 211 160 216 
Haemoglobin 219 231 231 231 231 221 168 226 
Ferritin 219 231 231 231 231 221 168 226 
Age 219 231 231 231 231 221 168 226 
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BMI 219 231 231 231 231 221 168 226 
IPAQ 211 221 221 221 221 221 161 217 
MCQ 160 168 168 168 168 161 168 165 
Iron 216 226 226 226 226 217 165 226 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Depression-Dejection 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .160a .026 -.019 2.961 .026 .574 7 152 .777 1.859 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Haemoglobin, Age, Ferritin 




Model Sum of Squares df Mean Square F Sig. 
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1 Regression 35.208 7 5.030 .574 .777b 
Residual 1333.014 152 8.770   
Total 1368.222 159    
a. Dependent Variable: Depression-Dejection 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 5.316 4.953  1.073 .285      
Haemoglobin -.010 .038 -.023 -.265 .791 -.023 -.022 -.021 .878 1.138 
Ferritin .005 .008 .053 .614 .540 .023 .050 .049 .848 1.179 
Age -.010 .030 -.028 -.323 .747 -.055 -.026 -.026 .851 1.175 
BMI -.103 .064 -.137 -1.617 .108 -.143 -.130 -.129 .896 1.116 
IPAQ 3.881E-5 .000 .028 .337 .736 .042 .027 .027 .959 1.043 
MCQ .009 .102 .007 .086 .932 -.004 .007 .007 .958 1.043 
Iron .036 .067 .044 .539 .591 .040 .044 .043 .979 1.022 








Model Iron BMI MCQ IPAQ Haemoglobin Age Ferritin 
1 Correlations Iron 1.000 .001 -.031 -.107 -.069 -.077 .041 
BMI .001 1.000 -.064 .030 -.156 -.271 -.013 
MCQ -.031 -.064 1.000 -.064 -.052 .005 .173 
IPAQ -.107 .030 -.064 1.000 .017 .133 .025 
Haemoglobin -.069 -.156 -.052 .017 1.000 .178 -.295 
Age -.077 -.271 .005 .133 .178 1.000 -.209 
Ferritin .041 -.013 .173 .025 -.295 -.209 1.000 
Covariances Iron .004 4.238E-6 .000 -8.204E-7 .000 .000 2.258E-5 
BMI 4.238E-6 .004 .000 2.215E-7 .000 -.001 -6.529E-6 
MCQ .000 .000 .010 -7.497E-7 .000 1.374E-5 .000 
IPAQ -8.204E-7 2.215E-7 -7.497E-7 1.323E-8 7.390E-8 4.535E-7 2.322E-8 
Haemoglobin .000 .000 .000 7.390E-8 .001 .000 -9.210E-5 
Age .000 -.001 1.374E-5 4.535E-7 .000 .001 -5.028E-5 
Ferritin 2.258E-5 -6.529E-6 .000 2.322E-8 -9.210E-5 -5.028E-5 6.617E-5 










Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.946 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .407 4.129 .00 .00 .38 .00 .00 .07 .27 .00 
3 .288 4.910 .00 .00 .01 .00 .00 .66 .34 .00 
4 .202 5.859 .00 .00 .49 .03 .01 .16 .36 .05 
5 .085 9.016 .00 .00 .04 .26 .01 .03 .00 .73 
6 .055 11.288 .01 .01 .00 .63 .06 .05 .03 .19 
7 .015 21.469 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 77.202 .97 .97 .07 .05 .00 .00 .00 .00 








 Anger-Hostility Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Anger-Hostility 1.000 .015 -.002 -.037 -.078 .130 -.006 -.012 
Haemoglobin .015 1.000 .272 -.076 .141 -.012 .015 .054 
Ferritin -.002 .272 1.000 .198 .103 -.075 -.169 -.022 
Age -.037 -.076 .198 1.000 .271 -.151 -.036 .050 
BMI -.078 .141 .103 .271 1.000 -.069 .049 .021 
IPAQ .130 -.012 -.075 -.151 -.069 1.000 .077 .100 
MCQ -.006 .015 -.169 -.036 .049 .077 1.000 .045 
Iron -.012 .054 -.022 .050 .021 .100 .045 1.000 
Sig. (1-tailed) Anger-Hostility . .411 .486 .294 .125 .030 .470 .428 
Haemoglobin .411 . .000 .126 .016 .431 .425 .211 
Ferritin .486 .000 . .001 .060 .132 .014 .371 
Age .294 .126 .001 . .000 .012 .323 .226 
BMI .125 .016 .060 .000 . .152 .263 .376 
IPAQ .030 .431 .132 .012 .152 . .167 .071 
MCQ .470 .425 .014 .323 .263 .167 . .283 
Iron .428 .211 .371 .226 .376 .071 .283 . 
N Anger-Hostility 218 218 218 218 218 209 158 215 
Haemoglobin 218 231 231 231 231 221 168 226 
Ferritin 218 231 231 231 231 221 168 226 
Age 218 231 231 231 231 221 168 226 
BMI 218 231 231 231 231 221 168 226 
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IPAQ 209 221 221 221 221 221 161 217 
MCQ 158 168 168 168 168 161 168 165 
Iron 215 226 226 226 226 217 165 226 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Anger-Hostility 
b. All requested variables entered. 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .153a .023 -.022 2.027 .023 .512 7 150 .824 1.962 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Haemoglobin, Age, Ferritin 
b. Dependent Variable: Anger-Hostility 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 14.734 7 2.105 .512 .824b 
Residual 616.508 150 4.110   
Total 631.242 157    
a. Dependent Variable: Anger-Hostility 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 1.069 3.413  .313 .754      
Haemoglobin .009 .026 .028 .327 .744 .015 .027 .026 .878 1.138 
Ferritin .000 .006 .004 .045 .964 -.002 .004 .004 .848 1.179 
Age .001 .020 .005 .057 .955 -.037 .005 .005 .851 1.175 
BMI -.038 .044 -.074 -.868 .387 -.078 -.071 -.070 .896 1.116 
IPAQ .000 .000 .130 1.576 .117 .130 .128 .127 .959 1.043 
MCQ -.009 .070 -.011 -.132 .895 -.006 -.011 -.011 .958 1.043 
Iron -.014 .046 -.025 -.307 .759 -.012 -.025 -.025 .979 1.022 













Model Iron BMI MCQ IPAQ Haemoglobin Age Ferritin 
1 Correlations Iron 1.000 .001 -.031 -.107 -.069 -.077 .041 
BMI .001 1.000 -.064 .030 -.156 -.271 -.013 
MCQ -.031 -.064 1.000 -.064 -.052 .005 .173 
IPAQ -.107 .030 -.064 1.000 .017 .133 .025 
Haemoglobin -.069 -.156 -.052 .017 1.000 .178 -.295 
Age -.077 -.271 .005 .133 .178 1.000 -.209 
Ferritin .041 -.013 .173 .025 -.295 -.209 1.000 
Covariances Iron .002 2.011E-6 -9.935E-5 -3.894E-7 -8.432E-5 -7.200E-5 1.072E-5 
BMI 2.011E-6 .002 .000 1.051E-7 .000 .000 -3.099E-6 
MCQ -9.935E-5 .000 .005 -3.558E-7 -9.621E-5 6.519E-6 6.803E-5 
IPAQ -3.894E-7 1.051E-7 -3.558E-7 6.279E-9 3.508E-8 2.152E-7 1.102E-8 
Haemoglobin -8.432E-5 .000 -9.621E-5 3.508E-8 .001 9.580E-5 -4.371E-5 
Age -7.200E-5 .000 6.519E-6 2.152E-7 9.580E-5 .000 -2.386E-5 
Ferritin 1.072E-5 -3.099E-6 6.803E-5 1.102E-8 -4.371E-5 -2.386E-5 3.141E-5 










Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.946 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .407 4.130 .00 .00 .38 .00 .00 .07 .27 .00 
3 .288 4.910 .00 .00 .01 .00 .00 .66 .34 .00 
4 .202 5.860 .00 .00 .49 .03 .01 .16 .36 .05 
5 .085 9.016 .00 .00 .04 .26 .01 .03 .00 .73 
6 .055 11.289 .01 .01 .00 .63 .06 .05 .03 .19 
7 .015 21.470 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 77.205 .97 .97 .07 .05 .00 .00 .00 .00 








 Vigour-Activity Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Vigour-Activity 1.000 -.002 .095 .138 .024 .083 .043 .096 
Haemoglobin -.002 1.000 .272 -.076 .141 -.012 .015 .054 
Ferritin .095 .272 1.000 .198 .103 -.075 -.169 -.022 
Age .138 -.076 .198 1.000 .271 -.151 -.036 .050 
BMI .024 .141 .103 .271 1.000 -.069 .049 .021 
IPAQ .083 -.012 -.075 -.151 -.069 1.000 .077 .100 
MCQ .043 .015 -.169 -.036 .049 .077 1.000 .045 
Iron .096 .054 -.022 .050 .021 .100 .045 1.000 
Sig. (1-tailed) Vigour-Activity . .485 .075 .018 .357 .110 .288 .075 
Haemoglobin .485 . .000 .126 .016 .431 .425 .211 
Ferritin .075 .000 . .001 .060 .132 .014 .371 
Age .018 .126 .001 . .000 .012 .323 .226 
BMI .357 .016 .060 .000 . .152 .263 .376 
IPAQ .110 .431 .132 .012 .152 . .167 .071 
MCQ .288 .425 .014 .323 .263 .167 . .283 
Iron .075 .211 .371 .226 .376 .071 .283 . 
N Vigour-Activity 231 231 231 231 231 221 168 226 
Haemoglobin 231 231 231 231 231 221 168 226 
Ferritin 231 231 231 231 231 221 168 226 
Age 231 231 231 231 231 221 168 226 
BMI 231 231 231 231 231 221 168 226 
IPAQ 221 221 221 221 221 221 161 217 
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MCQ 168 168 168 168 168 161 168 165 
Iron 226 226 226 226 226 217 165 226 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Vigour-Activity 
b. All requested variables entered. 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .213a .045 .002 6.274 .045 1.038 7 153 .407 1.797 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Haemoglobin, Age, Ferritin 
b. Dependent Variable: Vigour-Activity 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 286.111 7 40.873 1.038 .407b 
Residual 6022.081 153 39.360   
Total 6308.192 160    
a. Dependent Variable: Vigour-Activity 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 9.493 10.461  .907 .366      
Haemoglobin -.018 .081 -.019 -.225 .822 -.002 -.018 -.018 .878 1.138 
Ferritin .019 .017 .093 1.086 .279 .095 .087 .086 .848 1.179 
Age .099 .062 .136 1.586 .115 .138 .127 .125 .851 1.175 
BMI -.028 .135 -.017 -.205 .838 .024 -.017 -.016 .896 1.116 
IPAQ .000 .000 .097 1.200 .232 .083 .097 .095 .959 1.043 
MCQ .144 .215 .054 .670 .504 .043 .054 .053 .958 1.043 
Iron .142 .141 .080 1.007 .315 .096 .081 .080 .979 1.022 













Model Iron BMI MCQ IPAQ Haemoglobin Age Ferritin 
1 Correlations Iron 1.000 .001 -.031 -.107 -.069 -.077 .041 
BMI .001 1.000 -.064 .030 -.156 -.271 -.013 
MCQ -.031 -.064 1.000 -.064 -.052 .005 .173 
IPAQ -.107 .030 -.064 1.000 .017 .133 .025 
Haemoglobin -.069 -.156 -.052 .017 1.000 .178 -.295 
Age -.077 -.271 .005 .133 .178 1.000 -.209 
Ferritin .041 -.013 .173 .025 -.295 -.209 1.000 
Covariances Iron .020 1.890E-5 -.001 -3.659E-6 -.001 -.001 .000 
BMI 1.890E-5 .018 -.002 9.878E-7 -.002 -.002 -2.912E-5 
MCQ -.001 -.002 .046 -3.344E-6 -.001 6.126E-5 .001 
IPAQ -3.659E-6 9.878E-7 -3.344E-6 5.900E-8 3.296E-7 2.023E-6 1.036E-7 
Haemoglobin -.001 -.002 -.001 3.296E-7 .007 .001 .000 
Age -.001 -.002 6.126E-5 2.023E-6 .001 .004 .000 
Ferritin .000 -2.912E-5 .001 1.036E-7 .000 .000 .000 












Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.946 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .407 4.129 .00 .00 .38 .00 .00 .07 .27 .00 
3 .288 4.910 .00 .00 .01 .00 .00 .66 .34 .00 
4 .202 5.859 .00 .00 .49 .03 .01 .16 .36 .05 
5 .085 9.016 .00 .00 .04 .26 .01 .03 .00 .73 
6 .055 11.288 .01 .01 .00 .63 .06 .05 .03 .19 
7 .015 21.468 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 77.200 .97 .97 .07 .05 .00 .00 .00 .00 







 Fatigue-Inertia Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Fatigue-Inertia 1.000 .103 .005 -.064 -.129 .082 .052 .040 
Haemoglobin .103 1.000 .272 -.076 .141 -.012 .015 .054 
Ferritin .005 .272 1.000 .198 .103 -.075 -.169 -.022 
Age -.064 -.076 .198 1.000 .271 -.151 -.036 .050 
BMI -.129 .141 .103 .271 1.000 -.069 .049 .021 
IPAQ .082 -.012 -.075 -.151 -.069 1.000 .077 .100 
MCQ .052 .015 -.169 -.036 .049 .077 1.000 .045 
Iron .040 .054 -.022 .050 .021 .100 .045 1.000 
Sig. (1-tailed) Fatigue-Inertia . .060 .472 .166 .025 .112 .250 .273 
Haemoglobin .060 . .000 .126 .016 .431 .425 .211 
Ferritin .472 .000 . .001 .060 .132 .014 .371 
Age .166 .126 .001 . .000 .012 .323 .226 
BMI .025 .016 .060 .000 . .152 .263 .376 
IPAQ .112 .431 .132 .012 .152 . .167 .071 
MCQ .250 .425 .014 .323 .263 .167 . .283 
Iron .273 .211 .371 .226 .376 .071 .283 . 
N Fatigue-Inertia 231 231 231 231 231 221 168 226 
Haemoglobin 231 231 231 231 231 221 168 226 
Ferritin 231 231 231 231 231 221 168 226 
Age 231 231 231 231 231 221 168 226 
BMI 231 231 231 231 231 221 168 226 
IPAQ 221 221 221 221 221 221 161 217 
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MCQ 168 168 168 168 168 161 168 165 
Iron 226 226 226 226 226 217 165 226 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Fatigue-Inertia 
b. All requested variables entered. 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .201a .040 -.003 5.145 .040 .921 7 153 .492 2.126 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Haemoglobin, Age, Ferritin 
b. Dependent Variable: Fatigue-Inertia 
 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 170.604 7 24.372 .921 .492b 
Residual 4050.167 153 26.472   
Total 4220.772 160    
a. Dependent Variable: Fatigue-Inertia 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) -1.564 8.579  -.182 .856      
Haemoglobin .095 .066 .120 1.423 .157 .103 .114 .113 .878 1.138 
Ferritin .000 .014 .002 .026 .980 .005 .002 .002 .848 1.179 
Age -.004 .051 -.006 -.073 .942 -.064 -.006 -.006 .851 1.175 
BMI -.189 .110 -.143 -1.707 .090 -.129 -.137 -.135 .896 1.116 
IPAQ .000 .000 .066 .818 .415 .082 .066 .065 .959 1.043 
MCQ .112 .176 .051 .637 .525 .052 .051 .050 .958 1.043 
Iron .041 .116 .028 .355 .723 .040 .029 .028 .979 1.022 













Model Iron BMI MCQ IPAQ Haemoglobin Age Ferritin 
1 Correlations Iron 1.000 .001 -.031 -.107 -.069 -.077 .041 
BMI .001 1.000 -.064 .030 -.156 -.271 -.013 
MCQ -.031 -.064 1.000 -.064 -.052 .005 .173 
IPAQ -.107 .030 -.064 1.000 .017 .133 .025 
Haemoglobin -.069 -.156 -.052 .017 1.000 .178 -.295 
Age -.077 -.271 .005 .133 .178 1.000 -.209 
Ferritin .041 -.013 .173 .025 -.295 -.209 1.000 
Covariances Iron .013 1.271E-5 -.001 -2.461E-6 -.001 .000 6.774E-5 
BMI 1.271E-5 .012 -.001 6.644E-7 -.001 -.002 -1.958E-5 
MCQ -.001 -.001 .031 -2.249E-6 -.001 4.120E-5 .000 
IPAQ -2.461E-6 6.644E-7 -2.249E-6 3.968E-8 2.217E-7 1.360E-6 6.965E-8 
Haemoglobin -.001 -.001 -.001 2.217E-7 .004 .001 .000 
Age .000 -.002 4.120E-5 1.360E-6 .001 .003 .000 
Ferritin 6.774E-5 -1.958E-5 .000 6.965E-8 .000 .000 .000 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.946 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
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2 .407 4.129 .00 .00 .38 .00 .00 .07 .27 .00 
3 .288 4.910 .00 .00 .01 .00 .00 .66 .34 .00 
4 .202 5.859 .00 .00 .49 .03 .01 .16 .36 .05 
5 .085 9.016 .00 .00 .04 .26 .01 .03 .00 .73 
6 .055 11.288 .01 .01 .00 .63 .06 .05 .03 .19 
7 .015 21.468 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 77.200 .97 .97 .07 .05 .00 .00 .00 .00 













Bewilderment Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Confusion-Bewilderment 1.000 .057 -.054 -.101 -.121 .018 .062 .080 
Haemoglobin .057 1.000 .272 -.076 .141 -.012 .015 .054 
Ferritin -.054 .272 1.000 .198 .103 -.075 -.169 -.022 
Age -.101 -.076 .198 1.000 .271 -.151 -.036 .050 
BMI -.121 .141 .103 .271 1.000 -.069 .049 .021 
IPAQ .018 -.012 -.075 -.151 -.069 1.000 .077 .100 
MCQ .062 .015 -.169 -.036 .049 .077 1.000 .045 
Iron .080 .054 -.022 .050 .021 .100 .045 1.000 
Sig. (1-tailed) Confusion-Bewilderment . .195 .209 .063 .033 .397 .212 .115 
Haemoglobin .195 . .000 .126 .016 .431 .425 .211 
Ferritin .209 .000 . .001 .060 .132 .014 .371 
Age .063 .126 .001 . .000 .012 .323 .226 
BMI .033 .016 .060 .000 . .152 .263 .376 
IPAQ .397 .431 .132 .012 .152 . .167 .071 
MCQ .212 .425 .014 .323 .263 .167 . .283 
Iron .115 .211 .371 .226 .376 .071 .283 . 
N Confusion-Bewilderment 231 231 231 231 231 221 168 226 
Haemoglobin 231 231 231 231 231 221 168 226 
Ferritin 231 231 231 231 231 221 168 226 
Age 231 231 231 231 231 221 168 226 
BMI 231 231 231 231 231 221 168 226 
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IPAQ 221 221 221 221 221 221 161 217 
MCQ 168 168 168 168 168 161 168 165 
Iron 226 226 226 226 226 217 165 226 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Confusion-Bewilderment 
b. All requested variables entered. 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .190a .036 -.008 5.107 .036 .818 7 153 .574 1.848 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Haemoglobin, Age, Ferritin 
b. Dependent Variable: Confusion-Bewilderment 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 149.308 7 21.330 .818 .574b 
Residual 3990.275 153 26.080   
Total 4139.582 160    
a. Dependent Variable: Confusion-Bewilderment 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 5.116 8.515  .601 .549      
Haemoglobin .058 .066 .074 .878 .382 .057 .071 .070 .878 1.138 
Ferritin -.006 .014 -.040 -.463 .644 -.054 -.037 -.037 .848 1.179 
Age -.035 .051 -.060 -.698 .486 -.101 -.056 -.055 .851 1.175 
BMI -.152 .110 -.116 -1.388 .167 -.121 -.112 -.110 .896 1.116 
IPAQ -3.381E-5 .000 -.014 -.171 .864 .018 -.014 -.014 .959 1.043 
MCQ .119 .175 .055 .683 .495 .062 .055 .054 .958 1.043 
Iron .114 .115 .080 .992 .323 .080 .080 .079 .979 1.022 
a. Dependent Variable: Confusion-Bewilderment 
Coefficient Correlationsa 
Model Iron BMI MCQ IPAQ Haemoglobin Age Ferritin 
1 Correlations Iron 1.000 .001 -.031 -.107 -.069 -.077 .041 
BMI .001 1.000 -.064 .030 -.156 -.271 -.013 
MCQ -.031 -.064 1.000 -.064 -.052 .005 .173 
IPAQ -.107 .030 -.064 1.000 .017 .133 .025 
Haemoglobin -.069 -.156 -.052 .017 1.000 .178 -.295 
Age -.077 -.271 .005 .133 .178 1.000 -.209 
Ferritin .041 -.013 .173 .025 -.295 -.209 1.000 
Covariances Iron .013 1.252E-5 -.001 -2.425E-6 -.001 .000 6.673E-5 
BMI 1.252E-5 .012 -.001 6.546E-7 -.001 -.002 -1.929E-5 
MCQ -.001 -.001 .031 -2.216E-6 -.001 4.059E-5 .000 
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IPAQ -2.425E-6 6.546E-7 -2.216E-6 3.910E-8 2.184E-7 1.340E-6 6.862E-8 
Haemoglobin -.001 -.001 -.001 2.184E-7 .004 .001 .000 
Age .000 -.002 4.059E-5 1.340E-6 .001 .003 .000 
Ferritin 6.673E-5 -1.929E-5 .000 6.862E-8 .000 .000 .000 
a. Dependent Variable: Confusion-Bewilderment 
Collinearity Diagnosticsa 
Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.946 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .407 4.129 .00 .00 .38 .00 .00 .07 .27 .00 
3 .288 4.910 .00 .00 .01 .00 .00 .66 .34 .00 
4 .202 5.859 .00 .00 .49 .03 .01 .16 .36 .05 
5 .085 9.016 .00 .00 .04 .26 .01 .03 .00 .73 
6 .055 11.288 .01 .01 .00 .63 .06 .05 .03 .19 
7 .015 21.468 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 77.200 .97 .97 .07 .05 .00 .00 .00 .00 












Total Mood Disturbance 
Correlations 
 TMD Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation TMD 1.000 .084 -.008 -.187 -.138 .064 -.111 -.029 
Haemoglobin .084 1.000 .272 -.076 .141 -.012 .015 .054 
Ferritin -.008 .272 1.000 .198 .103 -.075 -.169 -.022 
Age -.187 -.076 .198 1.000 .271 -.151 -.036 .050 
BMI -.138 .141 .103 .271 1.000 -.069 .049 .021 
IPAQ .064 -.012 -.075 -.151 -.069 1.000 .077 .100 
MCQ -.111 .015 -.169 -.036 .049 .077 1.000 .045 
Iron -.029 .054 -.022 .050 .021 .100 .045 1.000 
Sig. (1-tailed) TMD . .111 .455 .003 .023 .182 .085 .338 
Haemoglobin .111 . .000 .126 .016 .431 .425 .211 
Ferritin .455 .000 . .001 .060 .132 .014 .371 
Age .003 .126 .001 . .000 .012 .323 .226 
BMI .023 .016 .060 .000 . .152 .263 .376 
IPAQ .182 .431 .132 .012 .152 . .167 .071 
MCQ .085 .425 .014 .323 .263 .167 . .283 
Iron .338 .211 .371 .226 .376 .071 .283 . 
N TMD 210 210 210 210 210 202 153 208 
Haemoglobin 210 231 231 231 231 221 168 226 
Ferritin 210 231 231 231 231 221 168 226 
Age 210 231 231 231 231 221 168 226 
BMI 210 231 231 231 231 221 168 226 
IPAQ 202 221 221 221 221 221 161 217 
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MCQ 153 168 168 168 168 161 168 165 
Iron 208 226 226 226 226 217 165 226 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: TMD 
b. All requested variables entered. 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .257a .066 .021 17.235 .066 1.468 7 145 .183 1.968 
a. Predictors: (Constant), Iron, BMI, MCQ, IPAQ, Haemoglobin, Age, Ferritin 
b. Dependent Variable: TMD 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 3052.561 7 436.080 1.468 .183b 
Residual 43069.981 145 297.034   
Total 46122.542 152    
a. Dependent Variable: TMD 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) .651 29.484  .022 .982      
Haemoglobin .251 .228 .094 1.099 .273 .084 .091 .088 .878 1.138 
Ferritin -.006 .048 -.011 -.125 .901 -.008 -.010 -.010 .848 1.179 
Age -.297 .176 -.147 -1.688 .094 -.187 -.139 -.135 .851 1.175 
BMI -.450 .380 -.100 -1.185 .238 -.138 -.098 -.095 .896 1.116 
IPAQ .000 .001 .047 .572 .568 .064 .047 .046 .959 1.043 
MCQ -.867 .605 -.117 -1.432 .154 -.111 -.118 -.115 .958 1.043 
Iron -.120 .398 -.024 -.301 .764 -.029 -.025 -.024 .979 1.022 
a. Dependent Variable: TMD 
Coefficient Correlationsa 
Model Iron BMI MCQ IPAQ Haemoglobin Age Ferritin 
1 Correlations Iron 1.000 .001 -.031 -.107 -.069 -.077 .041 
BMI .001 1.000 -.064 .030 -.156 -.271 -.013 
MCQ -.031 -.064 1.000 -.064 -.052 .005 .173 
IPAQ -.107 .030 -.064 1.000 .017 .133 .025 
Haemoglobin -.069 -.156 -.052 .017 1.000 .178 -.295 
Age -.077 -.271 .005 .133 .178 1.000 -.209 
Ferritin .041 -.013 .173 .025 -.295 -.209 1.000 
Covariances Iron .159 .000 -.007 -2.907E-5 -.006 -.005 .001 
BMI .000 .144 -.015 7.847E-6 -.014 -.018 .000 
MCQ -.007 -.015 .366 -2.656E-5 -.007 .000 .005 
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IPAQ -2.907E-5 7.847E-6 -2.656E-5 4.687E-7 2.618E-6 1.607E-5 8.227E-7 
Haemoglobin -.006 -.014 -.007 2.618E-6 .052 .007 -.003 
Age -.005 -.018 .000 1.607E-5 .007 .031 -.002 
Ferritin .001 .000 .005 8.227E-7 -.003 -.002 .002 
a. Dependent Variable: TMD 
Collinearity Diagnosticsa 
Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.946 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .407 4.130 .00 .00 .38 .00 .00 .07 .27 .00 
3 .288 4.911 .00 .00 .01 .00 .00 .66 .34 .00 
4 .202 5.860 .00 .00 .49 .03 .01 .16 .36 .05 
5 .085 9.017 .00 .00 .04 .26 .01 .03 .00 .73 
6 .054 11.290 .01 .01 .00 .63 .06 .05 .03 .19 
7 .015 21.472 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 77.214 .97 .97 .07 .05 .00 .00 .00 .00 










Predictors of subjective mood (PSS and SCI) 
PSS 
Correlations 
 PSS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation PSS 1.000 .095 -.107 -.128 -.004 -.039 .176 -.002 
Haemoglobin .095 1.000 .258 -.085 .127 -.021 -.002 .032 
Ferritin -.107 .258 1.000 .181 .104 -.091 -.173 -.031 
Age -.128 -.085 .181 1.000 .255 -.140 -.037 .068 
BMI -.004 .127 .104 .255 1.000 -.068 .053 .021 
IPAQ -.039 -.021 -.091 -.140 -.068 1.000 .105 .125 
MCQ .176 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron -.002 .032 -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) PSS . .074 .052 .025 .479 .281 .011 .486 
Haemoglobin .074 . .000 .098 .026 .374 .488 .312 
Ferritin .052 .000 . .003 .055 .087 .012 .322 
Age .025 .098 .003 . .000 .018 .317 .152 
BMI .479 .026 .055 .000 . .156 .248 .378 
IPAQ .281 .374 .087 .018 .156 . .091 .032 
MCQ .011 .488 .012 .317 .248 .091 . .157 
Iron .486 .312 .322 .152 .378 .032 .157 . 
N PSS 235 235 235 235 235 225 170 230 
Haemoglobin 235 235 235 235 235 225 170 230 
Ferritin 235 235 235 235 235 225 170 230 
Age 235 235 235 235 235 225 170 230 
BMI 235 235 235 235 235 225 170 230 
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IPAQ 225 225 225 225 225 225 163 221 
MCQ 170 170 170 170 170 163 170 167 
Iron 230 230 230 230 230 221 167 230 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: PSS 
b. All requested variables entered. 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .256a .066 .023 6.954 .066 1.556 7 155 .153 1.897 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 
b. Dependent Variable: PSS 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 526.684 7 75.241 1.556 .153b 
Residual 7495.353 155 48.357   
Total 8022.037 162    
a. Dependent Variable: PSS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 5.116 11.504  .445 .657      
Haemoglobin .116 .088 .108 1.317 .190 .095 .105 .102 .893 1.120 
Ferritin -.021 .019 -.095 -1.130 .260 -.107 -.090 -.088 .861 1.161 
Age -.086 .067 -.107 -1.285 .201 -.128 -.103 -.100 .865 1.156 
BMI .011 .148 .006 .076 .939 -.004 .006 .006 .907 1.103 
IPAQ .000 .000 -.076 -.956 .340 -.039 -.077 -.074 .950 1.052 
MCQ .483 .235 .164 2.054 .042 .176 .163 .159 .951 1.051 
Iron -.009 .155 -.005 -.061 .952 -.002 -.005 -.005 .969 1.032 
a. Dependent Variable: PSS 
Coefficient Correlationsa 
Model Iron BMI MCQ Haemoglobin IPAQ Age Ferritin 
1 Correlations Iron 1.000 .002 -.061 -.053 -.129 -.096 .038 
BMI .002 1.000 -.073 -.140 .034 -.254 -.029 
MCQ -.061 -.073 1.000 -.032 -.085 .013 .169 
Haemoglobin -.053 -.140 -.032 1.000 .021 .173 -.275 
IPAQ -.129 .034 -.085 .021 1.000 .125 .037 
Age -.096 -.254 .013 .173 .125 1.000 -.189 
Ferritin .038 -.029 .169 -.275 .037 -.189 1.000 
Covariances Iron .024 5.528E-5 -.002 -.001 -5.343E-6 -.001 .000 
BMI 5.528E-5 .022 -.003 -.002 1.325E-6 -.003 -8.062E-5 
MCQ -.002 -.003 .055 -.001 -5.353E-6 .000 .001 
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Haemoglobin -.001 -.002 -.001 .008 5.048E-7 .001 .000 
IPAQ -5.343E-6 1.325E-6 -5.353E-6 5.048E-7 7.156E-8 2.256E-6 1.858E-7 
Age -.001 -.003 .000 .001 2.256E-6 .005 .000 
Ferritin .000 -8.062E-5 .001 .000 1.858E-7 .000 .000 
a. Dependent Variable: PSS 
Collinearity Diagnosticsa 
Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.939 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .417 4.079 .00 .00 .38 .00 .00 .08 .25 .00 
3 .282 4.961 .00 .00 .00 .00 .00 .65 .38 .00 
4 .203 5.844 .00 .00 .51 .04 .01 .16 .34 .04 
5 .085 9.055 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 11.005 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.307 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 76.680 .97 .97 .06 .04 .00 .00 .00 .00 














 SCI Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation SCI 1.000 -.021 .062 .041 -.085 -.062 -.279 .089 
Haemoglobin -.021 1.000 .258 -.085 .127 -.021 -.002 .032 
Ferritin .062 .258 1.000 .181 .104 -.091 -.173 -.031 
Age .041 -.085 .181 1.000 .255 -.140 -.037 .068 
BMI -.085 .127 .104 .255 1.000 -.068 .053 .021 
IPAQ -.062 -.021 -.091 -.140 -.068 1.000 .105 .125 
MCQ -.279 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .089 .032 -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) SCI . .373 .174 .267 .098 .178 .000 .088 
Haemoglobin .373 . .000 .098 .026 .374 .488 .312 
Ferritin .174 .000 . .003 .055 .087 .012 .322 
Age .267 .098 .003 . .000 .018 .317 .152 
BMI .098 .026 .055 .000 . .156 .248 .378 
IPAQ .178 .374 .087 .018 .156 . .091 .032 
MCQ .000 .488 .012 .317 .248 .091 . .157 
Iron .088 .312 .322 .152 .378 .032 .157 . 
N SCI 235 235 235 235 235 225 170 230 
Haemoglobin 235 235 235 235 235 225 170 230 
Ferritin 235 235 235 235 235 225 170 230 
Age 235 235 235 235 235 225 170 230 
BMI 235 235 235 235 235 225 170 230 
IPAQ 225 225 225 225 225 225 163 221 
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MCQ 170 170 170 170 170 163 170 167 
Iron 230 230 230 230 230 221 167 230 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: SCI 
b. All requested variables entered. 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .316a .100 .059 6.812 .100 2.458 7 155 .020 1.940 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 
b. Dependent Variable: SCI 
ANOVAa 
Model Sum of Squares df Mean Square F Sig. 
1 Regression 798.353 7 114.050 2.458 .020b 
Residual 7191.950 155 46.400   
Total 7990.303 162    
a. Dependent Variable: SCI 









Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 27.208 11.268  2.415 .017      
Haemoglobin -.020 .086 -.019 -.233 .816 -.021 -.019 -.018 .893 1.120 
Ferritin .005 .018 .021 .259 .796 .062 .021 .020 .861 1.161 
Age .026 .066 .032 .391 .696 .041 .031 .030 .865 1.156 
BMI -.151 .145 -.084 -1.046 .297 -.085 -.084 -.080 .907 1.103 
IPAQ .000 .000 -.047 -.605 .546 -.062 -.049 -.046 .950 1.052 
MCQ -.807 .230 -.274 -3.506 .001 -.279 -.271 -.267 .951 1.051 
Iron .231 .152 .118 1.519 .131 .089 .121 .116 .969 1.032 
a. Dependent Variable: SCI 
Coefficient Correlationsa 
Model Iron BMI MCQ Haemoglobin IPAQ Age Ferritin 
1 Correlations Iron 1.000 .002 -.061 -.053 -.129 -.096 .038 
BMI .002 1.000 -.073 -.140 .034 -.254 -.029 
MCQ -.061 -.073 1.000 -.032 -.085 .013 .169 
Haemoglobin -.053 -.140 -.032 1.000 .021 .173 -.275 
IPAQ -.129 .034 -.085 .021 1.000 .125 .037 
Age -.096 -.254 .013 .173 .125 1.000 -.189 
Ferritin .038 -.029 .169 -.275 .037 -.189 1.000 
Covariances Iron .023 5.304E-5 -.002 -.001 -5.127E-6 -.001 .000 
BMI 5.304E-5 .021 -.002 -.002 1.272E-6 -.002 -7.736E-5 
MCQ -.002 -.002 .053 -.001 -5.136E-6 .000 .001 
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Haemoglobin -.001 -.002 -.001 .007 4.844E-7 .001 .000 
IPAQ -5.127E-6 1.272E-6 -5.136E-6 4.844E-7 6.866E-8 2.165E-6 1.783E-7 
Age -.001 -.002 .000 .001 2.165E-6 .004 .000 
Ferritin .000 -7.736E-5 .001 .000 1.783E-7 .000 .000 




Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.939 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .417 4.079 .00 .00 .38 .00 .00 .08 .25 .00 
3 .282 4.961 .00 .00 .00 .00 .00 .65 .38 .00 
4 .203 5.844 .00 .00 .51 .04 .01 .16 .34 .04 
5 .085 9.055 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 11.005 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.307 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 76.680 .97 .97 .06 .04 .00 .00 .00 .00 













Predictors of subjective workload (NASA-TLX) 
Correlations 
 Workload_2 Haemoglobin Ferritin YIE Age BMI IPAQ MCQ Iron 
Pearson Correlation Workload_2 1.000 .104 -.005 -.038 .022 .062 -.056 .075 .074 
Haemoglobin .104 1.000 .258 -.038 -.085 .127 -.021 -.002 .032 
Ferritin -.005 .258 1.000 .121 .181 .104 -.091 -.173 -.031 
YIE -.038 -.038 .121 1.000 .115 .046 -.055 -.021 .125 
Age .022 -.085 .181 .115 1.000 .255 -.140 -.037 .068 
BMI .062 .127 .104 .046 .255 1.000 -.068 .053 .021 
IPAQ -.056 -.021 -.091 -.055 -.140 -.068 1.000 .105 .125 
MCQ .075 -.002 -.173 -.021 -.037 .053 .105 1.000 .078 
Iron .074 .032 -.031 .125 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Workload_2 . .057 .468 .283 .371 .173 .203 .169 .134 
Haemoglobin .057 . .000 .284 .098 .026 .374 .488 .312 
Ferritin .468 .000 . .033 .003 .055 .087 .012 .322 
YIE .283 .284 .033 . .040 .244 .207 .391 .030 
Age .371 .098 .003 .040 . .000 .018 .317 .152 
BMI .173 .026 .055 .244 .000 . .156 .248 .378 
IPAQ .203 .374 .087 .207 .018 .156 . .091 .032 
MCQ .169 .488 .012 .391 .317 .248 .091 . .157 
Iron .134 .312 .322 .030 .152 .378 .032 .157 . 
N Workload_2 230 230 230 229 230 230 220 165 225 
Haemoglobin 230 235 235 234 235 235 225 170 230 
Ferritin 230 235 235 234 235 235 225 170 230 
YIE 229 234 234 234 234 234 224 169 229 
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Age 230 235 235 234 235 235 225 170 230 
BMI 230 235 235 234 235 235 225 170 230 
IPAQ 220 225 225 224 225 225 225 163 221 
MCQ 165 170 170 169 170 170 163 170 167 
Iron 225 230 230 229 230 230 221 167 230 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 
1 Iron, BMI, MCQ, 
Haemoglobin, 
YIE, IPAQ, Age, 
Ferritinb 
. Enter 
a. Dependent Variable: Workload_2 
b. All requested variables entered. 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .174a .030 -.020 12.45792 .030 .603 8 154 .774 2.132 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, YIE, IPAQ, Age, Ferritin 







Model Sum of Squares df Mean Square F Sig. 
1 Regression 748.977 8 93.622 .603 .774b 
Residual 23900.768 154 155.200   
Total 24649.745 162    
a. Dependent Variable: Workload_2 









Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 28.781 21.893  1.315 .191      
Haemoglobin .191 .158 .102 1.207 .229 .104 .097 .096 .889 1.125 
Ferritin -.010 .034 -.025 -.292 .771 -.005 -.024 -.023 .849 1.178 
YIE -.236 .406 -.047 -.582 .562 -.038 -.047 -.046 .955 1.048 
Age .025 .121 .018 .207 .836 .022 .017 .016 .862 1.161 
BMI .126 .264 .040 .476 .635 .062 .038 .038 .906 1.103 
IPAQ .000 .000 -.071 -.871 .385 -.056 -.070 -.069 .948 1.055 
MCQ .362 .421 .070 .859 .391 .075 .069 .068 .951 1.051 
Iron .267 .280 .077 .952 .343 .074 .076 .076 .952 1.050 





Model Iron BMI MCQ Haemoglobin YIE IPAQ Age Ferritin 
1 Correlations Iron 1.000 .005 -.061 -.061 -.132 -.134 -.086 .053 
BMI .005 1.000 -.073 -.141 -.019 .033 -.252 -.027 
MCQ -.061 -.073 1.000 -.031 .004 -.085 .012 .167 
Haemoglobin -.061 -.141 -.031 1.000 .069 .025 .168 -.281 
YIE -.132 -.019 .004 .069 1.000 .051 -.062 -.117 
IPAQ -.134 .033 -.085 .025 .051 1.000 .122 .031 
Age -.086 -.252 .012 .168 -.062 .122 1.000 -.180 
Ferritin .053 -.027 .167 -.281 -.117 .031 -.180 1.000 
Covariances Iron .079 .000 -.007 -.003 -.015 -1.805E-5 -.003 .000 
BMI .000 .070 -.008 -.006 -.002 4.133E-6 -.008 .000 
MCQ -.007 -.008 .177 -.002 .001 -1.714E-5 .001 .002 
Haemoglobin -.003 -.006 -.002 .025 .004 1.888E-6 .003 -.001 
YIE -.015 -.002 .001 .004 .165 9.882E-6 -.003 -.002 
IPAQ -1.805E-5 4.133E-6 -1.714E-5 1.888E-6 9.882E-6 2.302E-7 7.059E-6 5.005E-7 
Age -.003 -.008 .001 .003 -.003 7.059E-6 .015 -.001 
Ferritin .000 .000 .002 -.001 -.002 5.005E-7 -.001 .001 








Model Dimension Eigenvalue Condition Index 
Variance Proportions 
 
(Constant) Haemoglobin Ferritin YIE Age BMI IPAQ MCQ 
 
1 1 7.907 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
 
2 .418 4.350 .00 .00 .36 .00 .00 .00 .08 .25 
 
3 .282 5.294 .00 .00 .00 .00 .00 .00 .66 .37 
 
4 .211 6.119 .00 .00 .52 .00 .03 .00 .15 .35 
 
5 .085 9.661 .00 .00 .03 .00 .23 .01 .04 .00 
 
6 .063 11.247 .00 .00 .00 .03 .67 .02 .03 .01 
 
7 .021 19.327 .00 .00 .00 .44 .02 .55 .00 .00 
 
8 .012 25.870 .03 .06 .00 .47 .01 .41 .02 .00 
 
































rity Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Behavioural/Severity 1.000 .072 -.052 -.074 -.001 .052 .176 .026 
Haemoglobin .072 1.000 .258 -.085 .127 -.021 -.002 .032 
Ferritin -.052 .258 1.000 .181 .104 -.091 -.173 -.031 
Age -.074 -.085 .181 1.000 .255 -.140 -.037 .068 
BMI -.001 .127 .104 .255 1.000 -.068 .053 .021 
IPAQ .052 -.021 -.091 -.140 -.068 1.000 .105 .125 
MCQ .176 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .026 .032 -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Behavioural/Severity . .137 .216 .128 .496 .218 .011 .348 
Haemoglobin .137 . .000 .098 .026 .374 .488 .312 
Ferritin .216 .000 . .003 .055 .087 .012 .322 
Age .128 .098 .003 . .000 .018 .317 .152 
BMI .496 .026 .055 .000 . .156 .248 .378 
IPAQ .218 .374 .087 .018 .156 . .091 .032 
MCQ .011 .488 .012 .317 .248 .091 . .157 
Iron .348 .312 .322 .152 .378 .032 .157 . 
N Behavioural/Severity 235 235 235 235 235 225 170 230 
Haemoglobin 235 235 235 235 235 225 170 230 
Ferritin 235 235 235 235 235 225 170 230 
Age 235 235 235 235 235 225 170 230 
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BMI 235 235 235 235 235 225 170 230 
IPAQ 225 225 225 225 225 225 163 221 
MCQ 170 170 170 170 170 163 170 167 
Iron 230 230 230 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Behavioural/Severity 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .204a .042 -.002 1.92666 .042 .959 7 155 .463 2.011 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 







Model Sum of Squares df Mean Square F Sig. 
1 Regression 24.928 7 3.561 .959 .463b 
Residual 575.363 155 3.712   
Total 600.291 162    
a. Dependent Variable: Behavioural/Severity 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) .230 3.187  .072 .943      
Haemoglobin .022 .024 .076 .909 .365 .072 .073 .071 .893 1.120 
Ferritin -.002 .005 -.030 -.357 .722 -.052 -.029 -.028 .861 1.161 
Age -.012 .019 -.053 -.631 .529 -.074 -.051 -.050 .865 1.156 
BMI .000 .041 -.001 -.008 .993 -.001 -.001 -.001 .907 1.103 
IPAQ 2.297E-5 .000 .025 .310 .757 .052 .025 .024 .950 1.052 
MCQ .133 .065 .165 2.050 .042 .176 .162 .161 .951 1.051 
Iron .005 .043 .010 .126 .900 .026 .010 .010 .969 1.032 







Model Iron BMI MCQ Haemoglobin IPAQ Age Ferritin 
1 Correlations Iron 1.000 .002 -.061 -.053 -.129 -.096 .038 
BMI .002 1.000 -.073 -.140 .034 -.254 -.029 
MCQ -.061 -.073 1.000 -.032 -.085 .013 .169 
Haemoglobin -.053 -.140 -.032 1.000 .021 .173 -.275 
IPAQ -.129 .034 -.085 .021 1.000 .125 .037 
Age -.096 -.254 .013 .173 .125 1.000 -.189 
Ferritin .038 -.029 .169 -.275 .037 -.189 1.000 
Covariances Iron .002 4.243E-6 .000 -5.520E-5 -4.101E-7 -7.656E-5 8.430E-6 
BMI 4.243E-6 .002 .000 .000 1.017E-7 .000 -6.189E-6 
MCQ .000 .000 .004 -5.034E-5 -4.109E-7 1.525E-5 5.668E-5 
Haemoglobin -5.520E-5 .000 -5.034E-5 .001 3.875E-8 7.903E-5 -3.478E-5 
IPAQ -4.101E-7 1.017E-7 -4.109E-7 3.875E-8 5.493E-9 1.732E-7 1.427E-8 
Age -7.656E-5 .000 1.525E-5 7.903E-5 1.732E-7 .000 -1.817E-5 
Ferritin 8.430E-6 -6.189E-6 5.668E-5 -3.478E-5 1.427E-8 -1.817E-5 2.666E-5 









Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.939 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .417 4.079 .00 .00 .38 .00 .00 .08 .25 .00 
3 .282 4.961 .00 .00 .00 .00 .00 .65 .38 .00 
4 .203 5.844 .00 .00 .51 .04 .01 .16 .34 .04 
5 .085 9.055 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 11.005 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.307 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 76.680 .97 .97 .06 .04 .00 .00 .00 .00 






 Affective Meaning Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Affective Meaning 1.000 .081 -.063 -.079 -.056 .031 .188 .088 
Haemoglobin .081 1.000 .258 -.085 .127 -.021 -.002 .032 
Ferritin -.063 .258 1.000 .181 .104 -.091 -.173 -.031 
Age -.079 -.085 .181 1.000 .255 -.140 -.037 .068 
BMI -.056 .127 .104 .255 1.000 -.068 .053 .021 
IPAQ .031 -.021 -.091 -.140 -.068 1.000 .105 .125 
MCQ .188 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .088 .032 -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Affective Meaning . .107 .170 .113 .196 .324 .007 .092 
Haemoglobin .107 . .000 .098 .026 .374 .488 .312 
Ferritin .170 .000 . .003 .055 .087 .012 .322 
Age .113 .098 .003 . .000 .018 .317 .152 
BMI .196 .026 .055 .000 . .156 .248 .378 
IPAQ .324 .374 .087 .018 .156 . .091 .032 
MCQ .007 .488 .012 .317 .248 .091 . .157 
Iron .092 .312 .322 .152 .378 .032 .157 . 
N Affective Meaning 235 235 235 235 235 225 170 230 
Haemoglobin 235 235 235 235 235 225 170 230 
Ferritin 235 235 235 235 235 225 170 230 
Age 235 235 235 235 235 225 170 230 
BMI 235 235 235 235 235 225 170 230 
IPAQ 225 225 225 225 225 225 163 221 
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MCQ 170 170 170 170 170 163 170 167 
Iron 230 230 230 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Affective Meaning 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .239a .057 .015 2.07254 .057 1.347 7 155 .232 2.154 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 40.494 7 5.785 1.347 .232b 
Residual 665.789 155 4.295   
Total 706.283 162    
a. Dependent Variable: Affective Meaning 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 1.211 3.428  .353 .724      
Haemoglobin .030 .026 .093 1.127 .262 .081 .090 .088 .893 1.120 
Ferritin -.003 .006 -.039 -.464 .643 -.063 -.037 -.036 .861 1.161 
Age -.012 .020 -.048 -.574 .567 -.079 -.046 -.045 .865 1.156 
BMI -.034 .044 -.063 -.774 .440 -.056 -.062 -.060 .907 1.103 
IPAQ -1.008E-5 .000 -.010 -.126 .900 .031 -.010 -.010 .950 1.052 
MCQ .156 .070 .179 2.233 .027 .188 .177 .174 .951 1.051 
Iron .044 .046 .076 .955 .341 .088 .076 .074 .969 1.032 






Model Iron BMI MCQ Haemoglobin IPAQ Age Ferritin 
1 Correlations Iron 1.000 .002 -.061 -.053 -.129 -.096 .038 
BMI .002 1.000 -.073 -.140 .034 -.254 -.029 
MCQ -.061 -.073 1.000 -.032 -.085 .013 .169 
Haemoglobin -.053 -.140 -.032 1.000 .021 .173 -.275 
IPAQ -.129 .034 -.085 .021 1.000 .125 .037 
Age -.096 -.254 .013 .173 .125 1.000 -.189 
Ferritin .038 -.029 .169 -.275 .037 -.189 1.000 
Covariances Iron .002 4.910E-6 .000 -6.387E-5 -4.746E-7 -8.859E-5 9.755E-6 
BMI 4.910E-6 .002 .000 .000 1.177E-7 .000 -7.161E-6 
MCQ .000 .000 .005 -5.825E-5 -4.755E-7 1.765E-5 6.558E-5 
Haemoglobin -6.387E-5 .000 -5.825E-5 .001 4.484E-8 9.145E-5 -4.024E-5 
IPAQ -4.746E-7 1.177E-7 -4.755E-7 4.484E-8 6.356E-9 2.004E-7 1.651E-8 
Age -8.859E-5 .000 1.765E-5 9.145E-5 2.004E-7 .000 -2.102E-5 
Ferritin 9.755E-6 -7.161E-6 6.558E-5 -4.024E-5 1.651E-8 -2.102E-5 3.085E-5 









Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.939 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .417 4.079 .00 .00 .38 .00 .00 .08 .25 .00 
3 .282 4.961 .00 .00 .00 .00 .00 .65 .38 .00 
4 .203 5.844 .00 .00 .51 .04 .01 .16 .34 .04 
5 .085 9.055 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 11.005 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.307 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 76.680 .97 .97 .06 .04 .00 .00 .00 .00 







 Sensory Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Sensory 1.000 .107 -.061 -.154 -.093 .012 .132 -.034 
Haemoglobin .107 1.000 .258 -.085 .127 -.021 -.002 .032 
Ferritin -.061 .258 1.000 .181 .104 -.091 -.173 -.031 
Age -.154 -.085 .181 1.000 .255 -.140 -.037 .068 
BMI -.093 .127 .104 .255 1.000 -.068 .053 .021 
IPAQ .012 -.021 -.091 -.140 -.068 1.000 .105 .125 
MCQ .132 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron -.034 .032 -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Sensory . .052 .177 .009 .077 .432 .043 .302 
Haemoglobin .052 . .000 .098 .026 .374 .488 .312 
Ferritin .177 .000 . .003 .055 .087 .012 .322 
Age .009 .098 .003 . .000 .018 .317 .152 
BMI .077 .026 .055 .000 . .156 .248 .378 
IPAQ .432 .374 .087 .018 .156 . .091 .032 
MCQ .043 .488 .012 .317 .248 .091 . .157 
Iron .302 .312 .322 .152 .378 .032 .157 . 
N Sensory 235 235 235 235 235 225 170 230 
Haemoglobin 235 235 235 235 235 225 170 230 
Ferritin 235 235 235 235 235 225 170 230 
Age 235 235 235 235 235 225 170 230 
BMI 235 235 235 235 235 225 170 230 
IPAQ 225 225 225 225 225 225 163 221 
 411 
MCQ 170 170 170 170 170 163 170 167 
Iron 230 230 230 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Sensory 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .241a .058 .016 1.93015 .058 1.371 7 155 .221 2.140 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 35.764 7 5.109 1.371 .221b 
Residual 577.449 155 3.725   
Total 613.213 162    
a. Dependent Variable: Sensory 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 2.604 3.193  .816 .416      
Haemoglobin .036 .024 .120 1.458 .147 .107 .116 .114 .893 1.120 
Ferritin -.003 .005 -.044 -.521 .603 -.061 -.042 -.041 .861 1.161 
Age -.024 .019 -.110 -1.309 .192 -.154 -.105 -.102 .865 1.156 
BMI -.042 .041 -.083 -1.020 .309 -.093 -.082 -.079 .907 1.103 
IPAQ -1.831E-5 .000 -.020 -.247 .806 .012 -.020 -.019 .950 1.052 
MCQ .106 .065 .130 1.625 .106 .132 .129 .127 .951 1.051 
Iron -.021 .043 -.038 -.482 .631 -.034 -.039 -.038 .969 1.032 






Model Iron BMI MCQ Haemoglobin IPAQ Age Ferritin 
1 Correlations Iron 1.000 .002 -.061 -.053 -.129 -.096 .038 
BMI .002 1.000 -.073 -.140 .034 -.254 -.029 
MCQ -.061 -.073 1.000 -.032 -.085 .013 .169 
Haemoglobin -.053 -.140 -.032 1.000 .021 .173 -.275 
IPAQ -.129 .034 -.085 .021 1.000 .125 .037 
Age -.096 -.254 .013 .173 .125 1.000 -.189 
Ferritin .038 -.029 .169 -.275 .037 -.189 1.000 
Covariances Iron .002 4.259E-6 .000 -5.540E-5 -4.116E-7 -7.684E-5 8.461E-6 
BMI 4.259E-6 .002 .000 .000 1.021E-7 .000 -6.211E-6 
MCQ .000 .000 .004 -5.052E-5 -4.124E-7 1.530E-5 5.688E-5 
Haemoglobin -5.540E-5 .000 -5.052E-5 .001 3.889E-8 7.932E-5 -3.490E-5 
IPAQ -4.116E-7 1.021E-7 -4.124E-7 3.889E-8 5.513E-9 1.738E-7 1.432E-8 
Age -7.684E-5 .000 1.530E-5 7.932E-5 1.738E-7 .000 -1.823E-5 
Ferritin 8.461E-6 -6.211E-6 5.688E-5 -3.490E-5 1.432E-8 -1.823E-5 2.676E-5 









Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.939 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .417 4.079 .00 .00 .38 .00 .00 .08 .25 .00 
3 .282 4.961 .00 .00 .00 .00 .00 .65 .38 .00 
4 .203 5.844 .00 .00 .51 .04 .01 .16 .34 .04 
5 .085 9.055 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 11.005 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.307 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 76.680 .97 .97 .06 .04 .00 .00 .00 .00 







 Cognition/Mood Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Cognition/Mood 1.000 .068 -.041 -.022 -.088 .028 .073 .042 
Haemoglobin .068 1.000 .258 -.085 .127 -.021 -.002 .032 
Ferritin -.041 .258 1.000 .181 .104 -.091 -.173 -.031 
Age -.022 -.085 .181 1.000 .255 -.140 -.037 .068 
BMI -.088 .127 .104 .255 1.000 -.068 .053 .021 
IPAQ .028 -.021 -.091 -.140 -.068 1.000 .105 .125 
MCQ .073 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .042 .032 -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Cognition/Mood . .150 .267 .366 .091 .338 .171 .263 
Haemoglobin .150 . .000 .098 .026 .374 .488 .312 
Ferritin .267 .000 . .003 .055 .087 .012 .322 
Age .366 .098 .003 . .000 .018 .317 .152 
BMI .091 .026 .055 .000 . .156 .248 .378 
IPAQ .338 .374 .087 .018 .156 . .091 .032 
MCQ .171 .488 .012 .317 .248 .091 . .157 
Iron .263 .312 .322 .152 .378 .032 .157 . 
N Cognition/Mood 235 235 235 235 235 225 170 230 
Haemoglobin 235 235 235 235 235 225 170 230 
Ferritin 235 235 235 235 235 225 170 230 
Age 235 235 235 235 235 225 170 230 
BMI 235 235 235 235 235 225 170 230 
IPAQ 225 225 225 225 225 225 163 221 
 416 
MCQ 170 170 170 170 170 163 170 167 
Iron 230 230 230 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Cognition/Mood 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .153a .023 -.021 1.71951 .023 .532 7 155 .809 1.944 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 11.012 7 1.573 .532 .809b 
Residual 458.292 155 2.957   
Total 469.305 162    
a. Dependent Variable: Cognition/Mood 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 2.197 2.845  .772 .441      
Haemoglobin .024 .022 .094 1.119 .265 .068 .089 .089 .893 1.120 
Ferritin -.002 .005 -.044 -.520 .604 -.041 -.042 -.041 .861 1.161 
Age .004 .017 .022 .258 .797 -.022 .021 .020 .865 1.156 
BMI -.046 .037 -.104 -1.248 .214 -.088 -.100 -.099 .907 1.103 
IPAQ 8.807E-6 .000 .011 .133 .894 .028 .011 .011 .950 1.052 
MCQ .049 .058 .069 .842 .401 .073 .067 .067 .951 1.051 
Iron .015 .038 .031 .390 .697 .042 .031 .031 .969 1.032 






Model Iron BMI MCQ Haemoglobin IPAQ Age Ferritin 
1 Correlations Iron 1.000 .002 -.061 -.053 -.129 -.096 .038 
BMI .002 1.000 -.073 -.140 .034 -.254 -.029 
MCQ -.061 -.073 1.000 -.032 -.085 .013 .169 
Haemoglobin -.053 -.140 -.032 1.000 .021 .173 -.275 
IPAQ -.129 .034 -.085 .021 1.000 .125 .037 
Age -.096 -.254 .013 .173 .125 1.000 -.189 
Ferritin .038 -.029 .169 -.275 .037 -.189 1.000 
Covariances Iron .001 3.380E-6 .000 -4.397E-5 -3.267E-7 -6.098E-5 6.715E-6 
BMI 3.380E-6 .001 .000 .000 8.102E-8 .000 -4.929E-6 
MCQ .000 .000 .003 -4.010E-5 -3.273E-7 1.215E-5 4.514E-5 
Haemoglobin -4.397E-5 .000 -4.010E-5 .000 3.087E-8 6.295E-5 -2.770E-5 
IPAQ -3.267E-7 8.102E-8 -3.273E-7 3.087E-8 4.375E-9 1.379E-7 1.136E-8 
Age -6.098E-5 .000 1.215E-5 6.295E-5 1.379E-7 .000 -1.447E-5 
Ferritin 6.715E-6 -4.929E-6 4.514E-5 -2.770E-5 1.136E-8 -1.447E-5 2.124E-5 









Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.939 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .417 4.079 .00 .00 .38 .00 .00 .08 .25 .00 
3 .282 4.961 .00 .00 .00 .00 .00 .65 .38 .00 
4 .203 5.844 .00 .00 .51 .04 .01 .16 .34 .04 
5 .085 9.055 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 11.005 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.307 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 76.680 .97 .97 .06 .04 .00 .00 .00 .00 






 Total Fatigue Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Total Fatigue 1.000 .091 -.061 -.091 -.064 .035 .160 .035 
Haemoglobin .091 1.000 .258 -.085 .127 -.021 -.002 .032 
Ferritin -.061 .258 1.000 .181 .104 -.091 -.173 -.031 
Age -.091 -.085 .181 1.000 .255 -.140 -.037 .068 
BMI -.064 .127 .104 .255 1.000 -.068 .053 .021 
IPAQ .035 -.021 -.091 -.140 -.068 1.000 .105 .125 
MCQ .160 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .035 .032 -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Total Fatigue . .081 .178 .081 .163 .299 .019 .299 
Haemoglobin .081 . .000 .098 .026 .374 .488 .312 
Ferritin .178 .000 . .003 .055 .087 .012 .322 
Age .081 .098 .003 . .000 .018 .317 .152 
BMI .163 .026 .055 .000 . .156 .248 .378 
IPAQ .299 .374 .087 .018 .156 . .091 .032 
MCQ .019 .488 .012 .317 .248 .091 . .157 
Iron .299 .312 .322 .152 .378 .032 .157 . 
N Total Fatigue 235 235 235 235 235 225 170 230 
Haemoglobin 235 235 235 235 235 225 170 230 
Ferritin 235 235 235 235 235 225 170 230 
Age 235 235 235 235 235 225 170 230 
BMI 235 235 235 235 235 225 170 230 
IPAQ 225 225 225 225 225 225 163 221 
MCQ 170 170 170 170 170 163 170 167 
 421 
Iron 230 230 230 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Total Fatigue 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .216a .047 .004 1.69186 .047 1.085 7 155 .376 2.116 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 21.736 7 3.105 1.085 .376b 
Residual 443.670 155 2.862   
Total 465.406 162    
a. Dependent Variable: Total Fatigue 









Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 1.530 2.799  .547 .585      
Haemoglobin .028 .021 .107 1.285 .201 .091 .103 .101 .893 1.120 
Ferritin -.002 .005 -.044 -.524 .601 -.061 -.042 -.041 .861 1.161 
Age -.010 .016 -.053 -.624 .534 -.091 -.050 -.049 .865 1.156 
BMI -.030 .036 -.068 -.826 .410 -.064 -.066 -.065 .907 1.103 
IPAQ 2.390E-6 .000 .003 .037 .971 .035 .003 .003 .950 1.052 
MCQ .108 .057 .152 1.886 .061 .160 .150 .148 .951 1.051 
Iron .011 .038 .023 .288 .774 .035 .023 .023 .969 1.032 





Model Iron BMI MCQ Haemoglobin IPAQ Age Ferritin 
1 Correlations Iron 1.000 .002 -.061 -.053 -.129 -.096 .038 
BMI .002 1.000 -.073 -.140 .034 -.254 -.029 
MCQ -.061 -.073 1.000 -.032 -.085 .013 .169 
Haemoglobin -.053 -.140 -.032 1.000 .021 .173 -.275 
IPAQ -.129 .034 -.085 .021 1.000 .125 .037 
Age -.096 -.254 .013 .173 .125 1.000 -.189 
Ferritin .038 -.029 .169 -.275 .037 -.189 1.000 
Covariances Iron .001 3.272E-6 .000 -4.256E-5 -3.163E-7 -5.904E-5 6.501E-6 
BMI 3.272E-6 .001 .000 .000 7.844E-8 .000 -4.772E-6 
MCQ .000 .000 .003 -3.882E-5 -3.169E-7 1.176E-5 4.370E-5 
Haemoglobin -4.256E-5 .000 -3.882E-5 .000 2.988E-8 6.094E-5 -2.682E-5 
IPAQ -3.163E-7 7.844E-8 -3.169E-7 2.988E-8 4.236E-9 1.335E-7 1.100E-8 
Age -5.904E-5 .000 1.176E-5 6.094E-5 1.335E-7 .000 -1.401E-5 
Ferritin 6.501E-6 -4.772E-6 4.370E-5 -2.682E-5 1.100E-8 -1.401E-5 2.056E-5 








Model Dimension Eigenvalue Condition Index Variance Proportions 
 424 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.939 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .417 4.079 .00 .00 .38 .00 .00 .08 .25 .00 
3 .282 4.961 .00 .00 .00 .00 .00 .65 .38 .00 
4 .203 5.844 .00 .00 .51 .04 .01 .16 .34 .04 
5 .085 9.055 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 11.005 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.307 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 76.680 .97 .97 .06 .04 .00 .00 .00 .00 







Mental Fatigue (VAS) 
Correlations 
 Mental_Fatigue Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Mental_Fatigue 1.000 .043 -.073 .013 -.036 -.018 -.001 .042 
Haemoglobin .043 1.000 .258 -.085 .127 -.021 -.002 .032 
Ferritin -.073 .258 1.000 .181 .104 -.091 -.173 -.031 
Age .013 -.085 .181 1.000 .255 -.140 -.037 .068 
BMI -.036 .127 .104 .255 1.000 -.068 .053 .021 
IPAQ -.018 -.021 -.091 -.140 -.068 1.000 .105 .125 
MCQ -.001 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .042 .032 -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Mental_Fatigue . .257 .133 .421 .292 .394 .496 .262 
Haemoglobin .257 . .000 .098 .026 .374 .488 .312 
Ferritin .133 .000 . .003 .055 .087 .012 .322 
Age .421 .098 .003 . .000 .018 .317 .152 
BMI .292 .026 .055 .000 . .156 .248 .378 
IPAQ .394 .374 .087 .018 .156 . .091 .032 
MCQ .496 .488 .012 .317 .248 .091 . .157 
Iron .262 .312 .322 .152 .378 .032 .157 . 
N Mental_Fatigue 235 235 235 235 235 225 170 230 
Haemoglobin 235 235 235 235 235 225 170 230 
Ferritin 235 235 235 235 235 225 170 230 
Age 235 235 235 235 235 225 170 230 
BMI 235 235 235 235 235 225 170 230 
IPAQ 225 225 225 225 225 225 163 221 
 426 
MCQ 170 170 170 170 170 163 170 167 
Iron 230 230 230 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Mental_Fatigue 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .122a .015 -.030 18.30384 .015 .335 7 155 .937 2.270 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 786.797 7 112.400 .335 .937b 
Residual 51929.741 155 335.031   
Total 52716.538 162    
a. Dependent Variable: Mental_Fatigue 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 38.863 30.279  1.283 .201      
Haemoglobin .210 .232 .076 .905 .367 .043 .072 .072 .893 1.120 
Ferritin -.057 .049 -.099 -1.153 .251 -.073 -.092 -.092 .861 1.161 
Age .089 .177 .043 .501 .617 .013 .040 .040 .865 1.156 
BMI -.223 .389 -.048 -.573 .567 -.036 -.046 -.046 .907 1.103 
IPAQ .000 .001 -.026 -.318 .751 -.018 -.026 -.025 .950 1.052 
MCQ -.106 .619 -.014 -.171 .864 -.001 -.014 -.014 .951 1.051 
Iron .198 .408 .039 .484 .629 .042 .039 .039 .969 1.032 






Model Iron BMI MCQ Haemoglobin IPAQ Age Ferritin 
1 Correlations Iron 1.000 .002 -.061 -.053 -.129 -.096 .038 
BMI .002 1.000 -.073 -.140 .034 -.254 -.029 
MCQ -.061 -.073 1.000 -.032 -.085 .013 .169 
Haemoglobin -.053 -.140 -.032 1.000 .021 .173 -.275 
IPAQ -.129 .034 -.085 .021 1.000 .125 .037 
Age -.096 -.254 .013 .173 .125 1.000 -.189 
Ferritin .038 -.029 .169 -.275 .037 -.189 1.000 
Covariances Iron .167 .000 -.015 -.005 -3.702E-5 -.007 .001 
BMI .000 .151 -.018 -.013 9.181E-6 -.017 -.001 
MCQ -.015 -.018 .383 -.005 -3.709E-5 .001 .005 
Haemoglobin -.005 -.013 -.005 .054 3.498E-6 .007 -.003 
IPAQ -3.702E-5 9.181E-6 -3.709E-5 3.498E-6 4.958E-7 1.563E-5 1.288E-6 
Age -.007 -.017 .001 .007 1.563E-5 .031 -.002 
Ferritin .001 -.001 .005 -.003 1.288E-6 -.002 .002 









Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.939 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .417 4.079 .00 .00 .38 .00 .00 .08 .25 .00 
3 .282 4.961 .00 .00 .00 .00 .00 .65 .38 .00 
4 .203 5.844 .00 .00 .51 .04 .01 .16 .34 .04 
5 .085 9.055 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 11.005 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.307 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 76.680 .97 .97 .06 .04 .00 .00 .00 .00 








 Alertness Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation Alertness 1.000 -.033 .050 .108 .151 .055 -.157 -.037 
Haemoglobin -.033 1.000 .258 -.085 .127 -.021 -.002 .032 
Ferritin .050 .258 1.000 .181 .104 -.091 -.173 -.031 
Age .108 -.085 .181 1.000 .255 -.140 -.037 .068 
BMI .151 .127 .104 .255 1.000 -.068 .053 .021 
IPAQ .055 -.021 -.091 -.140 -.068 1.000 .105 .125 
MCQ -.157 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron -.037 .032 -.031 .068 .021 .125 .078 1.000 
Sig. (1-tailed) Alertness . .308 .225 .050 .010 .204 .021 .291 
Haemoglobin .308 . .000 .098 .026 .374 .488 .312 
Ferritin .225 .000 . .003 .055 .087 .012 .322 
Age .050 .098 .003 . .000 .018 .317 .152 
BMI .010 .026 .055 .000 . .156 .248 .378 
IPAQ .204 .374 .087 .018 .156 . .091 .032 
MCQ .021 .488 .012 .317 .248 .091 . .157 
Iron .291 .312 .322 .152 .378 .032 .157 . 
N Alertness 234 234 234 234 234 224 169 229 
Haemoglobin 234 235 235 235 235 225 170 230 
Ferritin 234 235 235 235 235 225 170 230 
Age 234 235 235 235 235 225 170 230 
BMI 234 235 235 235 235 225 170 230 
IPAQ 224 225 225 225 225 225 163 221 
 431 
MCQ 169 170 170 170 170 163 170 167 
Iron 229 230 230 230 230 221 167 230 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: Alertness 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .258a .067 .024 18.18269 .067 1.580 7 155 .145 1.857 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 3656.795 7 522.399 1.580 .145b 
Residual 51244.599 155 330.610   
Total 54901.394 162    
a. Dependent Variable: Alertness 









Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 37.700 30.079  1.253 .212      
Haemoglobin -.129 .231 -.046 -.560 .576 -.033 -.045 -.043 .893 1.120 
Ferritin .006 .049 .011 .129 .897 .050 .010 .010 .861 1.161 
Age .154 .176 .073 .877 .382 .108 .070 .068 .865 1.156 
BMI .728 .386 .154 1.885 .061 .151 .150 .146 .907 1.103 
IPAQ .001 .001 .099 1.243 .216 .055 .099 .096 .950 1.052 
MCQ -1.298 .614 -.168 -2.112 .036 -.157 -.167 -.164 .951 1.051 
Iron -.216 .406 -.042 -.534 .594 -.037 -.043 -.041 .969 1.032 





Model Iron BMI MCQ Haemoglobin IPAQ Age Ferritin 
1 Correlations Iron 1.000 .002 -.061 -.053 -.129 -.096 .038 
BMI .002 1.000 -.073 -.140 .034 -.254 -.029 
MCQ -.061 -.073 1.000 -.032 -.085 .013 .169 
Haemoglobin -.053 -.140 -.032 1.000 .021 .173 -.275 
IPAQ -.129 .034 -.085 .021 1.000 .125 .037 
Age -.096 -.254 .013 .173 .125 1.000 -.189 
Ferritin .038 -.029 .169 -.275 .037 -.189 1.000 
Covariances Iron .164 .000 -.015 -.005 -3.653E-5 -.007 .001 
BMI .000 .149 -.017 -.012 9.060E-6 -.017 -.001 
MCQ -.015 -.017 .378 -.004 -3.660E-5 .001 .005 
Haemoglobin -.005 -.012 -.004 .053 3.452E-6 .007 -.003 
IPAQ -3.653E-5 9.060E-6 -3.660E-5 3.452E-6 4.892E-7 1.542E-5 1.271E-6 
Age -.007 -.017 .001 .007 1.542E-5 .031 -.002 
Ferritin .001 -.001 .005 -.003 1.271E-6 -.002 .002 









Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.939 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .417 4.079 .00 .00 .38 .00 .00 .08 .25 .00 
3 .282 4.961 .00 .00 .00 .00 .00 .65 .38 .00 
4 .203 5.844 .00 .00 .51 .04 .01 .16 .34 .04 
5 .085 9.055 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 11.005 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.307 .03 .03 .00 .02 .93 .01 .00 .03 
8 .001 76.680 .97 .97 .06 .04 .00 .00 .00 .00 






Predictors of subjective wellbeing (SF-12) 
Physical functioning 
Correlations 
 PF_NBS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation PF_NBS 1.000 -.112 -.075 .004 -.112 .115 -.021 .112 
Haemoglobin -.112 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin -.075 .258 1.000 .182 .104 -.091 -.173 -.031 
Age .004 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI -.112 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ .115 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.021 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .112 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) PF_NBS . .043 .128 .473 .044 .043 .393 .045 
Haemoglobin .043 . .000 .097 .026 .375 .488 .309 
Ferritin .128 .000 . .003 .056 .087 .012 .319 
Age .473 .097 .003 . .000 .019 .317 .134 
BMI .044 .026 .056 .000 . .159 .248 .365 
IPAQ .043 .375 .087 .019 .159 . .091 .034 
MCQ .393 .488 .012 .317 .248 .091 . .157 
Iron .045 .309 .319 .134 .365 .034 .157 . 
N PF_NBS 234 234 234 234 234 224 170 229 
Haemoglobin 234 234 234 234 234 224 170 229 
Ferritin 234 234 234 234 234 224 170 229 
Age 234 234 234 234 234 224 170 229 
BMI 234 234 234 234 234 224 170 229 
 436 
IPAQ 224 224 224 224 224 224 163 220 
MCQ 170 170 170 170 170 163 170 167 
Iron 229 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: PF_NBS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .219a .048 .005 6.21924 .048 1.117 7 155 .355 2.027 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 







Model Sum of Squares df Mean Square F Sig. 
1 Regression 302.337 7 43.191 1.117 .355b 
Residual 5995.228 155 38.679   
Total 6297.566 162    
a. Dependent Variable: PF_NBS 









Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 65.488 10.268  6.378 .000      
Haemoglobin -.083 .079 -.087 -1.050 .295 -.112 -.084 -.082 .893 1.120 
Ferritin -.008 .017 -.043 -.507 .613 -.075 -.041 -.040 .861 1.162 
Age .025 .060 .034 .407 .684 .004 .033 .032 .864 1.157 
BMI -.158 .132 -.099 -1.197 .233 -.112 -.096 -.094 .907 1.102 
IPAQ .000 .000 .099 1.229 .221 .115 .098 .096 .951 1.051 
MCQ -.106 .210 -.041 -.505 .614 -.021 -.041 -.040 .951 1.051 
Iron .182 .139 .104 1.310 .192 .112 .105 .103 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 






Role limitations due to physical functioning 
Correlations 
 RP_NBS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation RP_NBS 1.000 -.023 .070 .004 -.069 .062 -.042 .002 
Haemoglobin -.023 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin .070 .258 1.000 .182 .104 -.091 -.173 -.031 
Age .004 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI -.069 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ .062 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.042 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .002 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) RP_NBS . .363 .144 .477 .147 .180 .293 .489 
Haemoglobin .363 . .000 .097 .026 .375 .488 .309 
Ferritin .144 .000 . .003 .056 .087 .012 .319 
Age .477 .097 .003 . .000 .019 .317 .134 
BMI .147 .026 .056 .000 . .159 .248 .365 
IPAQ .180 .375 .087 .019 .159 . .091 .034 
MCQ .293 .488 .012 .317 .248 .091 . .157 
Iron .489 .309 .319 .134 .365 .034 .157 . 
N RP_NBS 234 234 234 234 234 224 170 229 
Haemoglobin 234 234 234 234 234 224 170 229 
Ferritin 234 234 234 234 234 224 170 229 
Age 234 234 234 234 234 224 170 229 
BMI 234 234 234 234 234 224 170 229 
IPAQ 224 224 224 224 224 224 163 220 
 440 
MCQ 170 170 170 170 170 163 170 167 
Iron 229 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: RP_NBS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .131a .017 -.027 7.12640 .017 .384 7 155 .911 1.703 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 136.550 7 19.507 .384 .911b 
Residual 7871.756 155 50.786   
Total 8008.306 162    
a. Dependent Variable: RP_NBS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 58.113 11.766  4.939 .000      
Haemoglobin -.036 .090 -.033 -.396 .693 -.023 -.032 -.032 .893 1.120 
Ferritin .019 .019 .084 .983 .327 .070 .079 .078 .861 1.162 
Age .010 .069 .012 .138 .890 .004 .011 .011 .864 1.157 
BMI -.127 .151 -.070 -.841 .402 -.069 -.067 -.067 .907 1.102 
IPAQ .000 .000 .069 .840 .402 .062 .067 .067 .951 1.051 
MCQ -.091 .241 -.031 -.376 .707 -.042 -.030 -.030 .951 1.051 
Iron .001 .159 .000 .003 .997 .002 .000 .000 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 







 BP_NBS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation BP_NBS 1.000 -.135 -.119 .107 -.051 -.135 -.002 .048 
Haemoglobin -.135 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin -.119 .258 1.000 .182 .104 -.091 -.173 -.031 
Age .107 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI -.051 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ -.135 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.002 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .048 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) BP_NBS . .020 .034 .052 .217 .022 .491 .236 
Haemoglobin .020 . .000 .097 .026 .375 .488 .309 
Ferritin .034 .000 . .003 .056 .087 .012 .319 
Age .052 .097 .003 . .000 .019 .317 .134 
BMI .217 .026 .056 .000 . .159 .248 .365 
IPAQ .022 .375 .087 .019 .159 . .091 .034 
MCQ .491 .488 .012 .317 .248 .091 . .157 
Iron .236 .309 .319 .134 .365 .034 .157 . 
N BP_NBS 234 234 234 234 234 224 170 229 
Haemoglobin 234 234 234 234 234 224 170 229 
Ferritin 234 234 234 234 234 224 170 229 
Age 234 234 234 234 234 224 170 229 
BMI 234 234 234 234 234 224 170 229 
IPAQ 224 224 224 224 224 224 163 220 
 444 
MCQ 170 170 170 170 170 163 170 167 
Iron 229 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: BP_NBS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .254a .064 .022 6.82418 .064 1.523 7 155 .163 1.972 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 496.375 7 70.911 1.523 .163b 
Residual 7218.254 155 46.569   
Total 7714.629 162    
a. Dependent Variable: BP_NBS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 67.404 11.267  5.983 .000      
Haemoglobin -.095 .086 -.090 -1.094 .275 -.135 -.088 -.085 .893 1.120 
Ferritin -.027 .018 -.122 -1.456 .147 -.119 -.116 -.113 .861 1.162 
Age .090 .066 .114 1.361 .175 .107 .109 .106 .864 1.157 
BMI -.118 .145 -.067 -.819 .414 -.051 -.066 -.064 .907 1.102 
IPAQ .000 .000 -.143 -1.797 .074 -.135 -.143 -.140 .951 1.051 
MCQ -.014 .231 -.005 -.062 .951 -.002 -.005 -.005 .951 1.051 
Iron .112 .153 .058 .736 .463 .048 .059 .057 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 





 GH_NBS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation GH_NBS 1.000 .008 -.031 -.039 -.154 .137 -.104 .092 
Haemoglobin .008 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin -.031 .258 1.000 .182 .104 -.091 -.173 -.031 
Age -.039 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI -.154 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ .137 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.104 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .092 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) GH_NBS . .450 .320 .275 .010 .020 .090 .082 
Haemoglobin .450 . .000 .097 .026 .375 .488 .309 
Ferritin .320 .000 . .003 .056 .087 .012 .319 
Age .275 .097 .003 . .000 .019 .317 .134 
BMI .010 .026 .056 .000 . .159 .248 .365 
IPAQ .020 .375 .087 .019 .159 . .091 .034 
MCQ .090 .488 .012 .317 .248 .091 . .157 
Iron .082 .309 .319 .134 .365 .034 .157 . 
N GH_NBS 233 233 233 233 233 223 169 228 
Haemoglobin 233 234 234 234 234 224 170 229 
Ferritin 233 234 234 234 234 224 170 229 
Age 233 234 234 234 234 224 170 229 
BMI 233 234 234 234 234 224 170 229 
IPAQ 223 224 224 224 224 224 163 220 
 448 
MCQ 169 170 170 170 170 163 170 167 
Iron 228 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: GH_NBS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .248a .061 .019 8.23403 .061 1.449 7 155 .190 1.971 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 687.502 7 98.215 1.449 .190b 
Residual 10508.872 155 67.799   
Total 11196.374 162    
a. Dependent Variable: GH_NBS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 51.904 13.595  3.818 .000      
Haemoglobin .046 .104 .036 .442 .659 .008 .035 .034 .893 1.120 
Ferritin -.009 .022 -.034 -.408 .684 -.031 -.033 -.032 .861 1.162 
Age .013 .080 .014 .166 .868 -.039 .013 .013 .864 1.157 
BMI -.310 .174 -.145 -1.776 .078 -.154 -.141 -.138 .907 1.102 
IPAQ .001 .000 .129 1.622 .107 .137 .129 .126 .951 1.051 
MCQ -.424 .278 -.122 -1.525 .129 -.104 -.122 -.119 .951 1.051 
Iron .200 .184 .086 1.087 .279 .092 .087 .085 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 







 VT_NBS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation VT_NBS 1.000 -.008 .039 -.046 -.192 .173 -.051 .081 
Haemoglobin -.008 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin .039 .258 1.000 .182 .104 -.091 -.173 -.031 
Age -.046 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI -.192 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ .173 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.051 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .081 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) VT_NBS . .452 .279 .244 .002 .005 .253 .112 
Haemoglobin .452 . .000 .097 .026 .375 .488 .309 
Ferritin .279 .000 . .003 .056 .087 .012 .319 
Age .244 .097 .003 . .000 .019 .317 .134 
BMI .002 .026 .056 .000 . .159 .248 .365 
IPAQ .005 .375 .087 .019 .159 . .091 .034 
MCQ .253 .488 .012 .317 .248 .091 . .157 
Iron .112 .309 .319 .134 .365 .034 .157 . 
N VT_NBS 233 233 233 233 233 223 169 228 
Haemoglobin 233 234 234 234 234 224 170 229 
Ferritin 233 234 234 234 234 224 170 229 
Age 233 234 234 234 234 224 170 229 
BMI 233 234 234 234 234 224 170 229 
IPAQ 223 224 224 224 224 224 163 220 
 452 
MCQ 169 170 170 170 170 163 170 167 
Iron 228 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: VT_NBS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .274a .075 .033 8.20089 .075 1.800 7 155 .091 1.783 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 847.333 7 121.048 1.800 .091b 
Residual 10424.457 155 67.255   
Total 11271.790 162    
a. Dependent Variable: VT_NBS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 56.021 13.540  4.138 .000      
Haemoglobin .001 .104 .001 .010 .992 -.008 .001 .001 .893 1.120 
Ferritin .017 .022 .065 .780 .437 .039 .063 .060 .861 1.162 
Age .006 .079 .006 .073 .942 -.046 .006 .006 .864 1.157 
BMI -.404 .174 -.189 -2.327 .021 -.192 -.184 -.180 .907 1.102 
IPAQ .001 .000 .163 2.064 .041 .173 .164 .159 .951 1.051 
MCQ -.185 .277 -.053 -.667 .506 -.051 -.053 -.052 .951 1.051 
Iron .165 .183 .071 .903 .368 .081 .072 .070 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 





 SF_NBS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation SF_NBS 1.000 .007 .116 .089 .009 .052 -.083 .077 
Haemoglobin .007 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin .116 .258 1.000 .182 .104 -.091 -.173 -.031 
Age .089 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI .009 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ .052 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.083 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .077 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) SF_NBS . .457 .039 .090 .446 .221 .141 .126 
Haemoglobin .457 . .000 .097 .026 .375 .488 .309 
Ferritin .039 .000 . .003 .056 .087 .012 .319 
Age .090 .097 .003 . .000 .019 .317 .134 
BMI .446 .026 .056 .000 . .159 .248 .365 
IPAQ .221 .375 .087 .019 .159 . .091 .034 
MCQ .141 .488 .012 .317 .248 .091 . .157 
Iron .126 .309 .319 .134 .365 .034 .157 . 
N SF_NBS 231 231 231 231 231 222 168 226 
Haemoglobin 231 234 234 234 234 224 170 229 
Ferritin 231 234 234 234 234 224 170 229 
Age 231 234 234 234 234 224 170 229 
BMI 231 234 234 234 234 224 170 229 
IPAQ 222 224 224 224 224 224 163 220 
 456 
MCQ 168 170 170 170 170 163 170 167 
Iron 226 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: SF_NBS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .184a .034 -.010 7.81538 .034 .773 7 155 .611 1.975 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 330.362 7 47.195 .773 .611b 
Residual 9467.437 155 61.080   
Total 9797.799 162    
a. Dependent Variable: SF_NBS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 46.990 12.903  3.642 .000      
Haemoglobin -.015 .099 -.013 -.153 .878 .007 -.012 -.012 .893 1.120 
Ferritin .025 .021 .103 1.211 .228 .116 .097 .096 .861 1.162 
Age .065 .076 .073 .864 .389 .089 .069 .068 .864 1.157 
BMI -.024 .166 -.012 -.143 .887 .009 -.011 -.011 .907 1.102 
IPAQ .000 .000 .069 .857 .393 .052 .069 .068 .951 1.051 
MCQ -.246 .264 -.075 -.930 .354 -.083 -.074 -.073 .951 1.051 
Iron .158 .175 .072 .902 .368 .077 .072 .071 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 





Role limitations due to emotional functioning 
Correlations 
 RE_NBS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation RE_NBS 1.000 -.062 .152 .117 .047 .100 -.045 .028 
Haemoglobin -.062 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin .152 .258 1.000 .182 .104 -.091 -.173 -.031 
Age .117 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI .047 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ .100 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.045 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .028 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) RE_NBS . .172 .010 .037 .237 .067 .280 .336 
Haemoglobin .172 . .000 .097 .026 .375 .488 .309 
Ferritin .010 .000 . .003 .056 .087 .012 .319 
Age .037 .097 .003 . .000 .019 .317 .134 
BMI .237 .026 .056 .000 . .159 .248 .365 
IPAQ .067 .375 .087 .019 .159 . .091 .034 
MCQ .280 .488 .012 .317 .248 .091 . .157 
Iron .336 .309 .319 .134 .365 .034 .157 . 
N RE_NBS 234 234 234 234 234 224 170 229 
Haemoglobin 234 234 234 234 234 224 170 229 
Ferritin 234 234 234 234 234 224 170 229 
Age 234 234 234 234 234 224 170 229 
BMI 234 234 234 234 234 224 170 229 
IPAQ 224 224 224 224 224 224 163 220 
 460 
MCQ 170 170 170 170 170 163 170 167 
Iron 229 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: RE_NBS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .240a .058 .015 10.23955 .058 1.355 7 155 .228 1.828 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 994.792 7 142.113 1.355 .228b 
Residual 16251.512 155 104.848   
Total 17246.304 162    
a. Dependent Variable: RE_NBS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 54.301 16.906  3.212 .002      
Haemoglobin -.156 .130 -.100 -1.206 .230 -.062 -.096 -.094 .893 1.120 
Ferritin .054 .027 .166 1.980 .049 .152 .157 .154 .861 1.162 
Age .102 .099 .086 1.027 .306 .117 .082 .080 .864 1.157 
BMI .080 .217 .030 .368 .713 .047 .030 .029 .907 1.102 
IPAQ .001 .000 .128 1.605 .111 .100 .128 .125 .951 1.051 
MCQ -.128 .346 -.030 -.370 .712 -.045 -.030 -.029 .951 1.051 
Iron .046 .229 .016 .203 .839 .028 .016 .016 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 







 MH_NBS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation MH_NBS 1.000 .001 .143 .067 -.042 .081 -.120 .026 
Haemoglobin .001 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin .143 .258 1.000 .182 .104 -.091 -.173 -.031 
Age .067 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI -.042 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ .081 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.120 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .026 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) MH_NBS . .492 .015 .153 .260 .114 .060 .346 
Haemoglobin .492 . .000 .097 .026 .375 .488 .309 
Ferritin .015 .000 . .003 .056 .087 .012 .319 
Age .153 .097 .003 . .000 .019 .317 .134 
BMI .260 .026 .056 .000 . .159 .248 .365 
IPAQ .114 .375 .087 .019 .159 . .091 .034 
MCQ .060 .488 .012 .317 .248 .091 . .157 
Iron .346 .309 .319 .134 .365 .034 .157 . 
N MH_NBS 233 233 233 233 233 223 169 228 
Haemoglobin 233 234 234 234 234 224 170 229 
Ferritin 233 234 234 234 234 224 170 229 
Age 233 234 234 234 234 224 170 229 
BMI 233 234 234 234 234 224 170 229 
IPAQ 223 224 224 224 224 224 163 220 
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MCQ 169 170 170 170 170 163 170 167 
Iron 228 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: MH_NBS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .219a .048 .005 9.11021 .048 1.111 7 155 .359 1.893 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 645.272 7 92.182 1.111 .359b 
Residual 12864.362 155 82.996   
Total 13509.634 162    
a. Dependent Variable: MH_NBS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 46.788 15.041  3.111 .002      
Haemoglobin -.027 .115 -.019 -.230 .818 .001 -.018 -.018 .893 1.120 
Ferritin .039 .024 .134 1.590 .114 .143 .127 .125 .861 1.162 
Age .068 .088 .065 .774 .440 .067 .062 .061 .864 1.157 
BMI -.137 .193 -.059 -.711 .478 -.042 -.057 -.056 .907 1.102 
IPAQ .000 .000 .106 1.321 .188 .081 .106 .104 .951 1.051 
MCQ -.400 .308 -.104 -1.298 .196 -.120 -.104 -.102 .951 1.051 
Iron .059 .204 .023 .288 .774 .026 .023 .023 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 







 PCS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation PCS 1.000 -.015 -.120 -.074 -.108 .081 -.024 .047 
Haemoglobin -.015 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin -.120 .258 1.000 .182 .104 -.091 -.173 -.031 
Age -.074 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI -.108 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ .081 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.024 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .047 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) PCS . .411 .035 .133 .052 .116 .381 .240 
Haemoglobin .411 . .000 .097 .026 .375 .488 .309 
Ferritin .035 .000 . .003 .056 .087 .012 .319 
Age .133 .097 .003 . .000 .019 .317 .134 
BMI .052 .026 .056 .000 . .159 .248 .365 
IPAQ .116 .375 .087 .019 .159 . .091 .034 
MCQ .381 .488 .012 .317 .248 .091 . .157 
Iron .240 .309 .319 .134 .365 .034 .157 . 
N PCS 229 229 229 229 229 220 167 224 
Haemoglobin 229 234 234 234 234 224 170 229 
Ferritin 229 234 234 234 234 224 170 229 
Age 229 234 234 234 234 224 170 229 
BMI 229 234 234 234 234 224 170 229 
IPAQ 220 224 224 224 224 224 163 220 
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MCQ 167 170 170 170 170 163 170 167 
Iron 224 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: PCS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .181a .033 -.011 5.62508 .033 .749 7 155 .631 1.894 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 165.834 7 23.691 .749 .631b 
Residual 4904.428 155 31.641   
Total 5070.262 162    
a. Dependent Variable: PCS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 57.948 9.287  6.240 .000      
Haemoglobin .020 .071 .023 .275 .783 -.015 .022 .022 .893 1.120 
Ferritin -.020 .015 -.113 -1.333 .185 -.120 -.106 -.105 .861 1.162 
Age -.016 .054 -.026 -.303 .762 -.074 -.024 -.024 .864 1.157 
BMI -.125 .119 -.087 -1.045 .297 -.108 -.084 -.083 .907 1.102 
IPAQ .000 .000 .062 .760 .448 .081 .061 .060 .951 1.051 
MCQ -.116 .190 -.049 -.609 .543 -.024 -.049 -.048 .951 1.051 
Iron .068 .126 .043 .540 .590 .047 .043 .043 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 







 MCS Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
Pearson Correlation MCS 1.000 .010 .160 .104 .028 .100 -.072 .046 
Haemoglobin .010 1.000 .258 -.085 .127 -.021 -.002 .033 
Ferritin .160 .258 1.000 .182 .104 -.091 -.173 -.031 
Age .104 -.085 .182 1.000 .254 -.139 -.037 .074 
BMI .028 .127 .104 .254 1.000 -.067 .053 .023 
IPAQ .100 -.021 -.091 -.139 -.067 1.000 .105 .123 
MCQ -.072 -.002 -.173 -.037 .053 .105 1.000 .078 
Iron .046 .033 -.031 .074 .023 .123 .078 1.000 
Sig. (1-tailed) MCS . .441 .008 .059 .338 .070 .180 .248 
Haemoglobin .441 . .000 .097 .026 .375 .488 .309 
Ferritin .008 .000 . .003 .056 .087 .012 .319 
Age .059 .097 .003 . .000 .019 .317 .134 
BMI .338 .026 .056 .000 . .159 .248 .365 
IPAQ .070 .375 .087 .019 .159 . .091 .034 
MCQ .180 .488 .012 .317 .248 .091 . .157 
Iron .248 .309 .319 .134 .365 .034 .157 . 
N MCS 229 229 229 229 229 220 166 224 
Haemoglobin 229 234 234 234 234 224 170 229 
Ferritin 229 234 234 234 234 224 170 229 
Age 229 234 234 234 234 224 170 229 
BMI 229 234 234 234 234 224 170 229 
IPAQ 220 224 224 224 224 224 163 220 
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MCQ 166 170 170 170 170 163 170 167 
Iron 224 229 229 229 229 220 167 229 
 
Variables Entered/Removeda 
Model Variables Entered 
Variables 
Removed Method 





a. Dependent Variable: MCS 
b. All requested variables entered. 
 
Model Summaryb 
Model R R Square 
Adjusted R 
Square 





Change F Change df1 df2 Sig. F Change 
1 .227a .052 .009 9.54926 .052 1.204 7 155 .304 1.865 
a. Predictors: (Constant), Iron, BMI, MCQ, Haemoglobin, IPAQ, Age, Ferritin 








Model Sum of Squares df Mean Square F Sig. 
1 Regression 768.470 7 109.781 1.204 .304b 
Residual 14134.205 155 91.188   
Total 14902.676 162    
a. Dependent Variable: MCS 








Correlations Collinearity Statistics 
B Std. Error Beta Zero-order Partial Part Tolerance VIF 
1 (Constant) 40.218 15.766  2.551 .012      
Haemoglobin -.030 .121 -.021 -.252 .802 .010 -.020 -.020 .893 1.120 
Ferritin .046 .026 .152 1.799 .074 .160 .143 .141 .861 1.162 
Age .095 .092 .087 1.029 .305 .104 .082 .081 .864 1.157 
BMI .009 .202 .004 .043 .966 .028 .003 .003 .907 1.102 
IPAQ .001 .000 .127 1.588 .114 .100 .126 .124 .951 1.051 
MCQ -.235 .323 -.058 -.729 .467 -.072 -.058 -.057 .951 1.051 
Iron .091 .213 .034 .424 .672 .046 .034 .033 .968 1.033 






Model Dimension Eigenvalue Condition Index 
Variance Proportions 
(Constant) Haemoglobin Ferritin Age BMI IPAQ MCQ Iron 
1 1 6.937 1.000 .00 .00 .00 .00 .00 .00 .00 .00 
2 .418 4.074 .00 .00 .38 .00 .00 .08 .25 .00 
3 .283 4.954 .00 .00 .00 .00 .00 .66 .38 .00 
4 .204 5.835 .00 .00 .51 .04 .01 .16 .35 .04 
5 .084 9.076 .00 .00 .03 .25 .01 .04 .00 .77 
6 .057 10.984 .01 .01 .01 .64 .05 .04 .02 .16 
7 .015 21.262 .03 .03 .00 .02 .93 .01 .00 .02 
8 .001 76.520 .97 .97 .06 .04 .00 .00 .00 .00 






Table 0.1 Cognitive task analysis outcomes for haemoglobin and serum ferritin. R2, β-weightings and p 
values of the unadjusted or adjusted models for haemoglobin and serum ferritin. 
 
 










Serum ferritin -.067 .328 
   










Years in education 
 























Serum ferritin -.012 .858 






Serum ferritin -.057 .406 
Age .156 .020 









Serum ferritin -.036 .599 
BMI -.189 .004 
 
 
Table 0.2 Subjective mood analysis (POMS) outcomes for haemoglobin and serum ferritin. R2, β-weightings 
and p values of the unadjusted or adjusted models for haemoglobin and serum ferritin. 
 
 






























Serum ferritin -.075 .278 
Total Mood Disturbance Haemoglobin .008 .094 .195 
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Serum ferritin -.033 .645 
    
 
Table 0.3 Subjective mood analysis (PSS and SCI) outcomes for haemoglobin and serum ferritin. R2, β-
weightings and p values of the unadjusted or adjusted models for haemoglobin and serum ferritin. 
 
 





Serum ferritin -.111 .163 





Serum ferritin .021 .789 
 Menstrual blood loss -.275 .000 
 
 
Table 0.4 Subjective workload analysis (NASA-TLX) outcomes for haemoglobin and serum ferritin. R2, β-
weightings and p values of the unadjusted or adjusted models for haemoglobin and serum ferritin. 
 
 





Serum ferritin -.035 .614 
 
 
Table 0.5 Subjective fatigue analysis (PFS and VAS) outcomes for haemoglobin and serum ferritin. R2, β-
weightings and p values of the unadjusted or adjusted models for haemoglobin and serum ferritin. 
 
 





Serum ferritin -.044 .583 





Serum ferritin -.056 .480 

























Serum ferritin .034 .672 





Table 0.6 Subjective wellbeing analysis (SF-12) outcomes for haemoglobin and serum ferritin. R2, β-
weightings and p values of the unadjusted or adjusted models for haemoglobin and serum ferritin. 
 
 

























Serum ferritin .073 .283 
BMI -.189 .005 















































Figure 0.1 The correlation of haemoglobin and serum ferritin grouped by iron status 
 
 















































































































Figure 0.5 Disposition of enrolled participants throughout the thesis for a) number of iron sufficient women and b) 
number of non-anaemic iron deficient women. All participants enrolled in the study presented in Chapter 4 had 
been enrolled in the study presented in Chapter 2. All participants enrolled in the study presented in Chapter 5 




   
 481 
APPENDIX VI: Treatment guess questionnaire 
 
 
Study Code:  9BN1       Date: ____/____/____ 





Which treatment do you think you were administered? (please circle) 
 
1. Placebo (dummy pill) 
2. Active (iron) 
 



















9BN1 The effects of daily iron and iron + vitamin C supplementation 
on brain function, subjective mood and fatigue in women of 
reproductive age following a 16-week intervention 
 
 
Subject ID:               ______ 
 



























For the success of the study it is very important that you follow the instructions of the 
study team very carefully. Therefore, please find a short summary of the most 
important points.  
 
Treatment consumption instructions 
Take 1 tablet per day, immediately upon wakening. Take tablets with water. Do not 
exceed the recommended dose. 
 
Diet 
During the course of the whole study you should not change your dietary habits.  
 
Medication / Therapy or Health Problems or Symptoms 
If you take any new medication or therapy or if you have any health problems or 
unusual symptoms you should document in as much detail as possible in this diary on 
the appropriate pages and talk about it to the researcher during the next appointment. 
You do not need to write down routine medications which have already been 
discussed at the screening visit. 
 
In general, you should avoid, if possible, the use of non-prescription drugs during the 
study. However, if you intend to use non-prescription drugs within the week preceding 
the next appointment, please contact the research team. There is a chance that the 
visit might be postponed. 
 
On the morning of your last appointment, do not take your treatment. 
 
Please bring this diary and any unused tablets to the next 
appointment. 
 
If you have any questions or any problems occur, please contact: 
 
Name: Hannah Avery 
E-mail: hannah.l.avery@northumbria.ac.uk  
 












Please remember to take your treatment immediately upon wakening. In the table below, please record the date and time 
each day that take the treatment. If you forget to take it, please leave this box blank. Any ill health or intake of non-routine 






 Week 1 Week 2 Week 3 Week 4 
Date Time Date Time Date Time Date Time 
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Please remember to take your treatment immediately upon wakening. In the table below, please record the date and time 
each day that take the treatment. If you forget to take it, please leave this box blank. Any ill health or intake of non-routine 






























Week 5 Week 6 Week 7 Week 8 
Date Time Date Time Date Time Date Time 
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Have you taken any medication or dietary supplements? 
 
  No     
 Yes: please give details in the table below. Please include the product/drug/therapy name in full, the amount (e.g. 1x200mg tablet), 
the date you took it and what you took it for. 
 
Product/drug/therapy name Quantity Dose Date 
 
What you took it for? 
Example: paracetamol 2 / day 500 mg/tablet 25-Apr-12 headache 
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    






Product/drug/therapy name Quantity Dose Date 
 
What you took it for? 
Example: paracetamol 2 / day 500 mg/tablet 25-Apr-12 headache 
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
     
 
     
 
     
 





Have you experienced any new health problems or unusual symptoms? 
 
 No     
 Yes, please give details in the table below. Please include your symptom(s), the date(s) it/they started and stopped if applicable, 






Please rate the 
severity of the 
symptom in terms 







please give the 
date it stopped 
Did you do anything to relieve your health 
problems/symptoms (like drug, therapy)? 
Example: headache 25-Apr-12 moderate 25-Apr-12 paracetamol 
 
 
    
 
 
    




    
 
 








Please rate the 
severity of the 
symptom in terms 







please give the 
date it stopped 
Did you do anything to relieve your health 
problems/symptoms (like drug, therapy)? 
Example: headache 25-Apr-12 moderate 25-Apr-12 paracetamol 
 
 
    
 
 
    




    
 
 
    
 
 
    
 
 




APPENDIX VIII: Chapter 4 cognitive outcomes 
 








Fixed Effects Intercept 1 1 
Treatment 3 2 
Baseline_Episodic_Accuracy 1 1 
Baseline_sft 1 1 
Residual  1 
Total 6 6 
 
a. Dependent Variable: PD_Episodic_Accuracy. 
 
Information Criteriaa 
-2 Restricted Log Likelihood 217.157 
Akaike's Information Criterion 
(AIC) 
219.157 
Hurvich and Tsai's Criterion 
(AICC) 
219.193 
Bozdogan's Criterion (CAIC) 222.893 




The information criteria are displayed in 
smaller-is-better form.a 




Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 114 .055 .814 
Treatment 2 114 .782 .460 
Baseline_Episodic_Accuracy 1 114 29.951 .000 
Baseline_sft 1 114 .206 .651 
 





Estimates of Covariance 
Parametersa 
Parameter Estimate Std. Error 
Residual .311902 .041312 
 
a. Dependent Variable: 
PD_Episodic_Accuracy. 
 





Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
1 -.090b .091 114 -.271 .091 
2 .065b .087 114 -.107 .236 
3 -.036b .090 114 -.213 .142 
 
a. Dependent Variable: PD_Episodic_Accuracy. 
b. Covariates appearing in the model are evaluated at the following values: 
Baseline_Episodic_Accuracy = -.0249, Baseline_sft = 34.50. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








1 3 -.054 .128 114 .893 -.345 
 





Numerator df Denominator df F Sig. 
2 114 .782 .460 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 












Fixed Effects Intercept 1 1 
Treatment 3 2 
Baseline_Episodic_Speed 1 1 
Baseline_sft 1 1 
Residual  1 
Total 6 6 
 
a. Dependent Variable: PD_Episodic_Speed. 
 
Information Criteriaa 
-2 Restricted Log Likelihood 224.437 
Akaike's Information Criterion 
(AIC) 
226.437 
Hurvich and Tsai's Criterion 
(AICC) 
226.474 
Bozdogan's Criterion (CAIC) 230.137 




The information criteria are displayed in 
smaller-is-better form.a 




Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 110 1.287 .259 
Treatment 2 110.000 .683 .507 
Baseline_Episodic_Speed 1 110 94.702 .000 
Baseline_sft 1 110 .237 .627 
 




Estimates of Covariance 
Parametersa 
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Parameter Estimate Std. Error 
Residual .352986 .047597 
 
a. Dependent Variable: 
PD_Episodic_Speed. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
1 .038b .099 110 -.158 .235 
2 -.120b .093 110 -.305 .064 
3 -.048b .097 110 -.240 .144 
 
a. Dependent Variable: PD_Episodic_Speed. 
b. Covariates appearing in the model are evaluated at the following values: 
Baseline_Episodic_Speed = .0416, Baseline_sft = 34.10. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








1 3 .086 .139 110 .783 -.228 
 




Numerator df Denominator df F Sig. 
2 110.000 .683 .507 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
















Fixed Effects Intercept 1 1 




Baseline_sft 1 1 
Residual  1 
Total 6 6 
 
a. Dependent Variable: PD_Exec_Func_Accuracy. 
 
Information Criteriaa 
-2 Restricted Log Likelihood 234.025 
Akaike's Information Criterion 
(AIC) 
236.025 
Hurvich and Tsai's Criterion 
(AICC) 
236.061 
Bozdogan's Criterion (CAIC) 239.761 




The information criteria are displayed in 
smaller-is-better form.a 





Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 114 1.460 .229 
Treatment 2 114 .522 .595 
Baseline_Exec_Func_Accur
acy 
1 114 24.298 .000 
Baseline_sft 1 114 2.634 .107 
 





Estimates of Covariance 
Parametersa 
Parameter Estimate Std. Error 
Residual .362800 .048054 
 
a. Dependent Variable: 
PD_Exec_Func_Accuracy. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
1 .041b .098 114 -.153 .235 
2 -.075b .093 114 -.259 .110 
3 .047b .097 114 -.145 .238 
 
a. Dependent Variable: PD_Exec_Func_Accuracy. 
b. Covariates appearing in the model are evaluated at the following values: 
Baseline_Executive_Function_Accuracy = -.0054, Baseline_sft = 34.50. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








1 3 -.006 .138 114 .999 -.317 
 




Numerator df Denominator df F Sig. 
2 114 .522 .595 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
a. Dependent Variable: PD_Exec_Func_Accuracy. 
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Fixed Effects Intercept 1 1 
Treatment 3 2 
Baseline_Exec_Func_Speed 1 1 
Baseline_sft 1 1 
Residual  1 
Total 6 6 
 
a. Dependent Variable: PD_Exec_Func_Speed. 
 
Information Criteriaa 
-2 Restricted Log Likelihood 220.741 
Akaike's Information Criterion 
(AIC) 
222.741 
Hurvich and Tsai's Criterion 
(AICC) 
222.777 
Bozdogan's Criterion (CAIC) 226.477 




The information criteria are displayed in 
smaller-is-better form.a 




Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 114 .829 .365 
Treatment 2 114 .735 .482 
Baseline_Exec_Func_Speed 1 114 114.046 .000 
Baseline_sft 1 114 1.663 .200 
 





Estimates of Covariance 
Parametersa 
Parameter Estimate Std. Error 
Residual .321576 .042594 
 
a. Dependent Variable: 
PD_Exec_Func_Speed. 
 





Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
1 .063b .092 114 -.120 .246 
2 -.070b .088 114 -.244 .104 
3 .063b .091 114 -.118 .243 
 
a. Dependent Variable: PD_Exec_Func_Speed. 
b. Covariates appearing in the model are evaluated at the following values: 
Baseline_Executive_Function_Speed = .0120, Baseline_sft = 34.50. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








1 3 -8.961E-5 .130 114 1.000 -.294 
 




Numerator df Denominator df F Sig. 
2 114 .735 .482 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 













Fixed Effects Intercept 1 1 




Baseline_sft 1 1 
Residual  1 
Total 6 6 
 
a. Dependent Variable: PD_Attention_Acc. 
 
Information Criteriaa 
-2 Restricted Log Likelihood 272.512 
Akaike's Information Criterion 
(AIC) 
274.512 
Hurvich and Tsai's Criterion 
(AICC) 
274.548 
Bozdogan's Criterion (CAIC) 278.239 




The information criteria are displayed in 
smaller-is-better form.a 




Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 113 .070 .791 
Treatment 2 113 1.581 .210 
Baseline_Attention_Accurac
y 
1 113 83.356 .000 
Baseline_sft 1 113 .011 .918 
 







Estimates of Covariance 
Parametersa 
Parameter Estimate Std. Error 
Residual .515097 .068527 
 
a. Dependent Variable: 
PD_Attention_Acc. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
1 .001b .118 113 -.233 .235 
2 .086b .111 113 -.134 .306 
3 -.194b .115 113 -.422 .035 
 
a. Dependent Variable: PD_Attention_Acc. 
b. Covariates appearing in the model are evaluated at the following values: 
Baseline_Attention_Accuracy = -.0219, Baseline_sft = 34.45. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








1 3 .195 .165 113 .423 -.179 
 




Numerator df Denominator df F Sig. 
2 113 1.581 .210 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 












Fixed Effects Intercept 1 1 
Treatment 3 2 
Baseline_Attention_Speed 1 1 
Baseline_sft 1 1 
Residual  1 
Total 6 6 
 
a. Dependent Variable: PD_Attention_Speed. 
 
Information Criteriaa 
-2 Restricted Log Likelihood 197.013 
Akaike's Information Criterion 
(AIC) 
199.013 
Hurvich and Tsai's Criterion 
(AICC) 
199.049 
Bozdogan's Criterion (CAIC) 202.741 




The information criteria are displayed in 
smaller-is-better form.a 





Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 113 .176 .676 
Treatment 2 113 2.120 .125 
Baseline_Attention_Speed 1 113 209.242 .000 
Baseline_sft 1 113 .678 .412 
 







Estimates of Covariance 
Parametersa 
Parameter Estimate Std. Error 
Residual .263957 .035116 
 
a. Dependent Variable: 
PD_Attention_Speed. 
 





Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
1 -.106b .085 113 -.274 .062 
2 .092b .079 113 -.066 .249 
3 .116b .083 113 -.047 .280 
 
a. Dependent Variable: PD_Attention_Speed. 
b. Covariates appearing in the model are evaluated at the following values: 
Baseline_Attention_Speed = .0205, Baseline_sft = 34.45. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








1 3 -.222 .118 113 .122 -.490 
 




Numerator df Denominator df F Sig. 
2 113 2.120 .125 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
a. Dependent Variable: PD_Attention_Speed. 
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Fixed Effects Intercept 1 1 
Treatment 3 2 
Baseline_CLLT 1 1 
Baseline_sft 1 1 
Residual  1 
Total 6 6 
 
a. Dependent Variable: PD_CLLT. 
 
Information Criteriaa 
-2 Restricted Log Likelihood 235.236 
Akaike's Information Criterion 
(AIC) 
237.236 
Hurvich and Tsai's Criterion 
(AICC) 
237.275 
Bozdogan's Criterion (CAIC) 240.890 




The information criteria are displayed in 
smaller-is-better form.a 
a. Dependent Variable: PD_CLLT. 
 
Fixed Effects 
Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 105 .225 .637 
Treatment 2 105 2.494 .087 
Baseline_CLLT 1 105 .058 .811 
Baseline_sft 1 105 .084 .773 
 







Estimates of Covariance 
Parametersa 
Parameter Estimate Std. Error 
Residual .429299 .059249 
 
a. Dependent Variable: PD_CLLT. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
1 -.181b .114 105 -.407 .045 
2 .154b .109 105 -.062 .370 
3 .102b .107 105 -.111 .314 
 
a. Dependent Variable: PD_CLLT. 
b. Covariates appearing in the model are evaluated at the following values: 
Baseline_CLLT = -.0022, Baseline_sft = 34.83. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








1 3 -.283 .158 105 .148 -.642 
 




Numerator df Denominator df F Sig. 
2 105 2.494 .087 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 















Fixed Effects Intercept 1 1 
Treatment 3 2 
Baseline_WM_Speed 1 1 
Baseline_sft 1 1 
Residual  1 
Total 6 6 
 
a. Dependent Variable: PD WM Speed. 
 
Information Criteriaa 
-2 Restricted Log Likelihood 226.316 
Akaike's Information Criterion 
(AIC) 
228.316 
Hurvich and Tsai's Criterion 
(AICC) 
228.358 
Bozdogan's Criterion (CAIC) 231.911 




The information criteria are displayed in 
smaller-is-better form.a 
a. Dependent Variable: PD WM Speed. 
 
Fixed Effects 
Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 99 .166 .685 
Treatment 2 99 .079 .924 
Baseline_WM_Speed 1 99 118.963 .000 
Baseline_sft 1 99 .002 .962 
 
a. Dependent Variable: PD WM Speed. 
 
Covariance Parameters 
Estimates of Covariance 
Parametersa 
Parameter Estimate Std. Error 
Residual .441554 .062760 
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a. Dependent Variable: PD WM Speed. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
1 .009b .122 99 -.232 .250 
2 -.042b .108 99 -.257 .173 
3 -.054b .112 99 -.277 .169 
 
a. Dependent Variable: PD WM Speed. 
b. Covariates appearing in the model are evaluated at the following values: Baseline 
WM Speed = -.1018, Baseline_sft = 33.99. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








1 3 .063 .166 99 .914 -.315 
 




Numerator df Denominator df F Sig. 
2 99 .079 .924 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 





















Fixed Effects Intercept 1 1 
Treatment 3 2 
Baseline_WM_Acc 1 1 
Baseline_sft 1 1 
Residual  1 
Total 6 6 
 
a. Dependent Variable: PD_WM_Acc. 
 
Information Criteriaa 
-2 Restricted Log Likelihood 241.746 
Akaike's Information Criterion 
(AIC) 
243.746 
Hurvich and Tsai's Criterion 
(AICC) 
243.782 
Bozdogan's Criterion (CAIC) 247.473 




The information criteria are displayed in 
smaller-is-better form.a 




Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 113 2.445 .121 
Treatment 2 113 .424 .655 
Baseline_WM_Acc 1 113 74.254 .000 
Baseline_sft 1 113 2.696 .103 
 





Estimates of Covariance 
Parametersa 
Parameter Estimate Std. Error 
Residual .393058 .052292 
 
a. Dependent Variable: PD_WM_Acc. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
1 -.007b .103 113 -.210 .196 
2 .015b .099 113 -.180 .211 
3 -.107b .101 113 -.307 .092 
 
a. Dependent Variable: PD_WM_Acc. 
b. Covariates appearing in the model are evaluated at the following values: 
Baseline_WM_Acc = -.0113, Baseline_sft = 34.67. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








1 3 .100 .144 113 .738 -.226 
 




Numerator df Denominator df F Sig. 
2 113 .424 .655 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 






APPENDIX IX: Chapter 4 treatment comparisons for iron status parameters 
 
 
Table 0.7 Biochemical analysis outcomes for placebo, iron and iron and vitamin C treatment groups. Baseline 
raw scores and post-dose estimated marginal means and standard error (SE) are presented with F and p values 
of the main treatment effects from the linear mixed models 
 
 Baseline Post-dose Main Effects 
n Mean SE Mean SE F p 
Haemoglobin 
(g/L) 
Placebo 39 126.92 1.04 127.15 1.64   
Iron 38 127.74 1.04 132.45T 1.67 3.95 .022 
Iron + Vit C 42 125.10 0.98 133.07* 1.60   
Serum ferritin 
(µg/L) 
Placebo 37 37.90 4.94 38.80 4.39   
Iron 37 34.61 4.67 54.69* 4.25 9.19 < .001 
Iron + Vit C 39 31.26 3.42 59.00** 3.62   
* significant difference between placebo group and an active treatment group below p < .05; ** significant difference 
between placebo group and an active treatment group below p < .001; T trend towards a significant difference 
between placebo group and an active treatment group below p < .10.   
 
 
A significant effect of treatment for haemoglobin was identified [F (2, 114) = 3.95, p = .022]. 
Post hoc analyses revealed no significant differences between the iron group (132.45) and 
the iron and vitamin C group (133.07; p = .075).  
 
A significant effect of treatment for serum ferritin was also identified [F (2, 109) = 9.19, p < 
.001]. Post hoc analyses revealed no significant differences between the iron group (54.69) 





















APPENDIX X: Chapter 5 cognitive outcomes 
 











Fixed Effects Intercept 1  1 
  
Treatment 3  2 
  
Rep 3  2 
  



















Rep 3 Identity 1 
  




-2 Restricted Log Likelihood 892.845 
Akaike's Information Criterion 
(AIC) 
896.845 
Hurvich and Tsai's Criterion 
(AICC) 
896.923 
Bozdogan's Criterion (CAIC) 904.945 




The information criteria are displayed in 
smaller-is-better form.a 













Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 54.496 15.871 .000 
Treatment 2 32.681 1.828 .177 
Rep 2 80.363 .916 .404 
Treatment * Rep 4 77.486 .543 .705 
Baseline_SS3_Total 1 67.979 173.318 .000 
Baseline_sft 1 35.762 2.698 .109 
 




Estimates of Covariance Parametersa 
Parameter Estimate Std. Error 
Repeated Measures Variance 9.824917 1.627809 
Intercept [subject = 
Participant] 
Variance 4.816936 2.345204 
 
a. Dependent Variable: PD_SS3_Total. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 19.417b .670 32.740 18.053 20.780 
Y 21.115b .621 32.267 19.850 22.380 
Z 20.701b .658 33.042 19.363 22.039 
 
a. Dependent Variable: PD_SS3_Total. 
b. Covariates appearing in the model are evaluated at the following values: 










(I) Treatment (J) Treatment 
Mean 
Difference (I-








Y X 1.698 .915 32.556 .140 -.446 
 




Numerator df Denominator df F Sig. 
2 32.681 1.828 .177 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
a. Dependent Variable: PD_SS3_Total. 
 
2. Treatment * Rep 
 
Estimatesa 
Treatment Rep Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 1 19.172b .925 117.614 17.340 21.005 
2 18.928b .922 119.013 17.103 20.754 
3 20.149b .901 113.686 18.364 21.934 
Y 1 20.637b .834 112.809 18.985 22.289 
2 21.240b .870 120.885 19.519 22.962 
3 21.467b .834 113.184 19.814 23.120 
Z 1 20.041b .878 112.690 18.302 21.780 
2 21.480b .896 117.567 19.705 23.255 
3 20.582b .921 120.683 18.759 22.406 
 
a. Dependent Variable: PD_SS3_Total. 
b. Covariates appearing in the model are evaluated at the following values: Baseline_SS3_Total 
















Error df Sig.b 
  
  


























Rep Numerator df Denominator df F Sig. 
1 2 114.359 .693 .502 
2 2 119.319 2.398 .095 
3 2 116.186 .608 .546 
 
Each F tests the simple effects of Treatment within each level 
combination of the other effects shown. These tests are based on the 
linearly independent pairwise comparisons among the estimated 
marginal means.a 




























Fixed Effects Intercept 1  1 
  
Treatment 3  2 
  
Rep 3  2 
  



















Rep 3 Identity 1 
  




-2 Restricted Log Likelihood 501.812 
Akaike's Information Criterion 
(AIC) 
505.812 
Hurvich and Tsai's Criterion 
(AICC) 
505.890 
Bozdogan's Criterion (CAIC) 513.912 




The information criteria are displayed in 
smaller-is-better form.a 
a. Dependent Variable: PD_SS3_Errors. 
 
Fixed Effects 
Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 56.590 27.427 .000 
Treatment 2 49.603 3.253 .047 
Rep 2 103.080 .313 .732 
Treatment * Rep 4 102.319 .285 .887 
Baseline_SS3_Errors 1 152.202 1.332 .250 
Baseline_sft 1 54.715 1.257 .267 
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Estimates of Covariance Parametersa 
Parameter Estimate Std. Error 
Repeated Measures Variance 1.031698 .149006 
Intercept [subject = 
Participant] 
Variance .081791 .107688 
 
a. Dependent Variable: PD_SS3_Errors. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 1.171b .156 50.379 .857 1.485 
Y 1.137b .144 48.754 .847 1.427 
Z .678b .153 49.486 .370 .986 
 
a. Dependent Variable: PD_SS3_Errors. 
b. Covariates appearing in the model are evaluated at the following values: 
Baseline_SS3_Errors = .90, Baseline_sft = 33.98. 
 
Pairwise Comparisonsa 
(I) Treatment (J) Treatment 
Mean 
Difference (I-








Y X -.034 .213 49.759 .984 -.525 
 




Numerator df Denominator df F Sig. 
2 49.601 3.253 .047 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
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a. Dependent Variable: PD_SS3_Errors. 
 
2. Treatment * Rep 
 
Estimatesa 
Treatment Rep Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 1 1.132b .257 154.467 .624 1.641 
2 1.154b .256 154.608 .648 1.660 
3 1.225b .251 154.244 .730 1.720 
Y 1 1.208b .231 154.056 .752 1.663 
2 1.081b .243 154.868 .601 1.561 
3 1.122b .231 154.351 .666 1.577 
Z 1 .912b .245 154.141 .428 1.395 
2 .619b .249 154.483 .127 1.110 
3 .503b .257 154.320 -.006 1.011 
 
a. Dependent Variable: PD_SS3_Errors. 
b. Covariates appearing in the model are evaluated at the following values: 












Error df Sig.b 
  
  






























Rep Numerator df Denominator df F Sig. 
1 2 154.179 .409 .665 
2 2 154.614 1.353 .262 
3 2 154.295 2.409 .093 
 
Each F tests the simple effects of Treatment within each level 
combination of the other effects shown. These tests are based on the 
linearly independent pairwise comparisons among the estimated 
marginal means.a 















































Fixed Effects Intercept 1  1 
  
Treatment 3  2 
  
Rep 3  2 
  



















Rep 3 Identity 1 
  




-2 Restricted Log Likelihood 779.706 
Akaike's Information Criterion 
(AIC) 
783.706 
Hurvich and Tsai's Criterion 
(AICC) 
783.784 
Bozdogan's Criterion (CAIC) 791.818 




The information criteria are displayed in 
smaller-is-better form.a 














Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 59.975 14.617 .000 
Treatment 2 46.262 .709 .497 
Rep 2 99.339 5.239 .007 
Treatment * Rep 4 99.402 .229 .922 
Baseline_SS7_Total 1 65.534 299.136 .000 
Baseline_sft 1 55.800 .916 .343 
 




Estimates of Covariance Parametersa 
Parameter Estimate Std. Error 
Repeated Measures Variance 6.034528 .885343 
Intercept [subject = 
Participant] 
Variance .254714 .622127 
 
a. Dependent Variable: PD_SS7_Total. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 13.256b .365 45.277 12.522 13.991 
Y 13.764b .340 47.986 13.081 14.447 
Z 13.790b .343 45.199 13.098 14.482 
 
a. Dependent Variable: PD_SS7_Total. 
b. Covariates appearing in the model are evaluated at the following values: 









(I) Treatment (J) Treatment 
Mean 
Difference (I-








Y X .508 .499 46.612 .530 -.646 
 





Numerator df Denominator df F Sig. 
2 46.261 .709 .497 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
a. Dependent Variable: PD_SS7_Total. 
 
2. Treatment * Rep 
Estimatesa 
Treatment Rep Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 1 12.516b .610 156.089 11.312 13.721 
2 13.709b .608 156.217 12.508 14.910 
3 13.543b .609 156.088 12.339 14.747 
Y 1 12.792b .561 156.288 11.684 13.901 
2 14.119b .576 156.499 12.981 15.256 
3 14.380b .563 156.315 13.268 15.493 
Z 1 12.957b .562 156.033 11.847 14.068 
2 13.776b .594 156.439 12.602 14.949 
3 14.637b .561 156.184 13.529 15.745 
 
a. Dependent Variable: PD_SS7_Total. 
b. Covariates appearing in the model are evaluated at the following values: Baseline_SS7_Total 














Error df Sig.b 
  
  


























Rep Numerator df Denominator df F Sig. 
1 2 156.121 .144 .866 
2 2 156.364 .141 .869 
3 2 156.129 .932 .396 
 
Each F tests the simple effects of Treatment within each level 
combination of the other effects shown. These tests are based on the 
linearly independent pairwise comparisons among the estimated 
marginal means.a 




























Fixed Effects Intercept 1  1 
  
Treatment 3  2 
  
Rep 3  2 
  



















Rep 3 Identity 1 
  




-2 Restricted Log Likelihood 502.902 
Akaike's Information Criterion 
(AIC) 
506.902 
Hurvich and Tsai's Criterion 
(AICC) 
506.980 
Bozdogan's Criterion (CAIC) 515.001 




The information criteria are displayed in 
smaller-is-better form.a 
a. Dependent Variable: PD_SS7_Errors. 
 
Fixed Effects 
Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 66.441 21.449 .000 
Treatment 2 50.714 4.266 .019 
Rep 2 102.434 .127 .881 
Treatment * Rep 4 103.019 1.807 .133 
Baseline_SS7_Errors 1 148.893 15.523 .000 
Baseline_sft 1 56.280 .042 .839 
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Estimates of Covariance Parametersa 
Parameter Estimate Std. Error 
Repeated Measures Variance 1.072363 .155074 
Intercept [subject = 
Participant] 
Variance .045404 .105286 
 
a. Dependent Variable: PD_SS7_Errors. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 1.298b .156 51.460 .984 1.611 
Y 1.117b .144 51.032 .828 1.406 
Z .700b .145 48.804 .409 .990 
 
a. Dependent Variable: PD_SS7_Errors. 
b. Covariates appearing in the model are evaluated at the following values: 




(I) Treatment (J) Treatment 
Mean 
Difference (I-








Y X -.181 .214 52.187 .642 -.673 
 




Numerator df Denominator df F Sig. 
2 50.730 4.266 .019 
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The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
a. Dependent Variable: PD_SS7_Errors. 
 
2. Treatment * Rep 
Estimatesa 
Treatment Rep Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 1 1.135b .259 155.480 .625 1.646 
2 1.306b .264 155.509 .784 1.828 
3 1.452b .258 155.398 .943 1.962 
Y 1 1.574b .237 155.451 1.107 2.042 
2 .826b .245 155.281 .342 1.310 
3 .951b .237 155.438 .483 1.419 
Z 1 .576b .236 155.296 .109 1.043 
2 .892b .252 155.792 .394 1.390 
3 .631b .237 155.348 .163 1.099 
 
a. Dependent Variable: PD_SS7_Errors. 
b. Covariates appearing in the model are evaluated at the following values: 












Error df Sig.c 
  
  




























Rep Numerator df Denominator df F Sig. 
1 2 155.374 4.479 .013 
2 2 155.538 1.019 .363 
3 2 155.395 2.743 .067 
 
Each F tests the simple effects of Treatment within each level 
combination of the other effects shown. These tests are based on the 
linearly independent pairwise comparisons among the estimated 
marginal means.a 















































Fixed Effects Intercept 1  1 
  
Treatment 3  2 
  
Rep 3  2 
  



















Rep 3 Identity 1 
  




-2 Restricted Log Likelihood 1288.552 
Akaike's Information Criterion 
(AIC) 
1292.552 
Hurvich and Tsai's Criterion 
(AICC) 
1292.635 
Bozdogan's Criterion (CAIC) 1300.533 




The information criteria are displayed in 
smaller-is-better form.a 













Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 112.714 36.248 .000 
Treatment 2 45.165 1.239 .299 
Rep 2 90.045 1.029 .361 
Treatment * Rep 4 90.345 .486 .746 
Baseline_RVIP_Correct 1 133.054 34.160 .000 
Baseline_sft 1 44.477 1.711 .198 
 




Estimates of Covariance Parametersa 
Parameter Estimate Std. Error 
Repeated Measures Variance 195.151245 30.189487 
Intercept [subject = 
Participant] 
Variance 105.003016 40.761349 
 
a. Dependent Variable: PD_RVIP_Correct. 
 





Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 70.371b 3.091 44.840 64.144 76.598 
Y 76.759b 2.940 44.350 70.836 82.682 
Z 75.601b 3.127 45.890 69.307 81.895 
 
a. Dependent Variable: PD_RVIP_Correct. 
b. Covariates appearing in the model are evaluated at the following values: 









(I) Treatment (J) Treatment 
Mean 
Difference (I-








Y X 6.388 4.264 44.620 .262 -3.480 
 




Numerator df Denominator df F Sig. 
2 45.167 1.239 .299 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
a. Dependent Variable: PD_RVIP_Correct. 
 
2. Treatment * Rep 
 
Estimatesa 
Treatment Rep Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 1 69.704b 4.244 122.012 61.303 78.105 
2 70.012b 4.084 116.894 61.925 78.100 
3 71.396b 4.314 124.575 62.858 79.934 
Y 1 77.163b 4.140 128.190 68.972 85.355 
2 79.252b 3.966 119.180 71.399 87.106 
3 73.860b 3.798 113.541 66.336 81.385 
Z 1 75.488b 4.295 125.200 66.988 83.988 
2 79.530b 4.094 116.155 71.421 87.638 
3 71.785b 4.299 124.503 63.277 80.294 
 
a. Dependent Variable: PD_RVIP_Correct. 
b. Covariates appearing in the model are evaluated at the following values: 














Error df Sig.b 
  
  


























Rep Numerator df Denominator df F Sig. 
1 2 124.566 .865 .424 
2 2 117.099 1.762 .176 
3 2 121.176 .112 .894 
 
Each F tests the simple effects of Treatment within each level 
combination of the other effects shown. These tests are based on the 
linearly independent pairwise comparisons among the estimated 
marginal means.a 




























Fixed Effects Intercept 1  1 
  
Treatment 3  2 
  
Rep 3  2 
  



















Rep 3 Identity 1 
  




-2 Restricted Log Likelihood 1626.838 
Akaike's Information Criterion 
(AIC) 
1630.838 
Hurvich and Tsai's Criterion 
(AICC) 
1630.922 
Bozdogan's Criterion (CAIC) 1638.819 




The information criteria are displayed in 
smaller-is-better form.a 













Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 139.021 137.511 .000 
Treatment 2 45.634 .700 .502 
Rep 2 90.780 1.006 .370 
Treatment * Rep 4 90.112 .763 .552 
Baseline_RVIP_CorrectRT 1 144.116 7.293 .008 
Baseline_sft 1 44.449 .092 .763 
 




Estimates of Covariance Parametersa 
Parameter Estimate Std. Error 
Repeated Measures Variance 2049.494506 315.913912 
Intercept [subject = 
Participant] 
Variance 785.516270 360.690579 
 
a. Dependent Variable: PD_RVIP_CorrectRT. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 487.962b 9.116 45.000 469.602 506.323 
Y 473.129b 8.670 44.879 455.666 490.592 
Z 480.820b 9.262 46.503 462.181 499.458 
 
a. Dependent Variable: PD_RVIP_CorrectRT. 
b. Covariates appearing in the model are evaluated at the following values: 










(I) Treatment (J) Treatment 
Mean 
Difference (I-








Y X -14.833 12.552 44.892 .428 -43.873 
 




Numerator df Denominator df F Sig. 
2 45.636 .700 .502 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
a. Dependent Variable: PD_RVIP_CorrectRT. 
 
2. Treatment * Rep 
Estimatesa 
Treatment Rep Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 1 497.467b 12.907 130.449 471.934 523.001 
2 492.704b 12.584 126.912 467.803 517.604 
3 473.715b 13.213 133.235 447.581 499.849 
Y 1 475.321b 12.792 135.163 450.023 500.619 
2 465.043b 12.192 129.442 440.922 489.164 
3 479.024b 11.638 124.033 455.990 502.059 
Z 1 491.576b 13.257 133.183 465.355 517.797 
2 472.503b 12.612 125.918 447.545 497.461 
3 478.379b 13.282 132.607 452.107 504.652 
 
a. Dependent Variable: PD_RVIP_CorrectRT. 
b. Covariates appearing in the model are evaluated at the following values: 


















Error df Sig.b 
  
  


























Rep Numerator df Denominator df F Sig. 
1 2 133.010 .798 .452 
2 2 127.247 1.327 .269 
3 2 130.183 .051 .950 
 
Each F tests the simple effects of Treatment within each level 
combination of the other effects shown. These tests are based on the 
linearly independent pairwise comparisons among the estimated 
marginal means.a 




























Fixed Effects Intercept 1  1 
  
Treatment 3  2 
  
Rep 3  2 
  



















Rep 3 Identity 1 
  




-2 Restricted Log Likelihood 361.244 
Akaike's Information Criterion 
(AIC) 
365.244 
Hurvich and Tsai's Criterion 
(AICC) 
365.327 
Bozdogan's Criterion (CAIC) 373.225 




The information criteria are displayed in 
smaller-is-better form.a 














Type III Tests of Fixed Effectsa 
Source Numerator df Denominator df F Sig. 
Intercept 1 49.780 7.189 .010 
Treatment 2 44.699 1.017 .370 
Rep 2 92.995 .254 .776 
Treatment * Rep 4 92.357 .195 .940 
Baseline_RVIP_Fas 1 134.049 16.278 .000 
Baseline_sft 1 42.305 .025 .876 
 




Estimates of Covariance Parametersa 
Parameter Estimate Std. Error 
Repeated Measures Variance .474395 .072782 
Intercept [subject = 
Participant] 
Variance .044980 .056286 
 
a. Dependent Variable: PD_RVIP_FAs. 
 




Treatment Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X .559b .110 45.055 .338 .780 
Y .345b .103 43.038 .136 .553 
Z .451b .111 45.384 .228 .675 
 
a. Dependent Variable: PD_RVIP_FAs. 
b. Covariates appearing in the model are evaluated at the following values: 








(I) Treatment (J) Treatment 
Mean 
Difference (I-








Y X -.214 .151 43.938 .297 -.563 
 




Numerator df Denominator df F Sig. 
2 44.705 1.017 .370 
 
The F tests the effect of Treatment. This test is based on the 
linearly independent pairwise comparisons among the 
estimated marginal means.a 
a. Dependent Variable: PD_RVIP_FAs. 
 
2. Treatment * Rep 
Estimatesa 
Treatment Rep Mean Std. Error df 
95% Confidence Interval 
Lower Bound Upper Bound 
X 1 .598b .176 145.098 .250 .946 
2 .484b .171 144.234 .147 .821 
3 .595b .180 145.305 .238 .951 
Y 1 .435b .175 145.727 .089 .781 
2 .301b .165 144.983 -.026 .628 
3 .298b .159 143.852 -.016 .612 
Z 1 .488b .182 145.414 .129 .847 
2 .515b .171 143.998 .178 .853 
3 .351b .181 144.740 -.007 .709 
 
a. Dependent Variable: PD_RVIP_FAs. 
b. Covariates appearing in the model are evaluated at the following values: Baseline_RVIP_Fas 


















Error df Sig.b 
  
  


























Rep Numerator df Denominator df F Sig. 
1 2 145.412 .225 .798 
2 2 144.203 .483 .618 
3 2 144.706 .818 .443 
 
Each F tests the simple effects of Treatment within each level 
combination of the other effects shown. These tests are based on the 
linearly independent pairwise comparisons among the estimated 
marginal means.a 
a. Dependent Variable: PD_RVIP_FAs. 
 
 
 
 
